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ii. Abstract 
The stress inducible transcription factor, NF-κB, induces genes involved in 
proliferation and apoptosis. Aberrant NF-κB activity is common in cancer and 
contributes to therapeutic-resistance. Moreover, constitutive NF-κB activation has been 
shown to contribute to malignant progression through the regulation of gene expression. 
Poly(ADP-ribose) polymerase-1 (PARP-1) is activated during DNA strand break repair 
and is a known transcriptional co-regulator. The role of PARP-1 function during NF-κB 
activation using siRNA knockdown of either p65 or PARP-1, or the potent PARP-1 
inhibitor, AG-014699, was investigated. Survival and apoptosis assays showed that NF-
кB p65-/- mouse embryonic fibroblasts (MEFs) were more sensitive to ionising radiation 
(IR) than p65+/+ MEFs. Co-incubation with p65 siRNA, PARP siRNA or AG-014699 
radio-sensitised p65+/+, but not p65-/- MEFs, demonstrating that PARP-1 mediates its 
effects on survival via NF-κB.  Furthermore, a combination of p65 siRNA and AG-
014699 radio-sensitised p65+/+ MEFs to the same extent as either agent alone, strongly 
indicating that PARP-1 and NF-κB are mechanistically linked. PARP-1 is known to be 
vital for the repair of single strand breaks (SSBs). SSB repair kinetics, and the effect 
SSB repair inhibition by AG-014699 were similar in p65+/+ and p65-/- cells. Since 
inhibition of SSB repair did not radio-sensitise p65-/- cells, these data show that radio-
sensitisation by AG-014699 is due to downstream inhibition of NF-κB activation, and 
independent of SSB repair inhibition. PARP-1 catalytic activity was essential for IR-
induced p65 DNA binding and NF-κB-dependent gene transcription, whereas for TNF-
α treated cells, PARP-1 protein alone was sufficient. It can therefore be hypothesised 
that this stimulus-dependent differential is mediated via stimulation of the Poly(ADP-
ribose) (PAR) polymer, which was induced following IR, not TNF-α. Poly(ADP-ribose) 
glycohydrolase (PARG) is the major enzyme responsible for the catabolism of the PAR 
polymer. In order to inhibit degradation of the PAR polymer a potent and specific 
PARG inhibitor was used.  Increased polymer stability following IR, by virtue of 
inhibition of polymer degradation, led to the persistence of NF-κB DNA binding, an 
increase in anti-apoptotic gene expression and a protection against IR-induced cell 
death. These data confirm a role for the PAR polymer in the activation of NF-κB 
following DNA damage. 
Microarray analysis showed that the TNF-α driven transcription of NF-κB-
dependent inflammatory and immune response genes was unaffected by AG-014699, 
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suggesting that targeting DNA-damage activated NF-κB using AG-014699 may 
overcome toxicity observed with classical NF-κB inhibitors without compromising 
other vital inflammatory functions. An investigation into the role of PARP-1 in DNA 
damage activated NF-κB activation in glioblastoma cells was also undertaken to assess 
the potential utility of AG-014699 in tumour types known to express constitutively 
active NF-κB. PARP-1 activity was vital for both radio- and chemo-sensitisation of 
U251 glioblastoma cells, and in IR- or temozolomide- treated cells, PARP-1 mediated 
its effects on survival via NF-κB. Importantly, these data confirm the findings in the 
MEFs by demonstrating that radio- or chemo-sensitisation by AG-014699 is due to 
downstream inhibition of NF-κB activation, and independent of SSB repair inhibition. 
Hence, these data highlight the potential of PARP-1 inhibitors to overcome NF-κB-
mediated therapeutic resistance and widens the spectrum of cancers in which these 
agents may be utilised.  
 
The therapeutic potential of a potent inhibitor of NF-κB subunit DNA binding, PBS-
1086, was also assessed in the NF-κB p65+/+ and p65-/- MEFs and the MDA-MB-231, 
T47D and MCF7 breast cancer cell lines. DNA binding and luciferase reporter assays 
showed that PBS-1086 inhibited IR-induced p65 and p50 DNA binding and NF-κB-
dependent gene transcription in p65+/+ cells. Co-incubation with PBS-1086 or p65 
siRNA radio-sensitised p65+/+, but not p65-/- cells, demonstrating that PBS-1086 
mediates radio-sensitisation via the p65 NF-κB subunit. Gene expression analysis 
showed that PBS-1086 inhibited IR-induced transcription of known NF-κB-regulated 
anti-apoptotic genes. MDA-MB-231 cells were found to have the highest constitutive 
levels of DNA binding of all NF-κB subunits. PBS-1086 radio-sensitised all three breast 
cancer cell lines. In survival assays, all breast cancer cell lines tested were also sensitive 
to PBS-1086, however, MDA-MB-231 cells were the most sensitive to PBS-1086 alone. 
Thus, high NF-κB DNA binding activity appears to correlate with sensitivity to PBS-
1086. Collectively these data highlight the potential of modulating NF-κB activity, 
either by PARP-1, or directly via inhibition of subunit DNA binding, to restore radio- 
and chemo-sensitivity in cancers with aberrantly active NF-κB, and to overcome NF-κB 
mediated therapeutic resistance. 
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1.1 Cancer 
Cancer is often defined as being the overall name given to a large, heterogeneous class 
of diseases, in which cells have acquired properties which allow them to undergo 
uncontrolled growth and proliferation, evade cell death, invade the surrounding tissues, 
and in some cases metastasise to other locations via  the lymphatic system or 
bloodstream. Cell growth and genomic integrity is tightly regulated in normal cells, by 
several classes of genes, however in tumour cells this regulation is often lost, due to 
hereditary or acquired abnormalities in regulatory genes, such as tumour suppressors 
and oncogenes. A small percentage of cancers, approximately 5-10 % are hereditary, 
whereas spontaneous ones are associated with acquired mutations of key genes, through 
a number of risk factors including the exposure to genotoxic and mutagenic agents. 
 
Cancers are often classified by both the location of their origin and the type of cell that 
most resemble. These include the most common type of cancer, which are carcinomas, 
and tend to be tumours which have arisen from epithelial cells, for example those 
developing in the lung, breast or colon. Cancers originating in mesenchymal cells give 
rise to cancers in the connective tissues, called sarcomas. There are two major classes of 
cancers which arise in the haematopoietic cells and mature in the lymph nodes and 
blood are referred to as lymphomas and leukaemias, respectively. Finally, tumours 
derived from immature cells or embryonic tissues are often called blastomas and those 
which present in the testes or ovaries are sometimes called germ-cell tumours. 
 
In 2007, cancer was attributable for 7.9 million deaths worldwide, which was 13 % of 
all human deaths (Jemal et al., 2011). Although rates of cancer are rising, it should be 
noted that this is primarily a disease of old age, and it is highly likely that the increasing 
incidence is due to an increased ageing population, especially in developed countries. 
Encouragingly however, statistics from Cancer Research UK show that cancer survival 
rates have doubled in the last 40 years, that more than 7 out of 10 children with cancer 
are now successfully treated, breast cancer death rates have fallen by almost a fifth in 
the past 10 years and more than 95% of men with testicular cancer are now successfully 
treated (www.cancerresearchuk.org). This is due to new advances in treatment and also 
surgical techniques, often in used in combination with the existing therapeutic 
modalities, which are chemotherapy, radiotherapy and surgical resection. The prognosis 
of cancer is heavily dependent on the type of cancer, also the extent and location of the 
disease.  
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In 2000, a landmark review by Hanahan and Weinberg was published, in which the six 
‘Hallmarks of cancer’ were defined. These showed that a tumour cell had six key 
acquired or hereditary characteristics, which lead to the development, or spread, of 
cancer. These were; sustaining a proliferative signal, evading growth suppressors, 
activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis and resisting cell death (Hanahan and Weinberg, 2000). These hallmarks 
still provide a solid foundation for understanding tumour growth and metastatic 
dissemination, whilst also illustrating that there can be a large diversity in each type of 
cancer, and in an individual tumour. However, a large body of data has been generated 
since this review, and these hallmarks have been updated to include a number of new 
capabilities shared by tumour cells. Figure 1.1 is taken from this review and shows the 
now ten hallmarks of cancer, which along with the original six, include; avoiding 
immune destruction, tumour-promoting inflammation, genome instability and mutation 
and deregulating cellular energetics (Hanahan and Weinberg, 2011).   
 
Research in oncology over the last few years has also centred on targeted therapies, or 
personalised medicine, meaning that drugs specific to a mutation or type of cancer have 
been developed, such as the use of Poly (ADP-ribose) polymerase (PARP) inhibitors for 
BRCA-defective breast and ovarian cancers (reviewed in section 1.3.4.1). Figure 1.1 
also illustrates novel therapies, currently in development or clinical trials, which target 
each of the ten hallmarks, as a means of overcoming cancer by directly targeting these 
key characteristics. It is also the hope that by targeting these hallmarks, which are 
unique to cancer cells, there will be fewer side effects for patients, as the normal tissues 
do not share these cancerous characteristics, and therefore should remain unaffected by 
these new treatments. 
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1.1.1 Cancer therapeutics 
As previously mentioned, the three principle approaches to the treatment of cancer are 
surgery, radiotherapy and chemotherapy.  In the case of many solid tumours, such as 
breast or lung carcinomas, surgery is usually the first modality used. This is dependent 
on the tumour being accessible and aims to excise as much of the tumour mass as 
possible. However, it often means that some normal tissue, and in some cases the lymph 
nodes are also removed, in order to limit the risk of relapse. In many cases, it is not 
possible to surgically remove all of the cancerous tissue and as a result of this, 
radiotherapy is used as an adjunct therapy in many cases, with the aim of suppressing 
the rate of cell division in any tumour cells that remain following surgical resection.  In 
some very advanced tumours, surgery may be used as a means of palliative care, as it 
can significantly reduce the tumour burden for a patient. 
Figure 1.1: The Hallmarks of Cancer This figure shows the 10 ‘hallmarks’ of 
cancer as assigned by Hanahan and Weinberg (2011). It also shows some of the 
novel drugs which are designed to specifically target these hallmarks. Some of 
these drugs have been licenced for use and others are in clinical trials, however 
these are just a representation and there are many others in development that are 
associated with these. 
Taken from: (Hanahan and Weinberg, 2011) 
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Radiotherapy, like many chemotherapeutic agents, directly damages the DNA of the 
tumour cells. In this case the DNA damage is by ionising radiation (IR) and can be used 
either as the principle means of local control, in order to reduce tumour burden prior to 
surgery, or as an adjunct to surgery (described above).  It may be applied externally 
(beam therapy) or internally (brachy therapy) and the two approaches can be combined.  
Radio-therapy is a main-stay of treatment for a large range of solid tumours, such as 
breast, lung, prostate and brain tumours, including glioblastoma, and is one of the 
cornerstones of cancer treatment today. Interestingly, statistics from the Cancer 
Research UK, showed that 40% of people whose cancer is cured receive radiotherapy as 
part of their treatment (www.cancerresearchuk.org), which really highlights the 
importance of this type of treatment. 
 
Surgery and/or radiotherapy are only effective in locally-confined tumours and are 
therefore, not suitable in all cases, such as leukaemia and lymphomas. In these, and 
many other cases, chemotherapy is administered. It should be noted that the majority of 
patients will receive systemic chemotherapy at some point during their illness, and that 
this type of treatment can be given an an adjunct to either radio-therapy or surgery. 
There are many classes of chemotherapeutic drugs, and hence it is not possible to 
review them all in detail here. Briefly, these DNA-damaging therapies include 
alkylating agents such as temozolomide (TMZ), topoisomerase I and II posions, such as 
camptothecin and doxorubicin (DOX) and nucleoside analogues, such as fludarabine. 
These agents are very effective; however they can also be toxic to normal cells, 
particularly in cells which by their nature proliferate rapidly, such as those in the 
gastrointestinal tract, bone marrow, testes or ovaries. This can therefore lead to quite 
severe side effects, such as loss of fertility and myelosuppression. As a result, anti-
cancer drugs tend to have a steep dose response curve for both toxic and therapeutic 
effects,  
 
New therapeutics which could be used in combination with existing agents are 
constantly being developed, these include targeted drugs, such as those which inhibit 
key DNA repair proteins, such as PARP inhibitors (section 1.3.4). These agents may 
increase the therapeutic-index of the conventional radio- and chemotherapies being 
administered, thus reducing the side effects associated with these agents. Other forms of 
treatment include hormone therapy, gene therapy, immunotherapy, bone marrow 
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transplant and peripheral blood stem cell transplants in conjunction with high dose 
chemotherapy. More recent developments in cancer treatment include the introduction 
on monoclonal antibody therapies, which includes Rituximab that targets CD20 found 
on the surface of B cells, and is used to treat chronic lymphocytic leukaemia (CLL), as 
well as other forms of leukaemia and lymphoma. 
 
 
1.1.2 Oncogenes and tumour suppressors 
Carcinogenesis is dependent on both oncogenes and tumour suppressor genes. In 
general, an oncogene is a gene which has the potential to cause cancer, and in many 
tumour cells these oncogenes are mutated or highly expressed. A proto-oncogene is a 
‘normal’ gene, which has become an oncogene due to a ‘gain-of-function’ mutations or 
increased expression. Many proto-oncogenes encode proteins involved in signal 
transduction, cell proliferation or differentiation. These include RAS, WNT, MYC, and 
ERK. A further example of an oncogene is the Bcr-abl gene formed during a 
chromosomal translocation between chromosomes 9 and 22, and often referred to as the 
Philadelphia Chromosome. Bcr-Abl codes for a receptor tyrosine kinase which is 
constitutively active, leading to uncontrolled cell proliferation, and the development of 
chronic myeloid leukaemia (Chen et al., 2010). 
 
In contrast, tumour suppressor genes (TSGs) are genes which protect the cell and aid in 
the maintenance of genomic integrity. Mutations in TSGs tend to be ‘loss-of-function’ 
and may reduce or completely abolish activity of such genes which negatively regulate 
critical cellular functions. This can then lead to enhanced cellular proliferation, blocked 
differentiation, or the suppression of cell death pathways, and hence the progression of 
cancer. Unlike oncogenes, TSGs generally follow the Knudson two-hit hypothesis, 
which was first proposed for the retinoblastoma (Rb) protein, a known TSG (Knudson, 
1971). This hypothesis suggests that a mutation or loss of both alleles of a gene must be 
affected before an effect manifests itself. Knudson analysed a subset of retinoblastoma 
cases, which can be either familial or occur sporadically, and found that hereditary 
retinoblastoma occurred at a younger age than the sporadic disease. This lead Knudson 
to hypothesise that multiple ‘hits’ to DNA were necessary to cause cancer. In this case, 
a ‘hit’ is classified as a mutation in a key gene. In familial retinoblastoma tumours, the 
initial hit was inherited in the DNA, and any second insult would rapidly lead to cancer. 
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However, in sporadic retinoblastoma, two ‘hits’ must occur before the onset of 
tumourigenesis, hence explaining the age difference. 
 
Another important TSG is the p53 protein, encoded by the TP53 gene. This TSG is 
often referred to as the ‘guardian of the genome’ and is known to regulate the apoptotic 
pathway, particularly in response to DNA damage (Lane, 1992). p53 is an important 
transcription factor (section 1.1.3) and is a common target for genetic alterations in 
cancer, with around 50 % of tumours possessing mutations in the p53 gene (Ozaki and 
Nakagawara, 2011). This includes colorectal, breast and lung carcinomas, as well as 
many haematological malignancies and neurological cancers. Interestingly, p53 is a 
notable exception to the Knudson hypothesis, as heterozygous loss is enough to result in 
a loss of functional protein in this case.  
 
 
1.1.3 Transcription factors and cancer 
Transcription factors are vital proteins that bind to specific DNA consensus sequences 
and therefore control gene transcription and control a number of cellular processes. A 
number of transcription factors are de-regulated in cancer, and many are known 
oncogenes and TSGs (section 1.1.2), and some very brief examples will be discussed 
here. The MYC gene, which codes for the myc family of transcription factors, is over 
expressed in Burkitt's Lymphoma following a chromosomal translocation. This results 
in uncontrolled growth and is thought to drive the development of this type of 
lymphoma. Hence, MYC is often deemed to be an oncogene (Taub et al., 1982). The 
TSG, p53, is an important transcription factor, known to regulate genes associated with 
apoptosis and cell cycle progression. As previously discussed, p53 is frequently de-
regulated in many different types of cancer (Ozaki and Nakagawara, 2011). Other 
transcription factors which have been implicated in the progression and onset of various 
cancers include c-JUN, β-catenin, NOTCH, the STAT family of transcription factors, 
and also Nuclear Factor-kappaB (NF-κB) (Darnell, 2002). The role of NF-κB in cancer 
will be discussed in detail in section 1.2.4.3. 
 
1.2 Nuclear factor kappaB (NF-κB) 
Transcription factors, such as Nuclear Factor kappa-B (NF-κB) regulate and respond to 
changes in the environment, and mediate such responses through alterations in gene 
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expression (Hayden and Ghosh, 2004). The stress-inducible transcription factor NF-κB, 
has the ability to both induce and repress gene expression (Perkins, 2007) and plays a 
crucial role in many biological processes. NF-κB was first identified by its binding to 
the enhancer region of the immunoglobulin kappa (κ) light chain gene in B cells in 
order to regulate the human immune response (Suh and Rabson, 2004), and 
consequently it’s activity was initially associated with infection and immunity; however 
knockout mouse models (Table 1.1) have revealed a role for NF-κB family members in 
normal development, and their expression has been documented in various cell types. 
There are a number of genes regulated by NF-κB, including those controlling apoptosis, 
cell adhesion, inflammation, proliferation, immune responses, cellular stress and tissue 
remodelling (Bonizzi and Karin, 2004, Gerondakis et al., 1999, Hayden and Ghosh, 
2004, Pahl, 1999, Pasparakis et al., 2006).  
 
NF-κB activity has been found to be regulated by both tumour suppressors and 
oncogenes, hence having profoundly different effects, mediating either enhanced or 
inhibited cellular proliferation or apoptosis (Perkins and Gilmore, 2006). Consequently 
inappropriate NF-κB activity has been implicated in the pathology of inflammatory 
diseases and cancers (discussed in sections 1.2.4.1 and 1.2.4.3) and has made the 
transcription factor a target of much clinical investigation (Kim et al., 2006). Therefore 
NF-κB is a topic of investigation by many groups, in order to understand more about the 
role played by the transcription factor in terms of its activity, selectivity and role in 
signalling. However, the abundance of processes in which NF-κB is known to be 
associated means that there is a huge expanse of literature available surrounding the 
subject. Here, the aim is to review only those key aspects of its activity relevant to the 
study in question.  
 
 
1.2.1 The NF-κB superfamily and associated proteins 
The term NF-κB can be used to refer to either the entire family of transcription factors 
or simply a single subunit, but often it is used to denote specific transcriptionally active 
homo- or hetero-dimers. Members of the NF-κB superfamily are conserved throughout 
evolution, and present in most species, which the exception of yeast and C. elegans. 
Therefore, the majority of studies on model organism within this field are undertaken in 
mammalian cells (Gilmore, 2006).  
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1.2.1.1 NF-κB subunits 
All NF-κB proteins are characterised by a conserved N-terminal domain of 
approximately 300 amino acids named the Rel-homology domain (RHD) which is 
composed of β-sheets and bears a structural resemblance to the well-known 
immunoglobulin domain (Figure 1.2). This domain is responsible for DNA binding, 
dimerisation and interaction with Inhibitor of NF-κB (IκB) proteins. It is known that the 
Rel subfamily members (RelA, RelB and c-Rel) are found predominantly in the 
cytoplasm bound to inhibitor IκB proteins. This binding sequesters the NF-κB:IκB 
complex to the cytoplasm thereby keeping NF-κB in an inactive state (Perkins, 2007). 
.  
 
 
 
 
 
 
 
 
There are five NF-κB genes, NFKB1, NFKB2, RELA, c-REL and RELB, which encode 
the seven members of the human NF-κB family p105 (p50), p100 (p52), RelA/p65, c-
Rel, and RelB (Hayden and Ghosh, 2004). These family members are further 
subdivided according to their transcriptional properties, for example, c-Rel, RelB and 
p65 proteins all contain C-terminal, non-homologous, transactivation domains (TAD). 
Figure 1.2: The seven NF-κB/Rel family members RHD: Rel homology domain. 
NLS: Nuclear localisation sequence. TAD: Transactivation domain. LZ: Leucine 
zipper. GRR: Glycine rich region.  
Adapted from: (Chen and Greene, 2004) 
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These TAD are responsible for the transcriptional activity of these proteins at target 
gene promoters via interaction with the basal transcriptional machinery and co-
regulators (Chen et al., 2005b). The p105 and p100 proteins contain C-terminal ankyrin 
repeats with inhibitory properties which are removed during processing to reveal the 
active factors p50 and p52 respectively. The resultant p50 and p52 proteins do not 
contain TADs and therefore mediate their transcriptional activity via hetero-
dimerisation or interaction with transcriptional regulators, such as BCL3 (Hayden and 
Ghosh, 2004). 
 
The diversity afforded to the NF-κB family through the ability to homo- and hetero-
dimerise suggests a multifunctional role for these transcription factors and there is new 
data emerging constantly about novel functions of each of the subunits and associated 
proteins. Animal knock-out models have, however, provided a host of data purporting to 
the exact functionality of each subunit and also the associated proteins. This is 
summarised in Table 1.1. This table not only details the knockout of each of the five 
subunits, but also the inhibitory protein, BCL3 (discussed is section 1.2.1.2) and the 
inhibitor of kappa-B kinase (IKK) family members, which are discussed in section 
1.2.1.3. It should be noted here that these traditional gene knockouts may not provide 
the best route to determine the exact role of individual subunits as loss of one NF-κB 
subunit can result in a rebalancing of the other subunits, thus meaning there is a 
compensatory effect. Furthermore, p65 can regulate the expression of other subunits, it 
is important to take this into account. 
 
Knockout Phenotype Biological role Reference 
p65/RelA Embryonic lethal at E15-
16 due to massive liver 
degeneration  
Crucial for normal 
development and for the 
protection against TNF-
α apoptotic signalling 
(Beg et al., 
1995) 
p50 No developmental 
abnormalities. Multi-focal 
defects in immune 
response including 
decreased immunoglobulin 
production and defective 
humoral responses. B cells 
do not respond to 
lipopolysaccharide (LPS) 
Indicates the importance 
of dimers containing 
p50 in inflammatory 
signalling. Also 
suggests that p50 is 
redundant in TNF-α 
induced apoptotic 
signalling 
(Sha et al., 
1995) 
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stimulation 
p52 Mice are unable to 
generate antibodies to T-
dependent antigens. B cell 
follicles and dendrite cell 
networks are absent 
Mice lack both the p100 
precursor and the p52 
subunit. Suggests that 
p52 is important in 
neurological cell 
development 
(Franzoso et 
al., 1998) 
c-Rel Mice develop normally 
however they exhibit 
significantly reduced B-
cell proliferation and have 
irregular germinal centres 
and reduced numbers of 
marginal zone B cells 
Suggests that c-Rel has 
a role in haematopoiesis 
and B cell development 
(Kontgen et 
al., 1995) 
RelB Mixed inflammatory cell 
infiltration in multiple 
organs. Myeloid 
hyperplasia. Loss of 
dendritic cell function 
Indictaes that RelB has 
a role in maintaining 
cellular immunity 
(Weih et al., 
1995) 
BCL-3 Similar phenotype to that 
of p52 knockout. Mice fail 
to generate appropriate T-
dependent antibody 
response to some viruses 
and have impaired 
germinal centre reactions 
Role in antigen-specific 
priming of T and B cells 
(Bours et al., 
1993) 
IKKα Not embryonic lethal, 
however at E18.5 mice 
have rudimentary limbs 
and tail, craniofacial 
deformaties and skeletal 
abnormalities. Mice also 
have an increased 
thickness to the epidermis 
Crucial role for IKKα in 
skeletal and dermal 
development. Some 
evidence for hyper-
proliferation of cells in 
basal layers of the 
epidermis due to IKKα 
knockout 
(Li et al., 
1999a) 
IKKβ Embryos die at E14.5 due 
to liver degeneration and 
apoptosis. Do exhibit some 
basal NF-κB DNA binding 
activity in response to 
TNF-α/IL-1 
Similar to p65 
knockout. Essential role 
of IKKβ the protection 
apoptotic signalling 
(Li et al., 
1999b, Tanaka 
et al., 1999a) 
NEMO/IKKγ Embryos die at E12.5-13 
due to severe liver damage 
due to apoptosis. No NF-
Required for the 
protection against 
apoptosis and also the 
(Rudolph et 
43 
 
κB DNA binding activity 
in response to TNF-α/IL-1 
activation of NF-κB al., 2000) 
 
 
 
1.2.1.2 NF-κB inhibitory proteins 
The classical definition of an inhibitor of κB (IκB) protein is two fold: to bind to, and 
prevent activation of, an NF-κB dimer, and to undergo degradation upon stimulation to 
allow rapid activation of the transcription factor. There are seven well characterised 
members, which include IκB-α, IκB-β, IκB-ε, BCL-3 and IκB-γ, the structures of which 
are shown in Figure 1.3. The NF-κB precursor proteins, p100 and p105 are also 
classified as inhibitory proteins, and the structure of these are shown in Figure 1.2. 
Importantly, all seven inhibitory proteins contain five to seven ankyrin repeats that have 
the ability to form elongated cylinders to bind the dimerisation domain of NF-κB dimers 
(Hatada et al., 1992). 
 
  
 
 
 
 
 
The mechanism of NF-κB activation is both cell type and stimulus specific (see section 
1.2.2) and the indivdual IκB proteins have been linked to different activation pathways. 
Table 1.1: The biological role of NF-κB associated proteins This details the knockout 
of each of the five subunits, but also the inhibitory protein, BCL3 and the IKK family 
members, which are discussed later in this chapter 
Figure 1.3: The Inhibitor of NF-κB (IκB) proteins SS: Phosphorylation of two 
serine residues. PEST: Domain rich in proline (P), glutamate (E), serine (S) and 
threonine (T).  
Adapted from: (Chen and Greene, 2004) 
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IκB-α is involved in the canonical or traditional pathway of NF-κB activation induced 
by numerous agents including tumour necrosis factor-α (TNF-α) and lipopolysaccharide 
(LPS). Huxford et al., (1998) solved the crystal structure of IκBα in complex with the 
NF-κB p50/p65 heterodimer revealing a mechanism for the inhibition of this 
heterodimer (illustrated in Figure 5). This group reported that the IκB proteins mask a 
conserved nuclear localisation sequence (NLS) found in the RHD of p65, whilst the 
NLS of p50 remains accessible (Huxford et al., 1998). This accessible NLS on p50 
along with a nuclear export sequences (NES) on IκBα and p65 result in the constant 
shuttling of IκBα:NF-κB complexes between the nucleus and the cytoplasm, although 
the steady-state location is in the cytosol (Huang et al., 2000). The equilibrium between 
the localisations is altered on degradation of IκBα by removal of its NES and 
unmasking of the p65 NLS, resulting in the nuclear localization of active NF-κB 
(Hayden and Ghosh, 2004). 
 
Following stimulation, IκBα is phosphorylated by the IκB-kinase (IKK) complex 
(section 1.2.1.3) at residues Serine 32 and 36, targeting the protein for 
polyubiquitination. This ubiquitination of Lysine 21 and 22 of the IκBα protein then 
targets  it for degradation by the 26S proteasome (Hayden and Ghosh, 2004). Following 
degradation of the inhibitory protein, NF-κB dimers translocate to the nucleus where 
they initiate transcription using the promoters of target genes. The promoter of the 
NFKBIA gene, which encodes the IκBα protein, contains multiple NF-κB consensus 
sequences, and as a result the level of IκBα is regulated by NF-κB (Hertlein et al., 
2005), illustrating a negative feedback mechanism. 
 
The IκBβ and IκBε proteins are associated with dampening oscillations of 
transcriptional activity during long-term stimulation of NF-κB subunits during 
processes such as T-cell activation in the immune response (Chen et al., 2004, Saccani 
et al., 2004). IκBα and IκBβ have some structural and sequence similarity but unlike 
IκBα, IκBβ does not contain a NES which means that inhibitory complexes it forms 
with NF-κB dimers do not undergo a cytoplasmic-to-nuclear shuttling process in the 
resting state (Chen et al., 2004). IκBβ is not fully degraded following stimulation, and 
although p65 null cells display a marked reduction in IκBα, the IκBβ levels are barely 
detectable suggesting this protein is not regulated by NF-κB (Hertlein et al., 2005). 
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The non-canonical pathway of NF-κB activation (section 1.2.2.2) results in the 
processing and release of p52 NF-κB subunits from its precursor protein, p100. These 
precursors contain ankyrin repeats which are cleaved within a glycine rich region to 
produce the active subunits. Therefore it is thought that p105 and p100 display an 
inherent IκB activity of their own (Hayden and Ghosh, 2004). Interestingly, the study of 
lymphotoxin β (LTβ) mediated p100 processing has suggested that p100 is an inhibitor 
of p65 as well as p52. Cell lines deficient in the p100 protein displayed retarded p65 
activity in response to LTβ, but not TNF-α, suggesting a stimulus-specific role for this 
protein in regulating NF-κB activity (Basak et al., 2007).  
 
Other IκB proteins, including BCL-3, are different from those previously discussed as 
they are constitutively nuclear, not degraded following signalling and appear to 
facilitate transcriptional activation.  As previously mentioned, BCL-3 binding to either 
of the repressive subunits, p50 or p52 can facilitate DNA binding through complex 
formation (Perkins, 2007). 
 
1.2.1.3 IKK complex 
The activation of NF-κB signalling can be modulated by a diverse range of stimuli; 
however two of the three major pathways associated with these processes converge on 
the IKK complex. The IKK complex is a 700-900 kDa structure comprising IKKα, 
IKKβ and IKKγ (Figure 1.4), the latter of which is often referred to as the NF-κB 
essential modulator (NEMO). The IKK complex is responsible for the phosphorylation 
of IκB proteins, which in turn targets them for degradation and allows translocation of 
the active NF-κB dimer to the nucleus. The IKKα and IKKβ subunits display just over 
50 % sequence identity, both containing a N-terminal kinase domain, leucine zipper 
(LZ) and helix-loop-helix motifs (HLH) within their C-terminal regions. These proteins 
also share a key lysine 44 residue within the ATP-binding site of the kinase, which is 
essential for their activity. Mutational studies have revealed an essential role for the 
HLH and LZ domains within these IKK subunits in the phosphorylation of serine 
residues of target protein. Although IKKγ/NEMO lacks kinase activity, it has been 
shown to be essential for NF-κB transcriptional activation (Perkins, 2007). In fact 
knockout mouse models of individual IKK components (Table 1.1) have shown that 
both IKKβ and IKKγ/NEMO are essential for the protection against apoptosis and that 
IKKα is essential for skeletal and dermal development (Li et al., 1999b, Rudolph et al., 
2000, Tanaka et al., 1999a). 
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IKKα, IKKβ and IKKγ/NEMO remain the most well characterised members of the IKK 
complex, however other associated family members, including IKKε have been 
identified. During signalling, members of both the NF-κB and IκB superfamilies, as 
well as chaperone proteins, have been shown to associate with the IKK complex. 
Interestingly, IKKε has recently been shown to have oncogenic properties in breast 
cancer (Boehm et al., 2007), and the SUMOylation of this IKK protein is also essential 
for the activation of NF-κB following DNA damage by the topoisomerase II posion, 
etoposide (Renner et al., 2010). 
 
Importantly, the IKK complex has many known functions that are independent of its 
role in the activation of NF-κB (Chariot, 2009). Most recently it has been shown that the 
IKK complex is important in the induction of autophagy (Criollo et al., 2010). In 
particular, IKKβ can phosphorylate a number of other substrates, including the tumour 
suppressor, FOXO3a, which in this case results in a protection against apoptosis (Huang 
and Tindall, 2006). It can also activate 14-3-3β when the protein is complexed to 
tristetraprolin, resulting in the stabilization of cytokine, chemokine and growth factor 
mRNAs (Gringhuis et al., 2005), suggesting that like NF-κB, the IKK complex is an 
important mediator of inflammatory signalling. IKKβ has also been linked to the 
proliferative Mitogen-activated kinase pathway (MAPK) pathway since the p105 NF-
κB subunit is found complexed to the ERK kinase, TPL2, in some unstimulated cells. 
Hence, IKKβ-mediated proteolysis of the p105 subunit, can result in TPL2 release and 
Figure 1.4: Three core subunits of the IKK complex LZ: Leucine zipper. GRR: CC: 
Coiled-coil. ZF: Zinc finger. HLH: Helix-loop-helix. NBD: NEMO-binding domain. 
Adapted from: (Chen et al., 2004) 
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MAPK pathway activation (Waterfield et al., 2004). Tu et al., (2006) described that 
IKKα regulated oestrogen-induced cell-cycle progression by indirectly inducing the 
transcription factor, E2F1 in MCF7 cells (Tu et al., 2006). This IKK protein is thought 
to play a role in cell proliferation through the regulation cyclin D1 expression. IKKα 
regulates cyclin D1 expression in a number of ways, including, through the activation of 
the NF-κ p52 subunit (Rocha et al., 2003). 
 
It is often difficult to disentangle the NF-κB subunit specific effects and those which are 
NF-κB independent IKK effects due to the types of experiment performed. For example 
many mouse models are IKK knockouts or mutants, or cell culture experiments use the 
IκB super repressor. It is highly likely the tumour promoting effects (section 1.2.4.2) 
derive from a combination of both the NF-κB subunits and also independent IKK 
functions but this is an area which requires much further work. 
 
1.2.2 NF-κB activation pathways  
There are several distinct NF-κB activation pathway (Figure 1.5), often referred to as 
the canonical, non-canonical and atypical pathways (Perkins, 2007).   
 
1.2.2.1 Canonical pathway activation 
The canonical, or classical pathway of NF-κB activation is stimulated in response to 
inflammatory stimuli in the cellular environment, for example the pro-inflammatory 
cytokines TNF-α and interleukin-1 (IL-1), growth factors, such as epidermal growth 
factor (EGF) and transforming growth factor-α (TGF-α), engagement of the T-cell 
receptor (TCR) or exposure to bacterial products, such as lipopolysaccharides (LPS) 
(Hayden and Ghosh, 2004). This pathway, shown in Figure 1.5, is dependent on the 
IKK complex in particular IKKβ, which is responsible for the rapid phosphorylation of 
of IκBα at serine residues 32 and 36, which targets IκBα for ubiquitination and 
subsequent proteosomal degradation, which in turn results in the active NF-κB hetero-
dimer (commonly the p65:p50) dimer, in translocating to the nucleus. This in turn 
allows NF-κB to bind to specific consensus sequences in the promoter region of target 
genes, or κB elements, and regulate gene transcription. Subsequently, this rapid 
induction of the canonical pathway can be terminated by the NF-κB dependent 
endogenous inhibitors, for example A20, which serve to turn off this transient 
transcriptional activation (Hayden and Ghosh, 2004, Perkins, 2006). It should also be 
noted that other IκB proteins, including IκBβ and IκBε can also be phosphorylated in 
48 
 
response to canonical pathway stimuli, however the kinetics of this are much slower 
(Perkins, 2007). 
 
IKKβ and IKKγ/NEMO cooperate to mediate the classical NF-κB activation pathway, 
targeting IκBα in preference to the β protein and it has been reported that IKKγ/NEMO 
is key in the activation of the IKK complex since activation of the canonical pathway 
leads to complex, lysine 63-linked ubiquitination of signalling molecules, which 
ultimately results in the ubiquitination of IKKγ/NEMO, which is also lysine 63-linked 
(Perkins, 2006). This ubiquitination differs from lysine 48-linked ubiquitination, which 
mediates protein degradation, in that it is implicated in the signalling of proteins 
containing ubiquitin-binding domains (Burns and Martinon, 2004, Chen, 2005, 
Krappmann and Scheidereit, 2005). Kinases are then recruited to ubiquitinated 
IKKγ/NEMO and subsequently the IKK complex, such as TGFβ-actived kinase 1 
(TAK1), which has the ability to phosphorylate IKKβ at serine residues 177 and 181, 
resulting in the activation of this IKK component (Burns and Martinon, 2004, Chen, 
2005, Krappmann and Scheidereit, 2005, Perkins and Gilmore, 2006). 
 
The canonical pathway can also be activated by genotoxic stimuli, including IR and 
other DNA-damaging chemotherapeutic drugs, in a manner which is dependent on 
IKKγ/NEMO-IKKβ activation (Janssens and Tschopp, 2006). This is discussed in detail 
in section 1.4. Briefly, NEMO translocates to the nucleus and is SUMOylated and 
subsequently phosphorylated by the checkpoint kinase, ataxia telangiectasia mutated 
(ATM), known to signal and respond to double stranded DNA breaks (DSBs). The 
sumoylation of NEMO is then displaced by mono-ubiquitination, which results in the 
ATM:NEMO complex relocating back to the cytoplasm to activate IKKβ. Wu et 
al,.(2006) reported this link between ATM and NEMO in 2006, and also suggest that 
the process requires and IKK-associated protein called ELKS (a protein rich in 
glutamine (E), leucine (L) lysine, (K) and serine (S)) (Wu et al., 2006). ATM, along 
with other DNA repair proteins, poly(ADP)-ribose polymerase-1 (PARP-1) and the 
DNA-dependent protein kinase (DNA-PK) are also implicated in the regulation of NF-
κB in response to DNA damage and will be discussed further in sections 1.4 and 1.5. 
 
Most recently, hypoxia has been shown to activate NF-κB in an IKK-dependent manner 
through phosphorylation of the IKK complex by the upstream kinase TAK1 along with 
the calcium/calmodulin dependent kinase 2, the E2-ubiquitin ligase, Ubc13 and the E3 
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ligase XIAP (Culver et al., 2010, Melvin et al., 2011). Furthermore, NF-κB subunits 
have also demonstrated the ability to both bind and activate the hypoxia inducible factor 
1α (HIF-1α) gene (Rius et al., 2008, van Uden et al., 2008) 
 
1.2.2.2 Non-canonical pathway activation 
A second pathway for NF-κB activation is the non-canonical pathway (Figure 1.5), and 
whereas IKKβ is the predominant activator of NF-κB nuclear translocation in the 
canonical pathway (Bonizzi and Karin, 2004, Pasparakis et al., 2006), it is IKKα that is 
mainly involved in this pathway (Perkins, 2003). In this instance, IKKα is activated by 
the NF-κB-inducing kinase (NIK) in response to stimulation of the lymphotoxin-β and 
CD40 receptors, the latent membrane protein-1 (LMP-1) of the Epstein Barr virus or the 
B-cell activating factor of the TNF family (BAFF). This results in the formation of p52 
from p100 after IKK-α mediated phosphorylation of Lysine 855 (within the p100 
protein) results in the recruitment of a ubiquitination complex and targeting of the 
protein for cleavage (Scheidereit, 2006).  This results in the frequent activation of  
RelB:p52 heterodimers which may result in the activation of a distinct subset of NF-κB-
dependent genes (Perkins, 2007).  
 
1.2.2.3 Atypical pathway activation 
A third mechanism for NF-κB activation (Figure 1.5) has been described in response to 
stimuli such as hydrogen-peroxide and nerve growth factor (NGF) and is called the 
atypical, or IKK-independent pathway (Perkins, 2007).  The outcome in this case is the 
phosphorylation of IκBα at tyrosine 42 which leads to free NF-κB by either degradation 
or dissociation of the IκB member (Perkins, 2006, Perkins and Gilmore, 2006). 
Expression of the HER2 oncogene, which is over-expressed in approximately 25% of 
all breast cancers, and also treatment with ultraviolet (UV) light can also activate NF-
κB in an IKK-independent manner by mediating the phosphorylation of IκBα in its C-
terminal PEST domain, by casein-kinase-II (CK2) (Perkins, 2006). 
 
 1.2.3 NF-κB activation stimuli and the transcriptional response 
The NF-κB pathway is activated by a diverse range of agents ranging from endogenous 
cytokines to DNA-damaging agents and pathogens. Activation of NF-κB signalling 
pathways, by the well characterised stimuli, such as TNF-α or LPS, are relatively 
universal and converge at the IKK complex. However, the upstream signalling cascades 
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Figure 1.5: NF-κB activation pathways The canonical pathway (left) is activated by various stimuli including TNF-α and IL-1. This results in the 
phosphorylation of IκB, targeting it for ubiquitination by the IKK complex, which frees the p65-p50 heterodimer, allowing it to translocates to the nucleus. 
This pathway is also activated in response to genotoxic stress via the SUMOylation of NEMO and the complexing of this IKK component to ATM. The 
atypical pathway (centre) can be activated in 2 ways – the first by ultraviolet light which results in IκB phosphorylation by casein kinase2 and the second by 
hypoxia resulting in phosphorylation by a tyrosine kinase. The non-canonical pathway (right) results in activation of IKKα by NIK followed by 
phosphorylation of the p100 subunit by IKKα. Consequently proteosome-dependent processing of p100 to p52 leads to activation of p52-RelB heterodimers.       
Adapted from: (Perkins, 2007) 
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tend to be stimulus specific, and the transcriptional output is also governed by the 
activation stimulus. 
 
The most well characterised stimulators of NF-κB activation are those associated with 
the immune and inflammatory responses. Inflammatory cytokines, such as IL-1β and 
TNF-α, bind to cell surface receptors inducing a downstream signalling cascade which 
leads to NF-κB activation. Following either of these stimuli, the NF-κB transcriptional 
response is most often associated with the up-regulation of key inflammatory mediators, 
including cytokines and chemokines, such as CXCL10 (Hein et al., 1997) and IL-8 
(Kunsch and Rosen, 1993). Interestingly, both TNF-α and IL-1β are NF-κB target genes 
themselves. TNF-α mediates the activation of NF-κB as well as that of the Activator 
Protein-1 (AP-1) transcription factor. To this end, the two transcription factors work in 
concert in promoting programmed cell death, and the balance of these factors is key in 
determining the apoptotic function of a cell (Dutta et al., 2006). For example, TNF-α-
mediated NF-κB activation is known to up-regulate the expression of the Fas receptor 
(Chan et al., 1999) and its ligand (Matsui et al., 1998), which induce apoptosis. 
 
Similarly, bacterial pathogens such as LPS, a component of the gram positive cell 
bacterial wall, are able to stimulate NF-κB transcriptional activity and mediate the 
production of  immune and inflammatory response genes via the Toll-like receptor 
signalling (Coll and O'Neill, 2010). Whilst TNF-α activates NF-κB in a canonical 
pathway/IKKβ-dependent manner, it has been shown that CD-40 and LTß bind to 
members of TNF receptor (TNFR) family and mediate the non-canonical NFKB2 
processing.  In fact TNFR family ligands stimulate both the classical and non-classical 
NF-κB activation pathways with additional domains contained within their receptors 
thought to mediate this dual activation (Hayden and Ghosh, 2004, Hayden et al., 2006). 
 
Induction of NF-κB by genotoxic stress and subsequent DNA damage recognition 
pathways is a well-documented phenomenon, and in recent years many studies have 
started to elucidate the mechanisms by which DNA-damage activates NF-κB. (This is 
discussed is more detail in sections 1.4 and 1.5). The cellular response to DNA damage 
is somewhat complex. Whereas low doses of TNF-α have been shown to activate NF-
κB in many cellular systems, the activation of NF-κB by DNA-damaging agents is 
appears to be much more cell type specific. For example, Brach et al., (1993) illustrated 
that doses of IR as low the clinically relevant dose of 2 Gy were sufficient to activate 
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NF-κB in the human myeloid cell line, KG-1 using electrophoretic mobility shift assays 
(EMSAs) (Brach et al., 1993), whereas the optimum dose for the U1-Mel melanoma 
cell line was found to be 3-4.5 Gy (Sahijdak et al., 1994), whilst Ashburner et al., 
(1999) found that doses as high as 20 Gy failed to activate NF-κB in other human 
tumour cell lines (Ashburner et al., 1999).   
 
More recently, hyper-lethal doses of IR have been used to activate NF-κB, and study the 
downstream signalling associated with this (Stilmann et al., 2009, Veuger et al., 2009). 
Both of these groups have investigated the role of PARP-1 in the activation of NF-κB 
following DNA-damage, and have found that PARP-1 activity, which is known to be 
induced following single stranded DNA breaks (SSBs), is vital for the activation of NF-
κB after high doses of IR. This discussed in detail in section 1.3.2.1 Furthermore, other 
DNA repair proteins, such as ATM and DNA-PK are also required for the activation of 
NF-κB following DNA damage (Basu et al., 1998, Hinz et al., 2010, Ju et al., 2010, Liu 
et al., 1998, Panta et al., 2004, Veuger and Durkacz, 2011, Wu et al., 2006), and the 
mechanisms associated with this are discussed in section 1.4. 
 
The activation of NF-κB by DNA damaging agents is reported to confer a cell survival 
advantage through the induction of anti-apoptotic genes, such as the inhibitor of 
apoptosis proteins (IAPs) (Stehlik et al., 1998, You et al., 1999). It is not only anti-
apoptotic genes which are regulated by NF-κB, but genes associated with cell 
proliferation, angiogenesis and metastasis are also under the control of NF-κB, and are 
widely reported to contributes to malignant progression through this gene expression. 
Activation of NF-κB by DNA damaging chemotherapeutic agents is therefore 
postulated to be one of the major mediators of both chemo- and radio-resistance 
(Biswas et al., 2001, Wu and Kral, 2005), and hence the inhibition of NF-κB is an 
attractive therapeutic strategy (section 1.2.5).  
 
However, it should be noted that a subset of NF-κB activating agents are able to 
mediate a pro-apoptotic function for this transcription factor. Exogenous agents such 
and UV-C and daunorubicin, a commonly used chemotherapy drug, activate NF-κB via 
both IKK-dependent and -independent mechanisms resulting in a repression of anti-
apoptotic genes. This repressive function is mediated by the p65 NF-κB subunit which 
associates with the histone deacetylase -1 (HDAC1) protein repressing transcription at 
target promoters in response to these stimuli (Campbell et al., 2004). 
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1.2.4 NF-κB and disease 
NF-κB has been associated with numerous pathologies including inflammatory diseases 
such as arthritis, immune responses, atherosclerosis and the progression of many 
metastatic cancers (Hayden and Ghosh, 2004). It is the regulation of gene expression by 
NF-κB, which mediates this link with human disease, and therefore understanding the 
molecular events which result in the de-regulation of NF-κB activation, and its 
subsequent gene regulation, is key in the development of therapeutic targets for the 
treatment of these numerous disease states.  Much of the research surrounding NF-κB 
has been directed towards inflammatory diseases and malignancies, however, alterations 
in NF-κB activation has also been reported in asthma, HIV and AIDS, and liver disease, 
to name but a few (DeLuca et al., 1999, Kumar et al., 2004). The function of NF-κB in a 
selection of key diseases is discussed briefly below.  
 
1.2.4.1 NF-κB in inflammatory disease 
The role of NF-κB activation in inflammation (Tak and Firestein, 2001) is well 
documented and it is the kinase, IKKβ which has been reported as the primary 
participant in the production of proinflammatory stimuli associated with NF-κB 
activation (Aupperle et al., 1999). Aupperle et al., (1999) showed that IKKβ is 
expressed in fibroblast-like synoviocytes and has a crucial role in NF-κB activation 
following either TNF-α or IL-1 stimulation. This study used synoviocytes isolated from 
the synovium of patients with rheumatoid arthritis (RA) and osteoarthritis, and 
illustrates that, in both groups, immunoreactive forms of IKKα and IKKβ were 
constitutively expressed at the mRNA level. This would suggest that NF-κB is also 
constitutively active in these cell types, something which is supported by the induction 
of cytokines found here which are known to be regulated be NF-κB. These include IL-6, 
IL-8 and ICAM-1 (Aupperle et al., 1999). 
 
Other proinflammatory cytokines induced by NF-κB in concert with another 
transcription factor, AP-1, have also been implicated in the pathology of RA after NF-
κB over-expression was noted in the synovium of such patients. This study showed that 
when NF-κB and AP-1 are simultaneously activated by either IL-1 or TNF-α in 
synoviocytes, the expression of matrix metalloproteinases (MMPs) is increased. MMPs 
are known to contribute to the destruction of bone and cartilage in an RA joint (Han et 
al., 1998). The authors also found that NF-κB induced transcription of other known 
inflammatory response molecules including cyclooxygenase-2 (COX-2) and inducible 
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nitric oxide (iNOS) in these cell types (Han et al., 1998). Therapies targeted at NF-κB 
blockade are now being developed for use in RA patients and these include NF-κB 
decoy oligonucleotides which are administered either by injection or viral gene transfer. 
Results have shown that these can inhibit streptococcal cell wall-induced arthritis in 
rats, in part by decreasing the production of cytokines, and mediating the induction of 
apoptosis (Miagkov et al., 1998). 
 
Increased NF-κB nuclear activity in airway epithelial cells of asthmatic patients was 
found to be common, along with the high expression levels of the proinflammatory 
cytokines, chemokines, Cox-2 and iNOS (Hart et al., 1998). Another condition, 
Helicobacter pylori-associated gastritis is also marked by increased NF-κB, and in this 
case disease severity correlates with the number of NF-κB positive cells (van Den Brink 
et al., 2000). NF-κB has been implicated in the prolonged inflammation and resultant 
lack of bowel function in Chrohn’s disease and ulcerative colitis. Moreover, 
corticosteroids, which are known to inhibit NF-κB transcriptional activitation, have long 
been used to treat inflammatory bowel disease (IBD) (Kumar et al., 2004). Notably, 
patients that suffer from IBD have been shown to have an increased risk of developing 
bowel cancer, and it has been postulated that the NF-κB transcriptional axis is involved 
in this disease progression (Greten et al., 2004). 
 
The gene encoding the NEMO subunit of the IKK complex is located on the long arm 
of the X chromosome and its mutation is causative of a number of genetic pathologies, 
including Incontinentia pigmenti. This results in severe skin inflammation and 
cutaneous skin lesions (Berlin et al., 2002) as the associated truncated form of NEMO is 
able to interact with the α and β-subunits of the IKK complex, but it displays a defect in 
subsequent NF-κB activation. Similarly, rare inherited mutations in the IKBA gene 
result in severe immunodeficiency associated with a lack of immune memory. Critically 
these patients display a point mutation at Ser-32 within the IκB-α protein resulting in a 
deficit in the classical activation pathway of NF-κB (Courtois et al., 2003). 
 
1.2.4.2 NF-κB and Cancer 
NF-κB is known to regulate genes involved with apoptosis, cell proliferation and 
differentiation (Hayden and Ghosh, 2004); therefore it is unsurprising that this 
transcription factor is implicated in many cancers. Aberrant NF-κB activity has been 
documented in numerous tumour types including pancreatic, lung, breast and prostate, 
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as well as some haematological malignancies (Basseres and Baldwin, 2006). NF-κB has 
been shown to contribute to key events within tumour progression including metastasis, 
angiogenesis and the avoidance of apoptosis (Figure 1.6). The role of NF-κB in 
malignant progression is a topic of continuing research for a number of groups around 
the world, as is the development of compounds which inhibit NF-κB function. 
Currently, the mounting body of data suggests that NF-κB plays an important role in the 
progression of many cancers but it is important to mindful that most of these studies 
have been undertaken in cancer cell line models, and may not reflect the in vivo 
situation. Moreover, some studies are vague and do not elucidate the precise 
mechanisms by which NF-κB is associated with the progression of cancer. A brief 
discussion of the literature relevant to this study is undertaken here. 
 
There have been a number of links between chronic inflammation and the development 
of cancer. NF-κB was implicated in the production of growth factors crucial for the 
growth of neoplastic cell and cancer progression, when it was observed that loss of 
IKKβ, the primary participant in the production of pro-inflammatory stimuli associated 
with NF-κB activation (Aupperle et al., 1999), in myeloid cells led to a decrease in 
tumour size accompanied by reduced levels of tumour derived inflammatory cytokines 
(Kim et al., 2006). Another study observed a reduction in tumour number but not size, 
alongside reduced expression of NF-κB- dependent anti-apoptotic gene expression, in 
an IKKβ defective model of colitis associated bowel cancer (Karin, 2006). These data 
indicate a cell-type specific role for NF-κB in tumour progression. 
 
The majority of studies to date have concentrated on the role of p65 transcriptional 
activation in cancer, and there is a wide body of literature which documents the de-
regulation, and most commonly, the aberrant activation of this subunit in many forms of 
cancer and leukaemia where is correlates with poor prognosis and an increased 
metastatic potential (Prasad et al., 2010). It remains to be seen whether constitutive 
activation of p65 is more common than that of other subunits in cancer, or whether this 
is simply due to more research being undertaken. For example, traditional methods of 
assessing NF-κB DNA binding such as EMSAs, lent themselves to the assessment of 
the p65 and p50 subunits rather than the others as antibodies against these particular 
subunits were readily available and easy to use, however more recently robust 
antibodies have been developed against the other subunits.  
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More recently however, it was found that the human REL gene, that encodes the c-Rel 
protein, is the only NF-κB transcription factor for which there is a retroviral counterpart, 
that is acutely oncogenic. Moreover, retroviral vectors for the overexpression of 
chicken, mouse or human c-Rel were also found to transform chicken lymphoid cell in 
vitro (Gilmore, 1999, Starczynowski et al., 2003). Amplification of chromosome 2p, on 
which the REL gene is located have been detected at significant frequencies in human 
B- and T-lymphoma, including Hodgkin’s lymphoma and diffuse large B-cell 
lymphoma (DLBCL), where it has been shown to correlate with poor prognosis (Davis 
et al., 2001, Fukuhara et al., 2006, Houldsworth et al., 2004, Rosenwald et al., 2002, 
Rosenwald et al., 2003). These data suggest that the increased copy number of REL, in 
turns leads to over-expression of the c-Rel protein, which can saturate the IκB proteins 
and lead to aberrant activation of c-Rel and up-regulation of its target genes, however 
many studies are purely correlative in this case and have not explored the functional 
aspects of REL overexpression. 
 
Other NF-κB family members and associated proteins and genes have been implicated 
in oncogenesis and tumour progression in lymphomas and other haematological 
malignancies. A transforming truncation of the p100 gene at 10q24 has been recognised 
in the t(14:19) translocation involving the BCL3 protein have been demonstrated in 
DLBCL and CLL (Neri et al., 1991). Recently, Compagno et al., (2009) reported that 
over 50 % of some subsets of DLBCL carried multiple mutations in negative (A20) and 
positive (CARD11, TRAF2, TRAF5, MAP3K7 (TAK1) and TNFRSF11A (RANK)) 
regulators of NF-κB. They also found that A20, which is a target for NF-κB-dependent 
gene expression and encodes a ubiquitin-modifying enzyme involved in termination of 
NF-κB activation, was most commonly affected, with approximately 30% of patients 
displaying biallelic inactivation resulting from mutations or deletions. Interestingly, this 
group went on to undertake some functional studies by re-introducing A20 into some 
DLBCL cell lines carrying biallelic inactivation of the gene, and showed that A20 
induced apoptosis and cell growth arrest,. These data suggest a putative tumour 
suppressor role for A20 (Compagno et al., 2009). 
 
It has been postulated that aberrant NF-κB activation in cancer is responsible for the up-
regulation of anti-apoptotic genes, meaning that the tumour cell can evade death. These 
genes include; those coding for the TNF-receptor associated factor-1 (TRAF-1) and 
TRAF-2 (Pahl, 1999), IEX-1L (Wu et al., 1998) and importantly two members of the 
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Bcl-2 family, BFl-1/A-1 and Bcl-xl (Lee et al., 1999a, Zong et al., 1999).  Some groups 
have also reported that NF-κB activity enhances that of Bcl-2 in primary hippocampal 
neurons (Tamatani et al., 1999) and Epstein-Barr virus transformed lymphocytes 
(Feuillard et al., 2000). However, others have illustrated that it is Bcl-2 over-expression 
which enhances the activity of NF-κB (Ricca et al., 2000), nevertheless, both 
demonstrated that NF-κB activity induces anti-apoptotic genes. Using the breast cancer 
cell line, MCF-7 and the colon cancer cell line, HCT116, Bours et al., (2000) showed 
that NF-κB inhibition results in decreased Bcl-2 expression, and increased expression of 
Bax, a pro-apoptotic gene (Bours et al., 2000). 
 
 
 
 
 
 
 
NF-κB activation is known to induce genes associated with proliferation, such as cyclin 
D1 after the IκBα phosphorylation by IKKα. Cyclin D1 is known to aid in cell cycle 
control via CDK4 and CDK6 (Rocha et al., 2003). Guttridge et al., (1999) noted that, in 
mammary epithelium, a member of the TNF-family, RANK (receptor-activator of NF-
κB) induced the activation of NF-κB via IKKα, therefore inducing high levels of 
proliferation in these cells (Guttridge et al., 1999). It is noteworthy that there is a 
positive correlation between the over-expression of cyclins D and E and the 
Figure 1.6: NF-κB and the development of cancer NF-κB is involved in the initiation, 
development and spread of various cancers, including breast cancer in which the 
transcription factor is constitutively active. NF-κB is known to activate genes involved 
with cell proliferation, and the inhibition of apoptosis and angiogenesis, which are known 
to contribute to the development of cancer.  
Adapted from: (Wu and Kral, 2005) 
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pathogenesis of breast cancer (Wu and Kral, 2005). The cyclin D1 gene is up regulated 
in 20% of early stage human breast cancers, whilst the cyclin D protein is over-
expressed in over 50% (Dickson et al., 1995). It has been suggested that cyclin E is 
oncogenic as breast cancer develops in approximately 10% of transgenic mice 
expressing this cell cycle protein (Bortner and Rosenberg, 1997). Poor prognosis of the 
disease was associated with high levels of both cyclin E and cyclin D1 (Berglund and 
Landberg, 2006). Unlike cyclin D, it not known if cyclin E is an NF-κB target gene, 
however one group has reported an association between the two at G1-S phase (Chen 
and Li, 1998), indicating a further role for NF-κB in cell cycle progression.  
 
NF-κB is also implicated in the regulation of some known tumour suppressor proteins, 
including p53, BRCA1 and BRCA2, all of which are involved in the cellular response 
to DNA damage (see section 1.3.2.1). Negative regulation of p53 by NF-κB is thought 
to contribute to tumourgenesis, through a number of mechanisms (Perkins, 2007). 
Tergaonkar et al., (2002) detailed how levels of the E3 ubiquitin ligase, MDM2 are 
controlled by NF-κB, hence negatively regulating the stability of p53 (Tergaonkar et al., 
2002). The up-regulation of anti-apoptotic genes by NF-κB is also thought to antagonize 
the pro-apoptotic functions of the tumour suppressor. Ravi et al., (1998) provided 
evidence which documented how the p65 NF-κB subunit and p53 regulated each other’s 
activity by vying for finite pools of p300 and CBP (CREB binding protein), which are 
necessary for the transactivation of both factors (Ravi et al., 1998). The work of Huang, 
et al., (2007) furthered knowledge in this field by finding that CBP, although bound to 
p53 in unstimulated cells, becomes phosphorylated at serine residues 1382 and 1386, by 
IKKα, following TNF-α stimulation. This results in CBP becoming detached from p53, 
allowing it to bind to p65 and activate NF-κB (Huang et al., 2007). It has now been 
hypothesised that aberrant activation of NF-κB, leading to inhibition of p53 could 
contribute to tumourgenesis (Tergaonkar and Perkins, 2007), something which the work 
of Huang et al., (2007) indicted by finding that constitutive activation of IKKα and the 
subsequent phosphorylation of CBP were common in lung cancers (Huang et al., 2007). 
BCRA2 is a tumour suppressor gene associated with familial predisposition to breast 
and ovarian cancers (Wooster et al., 1995). It may also have a role in the regulation of 
cell growth and proliferation (Gretarsdottir et al., 1998). The over-expression of 
BRCA2 has been noted in many sporadic breast cancers, even though there are no 
known somatic mutations in the gene in these cases (Teng DH et al Nat Genet 1996). 
Wu et al., (2000) found that NF-κB binds to the BRCA2 promoter and induces 
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expression of the gene using MCF-7 cells. Cells transfected with p50 and p65 constructs 
had marked increases in the BRCA2 promoter and in BRCA2 mRNA (Wu et al., 2000). 
These findings illustrate that NF-κB regulates BRCA2 expression, and therefore that 
alterations in NF-κB expression could contribute to the findings that BRCA2 is also 
over-expressed in breast tumours (Bieche et al., 1999). BRCA1 is also associated with 
familial breast cancers, and this tumour suppressor is known to function as a co-
activator of NF-κB, increasing the activity of NF-κB target promoters (Benezra et al., 
2003). This may contribute to protection against apoptosis in BRCA1 mutated breast 
cancers. 
 
1.2.5 Development of NF-κB inhibitors 
NF-κB has been implicated in a number of pathologies, including inflammatory disease 
and cancer, therefore making the inhibition of this transcription factor an attractive 
target for therapy. To date there are over 750 known inhibitors of the NF-κB pathway, 
and these include both naturally-occurring and chemical compounds. These inhibitors 
can be divided into broad categories depending on where they act, such as at receptor or 
adaptor level, directly at the IKK complex or IκB phosphorylation, proteosomal 
degradation of IκB, nuclear translocation of NF-κB or at the NF-κB DNA binding level 
(Gilmore and Herscovitch, 2006). 
 
Inhibitors that act at the receptor level aim to block signal before it can activate the IKK 
complex, such as anti-TNF-α antibodies which have been shown to have the potential 
for the treatment of RA and inflammatory bowel disease (Filippova et al., 2002). The 
adaptor proteins, TRAFs are the next step in cytokine signalling for NF-κB activation 
via the canonical pathway (Bradley and Pober, 2001). TRAF-2 is recruited to TNF 
receptors and required for TNF-α mediated NF-κB activation, and a mutant TRAF2 
lacking its N-terminal RING finger domain has been found to inhibit this activation 
(Hsu et al., 1996). TRAF6, however, interacts with the IL-1 receptor and a dominant 
negative mutant of this protein inhibits NF-κB activation by IL-1 (Cao et al., 1996).  
 
There are a number of inhibitors that target the IKK complex. These include both 
natural and synthetic ATP analogues, including SC-839 which inhibits both IKKα and 
IKKβ, with a 100-fold preference for the latter (Gilmore and Herscovitch, 2006) and 
compounds such as BMS-345541 which has an allosteric effect on both kinases, again 
with greater affinity for IKKβ (Burke et al., 2003). Naturally-occurring compounds, 
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such as Parthenolide, derived from the Feverfew plant, have been shown to inhibit the 
IKK complex (Yip et al., 2004), and chemical inhibitors, including LC-1, have been 
developed as analogues of this. LC-1 has been widely studied, especially in the context 
of haematological malignancies. It has anti-tumour activity in acute myeloid leukaemia 
(Jenkins et al., 2008) and it also synergies with the nucleoside analogue, fludarabine, 
which is a standard treatment for CLL. To this end is it now in Phase I clinical trials in 
the UK for CLL (Hewamana et al., 2008a, Hewamana et al., 2008b, Hewamana et al., 
2009). Other IKK inhibitors also use IKKγ/NEMO as a target, for example May et al., 
(2000) described how the introduction of a cell permeable peptide of 10 amino acids 
that corresponds to the NEMO binding domain of IKKβ could block both the binding of 
NEMO to the other IKK complex components and thus, the induction of NF-κB via the 
canonical pathway (May et al., 2000). Most recently, a NEMO binding peptide (NBP), 
has been shown to inhibit constitutive NF-κB activity and as a result, reduces tumour 
burden in a canine model of relapsed, refractory DLBCL (Gaurnier-Hausser et al., 
2011).  
 
However, there have been some concerns over the use of IKK inhibitors, mainly due to 
toxicity issues. It is well documented that NF-κB activation is vital for the cellular 
inflammatory and immune responses, and it has been postulated that long-term 
inhibition of the entire pathway could have some negative impact on the cell. The IKK 
complex has many known functions within the cell (Chariot, 2009), and therefore it is 
thought that inhibition may be cytotoxic. Long-term NF-κB inhibition may also increase 
the likelihood of immunodeficiency, since it plays a pivotal role in the innate and 
adaptive immune response, and can possibly delay bone marrow recovery as indicated 
by some reports of chemotherapeutic induced apoptosis of hematopoietic progenitors 
(Grossmann et al., 1999, Turco et al., 2004). It has therefore been postulated that 
specifically targeting DNA-damage-activated NF-κB may be a viable therapeutic 
strategy (Hunter et al., 2011, Veuger and Durkacz, 2011, Veuger et al., 2009), although 
this would require much further investigation, to ensure that the essential inflammatory 
response functions of NF-κB were unaffected. 
 
Other groups have suggested that targeting the ATM:NEMO interaction described by 
Wu et al., (2006), using an ATM kinase inhibitor, could also provide a viable 
therapeutic strategy for targeting DNA-damaging induced NF-κB activation (Wu et al., 
2006). To this end, the recent work of Veuger and Durkacz (2011), used the known 
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ATM inhibitor, KU55933 (Hickson et al., 2004), to show that the radio-sensitisation of 
a panel of breast cancer cell lines by the inhibitor was mediated through the effects on 
NF-κB activation, not through the inhibition of DSB repair, challenging the traditional 
dogma surrounding these small molecule inhibitors of DNA repair enzymes (section 
1.4) (Veuger and Durkacz, 2011). 
 
The stabilisation of the IκB proteins or prevention of their degradation are other points 
in the NF-κB cascade that are targeted in order to inhibit NF-κB. The β-amyloid peptide 
which is deposited in the amyloid plaques which are characteristic of Alzheimer’s 
Disease, is known to upregulate IκB expression, thus lowering NF-κB activity (Bales et 
al., 1998). Zhou et al., (2005) reported that a protein from the bacterial pathogen, 
Yersinia called YopJ acts as a deubiquitinase for IκBα, thus stabilising it. YopJ also 
prevents the nuclear translocation of NF-κB, another point which is often targeted in the 
NF-κB activation pathway (Zhou et al., 2005). 
 
Bortezomib, a proteosome inhibitor has demonstrated considerable efficacy against 
multiple myeloma both in vitro and in vivo (Adams, 2004), along with some other 
tumours, as well as being an inhibitor of NF-κB of myeloma cells in vitro (Cusack et al., 
2000). Although proteosome inhibitors are targeted in the suppression of NF-κB, it is 
not clear whether it is the anti-tumour effects exhibited by bortezomib are mediated by 
inhibition of the transcription factor (Gilmore and Herscovitch, 2006). For example, 
there have been reports recently which have suggested that bortezomib can act 
synergistically with other NF-κB pathway inhibitors, such as the IKK inhibitor, LC-1 
(Hideshima et al., 2009, Walsby et al., 2010). Many other proteins are targeted for 
proteosomal degradation, including the tumour suppressor p53 (Asher and Shaul, 2005), 
so it is possible that the efficacy of bortezomib and other proteasome inhibitors is due to 
the stabilisation of other key proteins with known roles in cancer, other than NF-κB. 
 
It has been postulated that targeting the NF-κB transcriptional axis at the DNA binding 
and transcriptional level using a PARP-1 inhibitor, could overcome some of the toxicity 
problems associated with global NF-κB inhibition by IKK inhibitors, for example, as 
described above. There is increasing evidence that PARP-1 is required as a nuclear co-
activator of NF-κB-dependent transcriptional activation (Chang and Alvarez-Gonzalez, 
2001, Hassa et al., 2003, Hassa et al., 2001, Hassa et al., 2005, Hassa and Hottiger, 
1999, Hunter et al., 2011, Stilmann et al., 2009, Veuger et al., 2009), and this is 
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discussed in more detail in section 1.5. The work of Veuger et al., (2009) showed that 
inhibition of PARP-1, using the small molecule inhibitor, AG-14361, considerably 
reduces NF-κB activation in response to IR, thus suggesting that the potentiation of IR-
induced cytotoxicity by AG14361 is mediated by the inhibition of NF-κB activation 
(Veuger et al., 2009). However, although these data are very encouraging and suggest a 
novel therapeutic angle for the use on these compounds, the mechanism of action 
remains unclear. Moreover, studies thus far have used experimental PARP inhibitors, 
which may have off-target effects, hence an investigation using a potent and specific 
PARP inhibitor, used in clinical trials should be undertaken in order to elucidate the 
mechanism. 
 
Another mechanism of targeting NF-κB at the DNA binding and transcriptional level is 
to specifically inhibit the Rel domain of the subunits, meaning that these compounds 
inhibit subunit DNA binding, which results in the inhibition of NF-κB. In this class of 
inhibitors, PBS-1086 has been reported as a Rel inhibitor, which it is more potent at 
inhibiting the DNA binding of both RelA and RelB when compared with IKK inhibitors 
such as, parthenolide (Oh et al., 2011).  Oh et al., (2010), reported that PBS-1086 
suppressed spontaneous lympho-proliferation and inhibited the production of pro-
inflammatory cytokines in PBMCs from HTLV-I–associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) patients via the inhibition of NF-κB DNA binding. To 
this end, PBS-1086 was shown to be a Rel inhibitor and therefore inhibit the DNA 
binding of p65, p50 and RelB as well as luciferase expression in a 293/NF-κB-
luciferase reporter cell line (Oh et al., 2011). 
 
1.3 Poly(ADP-ribose) polymerase-1 (PARP-1) 
The report by Roitt (1956) was the first to suggest that there was a an enzyme capable 
of comsuming nicotinamide adenine dinucleotide (NAD+), by showing that intracellular 
NAD+ occurred in tumours that had been treated with alkylating agents (Roitt, 1956). 
This then led to the discovery of the enzyme responsible for this depletion of NAD+ by 
Chambon et al., (1963). This group found that the incorporation of radio-activity from 
[14C]-ATP into an acid insoluble material in a preparation from the nucleus of hen livers 
was decreased over 1000-fold in the absence of nicotinamide mononucleotide (NMN) 
(Chambon et al., 1963). They demonstrated that a polymer of ADP-ribose was 
generated from ATP and NMN, with NAD+ as an intermediate precursor (Chambon et 
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al., 1963). Another group then showed that NAD+ contained an ADP-ribose moiety 
which was incorporated into the ADP-ribose polymer, by a nuclear enzyme, and that 
this simultaneously resulted in the release of nicotinamide (Nishizuka et al., 1967, 
Reeder et al., 1967). The enzyme was initially called ADP-ribose synthetase (ADPRS) 
or ADP-ribose transferase (ADPRT) but was later renamed poly(ADP-ribose) 
polymerase-1 (PARP-1), which is the currently-used name. 
 
PARP-1 is an abundant 113kDa nuclear protein found in eukaryotes (Jagtap and Szabo, 
2005). It is ubiquitously expressed in all mammalian, and many eukaryotic cells, and it 
has been estimated that there are approximately 1 x 106 molecules per cell (Chatterjee 
and Berger, 2000). PARP-1 is considered to have a role in many cellular processes 
including DNA repair, gene expression and transcriptional regulation, chromatin 
structure formation, cell differentiation and transformation, and also cell dysfunction 
and necrosis due to its ability to deplete cellular energy pools (Zingarelli et al., 1998). 
 
PARP-1 is known to act a sensor and signalling molecule for both SSBs and DSBs 
(Veuger et al., 2004), and there have a been a number of reports which have shown that 
the catalytic activity of PARP-1 is dependent on its activation by DNA strand breaks 
(Benjamin and Gill, 1980). The transcription of the PARP-1 enzyme is unchanged in 
response to DNA damage (Bhatia et al., 1990), and remains at a constant high level. 
However, it is widely accepted that in the presence of DNA strand breaks, often by 
virtue of DNA damage, PARP-1 enzymatic activity is greatly increased (de Murcia et 
al., 1997). PARP-1 is responsible for catalysing the formation of ADP-ribose polymers 
from NAD+, by cleaving NAD+ at the N-glycosidic bond between the nicotinamide and 
ribose rings thus releasing nicotinamide as a by-product (Ueda and Hayaishi, 1985).  
This is shown in Figure 1.7. 
 
Alvarez-Gonzalez and Mendosa-Alvarez (1995) described the synthesis of poly(ADP-
ribose) (PAR) polymers as a 3-step process; initiation, elongation (which is the addition 
of successive ADP-ribose residues by ribose-ribose O-glycosidic linkages) and 
branching (which is the formation of ribose-ribose bonds between ADP-ribose 
moieties). It should be noted that PAR can be up to 200 residues long, and at this point 
they can form complex structures which can resemble nucleic acids (Alvarez-Gonzalez 
and Mendoza-Alvarez, 1995). PAR also have very short half-lives, as they are rapidly 
degraded by the poly(ADP-ribose) glycohydrolase (PARG) enzyme . PARG is 
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responsible for the rapid catabolism of PAR (shown in Figure 1.7). PARG is 
ubiquitously expressed at low levels in all cells and tissues (Bonicalzi et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Once PARP-1 is activated by DNA strand breaks and synthesises PAR, it then transfers 
the polymer to acceptor proteins by covalent modification of glycine residues (Figure 
1.7). PARP-1 itself is the main acceptor of the polymer chains in vivo, and this is often 
referred to as the automodication. PAR has a large overall negative charge, as do DNA 
binding regions of DNA, and therefore the automodification of PARP-1 results in the 
enzyme being dissociated from the DNA due to electrostatic repulsion (Ueda and 
Hayaishi, 1985). Other PAR acceptors include nuclear proteins such as histones, 
transcription factors, topoisomerases and DNA and RNA polymerases (D'Amours et al., 
1999). This is often referred to as automodification by PARP-1, or ADP-ribosylation, 
which can alter the function of proteins (Althaus and Richter, 1987). 
 
Figure 1.7: Metabolism of poly(ADP-ribose) during DNA damage and repair 
Following DNA-damage, PARP-1 and PARP-2 hydrolyse NAD+, releasing 
nicotinamide (Nam) and H+, and catalyse the successive transfer of the ADP-ribose 
moiety to nuclear protein acceptors. The reaction is initiated by the formation of an 
ester bond between the amino-acid acceptor (Glu, Asp or COOH-Lys) and the first 
ADP-ribose; polymer elongation involves the catalysis of a 2′–1′′ glycosidic bond; 
polymer branching occurs on average after 20 ADP-ribose units and branching points 
are located at regular distances (every 40–50 ADP-ribose units). The degradative 
nuclear enzyme PARG has endo- and exoglycolytic activities that cleave glycosidic 
bonds between ADP-ribose units. The concurrent actions of DNA-dependent PARPs, 
PARG and NAD+-recycling enzymes contribute to NAD+ consumption in heavily 
damaged cells. The stimuli that activate PARP-3–16 are not known. P, phosphate; Rib, 
ribose  
From: (Schreiber et al., 2006b) 
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It is important to note that although PARP-1 is the most well characterised component 
of the PARP family, at least 18 other family members have been documented. PARP 
orthologues are broadly characterised by the presence of the β-α-loop-β-α NAD+ fold. 
The specifics of the catalytic domain differ between family members, and result in a 
broad functionality of this protein group (Schreiber et al., 2006b). This includes PARP-
2, PARP-3, Tankyrase-1 and vault-PARP. Although this study is not necessarily 
concerned with the activities of the PARP superfamily proteins other than PARP-1, a 
very brief discussion of PARP-2, the most closely related family member is included 
here.  
 
The existence of residual DNA damage activated poly(ADP-ribosyl)ation in PARP-1-/- 
mouse embryonic fibroblasts (MEFs) allowed researchers to identify PARP-2, a 
structurally related protein with over 60 % homology (Ame et al., 2004). PARP-2 
protein is also activated by DNA strand breaks, and it has been reported that PARP-1 
and PARP-2 can heterodimerise to facilitate DNA repair. Despite a reduced ability of 
PARP-2, in comparison to PARP-1, to catalyse ADP-ribose polymerisation, a combined 
role for these proteins in genome maintenance is indicated by the fact that PARP-1 or 
PARP-2 knockout mice are viable, whereas double knock out animals are embryonic 
lethal (Schreiber et al., 2002, Schreiber et al., 2006b).  
 
 
1.3.1 Structure of PARP-1 
The PARP-1 gene is located on chromosome 1q41-42 (Cherney et al., 1987) and is 
known to encode a protein which contain 23 exons and 1014 amino acids, and has a 
molecular weight of 113 kDa (Kurosaki et al., 1987). PARP-1 consists of three 
functional domains, and its functionality in terms of DNA repair (section 1.3.2.1) can be 
related back to its structure (Figure 1.8). 
 
The N-terminal portion of the protein contains two zinc fingers, which are responsible 
for DNA-binding during complex formation (Mazen et al., 1989). It was not surprising 
that PARP-1 contained the metal ions since a variety of other DNA-dependent reactions 
require zinc. Mazen et al., (1989), found that PARP-1 binds DNA nicks in a zinc-
dependent manner (Mazen et al., 1989), and is has also been reported that the three zinc 
fingers (FI and FII) are differentially required for the recognition of strand breaks 
(Ikejima et al., 1990). The first zinc finger (FI), recognises both single and DSBs 
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(Gradwohl et al., 1990), whilst the second zinc finger (FII) detects predominantly SSBs, 
meaning that both fingers are required for activation by SSBs but only the first finger is 
required for activation by DSBs. Recently, a third zinc finger was identified, which was 
shown to co-ordinate DNA-dependent enzyme activation (Langelier et al., 2008). This 
DNA binding domain also contains a caspase cleavage site (Jagtap and Szabo, 2005), 
that is often cleaved in the early stages of apoptosis. Adjacent to the DNA binding 
domain, there is a nuclear localisation signal (NLS), which is vital for the transport of 
PARP-1 to the nucleus (Schreiber et al., 1992). 
 
  
 
 
 
 
 
 
ADP-ribosylation of PARP-1 occurs within the centrally located automodification 
domain of the protein, along with the heteromodification of histones H1 and H2B, and 
initiates chromatin- structure relaxation in order to allow DNA repair enzymes to access 
the break. This domain contains 15 highly conserved amino acid residues thought to be 
the major autoribosylation sites (Uchida et al., 1993). It also contains a BRCA-1 C-
terminal domain (BRCT) motif, which mediates interactions between several DNA 
repair and cell cycle checkpoint proteins and is found in a number of proteins involved 
in the response to DNA damage. In this case, it is important for interactions with 
XRCC1, histones, DNA polymerase-β and transcription factors (Bouchard et al., 2003).  
In addition, this domain is involved in PARP-1 dimerization and other protein-protein 
interactions (Burkle et al., 2002).  
 
Figure 1.8: Structure of human PARP-1 showing functional elements The three 
functional domains are visible in the modular organisation. The amino-terminal of PARP-
1 is responsible for DNA binding and damage sensing, via zinc fingers and the NLS 
(nuclear localisation sequence) portion. The automodification domain contains a breast 
cancer susceptibility protein with carboxy-terminus (BRCT) which is common in many 
DNA repair and cell-cycle proteins, and this portion aids in protein-protein interactions. 
The carboxy-terminus houses the catalytic centre of PARP-1 and it is this region which 
has the highest amount of homology with other PARP family members. 
Adapted from (Jagtap and Szabo, 2005) 
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The highly conserved catalytic domain is located at the C-terminal end of the enzyme 
(Kameshita et al., 1984, Lindahl et al., 1995), and is responsible for binding NAD+. This 
domain also contains what is often referred to as the ‘PARP signature’, which is a 
region of 50 amino acids that are 100 % conserved amongst invertebrates and 92 % 
across all species (de Murcia and Menissier de Murcia, 1994). 
 
1.3.2 The functions of PARP-1  
It is very important to note that the function of PARP-1 may be mediated by the 
synthesis of the PARs that confer a negative charge on modified proteins, although the 
precise physiological role of polymerisation in response to DNA damage is unclear, and 
is something which will be addressed as part of this thesis.   It has been postulated that 
the large overall negative charge caused by the attachment of the polymers results in 
electrostatic repulsion of PARP-1 from the negatively charged DNA (Ueda and 
Hayaishi, 1985). It is also fair to say that ADP-ribosylation of acceptor proteins, and 
those in close proximity, may alter their biochemical and physiological properties, 
altering their affinity for other cellular macromolecules or perhaps DNA.  
 
PARP-1 is known to act a sensor and signalling molecule for both SSBs and DSBs 
(Veuger et al., 2004). This enzyme not only has a role in DNA repair, but in cell 
dysfunction and necrosis due to its ability to deplete cellular energy pools (Zingarelli et 
al., 1998), and it has also been found to stimulate the transcription of pro-inflammatory 
genes (Jagtap and Szabo, 2005), a function that PARP-1 has in with NF-κB. 
Importantly, PARP-1 has also been implicated in the co-regulation of numerous 
transcription factors (Kraus, 2008, Kraus and Lis, 2003). These functions are described 
in more detail below. 
 
1.3.2.1 The role of PARP-1 in single strand break repair 
PARP-1 is a highly abundant enzyme (Chatterjee and Berger, 2000), which rapidly 
synthesises PAR in response to DNA damage (Ueda and Hayaishi, 1985). The rapid 
polymer synthesis consumes large amounts of cellular energy due to the depletion of 
NAD+ and ATP, and the fact that PARP-1 is highly conserved suggest that PARP-1 
plays a fundamental role in the early-DNA damage response network. The work of 
Durkacz et al., (1980) was the first to show that PARP-1 was required for cellular 
recovery from DNA damage. They reported that the classical PARP-1 inhibitor, 3-
aminobenzamide (3-AB) could potentiate the cytotoxicity of alkylating agents and 
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prevent DNA strand break re-joining (Durkacz et al., 1980). Moreover, intracellular 
levels of the PARP substrate, NAD+ have been shown to be acutely lowered by agents 
that generate DNA damage (Roitt, 1956). PARP-1-/- cell lines exhibit a similar 
phenotype to that of cells lacking in base excision repair (BER) proteins, and many 
studies using inhibitors of this ribsoylating enzyme have demonstrated its role in DNA 
repair (Dantzer et al., 1999). 
 
Studies using a variety of DNA damaging agents have pinpointed a role for PARP-1 in 
BER pathway. The most potent activators of PARP-1 include monofunctional alkylating 
agents, such as temozolomide, and IR, which induce legions repaired by the BER 
pathway. UV irradiation, which predominantly causes lesions that are repaired by 
nucleotide excision repair (NER), is not a potent PARP-1 activator (de Murcia and 
Menissier de Murcia, 1994) and furthermore, (Satoh et al., 1994) showed that any 
stimulation of PARP-1 activity by UV irradiation was due to the repair of minor 
pyridine hydrate lesions, known to be processed by BER. To this end, the repair of UV 
damage is not inhibited by PARP-1 inhibitors (Cleaver et al., 1983). Figure 1.9 
illustrates the differing types of DNA damage, and the different lesions which result 
from this damage along with the pathway used to repair the damaged DNA. 
 
 
 
 
Figure 1.9: DNA damage and repair mechanisms Common DNA damaging 
agents (top); examples of DNA lesions induced by these agents (middle); and most 
relevant DNA repair mechanism responsible for the removal of the lesions (bottom).  
From: (Hoeijmakers, 2001) 
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The BER pathway (Figure 1.10) has evolved to protect cells against mutations induced 
by oxidative, alkylating and other DNA-damaging agents (Hoeijmakers, 2001). BER is 
therefore one of the major pathways to repair base lesions and apyrimidinic/apurinic 
(AP) sites which cause, or are processed to produce, SSBs but do not result in a 
distortion of the DNA helix (Ataian and Krebs, 2006). DNA glycosylases, such as 
alkyl-adenine DNA glycosylase (AAG), initiate BER by recognising and removing 
modified or improper bases. These glycosylases cleave the N-glycosidic bond between 
the target base and the deoxyribose-phosphate backbone producing an AP site (Frosina 
et al., 1996). This site is then processed by either the short-patch or long-patch BER 
pathway (Figure 1.10). It must be noted that DNA glycosylases are essential in the 
initiation of both pathways, and their action is followed by a number of sequential steps 
(Prasad et al., 2001). The distinction between these two pathways may not be as clear 
cut as early reports suggested since they share some common factors (Le Page et al., 
1998). 
  
Lesions undergoing the short-patch mechanism (right hand side of Figure 1.10), which 
is dominant in mammalian cells, are processed by 5’-acting apurinic (AP) 
endonucleases, such as APE 1, which cleaves the adjacent phosphodiester bond leaving 
a 5’-terminal deoxyribose-phosphate (dRP) moiety and a 3’-hydroxyl group. DNA 
polymerase β (pol β) then fills the single nucleotide gap and removes the dRP group 
through lyase activity. The strand break is then sealed by a complex of DNA ligase III 
and XRCC1 (X-ray repair cross complementing 1), a scaffolding protein (Lindahl and 
Wood, 1999). 
 
Frosina et al., (1996) were the first to conclude that a second pathway for BER, which is 
proliferating cell nuclear antigen (PCNA)-dependent, is active in mammalian cells 
(Frosina et al., 1996). This was later termed the long-patch BER (left hand side of 
Figure 1.10), and is responsible for approximately 20 % of overall repair. This method 
involves the replacement of a short oligonucleotide sequence containing the AP 
(apurinic) site and approximately 6-13 nucleotides in the 3’ orientation from this site 
(Matsumoto et al., 1999). It has been found that PARP-1 is involved in triggering long-
patch BER, by recognising a single stalled nucleotide. PARP-1 has also been found to 
be cross-linked with BER intermediates (Lavrik et al., 2001). Once PARP-1 is bound 
and the PCNA is at the AP site, an AP endonuclease (Robson and Hickson, 1991) can 
generate a strand break with DNA pol δ/ε being recruited to extend the 3’-hydroxyl  
70 
 
 
 
 
 
 
 
 
 
Figure 1.10: The short-patch and long-patch BER pathways.  The DNA glycosylase, AAG 
removes damaged bases and the apurinic (AP) endonuclease produces an abasic site. BER can 
then proceed in 2 ways. The short-patch pathway uses DNA polβ and XRCC1, a scaffold 
protein to fill the gap and remove the baseless sugar. The nick is sealed by DNA ligase III. The 
long-patch pathway recruits PARP-1 and PCNA before polδ/ε can extend the 3’-hydroxyl 
group. The backbone is displaced and removed by FEN-1, which also works with DNA ligase 
1 to reseal the nick.  
Adapted from (Hoeijmakers, 2001) 
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group (by approximately 7 nucleotides) whilst also displacing the strand which contains 
the terminal deoxyribose phosphate (Klungland and Lindahl, 1997). Frosina et al. 
(1996) also suggested that the displaced strand is removed by formation of a DNA flap 
structure (a bifurcated structure, composed of double stranded DNA and the displaced 
strand). This was later called flap endonuclease 1 (FEN1), and it thought to work in 
conjunction with DNA ligase I, which reseals the nick (Klungland and Lindahl, 1997). 
 
PARP-1 is more widely associated with long-patch BER (Frosina et al., 1996) and 
evidence from Dantzer et al., (1999) support this with findings that PARP-1-deficient 
fibroblasts had significantly reduced (>50 %) long-patch repair activity, suggesting that 
the catalytic activity of this protein may augment this excision repair pathway without 
being essential (Dantzer et al., 1999). However, another publication from this group 
also suggests that PARP-1 is involved in the short-patch repair mechanism, to a certain 
degree, as the PARP-1-/- fibroblasts in their study exhibited some reduced activity in this 
branch of the BER pathway (Dantzer et al., 2000).   
 
It has also been suggested that PARP-1 may be a member of a multiprotein complex  
suggesting that PARP-1 may be involved in recruiting components of the BER complex 
to the damaged site. An association of PARP-1 with DNA pol β has been described by 
(Dantzer et al., 2000). XRCC1, a protein that acts as a molecular scaffold, interacts with 
all components of the complex individually.  Accordingly, an association of PARP-1 
with XRCC1, has been demonstrated (Caldecott et al., 1996, Masson et al., 1998). Most 
recently, a study used a laser to give cells a micro-site of DNA damage, similar to that 
from IR, at microscopic sites, and using fluorescence microscopy, they showed how 
XRCC1 was recruited to ADP-ribosylated PARP-1 (Okano et al., 2003, El-Khamisy et 
al., 2003). XRCC1 can be ADP-ribosylated in vitro, perhaps allowing XRCC1 to act in 
its role as a structural component of the BER complex (D'Amours et al., 1999). 
Alternatively, PARP-1 may itself undertake a structural role in order to stabilise the two 
broken ends thus enabling ligation to take place (Lindahl et al., 1995).  
 
Moreover, a role for PARP-1 in signalling direct SSBs in DNA, as a results of 
genotoxic agents such as IR and monofunctional alkylating agents, but not lesion 
modification associated BER has been postulated An emergence of evidence for 
additional functions for PARP-1 following double stranded DNA breaks indicates a 
promiscuous nature for this enzyme within the context of DNA repair.  
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1.3.2.2 The role of PARP in double strand break repair 
The majority of the literature focuses on the role of PARP-1 in the BER pathway, 
however the enzyme has been implicated in other DNA repair pathways (Figure 1.9). 
As discussed previously, PARP-1 is rapidly activated in response to DNA damage, and 
therefore has been deemed an essential modulator of genomic stability. Interestingly, 
disruption of the PARP1 gene results in gene amplification and sister chromatid 
exchange in response to DSBs, suggesting a defect in DSB repair. Similarly, the 
interaction of the Werner syndrome protein (WRN), a Rad51 associated helicase, and 
PARP-1, described by Susse et al., (2004) suggests a role for this enzyme in the error-
free Homolgous Recombination Repair (HRR) pathway (Susse et al., 2004). 
 
PARP-1 has been implicated in the repair of DSBs by a number of groups (Audebert et 
al., 2004, Loser et al., 2010, Mitchell et al., 2009, Veuger et al., 2004, Wang et al., 
2006). Veuger et al., (2004) showed that DSB repair was inhibited in cell lines deficient 
in DNA-PK when treating with PARP-1 inhibitors in response to IR, suggesting a role 
for PARP-1 enzyme in DSB repair (Veuger et al., 2004).  Following this, Wang et al., 
(2006) reported that PARP-1 was responsible for DSB repair via a slow operating Non-
Homologous End Joining (NHEJ) pathway (Wang et al., 2006). NHEJ is responsible for 
repair of the majority of DSBs mediated by DNA-PK, which is made up of the subunits, 
DNA-PKcs, Ku70, Ku80, and also XRCC4, DNA Ligase IV and Artemis (Khanna and 
Jackson, 2001, Sancar et al., 2004). However, Wang et al., (2006) showed that although 
NHEJ mutant cells exhibited an apparent inhibition of repair, there was some re-joining 
by an alternative NHEJ pathway. This report went on to show that PARP-1, in 
combination with DNA Ligase III, could repair DSBs in the absence of the Ku proteins 
(Wang et al., 2006), hence providing a back-up pathway for early DSBs encountered by 
the cell.  
 
Furthermore, Wang et al., (2006) demonstrated that PARP-1 could compete with the Ku 
proteins for DNA ends, but that PARP-1 has a much lower affinity for these, again 
supporting the theory that PARP-1 mediated DSB repair is an alternative to the classical 
NHEJ pathway. Mitchell et al., (2009) extended these existing data by investigating the 
activation of both PARP-1 and DNA-PK by differing DNA ends and their interaction in 
the response to IR. This group found that inactivation of both enzymes was not additive, 
suggesting that PARP-1 and DNA-PK cooperate within the same pathway to promote 
DSB repair. Moreover, they reported that the affinities of the two enzymes for 
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oligonucleotides with blunt, 3'-GGG or 5'-GGG overhanging termini were similar. 
However, DNA-PK was significantly more efficient when activated by a 5'-GGG 
overhang, whereas PARP-1 had a preference for blunt-ended DNA and required a 
separate factor for efficient stimulation by a 5'-GGG overhang (Mitchell et al., 2009). 
These data therefore suggested that both PARP-1 and DNA-PK were required for fast 
phase of resolution of IR-induced DSBs. 
 
1.3.2.3 PARP-1 as a regulator of chromatin structure 
Three early reports described how the formation of PAR at the sites of DNA damage 
could serve to temporarily extract histones from the DNA, hence loosening chromatin 
structure (Althaus et al., 1993, Althaus et al., 1994, Realini and Althaus, 1992). This 
phenomenon is often referred to as the histone shuttling model, and occurs due to the 
association between the positively charged histones and negatively charged PAR. The 
interaction between the two is either through attraction to automodified PARP-1 or by 
direct covalent modification of histone H1 by PARP-1. This results in electrostatic 
repulsion from the negatively charged DNA, and in turn the displacement of histones 
and the relaxation of chromatin structure. This effect is only transient and reassembly of 
the chromatin structure occurs following polymer degradation by PARG, which allows 
histones to re-associate with the DNA. 
 
It has been postulated that local disruption of chromatin structure may be critical for 
repair as this gives rise to a more open chromatin structure rendering the damaged site 
more accessible to repair enzymes. This is especially true in areas where chromatin is 
highly condensed, but also important as it can alter the steric hindrance imposed by the 
tightly wound chromatin structures. Many essential repair factors and enzymes are part 
of large complexes, DNA-PK for instance, and the function of such complexes may be 
impeded in the presence of chromatin. It is important to note that the shuttling of 
histones may not only be important in facilitating the DNA repair functions of PARP-1, 
but may also allow other proteins to access the DNA. This could include transcription 
factors, particularly since PARP-1 is known to function as a transcriptional co-regulator. 
To this end, Schreiber et al., (2006) demonstrated that PARP-mediated poly(ADP-
ribosyl)ation of histone proteins, in response to steroids that activate development of 
Drosophila melanogaster, facilitated their removal from the DNA strand, resulting in 
transcriptional activation (Schreiber et al., 2006a).  Importantly, a role for PARP-1 in 
the regulation of numerous transcription factors has emerged recently, and will be 
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discussed in more detail in section 1.3.2.4. A role for the catalytic activity of PARP-1 in 
the embryonic development of the model organism Drosophila melanogaster, had also 
been proposed (Tulin and Spradling, 2003, Tulin et al., 2002). The D.melanogaster 
genome contains a single PARP gene homologous to PARP-1. Mutation of this gene, 
alongside the use of inhibitors of the PARP enzyme, illustrated an essential role for this 
protein in the organisation of chromatin structure during the developmental process. 
These studies have not only demonstrated a role for PARP-1 enzymatic activity in non-
DNA repair processes, but also challenged the central dogma that PARP-1 is only 
activated in response to DNA strand breaks, an interesting theory that warrants further 
investigation.  
 
1.3.2.4 PARP-1 - a transcriptional co-regulator 
There is an increasing body of evidence suggesting that PARP-1 is a promoter-specific 
nuclear co-regulator (either a co-activator or co-repressor) of numerous transcription 
factors. This includes the sequence-specific DNA –binding transcriptional regulators, 
NF-κB, B-Myb, Oct-1, AP-1, Sp1, NFAT, Elk1, HIF-1α and HTLV-Tax-1 (Kraus, 
2008), however the role of PARP-1 in regulation of these factors can be diverse. PARP-
1 may act via through local modification of chromatin structure (Althaus et al., 1994) 
and/or modulation of transcription factor activity via direct binding to gene regulating 
sequences, or physical interactions with proteins including transcription factors (Kraus, 
2008, Kraus and Lis, 2003, Martin-Oliva et al., 2006). In some cases, the transcription 
factor is thought to recruit PARP-1 to the promoters of relevant targets but this is likely 
to dependent on both the cell type concerned and whether or not PARP-1 enzymatic 
activity is required for co-activation/-repression. A detailed review of the role of PARP-
1 in the activation of NF-κB is undertaken in section 1.5. 
 
1.3.2.4.1 Regulation of transcription factors by PARP-1 
One of the earliest reports regarding the role of PARP-1 as a transcriptional regulator 
was by (Nie et al., 1998). This group demonstrated that the transcription factor Oct-1 
could interact with the automodification domain of PARP-1 and that the interaction 
increased Oct-1 DNA binding to the octomer motif in the DRα promoter. Oct-1 is 
known to regulate genes involved in both cell cycle progression and differentiation 
(Pierani et al., 1990).  
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A report by Cervellera and Sala (2000) investigated the role of PARP-1 in the activator 
of the B-Myb transcription factor (Cervellera and Sala, 2000), which plays a role in the 
control of cell growth and differentiation (Nomura et al., 1988). Aberrant expression of 
B-Myb can contribute to tumourigenesis (Hibi et al., 1998, Raschella et al., 1999). 
Cervellera and Sala (2000) found that transient transfection of PARP-1 into the 
haematopoietic cell line, HL-60, increased B-Myb transactivation. Using two PARP-1 
catalytic mutants this group also demonstrated that PARP-1 enzymatic activity is not 
required for PARP-1-dependent co-activation of B-Myb (Cervellera and Sala, 2000). 
 
There have also been reports on the regulation of AP-1 by PARP-1 (Andreone et al., 
2003, Chiarugi, 2002). For example, the known inhibitors of PARP, 6(5H)-
phenanthridinone and benzamide have been shown to reduce both AP-1 and NF-κB 
DNA binding activity and hence inhibit the transcription of key target genes including 
TNF-α, IL-2 and IFNγ (Chiarugi, 2002). Furthermore, AP-1 DNA binding was 
completely abolished in PARP-1 deficient MEFs when compared with PARP-1 
proficient MEFs (Andreone et al., 2003). 
 
Martin-Oliva et al., (2006) used the PARP inhibitor 3,4-dihydro-5-[4-(1-
piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) to investigate the role of PARP-1 in 
the activation of the transcription factor, Hypoxia-Inducible Factor-1 (HIF-1α) (Martin-
Oliva et al., 2006). Hypoxia is a hallmark of cancer in solid tumours, and has been 
associated with poor response to chemotherapy and malignant progression. HIF-1α is 
the major regulator of tumour cell adaptation to hypoxic stress (Vaupel, 2004). Martin-
Oliva et al., used cDNA microarrays and found that key genes were differentially 
expressed in mice treated with the carcinogen 12-0-tetradecanoylphorbol-13-acetate 
(TPA) alone versus TPA in combination with DPQ. These included genes associated 
with inflammation and angiogenesis (Hif-1α, Nfkbiz and S1009a), and were all 
confirmed by real-time PCR. Further investigations using a luciferase reporter assay 
showed that HIF-1 activation was completely absent in PARP-1-deficient fibroblasts 
following treatment with the Iron chelator DFO (a known activator of HIF-1) and  this 
also was attenuated by DPQ in PARP-1 proficient MEFs. Furthermore, PARP inhibition 
resulted in a down-regulation of HIF-1α protein expression following treatment with 
DFO. Expression of HIF-1α target genes, Igfbp3, Bnip3 and Vegf-A was upregulated by 
DFO in PARP-1-proficient MEFs, however the effect was abbroagted by use of the 
PARP inhibitor, DPQ (Martin-Oliva et al., 2006). 
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A recent study also details the interplay between PARP-1 and the Extracellular signal-
related kinases (ERKs). ERKs are key components of the MAPK signalling pathways, 
thus regulating a myriad of cellular process including growth, proliferation and 
differentiation. After phosphorylation by the MAPK kinase, MEK1/2, ERK1 and ERK2 
can transolcate to the nucleus where they activate their substrates, including 
transcription factors, such as Elk1 (Lenormand et al., 1998). Cohen-Armon et al., 
(2007) showed that PARP-1 could be bound by activated ERK2, and that this binding 
stimulated PARP-1 enzymatic activity and resulted in increased automodification. 
PARP-1 that had been activated in this way was then shown to significantly increase 
ERK2 phosphorylation of its downstream effector, Elk1. This in turn resulted in an 
increase in histone acetylation and expression of target genes, including c-fos (Cohen-
Armon et al., 2007). 
 
It has been reported that some transcription factors can be poly ADP-ribosylated 
through an interaction with PARP-1 (Zaniolo et al., 2007). This includes, Sp1 a 
transcriptional activator from a zinc-finger family of transcription factors (comprising 
Sp1 to Sp9) (Lania et al., 1997). Zaniolo et al., reported that PARP-1-deficient cells 
expressed lower levels of Sp1 protein compared with PARP-1-proficient cells. They 
showed that PARP-1 and Sp1 physically interact using co-immunoprecipitation assays, 
and that this interaction allows Sp1 to be poly ADP-ribosylated, resulting in a reduction 
of Sp1 binding its DNA consensus sequence. To confirm these data, the group went on 
to use the PARP inhibitor, PJ-34 and showed that addition of this restored DNA binding 
of Sp1 (Zaniolo et al., 2007). 
 
PARP-1 has also been implicated in the regulation of the transcription factor, Nuclear 
factor of activated T-cells (NFAT), which is known to be the major regulator of IL-2 
(Jain et al., 1992). In 2008, Olabisi et al., showed that the C-terminal catalytic domain 
of PARP-1 binds to and poly ADP-ribosylates a Glutamate residue in the DNA binding 
domain of NFAT. They also demonstrated that ADP-ribsylation promoted NFAT DNA 
binding using the PARP inhibitor PJ-34, and that both PARP-1 and NFAT were 
recruited to the IL-2 trancription loci following T-cell activation (Olabisi et al., 2008). 
 
1.3.3 PARP-1 and disease 
As previously discussed, PARP-1 plays a key role in numerous DNA repair pathways, 
as well as cell death signalling and transcriptional regulation. De-regulation of PARP-1 
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has also been implicated in a range of human diseases, in particular malignant 
conditions, and intriguingly both elevated and decreased expression of the PARP1 gene 
has been demonstrated in human cancer cell lines (Masutani et al., 2005). Consistent 
with reports that PARP-1 is an essential mediator of genomic stability (PARP-1-
deficient cells have a much higher rate of sister chromatid exchange than PARP-1-
proficient cells (de Murcia et al., 1997), a reduction in PARP1 expression in breast, 
colon and leukaemic cell lines has been shown to correlate with heightened genomic 
instability and tumourigenesis (Masutani et al., 2005).  
 
Nosho et al., (2006) reported that elevated levels of the PARP-1 gene in the early stages 
of sporadic colorectal tumours were linked to elevated cyclin D1, β-catenin and c-myc 
expression, and correlated with increased tumour size and advanced histopathology 
(Nosho et al., 2006). Another group used the PARP inhibitor, PJ-34 in familial 
adenomatous polyposis (FAP), and reported a reduction in the incidence of tumours, 
suggesting that the use of PARP inhibitor in FAP represented a novel target for the 
prevention of this disease (Mabley et al., 2004). 
 
Polymorphisms in the PARP1 gene have been identified and one in particular, the 
V726A is associated with an increased risk of some types of cancer, including prostate 
and lung (Lockett et al., 2004, Zhang et al., 2005a). However, other studies into this 
polymorphism have shown that it is associated with a decreased risk of non-Hodgkins’ 
lymphoma (Jin et al., 2010).  Single nucleotide polymorphisms (SNPs) in both the 
APE1 and XRCC1 genes have been associated with poor prognosis and survival in 
colorectal and bladder cancers (Moreno et al., 2006, Sak et al., 2005). It should be noted 
that another study has shown that PARP-1 activity and expression were not dependent 
on SNPs (Zaremba et al., 2011). 
 
De-regulated PARP-1 activity has been shown to contribute to autoimmune diseases, 
something it shares with the transcription factor NF-κB. For example, Systemic lupus 
erythematosus (SLE) is a chronic autoimmune disease which affects multiple body 
tissues including the heart, lung and kidneys, and antibodies directed against the PARP-
1 protein have been detected in the serum of SLE patients. Polymorphisms in the 
PARP1 gene have also been associated with two common autoimmune conditions, 
rheumatoid arthritis and type 1 diabetes (Criswell et al., 2000, Tsao et al., 1999). 
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1.3.4 PARP inhibition 
The concept of DNA repair inhibition represents a valid clinical target for the treatment 
of cancer, along with many other diseases. For example, targeting the kinase activity of 
ATM, DNA-PK and the cell cycle checkpoint proteins CHK1 and 2 using small 
molecules has been widely studied for the treatment of malignant disease, and found to 
induce cell death in tumour cells (Lord et al., 2006). There is a huge amount of literature 
regarding the inhibition of DNA repair proteins and enzymes, and for this reason a brief 
discussion focussed on the most important aspects of PARP-1 inhibition and the clinical 
relevance will be undertaken here.  
 
As previously discussed, the ability of PARP-1-/- cell lines to repair genetic lesions 
induced by alkylating agents via the BER pathway is severely reduced (Dantzer et al., 
1999). However, whilst deficient cell lines represent a useful tool for the examination of 
protein functions, small molecule inhibitors have proven critical for the translational 
aspect of research surrounding PARP-1 function (reviewed in sections 1.3.2). PARP 
inhibitors are almost always competitive inhibitors of NAD+ (Bryant and Helleday, 
2004), and the design of early inhibitors, including the nicotinamides (Fujimura et al., 
1967) and the benzamides (BZ) (Purnell and Whish, 1980, Shall, 1975), designed in 
order to compete with NAD+ for the nicotinamide binding domain of PARP-1. There 
were a number of caveats associated with these rudimentary inhibitors, not least the lack 
of specificity. For example, the BZ derivative, 3-aminobenzamide (3-AB), which is still 
used in contemporary studies to assess PARP-1 function, has been shown to affect de 
novo purine synthesis at the concentrations required to inhibit PARP (Moses et al., 
1990). Further problems with these classical PARP inhibitors also include low potency 
and poor aqueous solubility (Griffin et al., 1995). 
 
Influential research undertaken over 30 years ago first demonstrated a defect in the BER 
pathway in the presence of the PARP inhibitor 3-AB (Durkacz et al., 1980), and this 
group were the first to suggest that this could be a viable therapeutic strategy for the 
treatment of leukaemia and cancers. Following this, a whole host of small molecule 
inhibitors of PARP function have been developed by a number of pharmaceutical 
companies (Drew and Plummer, 2009) and have been widely used in a range of studies, 
and have now entered early phase clinical trials. A brief history of PARP inhibitor 
development is given below.  
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A series of dihydroquinolinones were reported by Suto et al., (1991) as showing a 50-
fold improved potency over the previous bench-mark compound, 3-AB (Suto et al., 
1991). Following this, the Drug Development group at Newcastle University developed 
a series of novel inhibitors for the use as both chemo- and radio-sensitisers, which 
included the quinazolinone, 8-hydroxy-2-methyl-quinazolin-4-[3H]one (NU1025) 
(White et al., 2000) and the benzamidazoles, 2-(4-hydroxyphenyl)benzamidazole-4-
carboxamide (NU1085) and 2-methylbenzamidazole-4-carboxamide (NU1064) (White 
et al., 2000) (Figure 1.11). These compounds were rigourously tested in a range of cell 
culture systems, including human tumour cells, to exploit the potentiation of a range of 
anticancer agents (Curtin et al., 2004, Smith et al., 2005) however, like earlier inhibitors 
of PARP-1, these compounds were found to exhibit poor aqueous solubility. More 
recently, the tricyclic indoles which have enhanced solubility and potency have been 
developed through a collaboration with Agouron Pharmaceuticals. These include 
AG14361 (1-(4-dimethylaminoethylphenyl)-8,9-dihydr-7H-2,7,9a-benzo[cd]azulen-6-
one) (Calabrese et al., 2004), and the inhibitor used in the studies reported here, AG-
014699 (8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-azepino[5,4,3-
cd]indol-6(3H)-one), which is currently in Phase II clinical trials (Thomas et al., 2007). 
Small molecule inhibitors of PARP-1 are shown in Figure 1.11. 
 
 
 
 
Figure 1.11: Structural basis of PARP-1 inhibitiors 
Inhibitors of the PARP-1 enzyme were based upon the structure of the nicotinamide 
moiety (A). The structure of benzamide based inhibitors, such as 3-AB (B) was optimised 
to produce cyclic benzamidazoles such as NU1025 (C) and then AG14361 (D) and AG-
014699 (E) with improved potency and pharmacokinetics.  
Taken from (Calabrese et al., 2004, Thomas et al., 2007, White et al., 2000) 
 
80 
 
1.3.4.1 Therapeutic potential of PARP inhibitors 
There have numerous studies into the clinical uses of PARP inhibitors, both in 
combination with conventional chemotherapeutic agents, and as stand-alone agents 
(Drew and Plummer, 2009). These reports have shown many promising and exciting 
results, and a brief discussion will be undertaken here. The rationale for using PARP 
inhibitors in combination with radio- or chemo-therapeutic agents, is centred around the 
hypothesis that inhibition of DNA repair proteins, such as PARP-1, would prevent the 
repair of the genotoxic lesions caused by these DNA damaging chemotherapies or IR. 
Therefore, it is possible that the use of DNA repair inhibitors in combination with 
existing agents may improve the therapeutic index of the chemo-therapeutic agent. 
Importantly, tumour cells are more likely to undergo apoptosis in response to lower 
doses of cytotoxic agents, therefore potentially limiting the toxicities associated with 
many cancer treatments. 
 
A large body of literature has proved that PARP inhibition is efficacious in combination 
with radiotherapy and chemo-therapeutic agents, including the topoisomerase I poisons 
and the alkylating agent, temozolomide, all of which are known to induce SSBs, in 
tumour cell lines and xenograft models (Calabrese et al., 2004, Curtin et al., 2004, 
Delaney et al., 2000). Topoisomerase I poisons, including camptothecin, prevent the 
activity of this enzyme which is essential for DNA remodelling by stabilising the 
enzyme-DNA complex. This then results in the formation of SSBs, however many 
cancers and leukaemias acquire resistance to these widely used agents. Importantly, 
Smith et al., (2005) showed that the potent and specific PARP inhibitor, AG14361 
sensitised leukaemia cell lines to the effects of the camptothecin (Smith et al., 2005). A 
large number of studies have shown the cells are sensitised to IR when used in 
combination with PARP inhibitors (Zaremba and Curtin, 2007). For example, AG14361 
increased IR-induced cell death, an effect further enhanced by combined inhibition of 
DNA-PK activity (Veuger et al., 2003). Tentori et al., (2001) reported that exposure of 
leukemic cells to temozolomide in combination with a PARP inhibitor, resulted in a 
marked sensitisation to the alkylating agent (Tentori et al., 2001). These findings were 
supported using Calebrese et al., (2004) and others. A further discussion of the literature 
surrounding the use of PARP inhibitors in combination with temozolomide can be 
found in section 6.1. Taken together, these data support a clinical relevance for PARP-1 
inhibition in conjunction with conventional cancer treatments. 
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The potent and specific PARP inhibitor, AG-014699 has been shown to be efficacious 
both in vitro and in vivo (Daniel et al., 2010, Daniel et al., 2009, Drew et al., 2011, 
Plummer et al., 2008, Zaremba et al., 2009), and was the first PARP inhibitor to enter 
clinical trials for cancer therapy. Phase I trials showed that profound and sustained 
PARP inhibition could be achieved after a single intravenous infusion (Plummer et al., 
2005). Phase II trials combining AG-014699 with temozolomide in metastatic 
melanoma patients showed an improvement in the response rate in comparison with 
temozolomide alone (Plummer et al., 2008). A number of pharmaceutical companies are 
now undertaking clinical trials of PARP inhibitors for the treatment of cancer (Drew 
and Plummer, 2009).  
 
One hugely interesting aspect of DNA repair inhibition, and PARP inhibition in 
particular, is the possibility of the use of such agents as mono-therapies. It is important 
to remember that each cell has the ability to repair a single genotoxic lesion via more 
than one pathway, and that this accounts for the relatively low level of oncogenesis 
within a lifetime. Two seminal papers (Bryant et al., 2005, Farmer et al., 2005) were 
suggested that PARP-1 inhibitors could be used as stand-alone agents in BRCA2 
defective tumours, and were also among the first to introduce the concept of ‘synthetic 
lethality’. This phenomenon is exemplified by the repair of DSBs via HRR, which result 
from single strand break collapse in the presence of PARP-1 inhibitors. Patients with 
mutations in the BRCA1 or BRCA2 gene are at an increased risk of developing breast 
and gynaecological cancers due to their defect in efficient DSB repair. Critically, a 
selective killing of cell lines defective in the BRCA1 or BRCA2 and Rad51 members of 
the HRR cascade by PARP-1 inhibitors was demonstrated by a number of groups 
(Bryant et al., 2005, Drew et al., 2011, Farmer et al., 2005, McCabe et al., 2006). 
Strikingly, only the BRCA-defective cells are susceptible to PARP inhibition in this 
case, and therefore selective killing of the tumour cells is achieved with minimum 
toxicity to normal cells. PARP inhibitors, including AG-014699, are now in clinical 
trials for BRCA defective breast and ovarian cancer as single agent therapies 
(www.clinicaltrials.gov). Phase I trials with the AstraZeneca PARP inhibitor, olaparib, 
have shown that this drug has significant anti-tumour activity in BRCA1 and BRCA2 
mutation carriers (Fong et al., 2009, Fong et al., 2010). 
 
Not all clinical development of PARP-1 inhibitors has been focused within the 
oncology field. For example, reports have shown that PARP-1 activity is increased 
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during conditions that restrict blood flow to the brain, such as stroke and is in this case 
is associated with significant NAD+ depletion and results in neurological injury. In this 
case, PARP-1 inhibition has an important protective role by preventing cerebral 
ischemia and limiting the release of associated inflammatory mediators (Haddad et al., 
2006). Other uses of PARP inhibitors are described in section 1.5, detailing the role of 
PARP-1 as a transcriptional regulator. To this end it is important to note that 
understanding the mechanisms by which PARP-1 regulates other genes and 
transcription factors is vital to elucidate the effects of PARP-1 inhibitors, and this thesis 
will undertake the first investigation of the clinically relevant PARP inhibitors in the 
context of their potential utility as inhibitors of transcriptional activation. 
 
1.4 DNA repair and NF-κB  
There is a mounting body of literature which has shown that many DNA damaging 
agents activate not only damage repair pathways, but also the NF-κB transcriptional 
cascade in tandem (Janssens and Tschopp, 2006). These observations have led to an 
increasing number of investigations studying the cross-talk between these two 
pathways. In particular, the DNA repair proteins, ATM, DNA-PK and PARP-1 have 
now been implicated in transcriptional regulation both in response to, and in the absence 
of, DNA damaging agents. The role of both ATM and DNA-PK will be discussed 
below, whilst an in-depth discussion of PARP-1 as a co-regulator of NF-κB activation is 
added later (section 1.5). 
 
NF-κB induction following DNA damage is hypothesised to mediate a cell survival 
effect. Early studies using antioxidant compounds suggested that DNA damage-induced 
cytoplasmic events were responsible for the induction of NF-κB transcriptional activity 
independently of any DNA strand breaks. More recently however, studies have 
demonstrated that DNA repair proteins may mediate cytoplasmic signalling of nuclear 
DNA damage events which are related to the formation and detection of strand breaks 
within the genome (Janssens and Tschopp, 2006). It is, however, it is highly likely that 
the signalling to and effects of NF-κB activation following DNA damage are dependent 
upon the specific damaging agent used (Strozyk et al., 2006). 
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1.4.1 The role of ATM in NF-κB regulation  
The mammalian cell cycle has a number of key DNA damage response regulators with 
checkpoint activity and these include the protein kinases, ATM and DNA-PK. ATM 
and DNA-PK both contain domains which are commonly found in the lipid kinase 
phosphatidyl-inositol 3-kinase (PI3K) and are often termed ‘PI3K-like protein kinases’ 
(PIKKs) (Shiloh, 2003). Both ATM and DNA-PK respond to DNA double strand 
breaks (DSBs) by phosphorylating a number of key substrates in downstream pathways 
whilst other PIKK proteins such as ATR respond to UV damage and stalled replication 
forks (Abraham, 2001). 
 
Wu et al., published a seminal paper in 2006, which provided a great deal of insight into 
the activation of NF-κB by ATM (Wu et al., 2006). This study showed that following 
genotoxic stimuli, in particular ionising radiation, the canonical pathway of NF-κB 
activation, which is dependent on NEMO-IKKβ activation is initiated (Figure 1.12). In 
particular, Wu et al., (2006) showed that upon DNA damage, NEMO/IKKγ is 
translocated to the nucleus and is SUMOylated. Importantly however, Huang et al., 
stated that the addition of the SUMO moiety to NEMO occurs in an ATM-independent 
manner (Huang et al., 2003). SUMOylation prevents the nuclear export of NEMO and 
makes it a target for phosphorylation by ATM, as shown in Figure 1.12 (Wu et al., 
2003). Following this, the SUMO moiety is displaced by mono-ubiquitination allowing 
the ubiquitinated NEMO:ATM complex to translocate to the cytoplasm where it can 
activate the IKK complex (Bartek and Lukas, 2006). Traditionally, DNA repair proteins 
have been thought to be exclusively nuclear, an event attributed to their DNA associated 
function. However, immunoprecipitation experiments by Wu et al., demonstrate a 
multifaceted IKKβ/ATM/NEMO complex essential for NF-κB activation within the 
cytoplasm of damaged cells (Wu et al., 2006). 
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Data from Wu et al., (2006) suggested that the ATM-dependent activation of NF-κB 
only occurred in response to DNA damaging agents such as IR or genotoxic stress; 
however this has been contested by Wuerzberger-Davis et al., (2003). This group have 
suggested that ATM-dependent NF-κB activation can occur in the absence of DNA 
damage as the SUMOylation of NEMO can occur without DSB-inducing conditions. 
The combination of electroporation stress (which activates the post-translational 
SUMOylation of NEMO) and hypotonic shock (which activates ATM) induced, albeit 
weakly, NF-κB activation. This publication used the PI3K inhibitor, Wortmannin to 
show that this NF-κB activation could not occur without ATM (Wuerzberger-Davis et 
al., 2007). It should be noted that Wortmannin is known to inhibit ATM, along with 
DNA-PK and other members of the PI3K family (Rosenzweig et al., 1997). More 
Figure 1.12: The association of NEMO and ATM results in canonical pathway 
activation 
Genotoxic stress which causes DSBs produce a stress signal that prevents NEMO 
shuttling to the cytoplasm thus making it a target for SUMOylation. SUMOylated 
NEMO is a target for phosphorylation by ATM. Once phosphorylation has occurred, 
SUMO is displaced by a ubiquitin moiety and this allows the ATM-NEMO complex to 
translocate to the cytoplasm. The active IKK complex, which NEMO is a part of, 
requires ELKS (a protein rich in glutamine (E), leucine (L) lysine, (K) and serine (S)) in 
order to promote NF-κB translocation to the nucleus and the subsequent activation of 
target genes. 
From: (Bartek and Lukas, 2006) 
 
85 
 
recently, Veuger and Durkacz (2011) reported that the small molecule inhibitor of ATM 
kinase activity, KU55933 (Hickson et al., 2004) sensitised breast cancer cells to IR via 
the inhibition of NF-κB activation, rather than the widely reported inhibition of DSB 
repair (Veuger and Durkacz, 2011).  
 
Hinz et al., (2010) further elucidated the mechanism of ATM in the activation of NF-κB 
once the kinase is translocated to cytoplasm, as first reported by another group (Wu et 
al., 2006). Using HepG2 hepatocellular carcinoma cells, Hinz et al., showed that 
following DNA damage, by either IR or the topoisomerase II poison etoposide, there 
was a rapid accumulation of ATM in the cytosol and membrane cellular fractions, and 
that this translocation was calcium-dependent. They then used an RNAi screen, and 
found that IR-induced NF-κB mediated by ATM required the canonical pathway 
components TRAF6 and Ubc13, and that in fact ATM contained a TRAF-binding motif. 
This resulted in the activation of TRAF-6, subsequent Ubc13-mediated 
polyubiquitination, and recruitment of the cIAP1 protein. This ATM:TRAF6:cIAP1 
module then stimulates the canonical pathway protein TAB2, which in turn 
phosphorylates TAK1, allowing this activated complex to phosphorylate IKKβ. 
Simultaneously, the ATM:TRAF6:cIAP1 module promotes monoubiquitination of 
NEMO/ IKKγ at lysine 285, which Hinz et al., state is essential for the activation of NF-
κB following genotoxic stress. Once ubquitinated, NEMO/IKKγ can complex with the 
now activated IKKβ, and also IKKα, and initiate the series of downstream events in the 
canonical pathway of NF-κB activation (Hinz et al., 2010). 
 
1.4.2 The role of DNA-PK in NF-κB regulation  
Panta et al., (2004) proposed a common mechanism by which ATM and DNA-PKcs 
activate NF-κB through a MEK/extracellular signal-regulated kinase (ERK)/p90rsk 
signalling pathway in response to some forms of DNA damage (Panta et al., 2004). 
Mitogen-activated protein kinase (MAPK) pathways including the ERK pathway, were 
reported to be defected in γ-irradiated A-T cells (Kharbanda et al., 2000) and these 
pathways have also been implicated in the NF-κB response to DNA damage (Ryan et 
al., 2000). Panta et al., (2004) found that ATM-proficient cells activated NF-κB when 
treated with 5µM doxorubicin (DOX), a DSB-inducing agent, whereas ATM-deficient 
cells showed no NF-κB activation. After treating the ATM-proficient cells with the 
MEK inhibitor, PD98059 the NF-κB activation no longer occurred, therefore suggesting 
that ATM activates NF-κB via a MEK-dependent mechanism. MEK is phosphorylated 
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at serines 218 and 222 in an ATM-dependent manner, which results in the sequential 
phosphorylation of ERK and its downstream target p90rsk, which can associate with the 
IKK complex leading to activation of NF-κB (Panta et al., 2004). They also detail how 
DNA-PK activates NF-κB induction in the same MEK-to-IKK signalling pathway in 
response to treatment with 5µM AD288, N-benzyladriamycin (a catalytic inhibitor of 
topoisomerase II) but not in response to DOX as was the case with ATM. Interestingly, 
catalytic inhibitors of topoisomerase II do not cause DNA damage, unlike classical 
topoisomerase poisons, such as DOX, suggesting that DNA-PK mediated activation of 
NF-κB can occur in the absence of DNA damage. 
 
Liu et al., (1998) detailed that there are key phosphorylation events by DNA-PK at 
residues in both the N- and C-termini of IκBα and IκBβ which regulate NF-κB DNA 
binding (Liu et al., 1998). The N-terminus and ankyrin repeats of the IκB proteins are 
involved in the cytoplasmic regulation of NF-κB whilst the C-terminus is concerned 
with nuclear regulation (Luque and Gelinas, 1998) and therefore, the activity of these 
proteins is regulated by their phosphorylation state. Lui et al., (1998) reported that 
DNA-PK phosphorylates one of the key sites, serine 36 in the N-terminus that earmarks 
the IκB proteins for degradation and ultimately results in a translocation of the NF-κB 
subunits from the cytoplasm to the nucleus. However, they also demonstrated that 
DNA-PK does not phosphorylate the other key residue, serine 32. Finally, this group 
illustrated they DNA-PKcs phosphorylates IκBα at threonine 273 and postulate that this 
event contributes to increased nuclear accumulation of NF-κB, and subsequently NF-κB 
DNA binding (Liu et al., 1998).  
 
Basu et al., (1998) showed that the activation of NF-κB by DNA-PK was DNA damage 
dependent. This group used the PI3K inhibitor, Wortmannin at a dose known to inhibit 
DNA-PK (Rosenzweig et al., 1997) to prove the hypothesis that DNA-PK stimulated 
NF-κB activation following DNA damage. In response to both the DNA damaging 
agents, IR and etoposide, the DNA-PK inhibitor prevented the activation of NF-κB, 
whereas in response to TNF-α Wortmannin had no effect. This suggests that DNA-PK, 
like ATM is primarily involved in NF-κB activation is response to DNA damage (Basu 
et al., 1998). Conversely, Ju et al.,(2010) demonstrated that the phosphorylation of the 
p50 subunit of NF-κB by DNA-PKcs, in response to the cytokine, TNF-α, was required 
for the expression of the NF-κB-dependent gene, VCAM-1, suggesting that DNA-PK is 
important for the activation of NF-κB in the absence of DNA damage (Ju et al., 2010). 
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Finally, the DNA repair associated kinase CK2 is involved in an IKK-independent 
activation of the NF-κB signalling cascade (Loizou et al., 2004). Taken together, these 
data highlight a critical link between the DNA repair signalling and the activity of the 
NF-κB transcription factor. 
1.5 PARP-1 as a co-activator of NF-κB activation 
There have been a number of reports on the role PARP-1 as a co-activator of NF-κB in 
various cell types and tissues. Many of these studies detail a role for PARP-1 in 
mediating the inflammatory response via regulation of the transcription factor (Hassa et 
al., 2001, Hassa et al., 2005, Hassa and Hottiger, 1999, Kauppinen and Swanson, 2005), 
although some do start to determine whether PARP-1 also regulates NF-κB following 
DNA damage (Chang and Alvarez-Gonzalez, 2001, Hunter et al., 2011, Stilmann et al., 
2009, Veuger et al., 2009). 
 
1.5.1 PARP-1 as a co-activator of NF-κB following inflammatory stimuli 
Le Page et al., (1998) were the first to suggest that PARP-1 may act as a co-regulator of 
NF-κB using the classical PARP inhibitor, 3-AB in the macrophage cell line, 264.7 they 
showed that NF-κB activation by LPS was reduced in combination with 3-AB. They 
also showed that transcription of the NF-κB target gene, iNOS, was reduced in cells 
treated with LPS and 3-AB compared with LPS alone (Le Page et al., 1998).  
 
Another group then utilised the PARP knockout mouse model to investigate the role of 
PARP-1 in the activation of NF-κB following LPS or TNF-α in vivo. They showed that 
PARP-1-proficient mice treated with LPS exhibited rapid NF-κB activation in 
macrophages whereas PARP-1-deficient mice showed no NF-κB response. 
Furthermore, this report detailed that PARP-1-deficient cells were more sensitive to 
TNF-α induced cell death, and that this could be related to an impairment of NF-κB 
activation in these cells (Oliver et al., 1999b). Hassa and Hottiger (1999) extended this 
by demonstrating that NF-κB activation could be restored in vivo by the expression of 
PARP-1 in PARP-1-deficient cells. They also reported that PARP-1 and NF-κB could 
form a stable complex independent of DNA binding (Hassa and Hottiger, 1999). 
 
In 2001, Hassa et al., showed that PARP-1 enzymatic and DNA binding activity were 
not essential for TNF-α mediated PARP-1 co-activation of NF-κB. They demonstrated 
that although TNF-α-induced NF-κB activation was attenuated in PARP-deficient cells, 
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this was unaffected by either expression of a PARP-1 catalytic mutant or PARP 
inhibition (Hassa et al., 2001). Hassa et al., (2005) then went on to show that the 
acetylation of PARP-1, by HDAC1 and p300, regulated NF-κB activity (Hassa et al., 
2005). These data supported the earlier work by this group, when they illustrated how 
the physical presence of the PARP-1 C-terminal catalytic domain, but importantly not 
enzymatic activity, was required for PARP-1 and p300 to synergistically activate NF-
κB-dependent transcription following either TNF-α or LPS (Hassa et al., 2003).  More 
recently, Hassa et al., (2008) showed that PARP-1 synergistically co-activates NF-κB 
gene expression at the macrophage inflammatory protein 2 and human 
immunodeficiency virus 1 long terminal repeat promoters in concert with the CBP-p300 
complex, the coactivator-associated arginine methyltransferase 1 (CARM1) and the 
protein arginine methyltransferase 1 (PRMT1). PARP-1 and PRMT formed a complex 
with NF-κB in vivo , and it was reported that the methyltransferase activity of PRMT1 
was essential for this interaction (Hassa et al., 2008). 
 
Protein acetylation by CBP/p300 is essential for the expression of the NF-κB-dependent 
genes, ICAM-1 and VCAM-1, in TNF-α treated smooth muscle cells (Zerfaoui et al., 
2008). ICAM-1 and VCAM-1 are both adhesion molecules involved in the 
inflammatory response. However, the interaction between CBP/p300 and PARP-1 was 
only essential for the activation of ICAM-1, not VCAM-1. 
 
Many reports suggest that PARP inhibitors may be advantageous in inflammatory 
disorders due to their ability to inhibit transcriptional activation of key genes regulated 
by NF-κB and other factors, such as AP-1. Numerous reports have assessed the role of 
PARP-1 in glial models and those of brain injury. Ha et al., (2002) reported that PARP-
1 deficient glia exhibited reduced transcription factor binding (NF-κB, AP-1, Sp1 and 
Oct-1) and associated gene expression (Ha et al., 2002). Another report using rat glial 
and neuronal cultures showed that the use of PARP inhibitors significantly reduced 
activation of NF-κB target genes, including iNOS, IL-1β and TNF-α, resulting in a 
reduced neuro-inflammation and the neurotoxic potential of activated glia (Chiarugi and 
Moskowitz, 2003). Zingarilli et al., (2003) used the PARP inhibitors, 3-AB and 1,5-
dihydroxyisoquinoline in combination with the inflammatory stimulant 2,4,6-
trinitrobenzene sulfonic acid (TNBS) and showed that this combination markedly 
reduced DNA binding of both NF-κB and AP-1 in a rat model of colitis. This resulted in 
a reduction in neutrophil infiltration, resolved colonic damage and induced apoptosis 
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(Zingarelli et al., 2003b). Nakajima et al., (2004) also used cultured murine glial cells to 
show that the auto-ribosylation of PARP-1 lead to enhanced LPS-induced NF-κB DNA 
binding and in particular NF-κB p50-dependent gene transcription in this model 
(Nakajima et al., 2004). Furthermore, PARP-1 inhibition was able to alleviate TNF-α-
stimulated NF-κB-dependent MMP-9-mediated neurotoxicity in microglia in a model of 
brain injury (Kauppinen and Swanson, 2005). 
 
Two groups used cDNA microarrays to determine the role of PARP-1 in the regulation 
of gene transcription using the PARP-1 knockout mouse model (Carrillo et al., 2004, 
Zingarelli et al., 2003a). Zingarilli et al., (2003) found that PARP-1 deficient cells 
expressed 29 apoptosis-related genes differentially compared with PARP-1 wild-type 
cells. These included many known to be NF-κB regulated, such as the anti-apoptotic 
gene Bcl-2, which were significantly lower in PARP-1 deficient cells. This correlated 
with reduced activation of the IκB kinase complex and NF-κB DNA binding in these 
cells, and was thought to contribute to the reduction in myocardial damage observed in 
PARP-1-deficient mice (Zingarelli et al., 2003a). Carrillo et al., (2004) performed 
microarray analysis on TNF-α-treated heart endothelial cells from PARP-1 proficient 
and deficient mice. They reported that the up-regulation of several inflammatory 
response genes, known to be NF-κB regulated was reduced in PARP-1-deficient cells 
(Carrillo et al., 2004).  
 
Oumouna-Benachour et al., used a apolipoprotein (ApoE)-deficient mouse model and 
induced atherosclerosis using a high fat diet before treatment with the PARP inhibitor, 
thieno[2,3-c]isoquinolin-5-one. They found that PARP inhibition reduced the number 
and size of atherosclerotic plaques, and that in PARP-1 deficient macrophages LPS-
induced NF-κB nuclear translocation was reduced (Oumouna-Benachour et al., 2007). 
A study of unstable angina (UA) aimed to elucidate the role of PARP-1 in the 
production of TNF-α and IL-6, both NF-κB regulated genes. In mononuclear cells 
(MNCs) from UA patients the PARP activity and expression correlated with plasma 
levels of TNF-α and IL-6. Cultured MNCs from healthy volunteers were used to show 
that PARP-1 was component of the NF-κB DNA complex. Moreover, PARP inhibition 
inhibited LPS-mediated NF-κB DNA binding and consequently TNF-α and IL-6 
transcription (Huang et al., 2008). Taken together all of these again confirm that PARP-
1 is an important regulator of the inflammatory response, and many groups suggest that 
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PARP inhibitors may be utilised therapeutically in the protection against chronic 
inflammatory diseases.  
 
1.5.2 PARP-1 as a co-regulator of DNA-damage activated NF-κB 
Chang and Alvarez-Gonzalez (2000) were the first to describe a role for PARP-1 in the 
activation of NF-κB following DNA damage. Using the human cervical 
adenocarcinoma cell line, Hela, they showed that inactive PARP-1 could bind NF-κB 
p50 and block its sequence specific DNA binding, resulting in inhibition of 
transcriptional activation. Following treatment with the DNA damaging agent, H202, 
PARP-1 was activated and the binding of the p50 subunit was reversed, allowing the 
subunit to bind DNA and upregulate transcription. Co-incubation with the PARP 
inhibitor, 3-AB, also significantly reduced H202-induced NF-κB DNA binding (Chang 
and Alvarez-Gonzalez, 2001). 
 
Two reports from Martin-Oliver et al., (2004 and 2006) using the irritant TPA, illustrate 
the importance of PARP-1 in the regulation of NF-κB activation in murine papillomas. 
Susceptibility to papilloma in PARP-1-deficient mice was significantly lower than in 
PARP-1 proficient animals, and that the development of such lesions had a much longer 
latency in these mice after treatment with TPA. This was consistent with lower NF-κB 
activation and gene transcription during the initiation of tumour development in PARP-
1 deficient mice (Martin-Oliva et al., 2004). A later study by this group, used TPA in 
combination with the PARP inhibitor, DPQ, and showed that in this model system, 
PARP-1 activity did not alter NF-κB activation following TPA treatment (Martin-Oliva 
et al., 2006). 
 
Veuger et al., (2009) used the breast cancer cell lines, MDA-MB-231 and T47D to 
investigate the role of PARP-1 in IR-induced NF-κB. They show that activation of the 
IκB proteins and nuclear translocation of either NF-κB p65 or p50 are unaffected by 
PARP inhibition, suggesting that the role of PARP-1 is at the DNA binding and 
transcriptional level. PARP inhibition radio-sensitised p65 proficient but not deficient 
MEFs and reduced IR-induced XIAP protein expression (Veuger et al., 2009). This 
work is discussed extensively in chapter 6. 
 
The recent work of Stilmann et al. (2009) describes the formation of a PARP-1 
signaling scaffold via direct protein-protein interactions with NEMO/IKKγ, PIASγ and 
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ATM in response to DNA damage, by IR (Figure 1.13). This signalosome formation 
requires binding with PAR and leads to pro-survival NF-κB activation, and this was the 
first study to suggest that NF-κB activation following DNA damage was mediated via 
the active form of PARP-1. PARP-1 was essential for DNA damage induced IKK, and 
subsequent NF-κB activation, and NEMO/IKKγ could interact directly with 
automodified PARP-1 very quickly following DNA damage. They also showed that 
PIASγ was also recruited to PARP-1 with NEMO/IKKγ, and used a series of 
NEMO/IKKγ mutants to find that the association between either PARP-1- or PIASγ- 
and NEMO/IKKγ, was within the kinase domain of the protein. Stilmann et al., (2009) 
went on to show that PIASγ contained a C-terminal PAR binding motif (PARBM), 
which recruited the protein to the PARP-1 signalsome after DNA damage, and that this 
binding was essential for SUMOylation of NEMO/IKKγ and NF-κB activation 
(Stilmann et al., 2009). Moreover, they reported that ATM (itself activated upon DNA 
damage) was a member of this signalosome due to its known PARBM (Haince et al., 
2007). Stilmann et al., (2009) postulated that ATM was responsible for the 
phosphorylation of NEMO/IKKγ, and the subsequent downstream activation of NF-κB, 
supporting other work in the field (Wu et al., 2006). 
 
 
 
 
 
 
Most recently, Ohanna et al., (2011) reported that senescent melanoma cells develop at 
a PARP-1 and NF-κB-associated secretome, which they termed PNAS. They show that 
this secretome has pro-invasive and pro-tumourigenic properties due to the expression 
of many known NF-κB-dependent inflammatory response genes, in particular the 
Figure 1.13: The formation of a PARP-1 signaling scaffold via direct protein-protein 
interactions with NEMO/IKKγ, PIASγ and ATM in response to DNA damage, which 
results in NF-κB activation 
Taken from: (Stilmann et al., 2009) 
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chemokine, CCL2. Furthermore, they report that the secretion of CCL2 was increased 
following treatment with either oxidative stress (H2O2) or the chemo-therapeutic agent, 
TMZ, both of which are known to activate PARP-1, and also NF-κB activation using a 
luciferase reporter assay. Pharmacological inhibition of either PARP-1 using 3-AB, or 
NF-κB using sulfasalazine, inhibited the secretion of CCL2 induced by H2O2 or TMZ, 
to the same extent. Therefore, the authors concluded that secretome was dependent on 
the activation of PARP-1 and NF-κB (Ohanna et al., 2011). 
 
1.6 Justification 
Following activation by DNA damage the canonical pathway of NF-κB is known to 
regulate genes involved in apoptosis, cell proliferation, angiogenesis and metastasis. 
(Ghosh and Karin, 2002). Constitutively active NF-κB is common in many cancers and 
leukemias (Basseres and Baldwin, 2006) and correlates with increased metastatic 
potential, more rapid disease progression, a higher proportion of tumour recurrence and 
therapeutic resistance (Prasad et al., 2010). Cellular NF-κB activity is known to be 
induced by varying doses of IR and other chemo-therapeutic agents and this differential 
is likely to be both cell type- and tissue-specific (Brach et al., 1991, Campbell et al., 
2006b, Criswell et al., 2003). DNA damage-activated NF-κB induces anti-apoptotic 
genes, thereby inhibiting apoptosis and contributing to therapeutic resistance in many 
types of cancer (Barkett and Gilmore, 1999, Wang et al., 1998). For example, aberrant 
NF-κB contributes to radio- and chemo-resistance in breast tumours (Biswas et al., 
2001, Wu and Kral, 2005) and loss or inhibition of NF-κB has been shown to chemo- or 
radio-sensitize in many different tumour types (Criswell et al., 2003, Hewamana et al., 
2008a, Hewamana et al., 2008b, Jung and Dritschilo, 2001, Russo et al., 2001). 
 
 
Thus, inhibition of NF-κB represents a potential therapeutic strategy in cancer, and 
there are a number of inhibitors targeting various pathway components in development. 
These include inhibitors of the IKK complex, such as Parthenolide or proteosomal 
inhibitors like Bortezomib which may prevent degradation of IκB (Gilmore and 
Herscovitch, 2006). However, global inhibition of NF-κB can have adverse effects on 
the cell due to the vital role NF-κB plays in both the immune and inflammatory 
responses. Therefore, a novel strategy may be to inhibit DNA damage induced NF-κB 
activity to overcome the toxic or off-target effects often encountered with other NF-κB 
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inhibitors, since a number of DNA repair proteins, including ATM, DNA-PK and 
PARP-1, have been implicated in the activation of NF-κB following DNA damage. 
Thus, the inhibition of DNA damage activated NF-κB using inhibitors of these DNA 
repair proteins requires much further testing, and specifically the effect on NF-κB-
dependent gene expression should be studied closely. 
 
PARP-1 is known to co-regulate a number of transcription factors, including Oct-1, NF-
κB, AP-1 and HIF-1α (Gilmore and Herscovitch, 2006, Kraus, 2008, Kraus and Lis, 
2003, Martin-Oliva et al., 2006). This may be via local modification of chromatin 
structure (Althaus et al., 1994) and/or modulation of transcription factor activity via 
direct binding to gene regulating sequences, or physical interactions with proteins 
including transcription factors. Previous work using experimental PARP inhibitors, such 
as 3-AB, have shown that PARP-1 plays a role in the activation of NF-κB. 
Unfortunately, it is difficult to confidently conclude that the effects observed on NF-κB 
in these cases are solely due to PARP-1 as early inhibitors are known to have many off-
target effects (Moses et al., 1990). More recently, Veuger et al., (2009) showed that the 
PARP inhibitor, AG-14361 radio-sensitised p65 proficient but not deficient MEFs and 
also suggested that the role of PARP-1 in the activation of NF-κB following DNA 
binding was at the DNA binding and transcriptional level, by showing there was no 
effect on IκB degradation or subunit translocation to the nucleus (Veuger et al., 2009). 
However, mechanistic studies were absent in this case. 
 
The potent and specific PARP-1 inhibitor, AG-014699 has been used in Phase I and II 
clinical trials for solid tumours in combination with standard chemotherapeutics and 
also as a standalone treatment (Plummer et al., 2008). Studies have also shown that AG-
014699 enhances tumour regression in xenograft models (Daniel et al., 2010, Daniel et 
al., 2009). However the effect of this agent upon NF-κB transcriptional activity remains 
undetermined.  
 
Importantly, the role of PARP-1 catalytic activity in the activation of NF-κB is 
somewhat contentious, and is likely to be mainly dependent on stimulus, but also on cell 
type (Hassa et al., 2001, Hassa and Hottiger, 1999, Hassa and Hottiger, 2002). 
Therefore, it is necessary to compare two canonical activators of NF-κB, IR and TNF-α 
and determine whether PARP-1 is differentially required in the induction of NF-κB, in a 
given model system. Moreover, the recent work of Stilmann et al. (2009) describes the 
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formation of a PARP-1 signalling scaffold via direct protein-protein interactions with 
NEMO, PIASγ and ATM in response to DNA damage. This signalosome formation 
requires binding with PAR and leads to pro-survival NF-κB activation (Stilmann et al., 
2009).  
 
Although the work of Stilmann et al., (2009) provided a great deal of insight into the 
mechanism by which NF-κB is activated by PARP-1 in response to DNA damage, there 
are some caveats associated with it. Firstly, this study used hyper-lethal doses of IR, as 
high as 80 Gy, in PARP-1-/- MEFs, which are widely reported to be exhibit genomic 
instability. They are not the only group to use high doses of the DNA damaging agent, 
as the study by Veuger et al., (2009) used up to 50 Gy in some cases. These doses are 
not clinically relevant, and studies should be undertaken at lower doses which are as 
close to mimicking a clinical dose as is possible. Although the study by Stilmann et al., 
(2009) is purely functional, is does have wider implications for the use of PARP 
inhibitors, and the inhibition of NF-κB activation is diseases such as cancer. Therefore, 
an in depth study using a clinically used PARP inhibitor should be undertaken, rather 
than the classical inhibitor, 3-AB used by Stilmann et al., (2009), as these early 
compounds have a range of off target effects. Finally, although the model proposed by 
Stilmann et al., (2009) (Figure 1.13) eludes to the effect of the PARG enzyme on PAR 
and consequently NF-κB activation, no mechanistic studies were presented to support 
this, and thus warrant further investigation. 
 
1.7 Aims and hypothesis 
Therefore, the overall aims of this thesis are four-fold: 
1. To elucidate the underlying molecular mechanisms that transduce  signals from 
DNA damage-activated PARP-1 to the activation of NF-κB using the potent and 
specific PARP inhibitor, AG-014699 and siRNA targeting of  p65 and PARP-1 
2. To test the hypothesis that PARP-1 mediates cell survival following DNA 
damage primarily through activation of NF-κB  
3. To undertake preclinical testing of AG-014699 in cancer cell line models in 
which DNA damage- activated NF-κB mediates therapeutic resistance 
4. To undertake preclinical testing of a series of NF-κB subunit DNA binding 
inhibitors, both in combination with radio-therapy and as stand-alone agents 
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Chapter 2. Materials and Methods 
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2.1 Materials 
2.1.1 Chemical/reagents 
Routinely used chemicals, unless otherwise stated, were either analytical or molecular 
biology grade, and purchased from Sigma-Aldrich Company Ltd (Poole, UK), and 
VWR International (Leicestershire, UK), unless otherwise stated.  
 
2.1.2 General equipment 
Irradiator; RS320 irradiation system (Gulmay Medical, Surrey, UK) 
FacScan  (Beckton Dickinson, Oxford, UK) 
Spectromax 96-well microtitre plate reader (Molecular Devices, Berks, UK)  
Incubator (Heraeus Equipment Ltd., Beds., UK) 
Waterbath: Grant Model OLS200 (BDH, Dorset, UK) 
Centrifuge; Eppendorf model MSE3000/30001 (Scientific Laboratory Supplies, 
Nottingham, UK) 
Criterion electrophoresis tank and Criterion Blotting module (Bio-Rad, Herts., UK) 
Power pack 200 (BioRad, Hertfordshire, UK) 
Roller Mixer model SRT1 (Stuart Scientific, Surrey, UK)  
Fuji LAS 3000 (Fuji Photo Film Ltd., Japan) 
Milipore filtration system (Milipore Corporation, Bedford, Mass., USA) 
 
2.1.3 PARP inhibitor, AG-014699 
AG-014699 (8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1H-
azepino[5,4,3-cd]indol-6(3H)-one) is a PARP-1 inhibitor developed in a collaborative 
venture between Newcastle University and Pfizer GRD, CA (Thomas et al., 2007). AG-
014699 was provided by Pfizer (Surrey, UK). The inhibitor was dissolved in anhydrous 
DMSO and was stored at a concentration of 10 mM protected from light, at -20°C. The 
drug was diluted to stock concentrations in the mM range in sterile dimethyl sulphoxide 
(DMSO) and further diluted in full media (RPMI 1640, 10 % FBS). .AG-014699 was 
used at 0.4 µM in all assays, a dose known to inhibit PARP activity > 90 %, unless 
otherwise stated. The structure of AG-014699 is shown in Figure 2.1.  It should be 
noted that when diluted in tissue culture medium, a final concentration of <0.1 % (v/v) 
DMSO was achieved. For all inhibitors and chemotherapeutic agents used in this thesis, 
drug free controls were exposed to <0.1 % (v/v) DMSO. 
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2.1.4 PARG inhibitor, ADP-HPD 
ADP-HPD (Adenosine 5'-diphosphate (hydroxymethyl) pyrrolidinediol) is a 
commercially available PARG inhibitor, known to be highly specific for PARG over 
PARP-1 (Slama et al., 1995). ADP-HPD was obtained from ENZO Life Sciences 
(Exeter, UK). The inhibitor was dissolved in anhydrous DMSO and was stored at a 
concentration of 10 mM protected from light, at -20°C. The drug was diluted to stock 
concentrations in the mM range in sterile DMSO and further diluted in full media 
(RPMI 1640, 10 % FBS). ADP-HPD was used at 1 µM in all assays, unless otherwise 
stated. The structure of ADP-HPD is shown in Figure 2.2.  
 
 
 
 
 
 
2.1.5 NF-κB inhibitors, PBS--1079, PBS-1086, PBS-1088, PBS-1110, PBS-1135, 
PBS-1169, PBS-1170 
A range of NF-κB inhibitors, PBS-1079, PBS-1086, PBS-1088, PBS-1110, PBS-1135, 
PBS-1169, PBS-1170 were synthesised by Profectus BioSciences Inc. (Baltimore, MD, 
Figure 2.1: Structure of the PARP inhibitor, AG-014699 
From: (Thomas et al., 2007) 
 
Figure 2.2: Structure of the PARG inhibitor, ADP-HPD 
From: (Slama et al., 1995) 
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USA). These compounds are referred to as Rel inhibitors of NF-κB, specifically 
meaning that they target the Rel domain of the NF-κB subunits, therefore inhibiting 
subunit DNA binding and  resulting in the inhibition of NF-κB (Oh et al., 2011). These 
inhibitors were dissolved in anhydrous DMSO and were stored at a concentration of 5 
mg/ml protected from light, at -20°C. The inhibitors were diluted to stock 
concentrations in the mM range in sterile DMSO and further diluted in full media 
(RPMI 1640, 10 % FBS) for cell treatment at concentrations in the µM range. It should 
be noted that Profectus BioSciences Inc. have not disclosed the structure of these 
inhibitors. 
 
2.1.6 Ionising radiation (IR) 
Ionising radiation (IR) produces many types of DNA lesions through direct ionisation of 
the DNA or by hydroxyl radicals. It must be noted that the most common lesions are 
SSBs and DSBs but can also include base legions and sugar modifications (Lomax et 
al., 2002). A range of doses of IR were used within this thesis and they were achieved 
using the RS320 irradiation system (Gulmay Medical), at the dose rate of 2.86 
Gy/minute. 
 
2.1.7 Tumour necrosis factor-α (TNF-α) 
Mammalian Tumour Necrosis Factor α (TNF-α) was purchased from R & D systems 
(Abingdon, UK) and resuspended to a final concentration of 10µg/ml in PBS/BSA 
solution (PBS, 0.1 % w/v BSA) and aliquots were stored at -20°C. Prior to cell 
treatment, TNF-α was diluted to a final concentration of 10 ng/ml in full media (RPMI 
1640, 10 % FBS). Control cells were treated with the BSA/PBS solution in the absence 
of TNF-α.  
 
2.1.8. Doxorubicin 
The anthracycline, doxorubicin (DOX) is often referred to as a topoisomerase II (Topo 
II) poison due to its ability to intercalate with the DNA, thus inhibiting the progression 
of the Topo II enzyme. This results in the induction of double stranded DNA breaks, 
and consequently cell death, hence DOX is widely used in cancer therapeutics for the 
treatment of breast cancer and haematological malignancies (Hoogstraten et al., 1976). 
Doxorubicin hydrochloride is commercially available and was obtained from Sigma. It 
was dissolved in DMSO and was stored at a concentration of 10 mM protected from 
light, at -20°C. The drug was diluted to stock concentrations in the mM range in sterile 
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DMSO and further diluted in full media (RPMI 1640, 10 % FBS) for cell treatment at 
concentrations in the µM range. The structure of doxorubicin hydrochloride is shown in 
Figure 2.3.  
 
 
 
 
 
 
 
2.1.9 Temozolomide 
The alkylating agent, temozolomide (TMZ) is used for the treatment of glioblastoma 
and melanoma, as well as other forms of cancer. Alkylation by temozolomide occurs, in 
the most part at the N-7 position of guanine, and the N-3 position of adenine residues, 
resulting in single stranded DNA breaks and tumour cell death (Newlands et al., 1997). 
TMZ is commercially available and was obtained from Sigma. It was dissolved in 
DMSO and was stored at a concentration of 100 mM protected from light, at -20°C, for 
a maximum of 14 days. The drug was diluted to stock concentrations in the mM range 
in sterile DMSO and further diluted in full media (RPMI 1640, 10 % FBS) for cell 
treatment at concentrations in the µM range. The structure of TMZ is shown in Figure 
2.4. 
 
 
 
Figure 2.3: Chemical structure of doxorubicin hydrochloride 
From:http://www.sigmaaldrich.com/ 
 
Figure 2.4: Chemical structure of temozolomide 
From: (Newlands et al., 1997) 
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2.2 Mammalian cell culture 
Tissue culture plasticware including Petri dishes, and multi-well plates were obtained 
from Corning (Corning Ltd., UK) or Nunc (VWR International Ltd, UK). Sterile plastic 
pipettes and filter tips were purchased from and Starlabs (Buckinghamshire, UK), whilst 
tissue culture media, foetal calf serum and trypin-EDTA were all purchased from Sigma 
(Poole, Dorset, UK). Sterile PBS was obtained from stores at the Northern Institute for 
Cancer Research (NICR). 
 
2.2.1 Cell lines 
Table 2.1 details the cell lines that were utilised in the studies described;  
 
Cell Line Details Reference 
p65+/+  Spontaneously immortalised mouse 
embryonic fibroblasts derived from primary 
cells kindly provided by Professor Ron Hay 
(Dundee University) 
Described in (Wietek 
et al., 2003) 
p65-/- Mouse embryonic fibroblast. Knockout for 
p65 kindly provided by Professor Ron Hay 
(Dundee University) 
(Wietek et al., 2003) 
PARP-1+/+ Spontaneously immortalised mouse 
embryonic fibroblasts derived from primary 
cells kindly provided by Professor Gilbert de 
Murcia, Ecole Superieure de Biotechnologie 
de Strasbourg, France. 
(Trucco et al., 1998) 
PARP-1-/- Mouse embryonic fibroblast. Knockout for 
PARP-1 through disruption in exon 4 which 
encodes the DNA binding domain of this 
enzyme 
(Trucco et al., 1998) 
p65 null Mouse embryonic fibroblast. Knockout for 
p65 kindly provided by Professor Neil 
Perkins (Newcastle University).  
(O'Shea and Perkins, 
2010) 
p65 WT Mouse embryonic fibroblast. Knockout for 
p65, genetically complemented with WT p65, 
kindly provided by Professor Neil Perkins 
(Newcastle University). 
(O'Shea and Perkins, 
2010) 
MDA-MB-231 Estrogen-receptor negative epithelial breast 
cancer cell line initially derived from the 
mammary gland of a 51-year old female 
known to have an aggressive 
adenocarcinoma. 
(Walker-Nasir et al., 
1982) 
T47D Estrogen-receptor positive adherent breast 
cancer cell line initially derived from the 
mammary duct of a 54-year old female with a 
known ductal carcinoma 
(Horwitz et al., 1982) 
MCF7 Estrogen-receptor positive breast cancer cell 
line established from the pleural effusion 
(Westley and 
Rochefort, 1979) 
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from a 69-year-old female Caucasian 
suffering from a breast adenocarcinoma 
U251 Adherent glioblastoma cell line derived from 
a 44 year old female. 
(Quemener et al., 
1990) 
MO59J Adherent glioblastoma cell line derived from 
a 33 year old male. Fibroblastic morphology. 
Known to lack the DNA repair protein, DNA-
PK 
(Lees-Miller et al., 
1995) 
MO59J-Fus1 MO59J cells genetically complemented with 
chromosome 8, on which DNA-PK is located 
(Hoppe et al., 2000) 
A549 Adherent lung cancer cell line with epithelial 
morphology. Initially derived from a 58 year 
old Caucasian male with lung carcinoma 
(Smith, 1977) 
H522 Adherent lung cancer cell line initially 
derived from a 58 year old Caucasian male 
with non-small cell lung cancer 
 
U2OS Adherent osteosarcoma cell line initially 
derived from a 15 year old Caucasian female 
(Kanzaki et al., 1994) 
 
 
 
2.2.2 Recovery of cyropreserved cell lines from liquid nitrogen storage 
Cell lines, stored in cyrovials, were recovered from long-term storage in liquid nitrogen 
by warming at 37°C in order to thaw the cell suspension slowly, which was diluted in 
freezing media (section 2.2.5). Residual DMSO was removed from the cell suspensions 
via centrifugation and pellets were re-suspended in the appropriate growth media 
(section 2.2.3) and transferred to sterile tissue culture flasks. Medium was changed 
daily, to eliminate any traces of residual DMSO, until the cells were ready for 
subculturing. 
 
2.2.3 Continuous culture of cell lines 
All cell lines were cultured as monolayers in plastic tissue culture flask and grown in 
RPMI-1640 supplemented with 10 % (v/v) FBS, with the exception of the p65 null and 
p65 WT MEFs which were grown in Dulbeccos modified eagles medium (DMEM) 
supplemented with 10 % (v/v) foetal calf serum and 2 mM L-glutamine.  All lines were 
sub-cultured twice weekly to maintain the cells in exponential phase of growth and kept 
at 37°C, 5 % CO2 in a humidified incubator.  During routine sub-culturing, and in 
experiments, the medium was aspirated from the flask and the cells washed with 1 x 
sterile phosphate buffer saline (PBS, available from NICR in house stocks). An 
appropriate volume of Trypsin-EDTA solution was added and the cells incubated in this 
solution for 5 min at 37°C, 5 % CO2 . The Trypsin-EDTA solution was neutralised by 
Table 2.1: Cell lines used in these studies 
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addition of an equal volume of full media and the cell suspension centrifuged to remove 
any further traces of enzyme. The cell pellet was then resuspended in full media.  
 
It should also be noted that the p65 WT (p65 null cell genetically complemented with 
wild-type p65) and M059J-Fus1 (M059J genetically complemented with chromosome 
8) cell lines were maintained under antibiotic selection. In the case of the M059J-Fus1 
cells this was by an additional supplement of Gentamicin Sulphate (Gibco, Paisley, 
Scotland) which was added at a final concentration, in medium, of 200 µg/ml, and for 
the p65 WT cells this was by supplementation of cell culture media to a final 
concentration with 4 µg/ml Puromycin (Invivogen, Nottingham, UK). 
 
2.2.4 Counting cells using a Haemocytometer 
In all studies described within this thesis cells were counted using a haemocytometer. 
 
2.2.4.1 Principle 
A haemocytometer is a slide containing two mirrored chambers of known depth with a 
grid etched onto its lower surface.  When a cover slip is placed over the chambers, the 
depth is uniform (0.1 mm) across the chambers.  When using a Neubauer 
haemocytometer, the chamber is divided into 9 large 1 mm2 squares, which is 
subsequently divided into 16 smaller squares (Figure 2.5). The volume of each large 
square is (1 mm x 1 mm) x 0.1 mm = 0.1 mm3.  It is given that 1 mm3 ≡ 1 µl, and that 
the conversion factor for 1ml = x 104. Using this information, the cell number per ml of 
the original suspension can be calculated. 
 
 
 
 
 
 
Figure 2.5: Chamber layout of haemocytometer 
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2.2.4.2 Method 
Each sample was diluted 1:1 with 0.4 % v/v Trypan blue (Sigma). This is used as it 
gives an indication of the viability of the cells, as non-viable cells are stained blue due 
to them having compromised cell membranes. The cells:trypan blue mix was then 
loaded into a Neubauer haemocytometer chamber (Sigma) by capillary action.  At least 
100 cells were counted usually from the 4 corner squares, or if necessary, all large 9 
squares. Only viable cell were counted, and all counts were carried out in duplicate. 
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2.2.5 Preparation of cell line stocks for long term liquid nitrogen storage 
Cells were grown to 70 % confluence in the appropriate medium, washed once with 
sterile PBS and removed from the plate using Trypsin/EDTA. The trypsin enzyme was 
neutralised by addition of full media and cells pelleted at 2000rpm for 5 min. The cell 
pellet was then resuspended in freezing media (RPMI 1640, 20 v/v FBS, 10 % DMSO), 
to a concentration of 1 x 106 cells/ml and 1 ml aliquots of the solution transferred to 
cryovials. Cell suspensions were initially stored at -80°C then transferred to liquid 
nitrogen for long-term storage.  
 
2.2.6 Mycoplasma 
Mycoplasma is a common contamination of cell culture cells and is not detectable by 
morphological change in the cells or visual presence in the cell culture medium itself. 
However, mycoplasma infections can cause abnormal protein and nucleic acid synthesis 
and are also associated with chromosomal breakage. Cell cultures were periodically 
certified to be free of mycoplasma by routine testing using the Mycoalert Mycoplasma 
detection kit (Cambrex, Berkshire, UK) at the NICR, on a six weekly basis.  
 
2.2.7 Clonogenic survival assay 
2.2.7.1 Principle 
The clonogenic survival- or colony formation-assay is an in vitro cell survival assay 
based on the ability of a single cell to grow into a colony. The colony is defined to 
consist of at least 50 cells, and it is generally accepted that only viable cells are capable 
of carrying out the 5-6 rounds of cell division required to form a visible colony. 
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Therefore, this assay assesses every cell in a known population for the ability to 
undergo unlimited rounds of cell division, making the clonogenic assay the method of 
choice when determining cell survival after treatment with known cytotoxic agents. 
Only a fraction of seeded cells retain the capacity to produce colonies. Cells are exposed 
to drug for one doubling time (usually 24 h) after which cells are re-plated out at 
appropriate low cell densities and incubated for 1–3 weeks to allow colony formation. 
Clonogenic assays show the difference between cytotoxic and cytostatic effects which 
are not differentiated in growth inhibition assays.  
 
2.2.7.2 Method 
Cells were plated onto 6-well plates at a density that gave a final cell number of 3-5 x 
105 cells/ml on the day of experiment. Drug treatment schedules, regarding siRNA 
transfection and treatment with IR or drugs are as described in the individual chapters 
and figure legends. All drugs and inhibitors were added at final concentration of <0.1 % 
DMSO (v/v) in medium for all experiments. Inhibitors were added prior to either 
irradiation or drug treatment, at the timepoints described in the individual chapters and 
figure legends.  
 
For all experiments, cells were exposed to drug for 24 h incubated at 37 oC in a 
humidified atmosphere containing 5% CO2. Following this, the cells were trypsinised 
(as described in section 2.2.3) and re-suspended in 5 ml of drug free medium, an aliquot 
of each cell suspension was then counted using a haemocytometer (see section 2.2.4). 
Once cell counts had been undertaken, cells were diluted in medium to give suspensions 
of either 1 x 104cells/ml or 1 x 103 cells/ml. A volume of the diluted cell suspension 
corresponding to a number of cells calculated to produce a countable number of 
colonies (50-200) were then seeded in triplicate onto 92 mm plates in 10 ml of fresh 
medium. The plates were then incubated for 7-21 days depending on the cell line, to 
allow for colony formation.   
 
Following the formation of suitably large colonies, the medium was aspirated from the 
plates and the colonies fixed by the addition of 5 ml Carnoys fixative solution (3:1 
Methanol: Acetic acid).  After 5 min the fixative was removed and the colonies were 
allowed to dry in air.  Staining was achieved by the addition of 0.4 % (w/v) Crystal 
violet (Sigma) in water for one minute. Excess stain was gently washed off under 
running water and the plates allowed to air dry. 
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2.2.7.3 Analysis of results 
Plating efficiency (absolute cell survival) was calculated as the percentage of cells 
seeded which formed colonies using the following equation 
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Different cell lines have differing plating efficiencies, therefore it is important to 
determine this with untreated cells in the first instance. For example, the PARP-1+/+ 
MEFs have a plating efficiency of approximately 35 % whereas the PARP-1-/- MEFs 
have a plating efficiency of <10 %.  The relative survival of the treated cells was then 
expressed as a percentage of untreated controls. The LD50 and LD90 are defined as the 
dose of γ-irradiation or drug to give 50 % and 90 % reduction in survival, and from this 
the potentiation factor at 50% survival (PF50) was calculated as follows: 
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2.2.7.4 Advantages and disadvantages 
The clonogenic survival assay is generally accepted as the gold standard for the 
determination of cell survival, however there is another method of undertaking this 
assay, and this involves plating a much lower cell density initially and after an 
appropriate drug exposure, medium is changed on the cells but no re-plating occurs, 
therefore any dead cells which would have been aspirated off in the method used here, 
which are known to release apoptotic/death signals into the medium, perhaps signalling 
to other cells. However, this other method is less cost effective than the method utilised 
in this thesis, as it requires a much larger number of plates in the first instance and 
consequently uses more expensive reagents such as inhibitors and siRNA oligos.  
 
2.2.8 XTT cell proliferation assay 
2.2.8.1 Principle 
The XTT assay is a measurement of the metabolic activity of the cell and therefore 
cellular viability in a culture. The assay is based on the ability of viable cells to cleave 
the yellow tetrazolium salt, XTT, and produce an orange formazan dye (Figure 2.6). 
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The dye is soluble and is quantifiable by spectrophotometry with a peak absorbance of 
the formazan dye at ~480 nm. Thus an increase or decrease in cell number (due to 
increase or decrease in viability) in turn results in an increase or decrease in the 
mitochondrial dehydrogenase activity within the sample, which directly correlates with 
the absorbance of the sample as a result of the formazan dye. 
 
 
 
 
 
 
2.2.8.2 Advantages and disadvantages 
Importantly, this assay is very high throughput as it is undertaken in a 96-well format, 
allowing testing of series of new compounds at a large range of concentrations at any 
one time. However, the XTT assay measures cellular viability by an indirect method, 
since the production of the formazan dye depends on the activity of mitochondrial 
dehydrogenase within the sample. This therefore, does not indicate whether the cells 
within the sample are destined for apoptosis or whether they are simply arrested in the 
cell cycle. Cells which have arrested during the cell cycle may continue to replicate 
cellular contents without division. This can lead to an increase in mitochondrial 
dehydrogenase activity within the sample that does not correlate to cell proliferation. 
 
2.2.8.3 Method 
Exponentially growing U251 cells were trypinised, as described in section 2.2.3, and 
plated out into 96 well plates at 2 x103 cells/well. Cells were seeded in 90 µl of the 
growth medium and were then incubated at 37 oC in humidified atmosphere containing 
5% CO2 for 24 h, which allowed the cells to adhere, before 10 µl of medium containing 
the relevant drug concentration was added to the appropriate well. Where compounds 
were dissolved in DMSO, each well contained <0.1% DMSO, including untreated 
Figure 2.6: Metabolisation of XTT to the water soluble formazan salt, in viable cells 
From: http://www.roche.com/index.htm  
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controls. The ‘blank’ (control) lane contained 100 µl cell-free medium to allow for 
background subtraction. Cells were incubated for 5 days at 37 oC in humidified 
atmosphere containing 5% CO2 before addition of the XTT reagent. It should also be 
noted that all of the outer wells of the 96 well plate contained cell-free medium and 
were not used as part of the assay itself. These wells often experience evaporation of 
liquid, and therefore results obtained can be unreliable. This is often referred to as ‘edge 
effect,’ and it is for this reason that these wells were excluded from the assay.  
 
The XTT assay was obtained from Roche (Herts, UK), and is often referred to as the 
Roche Cell Proliferation Kit. The addition of the XTT reagent was as follows: 3.5 ml 
XTT labelling reagent (1mg/ml XTT (sodium 3’-[1-(phenylaminocarbonyl)- 3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulphonic acid hydrate in RPMI without 
Phenol red) was mixed with 70 µl electron coupling reagent (1.25 mM PMS (N-methyl 
dibenzopyrazine methyl sulphate in phosphate buffered saline) for each 96 well plate to 
be assayed. 50 µl of this mixture was added to each well (final XTT concentration 0.3 
mg/ml). Plates were incubated for 4 h in a humidified atmosphere at 37oC, 5% CO2. The 
XTT assay plates were read at 450 nm on a Spectromax Spectrophotometer (Molecular 
Devices, Berks, UK) at room temperature. 
 
Results were analysed using GraphPad Prism 4.0, and the growth inhibition of drug-
treated cultures was expressed as a percentage of control culture growth. 
 
2.3 Transient siRNA transfection 
2.3.1 Principle of siRNA technology 
RNA interference (RNAi) is now a widely used tool in the suppression of gene 
expression. It is a method of post-transcriptional gene silencing activated by double-
stranded RNA (dsRNA) which is homologous in sequence to the gene targeted for 
silencing (Fire, 1999). The key effectors in RNAi-mediated knockdown of gene 
expression are small interfering RNAs (siRNAs). These siRNAs are cleaved from a 
dsRNA silencing trigger, producing the 21-25 nucleotide molecules (Hannon G Nature 
2002). The cleavage is by an ATP-dependent enzyme, called DICER, which includes 
dual RNase-III catalytic domains, an RNA helicase domain and a binding motif 
(Bernstein et al., 2001). Following this, siRNAs become phosphorylated at their 5’-
hydroxyl group and are incorporated into the mutli-subunit protein-RNA complex, 
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called RISC (RNAi-induced silencing complex). The now activated RISC uses the 
siRNA as a guide to complex homologous substrate mRNA, and cleaves it exactly 10 
nucleotides upstream from the first complementary nucleotide of the 5’ end of the 
siRNA. The newly cleaved mRNA does not contain a poly-A tail, and is therefore 
quickly degraded by exonucleases, resulting in the loss of RNA transcripts and hence 
the suppression of gene expression. This is shown in Figure 2.7. 
 
 
 
 
 
 
Therefore this technique is widely used in molecular and cellular biology in order to 
validate potential targets, in the drug discovery process, to classify new functions for 
existing drugs, and to generate isogenic paired cell lines. This technique relies on the 
siRNA being imported into the cell using either lipid transfection methods, which can 
make a minute hole in the cell membrane in order to transport the nucleic acid across, or 
by electroporation, which uses an electro-static pulse to make the same type of hole in 
the cell membrane through which the siRNA can pass. In this thesis, lipid transfection 
methods have been favoured. 
 
2.3.2 Advantages and disadvantages 
The major advantage of siRNA technology is the ability to manipulate gene expression 
in vitro and in vivo within a relatively short timescale, for example some knockdown of 
gene expression occurs only 24 h after transfection. This therefore opens up enormous 
Figure 2.7: Mechanism of gene silencing using siRNA 
From: (Plasterk, 2002) 
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possibilities for the use siRNAs in a whole range of assays, and even as potential drug 
candidates in the future. However, knockdown of RNA transcript and therefore 
expression at the gene and protein levels, can have different effects from small molecule 
inhibition, and therefore this caveat should always be taken into consideration and will 
be discussed further in Chapter 3 and 4. 
 
2.3.3 Rehydration of siRNA 
Six siRNA molecules were used within this thesis; four were used in order to 
knockdown expression of murine p65, human p65, murine PARP-1 and human PARP-1 
and two were used as control/non-specific siRNAs (murine NS and human NS). The 
siRNA sequences are shown in Table 2.2. 
 
Target gene siRNA sequence 
Murine p65 GGAGUACCCUGAAGCUAUA 
Human p65 GCCCUAUCCCUUUACGUCA 
Murine PARP-1 GGAGGAAGGUGUCAACAAA 
Human PARP1 AAGCCUCCGCUCCUGAACAAU 
  
 
 
 
All siRNA molecules were synthesised by Dharmacon (Cramlington, UK), and required 
rehydration, which was undertaken according to manufacturers’ instructions. Briefly, 1 
ml of 1x siRNA buffer (Dharmacon, Cramlington, UK) was added to each individual 
tube of siRNA and pipetted up and down 5 times to mix. The solution was then placed 
on an orbital shaker for 30 min at room temperature before the concentration 
determined using the Nanodrop ND-1000 spectrophotometer (Labtech, East Sussex, 
UK), reading at OD260. This piece of equipment estimates the concentration of RNA, 
using only 1 µl of the RNA sample and also gives the 260:280 ratio. This ratio is an 
indicator of RNA quality and integrity and must be between 1.9 and 2.1. 
 
2.3.4 Transient transfection of siRNA  
Cells were plated at 1 x 104cells/ well in 6-well plates and then incubated at 37 oC in a 
humidified atmosphere containing 5% CO2, for 24 h, in order to adhere. Following this, 
cells were transfected with either 50 nM p65, PARP-1 or NS siRNA. siRNAs were 
incubated in serum free RPMI for 5 min (this is because serum can be very sticky and 
can therefore adhere to the siRNA molecules) before mixing with the transfection 
Table 2.2: siRNA sequences used in these studies 
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reagent, Lipofectamine 2000 (Invitrogen, Paisley, Scotland), also diluted in serum free 
RPMI. The resultant transfection cocktails were incubated at room temperature for a 
further 20 min (this allows the siRNA molecules to form complexes with the 
Lipofectamine 2000, which can then be transported into the cell) before applying to the 
6-well plates containing cells. Cells were then incubated at 37 oC in humidified 
atmosphere containing 5% CO2, for 5 h, before aspirating this media and replacing with 
full media (RPMI 1640, 10 % FBS) for a further 48 h at 37 oC in humidified atmosphere 
containing 5% CO2. Protein knockdown was assessed by Western blotting (section 2.5) 
in all silencing experiments of p65 and PARP-1 performed throughout this thesis. 
 
2.4 Quantification of PARP activity from permeabilised cells 
PARP activity was measured in whole cells by using the published method by 
(Plummer et al., 2005) which has been validated to Good Clinical and Laboratory 
Practise (GCLP) standards, and is currently used in Phase I and II clinical trials. The 
principle of this technique relies on the incorporation of the ADP-ribose moiety NAD+ 
into acid-insoluble poly (ADP-ribose) (PAR) polymer. The presence of a DNA 
oligonucleotide (see 2.4.2) activates PARP-1 which uses both itself and intracellular 
proteins as PAR acceptors. This is quantified against a standard curve of purified PAR 
(see section 2.4.3) and is detected by immunoblotting (see 2.4.6) with a purified 
antibody against PAR and in this case chemiluminescence is directly proportional to 
PARP activity.  It should be noted that neither the NAD+ or the oligonucleotide can 
enter intact cells, and therefore the plasma membrane was rendered ‘permeabilised’ by 
either hypotonic shock or treatment with digitonin (see 2.4.4).  A reaction schematic is 
shown in Figure 2.8. 
 
2.4.1 Preparation of NAD+ 
A stock solution of 7 mM NAD+ (Sigma) was freshly prepared in dH2O on the day of 
each assay. The optical density (OD) at 260 nm of a 1/100 dilution of this stock NAD+ 
solution was measured using spectrophotometer (WPA Biowave, S1200Diode array, 
Scientific Laboratory Supplies, Nottingham, UK) and a 1 cm silica cuvette. The Molar 
extinction coefficient (ε) for NAD+ at 260 nm is known to be 18000 and therefore 18 
OD = 1 mM NAD+ (Beer Lambert Law). The absolute molarity of the stock solution 
was calculated and a working solution of 700 µM NAD+ was prepared. 
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2.4.2 Preparation of oligonucleotide 
Pellets of a palindromic sequence oligonucleotide (CGGAATTCCG) were purchased 
from Invitrogen (Paisley, Scotland), and were dissolved in 500 µl 10 mM Tris/EDTA, 
pipetting vigorously to ensure the pellet is fully re-suspended. This solution is then 
heated to 60 °C in a waterbath and cooled by 1 °C/min to 24 °C by the addition of ice 
flakes, in order to ensure correct strand re-annealing. Once this has occurred, a further 
1.5 ml of 10 mM Tris/EDTA is added and a 1 in dilution is made (again with 10 mM 
Tris/EDTA) and the OD is measured at 260 nm. In this case 1 OD unit is equivalent to 
50 µg/ml, and the final stock is diluted to 200 µg/ml, and stored at -20 °C until use. 
 
2.4.3 Preparation of PAR standards 
Purified PAR is purchased from Biomol (Exeter, UK), as a branched and linear 
polymer, with an average chain length of 25 ADP-ribose monomers (range 3-300). 100 
µl of a 10 µg/ml solution is provided, and it is taken that 1 µl is equivalent to 2000 pmol 
ADP-ribose monomer. In order to dilute this solution, to use in the assay, it is diluted 1 
in 80 in dH2O to give a stock of 25 pmol of ADP-ribose polymer per 100 µl of solution. 
This solution is then serially diluted in dH2O at final concentrations of 25, 5, 1, 0.2, 0.04 
and 0 pmol, and this is loaded onto the immuno-blot (see section 2.4.6). 
 
 
 
Figure 2.8: Schematic protocol for the quantification of PARP activity from 
permeabilised cells 
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2.4.4 Preparation and use of quality control standards and samples 
The murine leukaemic L1210 cells are used as a quality control (QC) for this assay and 
aliquots provided were frozen down and stored at -80 °C by Dr. Evan Mulligan. On the 
day of assay, one aliquot was removed from -80 °C storage and thawed gently to room 
temperature before transferring into a 20 ml universal tube. At this point, samples (e.g. 
cell lines) to be assayed were trypinised and also transferred to 20 ml universal tubes. 
All samples, along with the QC were vortexed and pelleted at 500 xg for 5 min at 4 °C, 
before washing with PBS and this pelleting repeated. Cells were then re-suspended in 
50 µl of ice cold 0.15 mg/ml digitonin in dH2O, in order to permeabilise them, and left 
on ice for 5 min before the addition of 450 µl of ice cold isotonic buffer (7 mmol/L 
HEPES, 26 mmol/L KCl, 0.1 mmol/L, dextran, 0.4 mmol/L EGTA, 0.5 mmol/L MgCl2, 
45 mmol/L sucrose (pH 7.8)). A small aliquot was mixed in equal volumes with trypan 
blue and counted using a haemocytometer (see section 2.2.4). In this case, however it is 
expected that the digitonin/isotonic buffer will have permeabilised the cell membrane 
and hence the majority of cells should appear blue when visualised by microscopy. 
More than 90 % of cells must be permeabilised for the assay to continue. Once the 
count is complete, the cell suspension is diluted to 1.22 x 105/ml in ice cold isotonic 
buffer in preparation for the PARP reaction. 
 
2.4.5 PARP reaction 
Firstly, HybondN membrane and 2 pieces of 3 mm Whatman filter paper were soaked in 
PBS for at least 15 min prior to commencement of the PARP reaction. The 
oligonucleotide, prepared as described above, was thawed gently on ice and STOP 
solution, (AG-014699 diluted in PBS to a final concentration of 12.5 µM) was also 
prepared. Reaction tubes (15 ml falcon tubes) were set up as shown in Table 2.3, note 
that these tubes are set up in triplicate and set up in the presence or absence of NAD+ 
and oligonucleotide, in order to determine stimulated versus un-stimulated PARP 
activity. 
Reagent Stimulated Un-stimulated 
Oligonucleotide 5 µl - 
NAD+ 5 µl - 
dH2O - 10 µl 
Reaction buffer 40 µl 40 µl 
Cell suspension 50 µl 50 µl 
Reaction Total 100 µl 100 µl 
STOP solution 400 µl 400 µl 
Final volume 500 µl 500 µl 
 
Table 2.3: PARP reaction mix components 
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Reaction test tubes containing reaction buffer with either oligonucleotide and NAD+ or 
sterile water, and 1.5 ml tubes containing the cell suspension (section 2.4.4) were then 
warmed in a waterbath at 26 °C for 7 min. Following this the cell suspension was 
vortexed briefly and 50 µl added to each reaction tube. Reaction tubes were replaced in 
the 26 °C waterbath for a further 6 min, with gentle shaking and the reaction was 
stopped with the addition of an excess of the pre-prepared STOP solution. Reaction 
tubes were placed on ice and immunoblotting was undertaken within 1 hr. 
 
2.4.6 Loading of immunoblot manifold and subsequent immunoblotting 
Once samples and QCs had undergone the PARP reaction, they were blotted, along with 
the purified PAR standards, onto HybondN membrane (GE Healthcare, Amersham, 
UK). This membrane was chosen for its ability to bind up to 600 µg of nucleic acids per 
cm2. The membrane, along with two pieces of 3 mm filter paper (Whatman, GE 
Healthcare, Amersham, UK) were pre-soaked in PBS prior to immuno-blot loading onto 
the assay manifold (kindly provided by Prof. Nicola Curtin). PAR standards (400 µl), 
L1210 QC samples (500 µl) and the unknown samples (500 µl) were loaded onto the 
blot by pipetting. Once all wells were loaded, suction was applied using Vacusafe 
comfort (IBS integra Biosciences, Nottingham, UK), which was attached to the 
manifold equipment. Wells were then washed and fixed, firstly with a solution of 10 % 
Tricholoacetic acid (TCA, Sigma), 2 % Sodium pyrophosphate decahydrate (NaPPi, 
Sigma), and secondly with a 70 % ethanol solution. Again suction was applied to 
remove any excess liquid.  
 
The manifold was disassembled and the immuno-blot was washed in PBS to remove 
any traces of ethanol before blocking in non-fat dried milk dissolved in 0.05 % Tween 
in PBS (PBS-MT) to prevent nonspecific binding of antibodies to unoccupied sites on 
the membrane. Tween 20 (polyoxyethylene-sorbitanmonolaureate, Sigma) is a mild 
ionic detergent used in all buffers throughout immunodetection as it reduces non-
specific binding to nitrocellulose and antigens. PBS-MT was also used for the dilution 
of antibodies in the immunodetection procedure. To this end, the immune-blot was 
incubated overnight at 4 °C, in primary antibody (10 H, kindly provided by Prof. 
Alexander Burkle, University of Constanz) at a dilution of 1 in 1000 in PBS-MT. The 
immuno-blot was then washed with PBS-T before a 1 h incubation with goat-anti mouse 
HRP-conjugated secondary antibody (diluted 1 in 1000 in PBS-MT), at room 
temperature. Following this, the blot was washed with PBS-T for a further hour before 
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detection using ECL (GE Healthcare, Amersham, UK, section 2.5.7). Briefly, reagents 
were mixed in 1:1 ratio in a volume sufficient to cover the membrane equally which 
was then transferred onto the blot with a pipette. The blot was left for 1 min before 
excess reagent was removed. The blot was then wrapped in a plastic document wallet 
and placed protein side up in the Fuji LAS 3000 and the image captured with an 
exposure 5 min. 
 
2.4.7 Analysis of results using Aida Image Analyser 
Immuno-blot images captured using the Fuji LAS 3000 were analysed using Aida 
Image Analyser version 3.28.001 using the 2D, densiometric analysis function within 
the software. Regions of interest (samples or purified PAR standards) were identified 
and background measurements on unused portions of the immuno-blot were also 
assigned to allow for background subtraction. The software generates a standard curve 
from the purified PAR standards, and PARP activity (pmol PAR) of the unknown 
samples was extrapolated from this. 
 
2.5 Protein analysis 
2.5.1 Preparation of whole cell extracts 
Cell pellets were re-suspended in an appropriate volume of ice cold lysis buffer (50mM 
NaF, 20mM HEPES, 450mM Nacl, 25% v/v Glycerol, 200µM EDTA, 500µM DTT) at 
approximately 1 x 107 cells per 200 µl of lysis buffer, in a 1.5 ml microfuge tube. 
Samples were then lysed by freeze-thawing cycles (3 cycles of 2 minutes on dry ice and 
2 minutes in 30°C water bath).  Cell lysates were centrifuged at 14,000 rpm for 7 min at 
4 °C to remove cell debris and the supernatant removed for analysis. An aliquot from 
these whole cell lysates was then removed for protein estimation and the remaining 
volume was then snap frozen and stored at -80°C until use for Western blotting. 
 
2.5.2 Extraction of nuclear and cytoplasmic protein fractions using the Pierce NE 
PER kit 
Adherent cells were trypsinised and pelleted at 3000 rpm for 5 min and washed with 
PBS. Nuclear and cytoplasmic extracts were the prepared using the NE-PER Nuclear 
and Cytoplasmic extraction kit, according to manufacturers’ instructions (Pierce, Perbio 
Science UK Ltd., Cramlington, UK). Briefly, cell pellets were re-suspended in the CER 
I reagent, which was supplemented with protease inhibitor cocktail (Roche, West 
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Sussex, UK) and allowed to lyse on ice for 10 min, after which CER II reagent was 
added to facilitate full disruption of the cell membrane and release of cytoplasmic 
contents. Following centrifugation to isolate the cytoplasmic extract, the nuclear pellet 
was resuspended in the NER I reagent, supplemented with protease inhibitor cocktail, 
via repeated vortexing for 40 min. The supernatant (nuclear extract) was removed, and a 
small aliquot was taken for protein estimation, whilst the remaining volume was then 
snap frozen and stored at -80°C until use in the ELISA-based assays (section 2.9) or 
Western blotting.  
 
2.5.3 Quantification of protein using the Pierce protein assay 
2.5.3.1 Principle 
Protein estimation is possible through using the bicinchonic acid (BCA) method which 
combines the reduction of Cu2+ to Cu1+ by protein in alkaline conditions with the 
colorimetric detection of the cuprus cation (Cu1+). In this case the Cu1+ ion reacts with 
bicinchonic acid to form a purple BCA-Cu1+ complex product, formed by the chelation 
of two BCA molecules with one Cu1+ ion. This purple-coloured solution is detected 
spectrophometrically at 562 nm. This method was chosen as the cell lysis method does 
not interfere with this assay. 
 
2.5.3.2 Method 
The BCA protein assay (Pierce, Perbio Science UK Ltd., Cramlington, UK), was used, 
according to manufacturers’ instructions, to estimate the protein content of either whole 
cell extracts or nuclear and cytoplasmic cellular fractions. Briefly, the Albumin standard 
provided containing bovine serum albumin (BSA) at 2 mg/ml was used to prepare six 
standard solutions of 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mg/ml.  Unknown samples were 
typically diluted 1:10 with dH2O.  Standards, unknown samples and dH2O blanks were 
loaded in quadruplicate in 10 µl volumes onto 96 well plates.  BCA reagent A (20 mls) 
and BCA reagent B (4 mls) were combined and 190 µl of the mixture was added to each 
well and then mixed on a plate shaker for 30 seconds.  The plate was covered and 
incubated at 37 ºC for 30 minutes.  Absorbance at 562 nm was read on the Spectromax 
plate reader (Molecular Devices, Berks, UK) and unknown protein concentrations were 
calculated from the standard curve generated by the plate reader, taking into account the 
10-fold dilution factor. 
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2.5.4 Separation of protein extracts by molecular weight by SDS-polyacrylamide gel 
electrophoresis 
2.5.4.1 Principle 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique which has allowed the separation and analysis of proteins in a given sample. 
SDS is an amphiphillic 12 carbon alkyl sulphate molecule which denatures proteins and 
forms a charged micelle around polypeptide chains. This micelle ablates the native 
charge of the polypeptide and the SDS-protein aggregate has an equal resultant charge 
per unit volume dependent upon the size of the micelle which is determined by the size 
of the polypeptide chain. Thus proteins move through the electrophoresis gel toward the 
anode according to size. 
 
The polyacrylamide gel is formed from the polymerisation of acrylamide monomers 
into chains which are cross-linked by bisacrylamide, producing a gel with pores through 
which polypeptide chains travel. The size of the pores determines the rate at which the 
proteins travel. A gel with a variable gradient allows proteins of large size to be 
resolved on the same gel as small proteins which are retarded by higher acrylamide 
concentrations further down the gel. 
 
The protein expression assessed in this thesis included that of the large protein, DNA-
PK, which a molecular weight of 450 kDa, as well as the low molecular weight protein, 
β-actin (43 kDa). Therefore, the separation of such proteins by PAGE requires specific 
gel composition. The Criterion XT Tris-acetate gels are based on a Tris-acetate buffer 
system (pH 7.0). This uses discontinuous acetate and Tricine ion fronts to form moving 
boundaries to stack and then separate large denatured proteins by molecular weight. XT 
Tris-acetate gels are made without SDS, allowing the sample buffer and running buffer 
to dictate the separation mechanism. Protein samples are prepared in a reducing 
denaturing sample buffer. The sample buffer contains SDS which, along with heat is 
used to denature the proteins. 
 
2.5.4.2 Method 
Whole cell extracts, described in section 2.5.1, were mixed with 4X XT loading buffer 
(Biorad, Hertfordshire, UK) and fresh extraction buffer (section 2.5.1) to the final 
required protein concentration  of 30 µg in a final volume of 25 µl . Samples were then 
loaded into a heating block and incubated at 95 °C for 5 min to denature proteins in the 
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sample. Once allowed to cool, samples were loaded onto an 18 well (30 µl) pre-cast 3-
8% Tris-Acetate polyacrylamide gel (13.3 x 8.7 cm, 1mm thick, for electrophoresis 
(BioRad). HiMark pre-stained high molecular weight marker (Invitrogen, Paisley, 
Scotland) was also loaded onto the gel in order to estimate protein size in the samples. 
Gels were placed in a BioRad criterion gel tank according to the manufacturer’s 
guidelines and the electrophoresis tank filled with 1 x Tricine running buffer (Biorad, 
Herfordshire, UK). Electrophoresis was performed using a constant voltage of 90 V 
using a PowerPack 200 power supply (Biorad, Herfordshire, UK) and continued until 
the bromophenol blue in the loading dye had reached the bottom of the gel.  
 
2.5.5 Western blotting 
The immobilisation of macromolecules separated by electrophoresis was first performed 
for DNA (Southern, 1975), but has been extended for both RNA and proteins. In 
Western blotting, proteins are transferred from polyacrylamide gels onto a protein 
binding membrane such as nitrocellulose or polyvinylidene difluoride. This transfer is 
achieved through electro-elution in a transfer buffer. A transfer buffer with a low 
alcohol content is favoured in order to ensure the transfer of larger (>100 kD) proteins. 
Immobilisation of proteins onto the membrane is followed by immunodetection by 
specific antibodies. 
 
2.5.5.1 Method 
The electroblotting apparatus was set up as described in the manufacturer’s instructions 
(BioRad, Herfordshire, UK), with components, including the fibre pads, 3 mm filter 
paper (Whatman, GE Healthcare, Amersham,  UK) and HybondC nitrocellulose 
membrane (GE Healthcare, Amersham, UK) after being soaked in 1.5 x Novex transfer 
buffer (Invitrogen, Paisley, Scotland) for at least 15 min beforehand. HybondC 
nitrocellulose membrane was chosen for its protein binding capacity. This membrane 
has a binding capacity of 80-100 mg/cm2 due to electrostatic and hydrophobic 
interactions with the nitrocellulose web. The blotting cassette was constructed as shown 
in Figure 2.9, and care was taken to ensure there were no air bubbles between any of the 
layers.  The transfer of separated proteins from the gel to the nitrocellulose membrane 
was the achieved by the application of an electric current which passed through the gel 
in the direction of the membrane, carrying with it the protein.  In this case, the proteins 
were transferred for 1 h using a constant voltage of 100 V, on ice. Once transferred, the 
cassette was disassembled and the membrane recovered for immunoblotting. 
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2.5.6 Immunodetection 
The nitrocellulose membrane was blocked in non-fat dried milk dissolved in 0.05 % 
Tween in TBS to prevent nonspecific binding of antibodies to unoccupied sites on the 
nitrocellulose membrane. Tween 20 (Sigma) is a mild ionic detergent used in all buffers 
throughout immunodetection as it reduces non-specific binding to nitrocellulose and 
antigens. 0.05 % Tween in TBS was also used for the dilution of antibodies in the 
immunodetection procedure. After blocking, the membrane was incubated in a primary 
antibody specific to the protein of interest, as described along with the relevant 
conditions in Table 2.4. This was followed by a secondary antibody from a different 
species raised against the Ig of the first species, also described in Table x. This 
secondary antibody is conjugated to HRP which catalyses the reaction provided by the 
ECL system. 
 
Target Species 
(raised in) 
Manufacturer Catalogue 
number 
Dilution Conditions 
NF-κB p65 Mouse Santa Cruz 
Biotechnology 
sc-8008x 1 in 3000 1 h RT 
NF-κB p50 Mouse Santa Cruz 
Biotechnology 
sc-8414 1 in 1000 1 h RT 
NF-κB p52 Rabbit Santa Cruz 
Biotechnology 
sc-298 1 in 1000 o/n 4 °C 
NF-κB 
RelB 
Rabbit Santa Cruz 
Biotechnology 
sc-226 1 in 1000 o/n 4 °C 
NF-κB  
c-Rel 
Rabbit Santa Cruz 
Biotechnology 
sc-71 1 in 1000 o/n 4 °C 
PARP-1 Rabbit Santa Cruz 
Biotechnology 
H-250 1 in 1000 1 h RT 
Figure 2.9: Set up of the transfer cassette for Western blotting (Biorad system) 
119 
 
Lamin Mouse Santa Cruz 
Biotechnology 
sc-7293 1 in 500 o/n 4 °C 
β-actin Mouse Calbiochem CP01 1 in 10000 1 h RT 
DNA-PK 
(ser 2056) 
Rabbit Abcam Ab18192 1 in 100 o/n 4 °C 
DNA-PKcs Mouse Thermo-
Shandon 
MS-370-P 1 in 500 1 h RT 
Anti-mouse 
Ig-HRP 
Goat DAKO P0447 1 in 1000 1 h RT 
Anti-rabbit 
Ig-HRP 
Goat DAKO P0448 1 in 1000 1 h RT 
 
 
 
2.5.7 Enhanced chemiluminesence for protein detection 
2.5.7.1 Principle 
Enhanced chemiluminesence (ECL) is a light emitting, non-radioactive and highly 
sensitive system that is able to detect less than 1 pg of antigen on nitrocellulose. ECL 
requires the oxidation of luminol in the presence of an enhancer (phenol) under alkaline 
conditions by HRP, shown in Figure 2.10. This oxidation places luminol in an excited 
state which decays to ground state with the associated emission of light. Phenol increase 
the light output by 1000-fold and prolongs the time of emission so that peak emission 
occurs between 2 and 30 min following incubation with reagents. The maximum light 
emission occurs at 428 nm which can be detected by autoradiography film or charge 
couple devices such as Fuji LAS 3000. 
 
 
 
 
2.5.7.2 Method 
ECL was used as per manufacturer’s protocol (GE Healthcare, Amersham, UK). 
Briefly, luminol enhancer and peroxide reagents were mixed in 1:1 ratio in a volume 
sufficient to cover the membrane equally which was then transferred onto the blot with 
Table 2.4: Primary and secondary antibodies used in Western blotting 
Figure 2.10: The HRP conjugate on the secondary antibody catalyses the formation of 
2H2O + O22- from peracid, leading to the peroxidase catalysed degradation of 
Luminol, which in turn produces the luminescence 
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a pipette. The blot was left for 1 min before excess reagent was removed. The blot was 
then wrapped in a plastic document wallet and placed protein side up in the Fuji LAS 
3000 and the image captured with an exposure of the appropriate time.  
 
2.5.8 Quantification using Aida Image Analyser 
Immuno-blot images captured using the Fuji LAS 3000 were analysed using Aida 
Image Analyser version 3.28.001 using the 2D, densiometric analysis function within 
the software, as described in section 2.4.7.  
 
2.6 Analysis of apoptosis 
2.6.1 Annexin V FACs assay 
2.6.1.1 Principle 
It is widely accepted that loss of plasma membrane integrity is one of the earliest 
features of apoptosis. In cells undergoing apoptosis, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular environment. Annexin V is a 
35-36 kDa Ca2+ dependent phospholipid-binding protein that has a high affinity for PS, 
and binds to cells with exposed PS, hence identifying cells going through the early 
stages of apoptosis. Annexin V may be conjugated to fluorochromes including FITC, 
and still retains its high affinity for PS, therefore serving as a sensitive probe for flow 
cytometric analysis of cells that are undergoing apoptosis. FITC Annexin V staining 
precedes the loss of membrane integrity which is associated with the latest stages of cell 
death, known to result from either apoptotic or necrotic processes. For this reason, 
staining with FITC Annexin V is typically used in conjunction with a vital dye such as 
propidium iodide (PI), which can identify nuclear changes such as DNA fragmentation. 
Viable cells with intact membranes exclude PI, whereas the membranes of dead and 
damaged cells are permeable to PI. For example, cells that are considered viable are 
FITC Annexin V and PI negative; cells that are in early apoptosis are FITC Annexin V 
positive and PI negative; and cells that are in late apoptosis or already dead are positive 
for both FITC Annexin V and PI.   
 
2.6.1.2 Advantages and disadvantages 
The major advantage of this technique, over others which are used to investigate cellular 
levels of apoptosis is that this assay can differentiate between the stages of apoptosis. It 
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also a flow cytometric (FACs) based assay, and as with all FACs assays a known 
number of cells (referred to as ‘events’) are counted, across all samples, which means 
that any cell number is constant regardless of treatment status of each sample. An 
example of an annotated FACs plot is shown in Figure 2.11.  
 
 
 
 
FACs analysis is a technique for counting particles, such as cells and chromosomes, by 
suspending them in a stream of fluid and passing them by an electronic detection 
apparatus. It allows simultaneous multiparametric analysis of the physical and/or 
chemical characteristics of up to thousands of particles per second. Briefly, the 
principles of FACs analysis are centered around a beam of light (usually from a laser) of 
a single wavelength which is directed onto a hydrodynamically-focused stream of 
liquid. A number of detectors are aimed at the point where the stream passes through 
the light beam: one in line with the light beam (Forward Scatter or FSC) and several 
perpendicular to it (Side Scatter or SSC) and one or more fluorescent detectors. Each 
suspended particle from 0.2 to 150 micrometers passing through the beam scatters the 
ray, and fluorescent chemicals found in the particle or attached to the particle may be 
excited into emitting light at a longer wavelength than the light source. This 
combination of scattered and fluorescent light is picked up by the detectors, allowing 
analysis of the physical and chemical structure of each individual particle. FSC 
correlates with the cell volume and SSC depends on the inner complexity of the particle 
(i.e., shape of the nucleus, the amount and type of cytoplasmic granules or the 
membrane roughness).  
 
Figure 2.11: An example FACs plot from an annexin V assay 
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2.6.1.3 Method 
Cells were plated onto 6-well plates at a density that gave a final cell number of 3-5 x 
105 cells/ml on the day of experiment. Treatment schedules, regarding siRNA 
transfection and treatment with IR or drugs are as described in the individual chapters 
and figure legends. The PARP inhibitor, AG-014699 was added at final concentration 
of <0.1 % DMSO (v/v) in medium for all experiments. AG-014699 was added 1 h 
before γ-irradiation as described in the individual chapters and figure legends.  
 
For all experiments, cells were exposed to γ-irradiation then incubated at 37 oC in a 
humidified atmosphere containing 5% CO2 for 24 h. Following this the cells were 
trypsinised (as described in section 2.2.3) and counted using a haemocytometer (section 
2.2.4). The FITC Annexin V Apoptosis Detection Kit II (BD Biosciences, Oxford, UK), 
was then used to assess the levels of apoptosis in each sample, according to 
manufacturers’ instructions. Briefly, once counted, samples were re-suspended in 1x 
Binding buffer (provided) to a concentration of 1 x 106cells/ml, and 100 µl of this 
solution was transferred to a 5 ml FACs tube. 5 µl of FITC Annexin V and 5 µl of PI 
(both provided) were then added to each tube before vortexing, and incubation for 15 
min, at room temperature in the dark. Following this a further 400 µl of 1x Binding 
buffer was added to each sample and then sample were then analysed using the Becton 
Dickinson FACScan (Becton Dickinson, Oxford, UK) and Cell Quest Software (Becton 
Dickinson, Oxford, UK). Results were expressed as a percentage increase in apoptosis 
of treated sample, compared with untreated controls. 
 
2.6.2 Caspase 3/7 assay 
2.6.2.1 Principle  
The Caspase-Glo 3/7 Assay is a homogeneous, luminescent assay that measures 
caspase-3 and -7 activities from Promega (Southampton, UK). The assay provides a 
luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD, in 
a reagent optimized for caspase activity, luciferase activity and cell lysis. This peptide 
also contains a site which is cleaved by the caspases 3 and 7. The addition of the 
Caspase-Glo 3/7 Reagent in results in cell lysis, followed by caspase cleavage of the 
substrate and generation of a luminescent signal, produced by luciferase (Figure 2.12). 
The luminescence observed is proportional to the amount of caspase activity present. 
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2.6.2.2 Advantages and disadvantages 
This assay is undertaken in 96-well plate format, and hence compared with some other 
methods used to investigate the induction of apoptosis, it is much higher throughput. 
The luminescent assay also avoids interference from fluorescence signals, which can be 
an issue when screening new compounds.  This assay also requires fewer cells than 
many other methods, however the drawback to it is that is relies on the fact that the 
absolute cell number per well is constant, which may not always be the case in drug 
treated versus control samples. 
 
2.6.2.3 Method 
Cells were plated onto 96-well plates at a density that gave a final cell number of 2 x 
104cells/ml on the day of experiment. Treatment schedules, regarding siRNA 
transfection and treatment with IR or drugs are as described in the individual chapters 
and figure legends. The PARP inhibitor, AG-014699 was added at final concentration 
of <0.1 % DMSO (v/v) in medium for all experiments. AG-014699 was added 1 h 
before γ-irradiation as described in the individual chapters and figure legends.  
 
For all experiments, cells were exposed to γ-irradiation then incubated at 37 oC in a  
humidified atmosphere containing 5% CO2 for 24 h. Caspase-Glo 3/7 Reagent was 
prepared, according to manufacturers’ instructions by mixing 10 ml of the Caspase-Glo 
3/7 buffer with the Caspase-Glo 3/7 substrate (both provided). This was mixed gently 
Figure 2.12: Caspase-3/7 cleavage of the luminogenic substrate containing the 
DEVD sequence. Following caspase cleavage, a substrate for luciferase 
(aminoluciferin) is released, resulting in the luciferase reaction and the production of 
light 
From:http://www.promega.com/ 
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by inverting before adding it to the culture medium at a 1:1 ratio. Plates were then 
shaken for 30 s and incubated at room temperature for 2 h. Cell lysates were transferred 
to a white-walled 96-well plate. Luminescence was measured using a microplate 
luminometer (Perkin Elmer, Buckinghamshire, UK). Results were expressed as a 
percentage increase in apoptosis of treated sample, compared with untreated controls. 
 
2.7 Quantification of single stranded DNA breaks following DNA damaging agents 
2.7.1 Alkaline Comet assay 
2.7.1.1 Principle 
The alkaline Comet assay kit (Trevigen, Gaithersberg, MD, USA) is used to analyse the 
DNA fragmentation associated with DNA damage, in particular damage caused by 
SSBs. Cells are mixed with low melting point agarose and are pipetted onto  specially 
treated pre-coated slides in order to promote agarose adherence. Alkaline conditions are 
then used to unwind and relax DNA, which is then able to migrate out of the cell during 
electrophoresis. DNA can then be visualised using SYBR Green nucleic acid gel stain. 
Cells that have accumulated DNA damage appear as fluorescent comets with tails of 
fragmented DNA, whereas, normal undamaged DNA does not migrate far from the 
origin. This is shown in Figure 2.13. 
 
 
 
 
 
 
2.7.1.2 Advantages and disadvantages 
This assay allows analysis of SSBs at the single cell level and therefore allows insight 
into the extent and diversity of DNA damage across an entire population of cells. It 
should be noted that although this alkaline Comet assay is used to identify SSBs, it can 
detect some DSBs and alkali labile sites, therefore it is important to choose doses of 
Figure 2.13: Comet assay workflow 
From: http://www.trevigen.com/  
125 
 
DNA damaging agents (known to activate both SSBs and DSBs), that are reported to 
activate a greater proportion of SSBs, compared with DSBs. However, there is another 
version of the Comet assay which uses neutral conditions, which detects primarily 
DSBs. 
 
2.7.1.3 Method 
Cells were plated onto 6-well plates at a density that gave a final cell number of 3-5 x 
105 cells/ml on the day of experiment and treated with siRNA and IR or drugs are as 
described in the individual chapters and figure legends. For all experiments, cells were 
exposed to drug for a given length of time (see individual figure legends) and incubated 
at 37 oC in humidified atmosphere containing 5% CO2. Following this the cells were 
trypsinised (secion 2.2.3) and pelleted at 500 xg for 5 min. Cells were washed once with 
PBS and re-pelleted as before, then counted using a haemocytometer (section 2.2.4). 
Following this, cells were re-suspended in ice cold PBS to a concentration of 1 x 
105cells/ml. Cells were then mixed with proprietary low melting point agarose, which 
had been pre-warmed to 37 °C. This cell/agarose mix was then pipetted on Comet slides 
and placed at 4 °C in order to gel. Once set, the slides were incubated for 30 min in 
Comet lysis solution at 4° C in the dark in order to relax the DNA. Slides were 
protected from light to prevent any further DNA damage, and kept at 4 °C in order to 
prevent DNA repair. Following this, slides were incubated in Alkaline unwinding 
solution (300 mM sodium hydroxide, 1 mM EDTA, pH>13), which unwinds the DNA, 
before being subjected to electrophoresis under alkaline conditions (Alkaline 
electrophoresis solution: 300 mM sodium hydroxide, 1 mM EDTA, pH>13) at 20 V for 
40 min, in the dark, and then fixed, with 70 % ethanol. After drying at room 
temperature overnight, in the dark, slides were stained with SYBR Green nucleic acid 
gel stain in TE buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA).  
 
2.7.2 Fluorescence microscopy to visualise Comet slides and quantification using 
Komet 5.5 
An Olympus BH2-RFCA fluorescence microscope (10x objective) (GX Optical, 
Suffolk, UK) with Hamamatsu ORCAII BT-1024 cooled CCD camera (Hamamatsu 
Photonics, Massy, France) was used to capture images. Image Pro Plus (Media 
Cybernetics, Bethesda, MD, USA) was used for image capture. The software package, 
Komet 5.5 (Kinetic Imaging, Nottingham, UK), was used to analyse results providing 
extensive Comet measurements and data including  percentage head DNA, percentage 
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tail DNA, tail length, olive tail moment and Comet optical intensity. Data is represented 
in two forms, firstly using the Olive Tail Moment (OTM), which is used as a measure of 
both the smallest detectable size of migrating DNA (reflected in the comet tail length) 
and the number of relaxed / broken pieces (represented by the intensity of DNA in the 
tail), and secondly by the percentage DNA in the comet tail, both are recommended by 
the Comet Assay Interest Group. 
 
2.8 Quantification of NF-κB DNA binding activity 
2.8.1 Measurement of NF-κB DNA binding using the Pierce EZ detect p65 DNA 
binding ELISA 
The ability of murine NF-κB p65 or p50 to bind a specific κB consensus sequence was 
assessed using an EZ-Detect Chemiluminescent Transcription Factor Assay (Pierce, 
Perbio Science UK Ltd., Cramlington, UK) according to the manufacturer’s 
instructions. Cells were plated onto 6-well plates at a density that gave a final cell 
number of 3-5 x 105 cells/ml on the day of experiment and treated with siRNA and IR 
or drugs are as described in the individual chapters and figure legends. For all 
experiments, cells were exposed to drug for 24 h incubated at 37 oC in a humidified 
atmosphere containing 5% CO2. Following this the cells were trypsinised (as described 
in section 2.2.3) and harvested at various timepoints (see figure legends) for nuclear 
extraction. Nuclear lysates of equivalent protein levels, prepared using the NE PER kit 
(section 2.5.2) were allowed to bind to the consensus sequence (Table 2.5), which was 
pre-bound to a 96-well Enzyme-linked immunosorbent assay (ELISA) plate provided 
with the assay in the presence of poly dI•dC and an NF-κB binding buffer for 1 h at 
room temperature with gentle agitation. Importantly, the poly dI•dC was added to 
prevent any non-specific binding. Non-specific DNA binding was assessed via 
incubation of nuclear lysates with mutant or wild type competitor duplexes (Table 2.5), 
thus providing a robust control for the assay.  
 
κB consensus sequence GGGACTTTCC 
Wild-type competitor duplex 5’-CACAGTTGAGGGGACTTTCCCAGGC-3’ 
3’-GTGTCAACTCCCCTGAAAGGGTCCG-5’ 
Mutant competitor duplex 5’-CACAGTTGAGGCCACTTTCCCAGGC-3’ 
3’-GTGTCAACTCCGGTGAAAGGGTCCG-5’ 
 
Table 2.5: Competitor duplexes for NF-κB DNA binding assay (Pierce) 
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The plate is then washed three times with the wash buffer provided and incubated with a 
primary antibody against the p65, or p50, NF-κB subunit for 1 h. Following washes, the 
plate is then incubated in the presence of an HRP-tagged secondary antibody directed 
against the anti-p65 or anti-p50 primary antibody for a further hour. Antibody binding is 
detected via incubation of the plate with a chemiluminescent substrate and read using a 
Fuji LAS 3000. The reaction scheme is shown in Figure 2.14. Images were analysed 
using Aida Image Analyser version 3.28.001 using the 2D, densitometric analysis 
function within the software, as described in section 2.4.7. Values were corrected for 
background activity and expressed as mean fold values of triplicates. 
 
 
 
 
 
 
2.8.2 Measurement of NF-κB DNA binding using the TransAM Family ELISA 
The ability of human NF-κB p65, p50, p52, RelB or c-Rel to bind a specific κB 
consensus sequence was assessed using a TransAM Family ELISA Assay (Active 
Motif, Rixensart, Belgium) according to the manufacturer’s instructions. Cell treatment 
and nuclear extraction was as described in section 2.8.1, for the EZ Detect ELISA 
Assay. In this case, nuclear lysates of equivalent protein levels, prepared using the NE 
PER kit (section 2.5.2) were allowed to bind to the consensus sequence, which was pre-
bound to a 96-well ELISA plate  in the presence of herring sperm DNA and an NF-κB 
binding buffer for 1 h (both provided) at room temperature with gentle agitation. Once 
again, non-specific DNA binding was assessed via incubation of nuclear lysates with 
mutant or wild type competitor duplexes. The plate was then washed three times with 
the wash buffer provided and incubated with a primary antibody against the p65, p50, 
Figure 2.14: Schematic protocol for EZ-Detect NF-κB p50 and NF-κB p65 
Transcription Factor Assay Kits. 
From: http://www.qcbio.com/pierce/89858.htm 
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p52, RelB or c-Rel for 1 h. Following washes, the plate was then incubated in the 
presence of an HRP-tagged secondary antibody directed against the chosen primary 
antibody for a further hour. Antibody binding was detected via a colourimetric reaction, 
and in this case the plate was incubated with developing solution for 5 min at room 
temperature until the wells developed a blue colour. This reaction was stopped by the 
addition of the stop solution containing an acid, which turns the blue colour yellow. 
Absorbance was then read at 450 nm on the Spectromax plate reader (Molecular 
Devices, Berks, UK), and values were corrected for background activity and expressed 
as mean fold values of triplicates.  
 
2.8.4 Advantages and disadvantages 
There are other methods used to assess the DNA binding of transcription factors, 
including the classical gel retardation, or EMSA. Although this assay is highly sensitive, 
it is not as high throughput as the ELISA-based assays used here. In an EMSA, nuclear 
extracts are incubated with a radio-active double-stranded oligonucleotide probe 
containing the transcription factor consensus sequence, therefore if the transcription 
factor is active, it will bind to the probe. Sample are resolved using electrophoresis on 
poly-acrylamide gels and probed using methods similar to those described for Western 
blotting in section 2.5. This method is much more time consuming and also requires the 
use of radio-chemicals, which therefore make the ELISA assays, a better choice for the 
assessment of transcription factor DNA binding. Importantly, a large number of DNA 
binding assays were undertaken as part of this thesis, and therefore the ELISA was the 
method of choice in these cases due to the fact it is a high-throughput assay, which 
allowed the direct comparison of a number of extracts within one plate. 
 
2.9 Quantification of NF-κB-dependent gene transcription 
2.9.1 Competent cells 
Competent cells used for transformation of plasmid DNA were Top10 (purchased from 
Invitrogen, Paisley, Scotland.) 
 
2.9.2 Bacterial transformations 
1-2 µg of plasmid DNA was added to 100µl of competent cells and mixed by gentle 
pipetting. A control aliquot of competent cells with no DNA added was also 
transformed in tandem. Cells and DNA mixtures were placed on ice for 20 min, heat 
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shocked at 37°C for 5 min and then returned to the ice for a further 5 min. 1ml of sterile 
SOC medium (2 % tryptone, 0.5 % yeast extract, 10 mM NaCl, 2. 5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose) was added and cell suspensions were 
incubated at 37°C for 1 h with agitation. Cells were then spread onto sterile LB-agar 
plates (Sigma, Poole, Dorset) containing an antibiotic appropriate to the resistance of 
the plasmid and incubated overnight at 37°C.  
2.9.3 Extraction of plasmid DNA using Qiagen MAXI-prep 
A single bacterial colony was picked and used to inoculate 200ml LB (2 % Tryptone, 1 
% Yeast, 1 % NaCl) containing the appropriate antibiotic for plasmid selection. 
Cultures were incubated at 37°C at 180 rpm in an orbital shaker overnight until an 
appropriate cell density was reached. Plasmid DNA was extracted using the Qiagen 
Maxi Prep Kit (Qiagen, West Sussex, UK) according to the manufacturer’s instructions. 
Bacterial cell pellets were lysed under alkaline conditions, clarified and loaded onto a 
QIAGEN-tip column. DNA was washed and eluted in an appropriate buffer. Plasmid 
DNA was precipitated using isopropanol and pellets washed in 70 % ethanol before 
being resuspended in endotoxin free TE Buffer (10 mM Tris-HCl pH 8. 0, 1 mM 
EDTA). Plasmid DNA concentration was determined using a NanoDrop ND-1000 
spectrophotometer (Labtech, East Sussex, UK), as described previously (section 2.3.3). 
 
2.9.4 Transient transfection of plasmid DNA and siRNA 
Cells were seeded at 2 x 103 cells/well onto 24-well tissue culture treated plates and 
incubated at 37 oC in humidified atmosphere containing 5% CO2 to adhere overnight. 
The following day cells were transfected with 200ng of an NF-κB-luciferase construct 
containing 3 tandemly repeated NF-κB consensus sequence binding sites in the 
promoter (kindly provided by Prof. Ron Hay, Dundee University) and 200 ng of a 
pCMB-β-galactosidase plasmid containing a minimal promoter element up-stream from the 
β-galactosidase gene as well 50 nM p65, PARP-1 or NS siRNA (described in section 
2.3). Plasmid DNA and siRNA were incubated in serum free RPMI for 5 min before 
mixing with the transfection reagent, Lipofectamine 2000 (Invitrogen, Paisley, 
Scotland), also diluted in serum free RPMI. The resultant transfection cocktails were 
incubated at room temperature for a further 20 min before applying to the 24-well plates 
containing cells. Cells were then incubated at 37 oC in humidified atmosphere 
containing 5% CO2, for 5 h, before aspirating this media and replacing with full media 
(RPMI 1640, 10 % FBS) for a further 48 h at 37 oC in humidified atmosphere 
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containing 5% CO2. This allows the knockdown of the target proteins and to ensure the 
plasmids are expressing in the cells before a 1 h pre-treatment with AG-014699 prior to 
treatment with γ-irradiation or TNF-α. 
2.9.5 Harvesting cells for luciferase and β-galactosidase assays 
Following treatment, cells were washed in PBS at appropriate timepoints (see figure 
legends) and stored overnight at -20°C, until lysis. Cells were lysed in 100µl Reporter 
lysis buffer (Promega, Southampton, UK) by scraping with a sterile pipette tip to 
facilitate full cell lysis. Once cells were fully lysed the cell/Reporter lysis buffer mix 
was assayed for both β-galactosidase and luciferase activity. 
2.9.6 β-galactosidase assay 
A control plasmid containing a β-Galactosidase gene which is ubiquitously expressed in 
transfected cells was co-transfected with reporter constructs to account for discrepancies 
in transfection efficiencies and cell death between experiments. To assess the β-
Galactosidase activity of transfected cells, cell lysate was incubated in a 96 well assay 
plate with an equal volume of β-Galactosidase buffer (1 mM MgCl2, 45 mM β-
mercaptoethanol, 40µg/ml o-nitrophenyl-beta-galactopyranoside solution, 1 mM 
NaxHyPO4 buffer (pH 7.5)) for approximately 20 min at 37°C until colour developed. 
The reaction was terminated by the addition of 1M Na2CO3 and absorbance read at 450 
nM using a Bio-Rad 680 Microplate reader (Bio-Rad Laboratories, Hertfordshire, UK).  
2.9.7 Luciferase reporter assay 
In order to assess the relative luciferase activity of each sample, cell lysates were loaded 
in triplicate onto a white walled 96 well assay plate and incubated with luciferase assay 
buffer (Promega, UK) and read immediately on Micro Beta Plus liquid scintillation 
counter (Wallac, Millipore, Watford UK). Luciferase values were corrected for β-
galactosidase activity and expressed as mean fold values of triplicates.  
2.10 Quantification of specific gene transcription 
2.10.1 Preparation of RNA for real time reverse transcriptase polymerase chain 
reaction (qRT-PCR) and gene expression microarray 
2.10.1.1 Harvesting cells for RNA extraction 
Cells were plated onto 6-well plates at a density that gave a final cell number of 3-5 x 
106 cells/ml on the day of experiment and treated with siRNA and IR or drugs are as 
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described in the individual chapters and figure legends. For all experiments, cells were 
exposed to drug for 24 h incubated at 37 oC in humidified atmosphere containing 5% 
CO2. Following this, the cells washed with ice cold PBS before being gently scraped 
from the plate using a cell scraper (Corning, UK). It should be noted that scraping was 
performed on ice in order to minimise RNA degradation. Cells were transferred to 1.5 
ml tubes and pelleted at 500 xg for 5 min in a cooled centrifuge. The PBS supernatant 
was removed and the pellets stored at -80 °C until RNA extraction took place.  
 
2.10.1.2 Extraction of RNA using Qiagen RNeasy Mini Kit 
The RNeasy Mini kit (Qiagen, West Sussex, UK) was used to extract RNA from cell 
pellets. The pellets, collected as above, were defrosted slowly on ice and, all steps were 
performed on ice or in a cooled centrifuge to minimise RNA degradation. The pellet 
was loosened before 350 µl RLT buffer was added. This contains guanidine 
isothiocyanate and β-mercaptoethanol to stabilise the RNA species in the sample. 
Samples were then homogenised by passing through a 20-gauge needle 5 times, then 1 
volume of 70 % ethanol was added to promote binding of RNA to the silica gel 
membrane in the spin column. The sample was applied to the column and centrifuged at 
8000 xG for 15 sec before washing with RW1 buffer and repeated centrifugation. Two 
subsequent washes with RPE buffer were performed, followed by centrifugation. The 
flow-through was discarded after each step. After these washes 30 µl of RNase-free 
H2O was applied to the column to elute the RNA. 
 
2.10.1.3 Assessing RNA concentration and quality 
The RNA concentration in each sample was assessed using the Nanodrop ND-1000 
spectrophotometer (Labtech, East Sussex, UK), as described in section 2.3.3.  
 
2.10.2 Reverse transcriptase Real time PCR 
2.10.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a method by which large copies of a target 
DNA sequence can be synthesised. A PCR reaction generally contains; target DNA, 
primers, the four deoxyribonucleoside triphosphates (dNTPs) and a DNA polymerase 
that is thermally stable. A standard PCR reaction has 3 steps; denaturation, primer 
annealing and elongation. The denaturation step heats the PCR mix to 95 °C to denature 
the DNA into single strands for replication, the primers are then annealed to the target 
DNA as the PCR mix is rapidly cooled to approximately 60 °C. The primers are 
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designed such that they are complementary to the two strands flanking the target DNA. 
The primers are in excess and consequently, the two original DNA strands do not re-
anneal. The DNA polymerase finally elongates the primer and produces a 
complementary strand of DNA by copying the single stranded templates. This process is 
repeated again, in cycles and as a result the target DNA is amplified (Saiki et al., 1989). 
 
2.10.2.2 Principles of qRT-PCR 
qRT-PCR was developed to monitor PCR reactions as they occur due to collection of 
data as the reaction progresses. It is generally accepted the higher the starting level of 
target sequence, the sooner a significant level is reached, and with this method the 
specific PCR product is detected as it accumulates. For experiments described in this 
thesis, the Taqman (Applied Biosystems, Carlsbad, CA, USA) system was used. This 
widely used method uses a fluorogenic labelled probe that binds to the target sequence, 
which is made up of a high energy reporter dye at the 5’ end, and a lower energy 
quencher dye at the 3’ end, both of which are in close proximity to one another. The 
reporter dye, fluorescein (FAM) is excited by the light source, and rather than emitting 
fluorescence it transfers this energy to the quencher dye (TAMRA) through 
fluorescence resonance energy transfer (FRET). 
 
The probe is designed to anneal to the target sequence downstream of the primer and as 
the DNA polymerase (which has a 5’-exonuclease activity) extends the primer it 
encounters this probe and digests it. This then releases the quencher dye from the probe 
so the two dyes are no longer in close proximity. When the reporter dye is excited by 
the light source, fluorescence emissions are considerably higher, and the cleaving of the 
probe and extension time of the primer increases the overall fluorescence intensity of 
the reaction. The increase in reporter signal is captured by the sequence detection 
instrument whilst the rest of the probe is removed from the target sequence allowing 
primer extension to continue. It should also be noted that probe binding to the target 
sequence, does not affect the overall PCR reaction. As cycles progress, additional 
reporter dye molecules are cleaved from the probes increasing the fluorescence intensity 
proportional to the amount of PCR product (Higuchi et al., 1993). qRT-PCR uses these 
principles in order to determine the mRNA transcript levels of a chosen gene, however 
before this reaction can proceed, mRNA must be reverse transcribed into 
complementary DNA (cDNA). The primers designed to detect cDNA were designed to 
cross exon-exon boundaries in the mRNA to avoid contaminating DNA from being 
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amplified in the PCR reaction (Foley et al., 1993). This reaction is described in section 
2.10.2.4.1. 
 
2.10.2.3 Advantages and disadvantages of qRT-PCR 
qRT-PCR is a fully quantitative technique and is therefore often favoured over 
traditional PCR assays for the assessment of gene expression. Conventional PCR 
experiments run for a set number of cycles, usually 40, and the products are separated 
using agarose-gel electrophoresis. Gels are subsequently stained with ethidum bromide 
(EtBr), and the end point measures the amount of product, making it only semi-
quantitative. EtBR staining makes it more difficult to determine small changes in gene 
expression, whereas measurements from qRT-PCR assays are taken during the 
exponential phase of the reaction, allowing greater sensitivity.  
 
2.10.2.4 Quantitative real-time PCR method 
2.10.2.4.1 Reverse transcriptase step 
In order to generate cDNA for qRT-PCR, a reverse transcriptase step was performed 
using the High capacity cDNA reverse transcription kit with RNase inhibitor (Applied 
Biosystems, Carlsbad, CA, USA). 1 µg of RNA was transcribed for each sample, in a 
final volume of 20 µl (including the master mix). The reaction is summarised in Table 
2.6: 
 
Reagent Volume (µl) 
10x RT buffer 2.0 
25x dNTP mix 0.8 
10x RT primers 2.0 
Reverse transcriptase 1.0 
RNase inhibitor 1.0 
Nuclease-free H2O 3.2 
RNA (diluted in nuclease-free H2O) 10.0 
 
 
The reaction mix was made up in 0.2 ml PCR tubes (Starlabs, Notts, UK) on ice and 
then transferred to a thermal cycler for the following programme: 25 °C for 10 min, 37 
°C for 120 min, 85 °C for 5 min. cDNAs were stored at -20°C until qRT-PCR reactions. 
 
 
 
Table 2.6: Reaction mix for reverse transcriptase PCR 
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2.10.2.4.2 Quantitative PCR step 
The primers and probes used were all from Applied Biosystems (assay on demand) and 
details are given in the chapters where they are specifically used. All of the results were 
normalised to a control gene. Firstly, cDNA was diluted 1 in 5 to 10 ng/µl with with 
nuclease free H2O, so for a final concentration of 20ng cDNA, each reaction required 2 
µl of diluted cDNA. Taqman gene expression, for example the β actin assay reagents, 
were thawed gently on ice and the reactions set up, in triplicate as described in Table 
2.7: 
 
Component 1 x repeat (µl) 3 x repeat (µl) 
Taqman master mix 12.5 37.5 
Gene expression assay 1.25 3.75 
cDNA 2 (10 ng/µl) 6 (10 ng/µl) 
Nuclease-free H2O 9.25 27.75 
 
 
 
Samples were then pipetted into a 96-well qRT-PCR plate (Applied Biosystems), on 
ice, along with a control which contains no cDNA. Any bubbles were removed using a 
sterile needle before the plate was covered with a plastic plate sealer (Applied 
Biosystems). The plate was then loaded onto the 7500 Fast System (Applied 
Biosystems) and then assayed using the following protocol: 50 °C – 2 min (1 cycle), 95 
°C – 10 min (1 cycle), 95 °C – 15 sec then 60 °C – 1 min (for a total of 40 cycles). 
Results were analysed using the 7500 Fast System Software, which generates an 
amplification plot, and the ∆∆Ct method was used to determine the expression of each 
gene of interest relative to the β-actin control. 
 
2.11 Statistical analysis 
2.11.1 Statistical analysis using GraphPad Prism software 
GraphPad Prism software v4.0 (La Jolla, CA, USA) was used to analyse data, undertake 
statistical testing and represent data graphically. 
 
 
 
 
Table 2.7: Reaction mix for qRT-PCR 
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Chapter 3. Investigation into the role of PARP-1 as a regulator of 
DNA-damage activated NF-κB 
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3.1 Introduction 
There is an increasing body of evidence suggesting that PARP-1 is a promoter-specific 
nuclear co-regulator (either a co-activator or co-repressor) of numerous transcription 
factors, reviewed extensively in section 1.5. This includes the sequence-specific DNA –
binding transcriptional regulators, NF-κB, B-Myb, Oct-1, AP-1, Sp1, NFAT, Elk1, HIF-
1α and HTLV-Tax-1 (Kraus, 2008, Krishnakumar and Kraus, 2010), however the role 
of PARP-1 in regulation of these factors can be diverse. PARP-1 may act via through 
local modification of chromatin structure (Althaus et al., 1993, Althaus et al., 1994) 
and/or modulation of transcription factor activity via direct binding to gene regulatory 
sequences, or physical interactions with proteins including transcription factors(Kraus 
and Lis, 2003, Martin-Oliva et al., 2006). In some cases, the transcription factor is 
thought to recruit PARP-1 to the promoters of relevant targets but this is likely to 
dependent on both the cell type concerned and whether or not PARP-1 enzymatic 
activity is required for co-activation/-repression. This latter point will be discussed in 
depth in Chapter 4.  
 
In terms of modifying chromatin structure, Althaus et al., (1994) proposed that the large 
overall negative charge of PAR had the ability to relax the chromatin structure, which is 
usually extremely tightly wound, and displace histones from DNA. This PAR-induced 
relaxation would then allow large regions surrounding the DNA strand breaks to 
become accessible to other proteins, such as p65 (Althaus et al., 1994). 
 
PARP-1 also functions as a co-regulator by mediating the transcriptional complexes 
assembled at the promoters of target genes. In these cases, PARP-1 functions as a 
promoter exchange factor that promotes the release of inhibitory factors. For example, 
Pavri et al., (2005) detailed that PARP-1 was responsible for the exchange of an 
inactive cdk8-postive mediator for an active cdk8-negative mediator during retinoic 
acid-regulated activation (Pavri et al., 2005). 
 
Chang and Alvarez-Gonzalez (2000) described the interaction between PARP-1 and 
NF-κB following DNA damage. They showed that inactive PARP-1 could bind NF-κB 
p50 and block its sequence specific DNA binding, resulting in inhibition of 
transcriptional activation in Hela cells. Following treatment with the DNA damaging 
agent, H202, PARP-1 was activated and the binding of the p50 subunit by PARP-1 was 
released, allowing the subunit to DNA bind and upregulate transcription. Co-incubation 
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with the PARP inhibitor, 3-amino-benzamide (3-AB), also significantly reduced H202-
induced NF-κB DNA binding (Chang and Alvarez-Gonzalez, 2001). 
 
Most recently, Stilmann et al., (2009) have described the formation of a PARP-1 
signaling scaffold via direct protein-protein interactions with NEMO, PIASγ and ATM 
in response to DNA damage, induced by ionising radiation (IR). This signalosome 
formation requires binding with PAR and leads to pro-survival NF- κB signaling 
(Stilmann et al., 2009).  In particular, this group detail that impaired sumoylation 
following treatment with the PARP inhibitor, 3-AB, results in reduced IKK activation 
and therefore inhibition of p65 induction. However, Stilmann et al., (2009) use hyper-
lethal doses of IR (80 Gy) in combination with the highly non-specific PARP inhibitor, 
3-AB which has been shown by us and others to have many off-target effects (Moses et 
al., 1990). 
 
3.2 Aims 
The aim of this chapter was to test the hypothesis that PARP-1 mediates cell survival 
following DNA damage primarily through activation of NF-κB. The potent and specific 
PARP inhibitor (AG-014699) together with mouse embryonic fibroblasts (MEFs) 
proficient and deficient for NF-κB or PARP-1, and siRNA targeting either p65 or 
PARP-1 were used. Previous studies investigating the role of PARP-1 in the activation 
of NF-κB following DNA damage have tended to use hyper-lethal doses of damaging 
agents, such as IR and classical PARP inhibitors, known to have off-target effects. 
Hyper-lethal damage refers to large doses of a DNA damaging agent, which are much 
higher than the clinically relevant dose. For example, the recent study by Stilmann et 
al., (2009) used singular doses of IR as high as 80 Gy IR, which is forty times the single 
clinical dose of 2 Gy. Therefore, it is vital to test this hypothesis not only using a potent 
and highly specific PARP inhibitor, which is in clinical trials, but also at clinically 
relevant doses of IR. 
 
IR is known to produce both single and double stranded DNA breaks. The majority of 
these breaks are in the phosphodiester linkages in one of the DNA strands (Lomax et al., 
2002), suggesting that SSBs are most prevalent following IR. It has been reported that 
the ratio of SSB to DSBs is 20 : 1 following IR (Lomax et al., 2002). PARP-1 is vital 
for the repair of SSBs via the BER pathway and hence a further aim of this study was to 
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determine the effects of PARP inhibition on SSB repair in MEFs proficient and 
deficient for p65. The widely accepted notion surrounding PARP inhibition is that any 
radio- or chemo-sensitisation observed is a repair-driven response (Bryant and 
Helleday, 2004, Calabrese et al., 2004). Hence, the hypothesis that PARP inhibition 
mediates radio-sensitisation through inhibition of NF-κB activation, rather than 
inhibition of SSB repair, was also tested within this chapter.  
 
3.3 Results 
3.3.1 Characterisation of cell lines 
Prior to commencement of any assays used to directly test the hypotheses described in 
section 3.2, the expression levels of PARP-1, NF-κB p65, NF-κB p50, NF-κB p52, c-
Rel and RelB, were determined by Western blotting in whole cell extracts from 
exponentially growing p65+/+ , p65-/- , PARP-1+/+ and PARP-1-/- mouse embryonic 
fibroblasts (MEFs). Briefly, p65+/+ , p65-/- , PARP-1+/+ and PARP-1-/- MEFs were seeded 
and harvested 48 h later, whole cell extracts were prepared (as described in section 
2.5.1) and protein quantification was undertaken using the Pierce BSA protein assay, 
according to manufacturers’ instructions. The levels of p65, p50, p52, RelB, c-Rel or 
PARP-1 were determined by Western analyses and the house-keeping protein, β-actin, 
was used as a loading control. 
 
 
Figure 3.1 shows that the p65-/- MEFS lacked p65 but expressed levels of PARP-1, p50 
and p52 similar to the p65+/+ MEFs. PARP-1-/- MEFs did not express PARP-1 protein 
but had bands of similar intensity to that of the PARP-1+/+ MEFs for p65, p50 and p52. 
In all cases the house-keeping protein, β-Actin was used a loading control. RelB and c-
Rel were not detectable in any of the cells lines assessed; however this is unsurprising 
as these two subunits are most commonly found in haematopoietic cells and tissues 
(Rayet and Gelinas, 1999, Ryseck et al., 1996). Previous studies from our laboratory 
have shown all four of these cell lines show comparable levels IκBα and IκBβ (Veuger 
et al., 2009).  
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This study would be mainly centred around the use of the p65+/+ and p65-/- MEFs, and 
the role of PARP-l in the activation of NF-κB following DNA damage in these cells, 
hence it was important to ensure these cell lines had similar PARP-1 activity levels, 
prior to further study. Once, protein expression had been determined, PARP activity 
was also assessed in the four cell lines using a validated assay (Plummer et al., 2005, 
Zaremba et al., 2009), this would also confirm that the lack of detectable protein in the 
PARP-1-/- cells correlated with an absence of enzymatic activity.  
 
Briefly, basal PARP activity present in cells was measured in 1x104 permeabilized cells 
that had been incubated with NAD+ and oligonucleotide (to maximally stimulate PARP 
activity). The reaction was terminated with excess AG-014699, and replicate samples 
were blotted onto nitrocellulose membrane. A standard curve of purified PAR (pmol of 
PAR) was also blotted to aid with quantification. The membrane was probed with PAR-
specific antibody and chemiluminescence was detected prior to densiometric analysis. 
The results shown are the mean of 3 independent experiments.  
 
Figure 3.2 shows stimulated PARP activity, quantified against a standard curve of 
purified PAR. PARP activity was similar in all cell lines apart from the PARP-1-/- MEFs 
Figure 3.1: Characterisation of cell lines  
Western blots of whole cell extracts of untreated p65+/+, p65-/-, PARP-1+/+ and 
PARP-1-/- MEFs; blots were probed using antibodies against PARP-1, p65, p50, 
p52, c-Rel, RelB and β-actin  
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which showed very low (<2%) detectable PARP activity. This low residual PARP 
activity could be attributable to other members of the PARP superfamily, for example, 
PARP-2, which like PARP-1 has been implicated in the BER process (Schreiber et al., 
2002). Importantly however, the PARP-1+/+ cells show significantly higher activity 
when compared with the PARP-1-/- cells (p< 0.0001, unpaired Student’s t-test), whereas 
there is no significant difference in PARP activity between the p65+/+ and p65-/- cells 
(p=0.105, unpaired Student’s t-test). 
 
 
 
 
 
 
 
3.3.2 Knockdown of target proteins using siRNA technology 
Small inhibitory RNA (siRNA) techniques were used to determine optimal conditions 
for the abrogation both of p65 and PARP-1 expression in the p65+/+, p65-/-, PARP-1+/+ 
and PARP-1-/- MEFs.  Firstly, it was important to determine the optimum timepoint for 
tranfection, hence p65+/+ MEFs were seeded and left for 24 h to adhere before lipid 
transfection with 50 nM of siRNA oligos targeting either p65 or PARP-1, or a non-
specific (NS) control (Table 2.2). The levels of p65 expression were determined at 24, 
48, 72 and 96h following lipid transfection. Whole cell extracts were prepared (as 
described in section 2.5.1) and the levels of p65 or PARP-1 were determined by 
Western analyses and compared to the house-keeping protein, β-actin. 
 
Figure 3.3A shows that 24 h hours following siRNA transfection, p65 protein was >90 
% reduced in the p65+/+ MEFs, and that p65 knockdown was maximal (>95 %) 48 h 
Figure 3.2: Cellular PARP activity 
Oligonucleotide and NAD+-stimulated maximal PARP activity in p65+/+, p65-/-, 
PARP-1+/+ and PARP-1-/- MEFs. Results shown are the mean + SEM of 3 independent 
experiments. *** Significance PARP-1+/+ versus PARP-1-/- in a Student’s unpaired t-
test p<0.001  
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following transfection. This knockdown persisted for 96 h following transfection. 
Importantly the control (NS siRNA) had no effect on p65 protein knockdown, compared 
with mock (vehicle alone) controls. Similarly, Figures 3.3B shows that 24 h hours 
following siRNA transfection PARP-1 protein was >60 % knockdown in the p65+/+ 
MEFs, and that PARP-1 knockdown was maximal (>95 %) 48 h following transfection. 
This knockdown persisted for 96 h following transfection, and the control (NS siRNA) 
had no effect on PARP-1 protein knockdown, compared with mock (vehicle alone) 
controls. These data suggest that for maximal knockdown of either p65 or PARP-1, the 
48 h time-point should be used. 
 
 
 
 
 
Figure 3.3 illustrated that maximal knockdown of either p65 or PARP1 was achievable 
48 h after transfection in the p65+/+ MEFs. Hence, this time-point was utilised for all 
future studies in this cell line, and also in the PARP+/+ and PARP-1-/- MEFs in order to 
keep the conditions as constant as possible. This however, was tested initially using 
Western blotting analyses. Briefly, p65+/+, p65-/-, PARP-1+/+ and PARP-1-/- MEFs were 
seeded and left for 24 h to adhere before lipid transfection with 50 nM of siRNA oligos 
targeting p65 or a non-specific (NS) control (Table 2.2). The levels of p65 expression 
were determined 48 following lipid transfection. Whole cell extracts were prepared (as 
described in section 2.5.1) and protein quantification was undertaken using the Pierce 
BSA protein assay, according to manufacturers’ instructions. The levels of p65 or 
PARP-1 were determined by Western analyses and densiometric analysis was used to 
assess the levels of protein knockdown compared to the house-keeping protein, β-actin. 
Figure 3.3: Timecourse of siRNA knockdown of NF-κB p65 or PARP-1 
(A) Western blots of whole cell extracts of p65+/+ MEFs at 24, 48, 72 and 96 h after 
transfection with vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. (B) Western 
blots of whole cell extracts of p65+/+ MEFs at 24, 48, 72 and 96 h after transfection with 
vehicle alone (Mock), non-specific (NS) siRNA or PARP-1 siRNA.  
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A reproducible reduction in p65 protein (> 95% knock-down) could be seen 48 h post-
transfection using 50 nM siRNA in the p65+/+, PARP-1+/+ and PARP-1-/- MEFs (Figure 
3.4A and 3.4C). Figure 3.4B illustrates that p65 protein levels are significantly reduced 
by 50 nM p65 siRNA, compared with NS siRNA controls in the p65+/+ MEFs 
(p<0.0001, unpaired Student’s t-test). Similarly, Figure 3.4D illustrates that p65 protein 
levels are significantly reduced by 50 nM p65 siRNA, compared with NS siRNA 
controls in the PARP-1+/+ and PARP-1-/- MEFs (p<0.0001 and p<0.0001, respectively, 
unpaired Student’s t-tests). As expected, p65 siRNA had no effect in the p65 deficient 
cells (Figure 3.4A). These data show that the optimal conditions for transfection of p65 
siRNA in either the p65+/+, p65-/-, PARP-1+/+ or PARP-1-/- MEFs, is the concentration of 
50 nM and the 48 h time-point.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: siRNA knockdown of NF-κB p65 using optimal conditions 
(A) Western blots of whole cell extracts of p65+/+ and p65-/- MEFs at 48 h after 
transfection with vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. (B) p65 
protein expression in p65+/+ cells expressed as a percentage of NS siRNA treated cells. 
Results shown are the mean + SEM of 3 independent experiments. (C)Western blots of 
whole cell extracts of PARP-1+/+ and PARP-1-/- MEFs at 48 h after transfection with 
vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. (D) p65 protein 
expression in PARP-1+/+  and PARP-1-/- cells expressed as a percentage of NS siRNA 
treated cells. Results shown are the mean + SEM of 3 independent experiments. . *** 
Significance relative to NS siRNA control was p<0.0001 using Student’s unpaired t-tests. 
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It was important to assess the effects of p65 knockdown on the expression of the other 
NF-κB subunits as p65 is known to dimerise with each one of the other four subunits 
(Gilmore, 2006), and in particular p50 is the most common hetero-dimeric partner of 
p65 (Chen et al., 1998). Therefore, Western analyses were used to determine whether 
siRNA targeting p65 had any effect on p50 or p52, as it had already been confirmed that 
these cells did not express RelB or c-Rel (Figure 3.1). Using the optimal conditions 
(described above), p65+/+ MEFs were seeded and left for 24 h to adhere before lipid 
transfection with 50 nM p65 siRNA or NS control (Table 2.2). Whole cell extracts were 
prepared 48 h following transfection (as described in section 2.5.1) and the levels of 
p65, p50, p52 or PARP-1 were determined by Western analyses and compared to the 
house-keeping protein, β-actin. 
 
Figure 3.5 illustrates that knockdown of p65 had no effect on the other NF-κB subunits 
expressed by the p65+/+ MEFs. The expression levels of both p50 and p52 remained 
constant in cells treated with either vehicle alone (mock), NS siRNA or p65 siRNA. 
Importantly, the knockdown of p65 did not affect the expression of PARP-1 either. 
 
 
 
 
 
 
 
The data in figure 3.3B suggested that PARP-1 knockdown in the p65+/+ MEFs was 
maximal 48 h following transfection. Taken with the data in Figure 3.4 showing the 
optimal conditions for all the cell lines regarding p65 siRNA, it was decided to test 
Figure 3.5: Knockdown of NF-κB p65 does not affect expression of other NF-κB 
subunits 
Western blots of whole cell extracts of p65+/+ MEFs at 48 h after transfection with 
vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. Blots were probed with 
antibodies against p65, p50, p52, PARP-1 and β-actin 
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these identical conditions for PARP-1 knockdown in all cell lines. This would therefore 
keep the conditions and nucleic acid ratios as constant as possible across the panel of 
cell lines. Hence,  p65+/+, p65-/-, PARP-1+/+ and PARP-1-/- MEFs were seeded and left 
for 24 h to adhere before lipid transfection with 50 nM of PARP-1 or NS siRNA (Table 
2.2). The levels of PARP-1 expression were determined 48 following lipid transfection. 
Whole cell extracts were prepared (as described in section 2.5.1) and the levels of 
PARP-1 or p65 were determined by Western analyses and densiometric analysis was 
used to assess the levels of protein knockdown compared to the house-keeping protein, 
β-actin. 
 
 
 
 
 
 
 
 
 
 
 
 
A reproducible reduction in PARP-1 protein (> 95% knock-down) could be seen 48 h 
post-transfection using 50 nM siRNA in the p65+/+, p65-/- and PARP-1+/+ MEFs (Figure 
Figure 3.6: siRNA knockdown of PARP-1 using optimal conditions 
(A) Western blots of whole cell extracts of PARP-1+/+ and PARP-1-/- MEFs at 48 h 
after transfection with vehicle alone (Mock), non-specific (NS) siRNA or PARP-1 
siRNA. (B) PARP-1 protein expression in PARP-1+/+ cells expressed as a percentage 
of NS siRNA treated cells. Results shown are the mean + SEM of 3 independent 
experiments. (C)Western blots of whole cell extracts of p65+/+ and p65-/- MEFs at 48 h 
after transfection with vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. 
(D) PARP-1 protein expression in p65+/+  and p65-/- cells expressed as a percentage of 
NS siRNA treated cells. Results shown are the mean + SEM of 3 independent 
experiments. *** Significance relative to NS siRNA control was p<0.0001 using 
Student’s unpaired t-tests. 
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3.6A and 3.6C). Figure 3.6B illustrates that PARP-1 protein levels are significantly 
reduced by 50 nM PARP-1 siRNA, compared with NS siRNA controls in the PARP-
1+/+ MEFs (p<0.0001, unpaired Student’s t-test). Similarly, Figure 3.6D illustrates that 
PARP-1 protein levels are significantly reduced by 50 nM p65 siRNA, compared with 
NS siRNA controls in the p65+/+ and p65-/- MEFs (p<0.0001 and p<0.0001, respectively, 
unpaired Student’s t-tests). As expected, PARP-1 siRNA had no effect in the PARP-1 
deficient cells (Figure 3.6A). These data show that the optimal conditions for 
transfection of PARP-1 siRNA in either the p65+/+, p65-/-, PARP-1+/+ or PARP-1-/- 
MEFs, is the concentration of 50 nM and the 48 h time-point. It should also be noted 
that Figure 3.6A and 3.6C show that PARP-1 siRNA had no effect on p65 protein 
expression. 
 
In order to confirm PARP knockdown and specificity of the PARP inhibitor, AG-
104699, PARP activity was assessed in p65+/+ and p65-/- MEFs following transfection 
with PARP-1 or p65 siRNA, or following treatment with AG-014699 (Figure 3.7). A 
combination of p65 siRNA and AG-014699 was also assessed, using the validated 
PARP activity assay (Plummer et al., 2005, Zaremba et al., 2009). Briefly, p65+/+ or p65-
/- MEFs were seeded and allowed to adhere for 24 h prior to transfection with 50 nM 
p65, PARP-1 or NS siRNA, or AG-014699. Cells were then incubated for a further 48 h 
before permeabilisation, and the assay undertaken as described in section 2.4.  
 
Figures 3.7A shows that p65+/+ cells treated with AG-014699, or a combination of AG-
014699 and p65 siRNA exhibited very low (< 5%) PARP activity (p=0.03 and p=0.02 
respectively, compared with NS siRNA controls, unpaired Student’s t-test).  Cells 
treated with PARP-1 siRNA exhibited 25% PARP activity compared with controls 
(p=0.04, p65+/+ and p=0.04, p65-/-, unpaired Student’s t-test), in both cell lines (Fiures 
3.7A and B), which confirms the results from Western analysis.  siRNA targeting p65 
did not have any significant effect on PARP-1 activity in either cell line, when 
compared with NS siRNA controls. It must be noted that there is some reduction in 
PARP activity when comparing NS siRNA with Mock treated controls. Other groups 
have documented the effects of transfection on cellular processes including cell 
viability, proliferation, cell cycle distribution, apoptosis, and migration (Jackson and 
Linsley, 2004, Tschaharganeh et al., 2007). It is possible that this could perhaps to due 
to the increased nucleic acid ratio in NS siRNA-treated cells versus mock transfected 
controls, causing the cells some stress. 
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3.3.3 Radio-sensitisation by p65 knockdown, PARP-1 knockdown or AG-014699 
Once the knockdown of p65 and PARP-1 could be reproducibley achieved, and the 
specificity of AG-014699 verified, the ability of p65 knockdown, PARP-1 knockdown 
or AG-014699 to sensitise p65+/+ and p65-/- MEFs, and PARP-1+/+ and PARP-1-/- MEFs 
to IR was assessed using colony forming assays (section 2.2.7). In this particular assay 
p65+/+ or p65-/- MEFs were plated and left to adhere for 24 h before transfection with 50 
nM p65 PARP-1 or NS siRNA, (or vehicle control). Cells were then left for 48 h, and 
pre-treated with AG-014699, or DMSO control 1 h prior to treatment with increasing 
doses of IR before being re-plated after a further 24 h and allowed to form colonies for 
7-21 days. (Figure 3.8). 
 
Previous work from the group showed that the p65-/- MEFs were 1.3-fold more sensitive 
to IR alone compared with p65+/+ MEFs (Veuger et al., 2009) when comparing PF50 
values. PF50 values (potentiation factor at 50% cell kill) were calculated from the ratio 
of the individual LD50 (lethal dose producing 50% cell kill) values:- i.e., LD50 divided 
by LD50 in the presence of AG-014699. This is consistent with NF-κB conferring radio-
resistance (Biswas et al., 2001, Wu and Kral, 2005) and is also illustrated here in Figure 
3.8A versus 3.8B. Furthermore, Figure 3.8A illustrates that co-incubation with IR and 
Figure 3.7: PARP activity following PARP-1 siRNA or treatment with AG-014699 
(A) Bar chart showing PARP activity, measured using a validated immunoblot assay which 
quantifies PAR formation, in p65+/+ MEFs after transfection with vehicle alone (mock), p65 
siRNA, AG-014699 (AG), PARP-1 siRNA, a combination of p65 siRNA + AG or NS 
siRNA. (B) PARP activity in p65-/- MEFs following transfection with vehicle alone (mock), 
p65 siRNA, AG, PARP-1 siRNA, a combination of p65 siRNA + AG or NS siRNA. Data 
are represented as the mean ± SEM of three independent experiments. *Significance 
relative to NS siRNA control was p<0.05 using unpaired Student’s t-test. 
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either AG-014699, p65 siRNA or PARP-1 siRNA reduced survival of the p65+/+ cells 
compared with IR alone or in combination with NS siRNA, resulting in a 1.3-fold 
potentiation factor. Statistical analysis using an unpaired Student’s t-test confirm that, at 
the LD50 values AG-014699, p65 or PARP-1 siRNA significantly radio-sensitised the 
p65+/+ cells compared with IR in combination with NS siRNA (p=0.017, p=0.031 and 
p=0.038, respectively, unpaired Student’s t-test). Importantly, a co-incubation with p65 
and AG-014699 in combination with IR, did not further reduce p65+/+ cell survival 
compared with either agent alone, consistent with existing reports that NF-κB and 
PARP-1 are mechanistically linked in a common pathway (Chang and Alvarez-
Gonzalez, 2001, Hassa et al., 2001, Hassa and Hottiger, 1999, Martin-Oliva et al., 2004, 
Stilmann et al., 2009, Veuger et al., 2009).  
 
 
 
 
 
 
Figure 3.8: Radio-sensitisation by p65 knockdown, PARP-1 knockdown or AG-014699 
The effects of increasing doses of IR either alone, or co-incubated with p65 siRNA, AG-014699, 
PARP-1 siRNA or a combination of p65 siRNA and AG-014699, on cell survival were assessed 
using the clonogenic survival assay in (A) p65+/+ MEFs, (B) p65-/- MEFs. Cells were treated with 
relevant siRNA, (or vehicle control), left for 48 h, pre-treated with AG-014699, or DMSO control 1 
h prior to IR then re-plated after a further 24 h and allowed to form colonies for 7-21 days. The 
effects of increasing doses of IR either alone, or co-incubated with NS siRNA on cell survival were 
assessed using the clonogenic survival assay in (C) p65+/+ MEFs or (D) p65-/- MEFs. Results shown 
are the mean + SEM of three independent experiments 
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Furthermore, Figure 3.8B shows that, co-incubation with either AG-014699, p65 siRNA 
or PARP-1 siRNA had no effect in p65-/- MEFs (p=0.665, p=0.584 and p=0.233, 
respectively, unpaired Student’s t-test on LD50 values). Importantly, Figures 3.8C and 
3.8D show that a combination of IR and NS siRNA had no significant effects on the 
survival of the p65+/+ or p65-/- MEFs when compared with IR alone (p=0.778 and 
p=0.853, respectively, unpaired Student’s t-test). 
 
The survival curves in Figure 3.8 indicate that PARP-1 and NF-κB are mechanistically 
linked in a common pathway, and importantly that radio-sensitisation by the PARP 
inhibitor, AG-014699 or PARP-1 was only achievable in cells containing NF-κB p65. 
Therefore, it was important to confirm these data using the PARP-1 proficient and 
deficient in order to further demonstrate the role of PARP-1 on cell survival in the 
activation of NF-κB following DNA damage. In order to do this clonogenic assays were 
performed using PARP-1+/+ or PARP-1-/- MEFs, as described above. 
 
Similarly, the clonogenic assays shown in Figures 3.9A and 3.9B illustrated that the 
PARP-1-/- MEFs were 2.7-fold more sensitive to IR compared with PARP-1+/+ MEFs. 
This is consistent with reports that PARP-1 knockout animals are hyper-sensitive to 
irradiation due to their compromised DNA repair response (Masutani et al., 2005). 
Moreover, PARP-1+/+ MEFs exhibited a 1.3-fold sensitisation to IR by AG-014699, p65 
knockdown or PARP-1 knockdown, compared with IR alone or in combination with NS 
siRNA (Figure 3.9A). Statistical analysis using an unpaired Student’s t-test confirm 
that, at the LD50 values, AG-014699, p65 or PARP-1 siRNA significantly radio-
sensitised the PARP-1+/+ cells compared with IR in combination with NS siRNA 
(p=0.009, p=0.030 and p=0.048, respectively, unpaired Student’s t-test). Importantly, 
the combination of p65 and AG-014699 in combination with IR, did not further reduce 
PARP1+/+ cell survival compared with either agent alone, once again suggesting that 
PARP-1 and NF-κB are mechanistically linked. Furthermore, Figure 3.9B shows that, 
co-incubation with either AG-014699, p65 siRNA or PARP-1 siRNA had no effect in 
PARP-1-/- MEFs (p=0.328, p=0.479 and p=0.415, respectively, unpaired Student’s t-test 
on LD50 values). Importantly, Figures 3.9C and 3.9D show that a combination of IR and 
NS siRNA had no significant effects on the survival of the PARP-1+/+ or PARP-1-/- 
MEFs when compared with IR alone (p=0.869 and p=0.924, respectively, unpaired 
Student’s t-test). Therefore these data corroborate the results observed in the p65+/+ and 
p65-/- MEFs. 
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Spontaneous immortalisation of primary MEFs frequently leads to mutations in p53 
meaning that the p65 proficient and deficient MEFs may not be a truly isogenic pair. 
For example, it has been reported that the p65-/- MEFs have mutant p53 (Gilmore), and 
Figure 3.9: Radio-sensitisation by p65 knockdown, PARP-1 knockdown or AG-
014699 The effects of increasing doses of IR either alone, or co-incubated with p65 
siRNA, AG-014699, PARP-1 siRNA or a combination of p65 siRNA and AG-
014699, on cell survival were assessed using the clonogenic survival assay in (A) 
PARP-1+/+ MEFs, (B) PARP-1-/- MEFs. Cells were treated with relevant siRNA, (or 
vehicle control), left for 48 h, pre-treated with AG-014699, or DMSO control 1 h 
prior to IR then re-plated after a further 24 h and allowed to form colonies for 7-21 
days. The effects of increasing doses of IR either alone, or co-incubated with NS 
siRNA on cell survival were assessed using the clonogenic survival assay in (C) 
PARP-1+/+ MEFs or (D) PARP-1-/- MEFs. Results shown are the mean + SEM of three 
independent experiments 
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this is also known to be the case for the PARP-1+/+ MEFs (Trucco et al., 1998). Hence, 
to truly confirm the results on cell survival observed in the p65 paired MEFs, colony 
forming assays with IR alone, or in combination with AG-014699, in p65-/- cells that 
had been genetically complemented with wild-type (WT) p65, and in relevant control 
cells were also undertaken.  
 
The data in Figures 3.10A and 3.10B support that shown in Figures 3.8 and 3.9, by 
illustrating firstly that the cells containing WT p65 were more radio-resistant than their 
p65 null counterparts, and, secondly that AG-014699 radio-sensitised cells containing 
WT p65 but not the p65 null cells. Moreover, this radio-sensitisation was statistically 
significant, when unpaired Student’s t-tests were performed on LD50 values (p=0.046, 
LD50 IR alone: 2.31 Gy, compared with LD50 IR in combination with AG-014699: 1.76 
Gy). 
 
 
 
 
 
 
 
 
3.3.4 p65 knockdown, PARP-1 knockdown or AG-014699 is associated with the 
induction of apoptosis following ionising radiation 
In order to be confident that the effects observed on cell survival in the both the p65+/+ 
(Figure 3.8) and PARP-1+/+ cells (Figure 3.9) were associated with the induction of 
Figure 3.10: Radio-sensitisation of reconstituted p65-/- MEFs by AG-014699 
The effects of increasing doses of IR either alone, or co-incubated with AG-014699, on 
cell survival were assessed using the clonogenic survival assay. Cells were treated with 
AG-014699, or control 1 h prior to IR then re-plated after a further 24 h and allowed to 
form colonies for 7-21 days. (Survival curve (A) shows p65-/-MEFs, (B) p65 WT MEFs,) 
Results shown are mean+ SEM of three independent experiments 
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apoptosis, assays assessing the effects of IR in combination with either AG-014699 or 
p65 siRNA were undertaken. NF-κB is known to affect the transcription of a number of 
genes associated with apoptosis (Pahl, 1999). Furthermore, following DNA damage it 
has been reported that NF-κB induces the transcription of genes such as XIAP and Bcl-
xL, known to be associated with the protection against apoptosis (Stehlik et al., 1998, 
You et al., 1999). Thus in view of the survival data in Figures 3.8 and 3.9, it could 
therefore be hypothesised that knockdown of p65 or inhibition of PARP-1 would further 
activate IR-induced apoptosis, due to the inhibition of NF-κB-dependent transcriptional 
activation. 
 
In order to assess the effects on apoptosis in the p65+/+ and p65-/- MEFs, FITC-
conjugated Annexin, which has a high affinity for membrane phospholipid 
phosphatidylserine was used. Briefly, cells were transfected with p65 siRNA (or vehicle 
control) 48 h prior to 1 h pre-treatment with AG-014699 and subsequent irradiation. 
Cells were harvested and the FITC Annexin V Apoptosis Detection Kit I and used 
according to manufacturers’ guidelines (section 2.6.1).  
 
Firstly, it was found that p65-/- MEFs have a 3-fold higher intrinsic levels of apoptosis 
following IR, compared with p65+/+ (33.73 ± 3.1 for p65-/- versus 12.60 ± 2.7 for p65+/+). 
These data were used to calculate percentage increase in apoptosis, shown in Figure 
3.11. This is consistent with reports that NF-κB activation increases survival following 
DNA damage (Criswell et al., 2003, Russo et al., 2001). The levels of apoptosis were 
measured following IR (2 Gy or 5 Gy) in combination with either p65 knockdown or 
AG-014699 in p65+/+ and p65-/- MEFs (Figure 3.11A versus 3.11B). A combination of 
p65 siRNA and AG-014699 were also assessed. Compared to IR alone (mock), both 
p65 knockdown and AG-014699 significantly increased apoptosis following 2 Gy IR 
(approx 2.5-fold) in the p65+/+ MEFs (p=0.03 and p=0.04, respectively, unpaired 
Student’s t-test). Importantly, when AG-014699 was used in conjunction with p65 
knockdown, there was no change in the level of apoptosis in the p65+/+ MEFs, compared 
to either agent alone. No increase in apoptosis was observed in the p65-/- MEFs (Figure 
3.11B) with any of the treatments, compared with IR alone.  
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These data were confirmed using a caspase 3/7 activity assay. The proteases, caspase-3 
and caspase-7, are frequently activated, by proteolytic cleavage, during mammalian cell 
apoptosis (Nicholson and Thornberry, 1997). Caspase-3, in particular, plays a very 
important role in the survival of many cell types, demonstrated by the development of 
caspase-3 knockout mice. These animals are born in low litter numbers, and have a 
striking phenotype in which there are skull defects due to etopic masses of 
supernumerary cells, representing a failure of programmed cell death during brain 
Figure 3.11: The induction of apoptosis measured using the Annexin V FACs assay 
The effect of IR alone (mock, white bar) ± p65 siRNA (hatched bar) ± AG-104699 (AG 
alone, black bar, AG + p65 siRNA, striped bar) on the induction of apoptosis in p65+/+ 
(A) and p65-/- MEFs (B). Cells were treated with relevant siRNA, or control left for 48 
h, pre-treated with AG-014699, or control 1 h prior to IR then allowed to repair for a 
further 24 h before harvesting and assessment of the induction of apoptosis by Annexin 
V FACs analysis. Results shown are calculated as a percentage increase of the untreated 
controls. All data shown are represented as the mean ±SEM of three independent 
experiments. *Significance relative to mock treated control was p<0.05 using unpaired 
Student’s t-test. 
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development, and resulting in mice dying only a few weeks after birth (Kuida et al., 
1996). Caspase-3 has also been reported to be essential for apoptotic chromatin 
condensation and DNA fragmentation (Porter and Janicke, 1999). Caspase-3 activity 
was determined using the Caspase-Glo 3/7 kit (described in section 2.6.2). p65+/+ or p65-
/-
 MEFs were transfected with 50 nM p65 siRNA (or vehicle control) and incubated for 
48 h. Cells were then pre-treated with AG-014699 for 1 h before IR and allowed to 
recover at 37°C, 5 %CO2 for 24 h before apoptosis was assessed using the Caspase-Glo 
3/7 assay.  
 
 
 
 
 
 
 
Figure 3.12: The induction of apoptosis measured using the caspase 3/7 assay The 
effect of IR alone (mock, white bar) ± p65 siRNA (hatched bar) ± AG-104699 (AG 
alone, black bar, AG + p65 siRNA, striped bar) on the induction of apoptosis in p65+/+ 
(A) and p65-/- MEFs (B). Cells were treated with relevant siRNA, or control left for 48 
h, pre-treated with AG-014699, or control 1 h prior to IR then allowed to repair for a 
further 24 h before harvesting and assessment of the induction of apoptosis by caspase 
3/7 activation. Results shown are normalised to untreated controls.  
All data shown are represented as the mean ±SEM of three independent experiments. 
*Significance relative to mock treated control was p<0.05 using unpaired Student’s t-
test. 
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The data generated using the caspase3/7 assay required slightly higher doses of IR (5 
Gy and 10 Gy) to induce apoptosis, when compared with the Annexin V assay (2 Gy 
and 5 Gy), and this will be discussed further in section 3.4. Figure 3.12A versus Figure 
3.12B confirmed the findings from the Annexin V assay, showing that the p65-/- MEFs 
have higher intrinsic levels of apoptosis, measured by caspase 3/7 cleavage, following 
IR, compared with p65+/+ MEFs.  Furthermore, when compared with IR alone (mock), 
both p65 knockdown and AG-014699 significantly increased caspase 3/7 activation 
following 5 Gy IR in the p65+/+ MEFs (p=0.0086 and p=0.044 respectively, Student’s 
unpaired t-test). Importantly, when AG-014699 was used in conjunction with p65 
knockdown, there was no further increase in caspase 3/7 activity in the p65+/+ MEFs, 
compared to either agent alone. It should be noted here that following 5 Gy IR, it 
appears that p65 siRNA has a greater effect on the induction of apoptosis in the p65+/+ 
MEFs, compared with AG-014699, even though these two agents have a similar effect 
on survival (Figures 3.8 and 3.9). However, when an unpaired Student’s t-test was 
performed on p65 siRNA versus AG-014699 following 5 Gy IR, there was no 
significant difference on apoptosis induction (p=0.209). Importantly, no increase in 
apoptosis was observed in the p65-/- MEFs (Figure 3.12B) with any of the treatments, 
compared with IR alone, confirming the Annexin V results (Figure 3.11).  
 
 
3.3.5 AG-014699 inhibits Single strand break (SSB) repair to a similar extent 
regardless of cellular NF-κB status 
The results observed from the survival and apoptosis assays suggested that PARP-1 and 
NF-κB are mechanistically in a common pathway, thus supporting existing work 
(Chang and Alvarez-Gonzalez, 2001, Hassa et al., 2001, Hassa and Hottiger, 1999, 
Martin-Oliva et al., 2004, Stilmann et al., 2009, Veuger et al., 2009). The data presented 
in this chapter also postulate that the radio-sensitisation observed with the PARP 
inhibitor, AG-014699, is mediated via NF-κB. However, PARP-1 is most widely known 
for its role in the repair of SSBs via the BER pathway. Hence, it was important to 
determine the effects of PARP inhibition on SSB repair in the p65+/+ and p65-/- MEFs. 
The widely accepted notion surrounding PARP inhibition is that any radio- or chemo-
sensitisation observed is a repair-driven response (Bryant and Helleday, 2004, 
Calabrese et al., 2004), and not mediated through the inhibition of NF-κB activation. 
Hence, the alkaline Comet assay was used to test the hypothesis that PARP inhibition 
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mediates radio-sensitisation through inhibition of NF-κB activation, rather than 
inhibition of SSB repair.  
 
The alkaline Comet assay was used to examine IR-induced SSB formation and repair at 
the individual cell level in the p65+/+ and p65-/- cells. The method is described in detail in 
section 2.7, however, briefly, p65+/+ or p65-/- cells were plated and allowed to adhere 
overnight before pre-treated with AG-014699 (or DMSO control) 1 h prior to treatment 
with 10 Gy IR. Cells harvested at various timepoints following IR (0, 15, 30, 60 min) 
and the asssy undertaken as described in section 2.7. Data is represented in two forms, 
firstly using the Olive Tail Moment (OTM), which is used as a measure of both the 
smallest detectable size of migrating DNA (reflected in the comet tail length) and the 
number of relaxed / broken pieces (represented by the intensity of DNA in the tail), and 
secondly by the percentage DNA in the comet tail, both are recommended by the Comet 
Assay Interest Group. It should be noted that in each scatter diagram, one dot represents 
one individual cell. All data were shown to exhibit a Gaussian distribution and the lines 
shown on the scatter plots in Figure 3.13A-D indicate the mean of the data plotted.  
 
Figure 3.13A, 3.13B, 3.13C and 3.13D show that immediately following 10 Gy IR, both 
the p65+/+ and the p65-/- cell lines had the same initial level of SSBs as demonstrated by 
both OTM and percentage Comet tail DNA. These scatter plots also illustrate how, in 
both cell lines, the number of SSB are repaired over time. Markedly, there was no 
significant difference in the SSB levels remaining in the two cell lines 60 min post-IR, 
with > 85 % of breaks rejoined despite the difference in radio-sensitivity (shown in 
Figures 3.8A and 3.8B). Most importantly however, AG-014699 inhibited SSB repair 
(as demonstrated by increased residual SSB levels at all time-points post-IR) to the 
same extent in both cell lines, regardless of the p65 status, and despite the observed 
radio-potentiation by AG-014699 in p65+/+ cells, not the p65-/- cells.  
 
The kinetics of SSB repair in both cells line are illustrated in Figures 3.13E and 3.13F 
by line graphs. These clearly show that the SSBs generated by IR are repaired rapidly 
over time (solid black line), and that in both cells line the kinetics of repair were very 
similar. The broken line shows how cells pre-treated with AG-014699 prior to treatment 
with IR, have slower repair kinetics in both cell lines, regardless of p65 status. 
 
 
156 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: AG-014699 inhibits SSB repair to a similar extent regardless of 
cellular NF-κB status Scatter diagrams showing the extent of single strand breaks 
(SSBs) in p65+/+ and p65-/- MEFs treated with 10 Gy IR ± AG-014699 (AG, denoted by 
+) and allowed to repair (0 min, 15 min, 30 min and 60 min). (A) and (B) represent 
OTM and (C) and (D) represent % Tail DNA. Line graph showing the kinetics of 
single strand break repair in p65+/+ (E) and p65-/- MEFs (F). Data was normalised to 
relevant controls and in both cases solid black lines represent repair over time of cells 
treated with 10 Gy IR, and dotted lines represent repair over time of cells treated with 
10 Gy IR + AG-014699. 
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To further confirm these findings, these experiments were repeated in p65-/- cells that 
had been genetically complemented with WT p65, and also in p65 null controls, for the 
reasons discussed in section 3.3.3. Once again the alkaline Comet assay was undertaken 
for these experiments. Figure 3.14A, 3.14B, 3.14C and 3.14D  show that immediately 
following 10 Gy IR, both the p65 WT and the p65 null control cell lines had the same 
initial level of SSBs as demonstrated by both OTM and percentage Comet tail DNA, 
which is exactly what had been observed in the p65+/+ and p65-/- cells. These scatter 
plots also illustrate how, in both the p65 WT and p65 null control cells, the number of 
SSB are repaired over time. Importantly, there was no significant difference in the SSB 
levels remaining in the two cell lines 60 min post-IR, with > 85 % of breaks rejoined, as 
seen in the p65+/+ and p65-/- cells. Once again the SSB repair kinetics and the extent of 
SSB inhibition by AG-014699 were very similar in both the p65 WT and p65 null 
control cells (Figure 3.10A and 3.10B). The kinetics of SSB repair in both cells line are 
illustrated in Figures 3.14E and 3.14F by line graphs. These clearly show that the SSBs 
generated by IR are repaired rapidly over time (solid black line), and that in both cells 
line the kinetics of repair were very similar. The broken line shows how cells pre-
treated with AG-014699 prior to treatment with IR, have slower repair kinetics in both 
cell lines, regardless of p65 status. These data corroborate the data generated in the 
p65+/+ and p65-/- MEFs, thus confirming the hypothesis that radio-sensitisation by AG-
014699 is mediated solely via the inhibition of NF-κB and is therefore independent of 
the widely reported inhibition of SSB repair. 
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Figure 3.14: AG-014699 inhibits SSB repair to a similar extent regardless of 
cellular NF-κB status Scatter diagrams showing the extent of single strand breaks 
(SSBs) in p65WT and p65 null MEFs treated with 10 Gy IR ± AG-014699 (AG, 
denoted by +) and allowed to repair (0 min, 15 min, 30 min and 60 min). (A) and (B) 
represent OTM and (C) and (D) represent % Tail DNA. Line graph showing the 
kinetics of single strand break repair in p65WT (E) and p65null MEFs (F). Data was 
normalised to relevant controls and in both cases solid black lines represent repair 
over time of cells treated with 10 Gy IR, and dotted lines represent repair over time 
of cells treated with 10 Gy IR + AG-014699. 
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3.4 Discussion 
This investigation has demonstrated that PARP-1 knockdown and the PARP inhibitor, 
AG-014699 significantly decreased survival and induced apoptosis following IR in 
p65+/+ MEFs whilst having no effect in p65-/- MEFs. Radio-sensitisation was 1.3-fold 
and importantly occurred at clinically relevant doses of IR. A combination of AG-
014699 and p65 knockdown did not further enhance this response, which is consistent 
with reports that PARP-1 and NF-κB are mechanistically linked in a common pathway 
(Chang and Alvarez-Gonzalez, 2001, Hassa et al., 2001, Hassa and Hottiger, 1999, 
Martin-Oliva et al., 2004, Stilmann et al., 2009, Veuger et al., 2009). This is also 
consistent with reports that loss or inhibition of NF-κB has been shown to chemo- or 
radio-sensitise in many different tumour types (Criswell et al., 2003, Hewamana et al., 
2008a, Hewamana et al., 2008b, Jung and Dritschilo, 2001, Russo et al., 2001). 
However, is it important to note that the dose of IR required to active NF-κB may be 
cell type or tissue-dependent. For example, Brach et al., (1991) showed that the 
clinically relevant dose of 2 Gy could induce NF-κB activation in the myeloid cell line, 
KG-1 (Brach et al., 1991). Furthermore, in the EBV-transformed 244B human 
lymphoblastoid cell line, 0.5 Gy IR was shown to activate NF-κB activation (Sahijdak 
et al., 1994). Whereas, other studies such as Stilmann et al. (2009), used hyper-lethal 
doses, of 80 Gy IR when studying the NF-κB response of other cell lines. Importantly, 
the doses of IR used within this study are low and as close to a clinically relevant dose 
as possible. The clinical single dose of 2 Gy IR was used in both the clonogenic and 
annexin V flow cytometry assays. A slightly higher dose of 5 Gy IR was required for 
the caspase 3/7 assay, as this assay did not appear as sensitive as the FACs based 
method. The FACs assay counts a maximum of 10,000 events whilst the caspase assay 
also requires that the absolute cell numbers are constant between the control and treated 
wells. In reality this is much more difficult to control, since the clonogenic assay data 
shows that p65 siRNA or AG-014699 both reduce cell survival compared with controls, 
and hence there could be a lower cell number in these wells. 
 
Moreover, the work of Stilmann et al., (2009) used hyper-lethal doses of IR (80 Gy) in 
the PARP-1+/+ and PARP-1-/- MEFs however they did not study survival following such 
doses of IR, just the induction of apoptosis (Stilmann et al., 2009). The survival data 
shown within this investigation illustrate that the PARP-1-/- MEFs are very radio-
sensitive at low doses of IR (LD50 value: 0.9 Gy versus 2.3 Gy in PARP-1+/+ cells). This 
is consistent with many other reports that loss or inhibition of PARP-1 is associated 
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with chemo-and radio-sensitisation due to inhibition of efficient DNA repair (Calabrese 
et al., 2004, de Murcia et al., 1997, Masutani et al., 2005). PARP-1-/- cells have also 
been shown to have high genomic instability (Wang et al., 1997), hence the use of such 
high doses of IR, by Stilmann et al., (2009) is likely to exacerbate this phenotype.  
 
Many reports into the role of PARP-1 in the activation of NF-κB have used classical 
PARP inhibitors such 3-AB and nicotinamide derivatives (Chang and Alvarez-
Gonzalez, 2001, Martin-Oliva et al., 2006, Martin-Oliva et al., 2004, Stilmann et al., 
2009). However, reports have shown that these compounds have many off target effects 
at the concentrations used (Moses et al., 1990). Early compounds, such as 3-AB showed 
selectivity problems, due to their weak inhibition of the enzyme, and having to be used 
at physiologically non-specific concentrations, usually in the millimolar range. This 
investigation not only used the potent PARP inhibitor, AG-014699, at a sub-micromolar 
concentration, known to be a highly potentcy for PARP (Ki  1.4 nmol/L) (Thomas et al., 
2007), but PARP-1 siRNA as a direct comparison in order to verify the results seen with 
the PARP inhibitor. 
 
It is widely accepted that use of small molecule inhibitors should be compared directly 
with siRNA knockdown of a target protein, if this is a viable option. Loss-of-function 
data obtained at the single-cell level is now achievable through siRNA molecules which 
are now readily available and affordable. This technology has provided a 
complementary approach to more traditional pharmacological procedures, via small 
molecule inhibition, and other methods including the generation of genetic knockout 
animals, which are generally in whole organisms rather than single cells. For example, 
p65/RelA knockout animals were found to be embryonic lethal at E15-16 due to 
massive liver degeneration as a consequence of chronic inflammation and subsequently 
apoptosis (Beg et al., 1995). The generation of chemical agents which target protein-
protein or protein-DNA interactions, such as those of transcription factors, like NF-κB, 
have been more challenging than pharmacological approaches that target proteins which 
have a defined substrate, such as PARP-1 or kinases, for example DNA-PK or ATM. In 
this case, use of p65 siRNA in comparison or in combination with the PARP inhibitor, 
AG-014699, has allowed a direct assessment of the role of PARP-1 in the regulation of 
NF-κB.  
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The use of siRNA targeting PARP-1 as a direct comparison to the use of AG-014699, 
has shown that regulation of DNA-damage activated NF- κB is mediated by PARP-1, 
and not any of the other PARP superfamily proteins. Although inhibition of other PARP 
family proteins (such as PARP-2) by AG-014699 cannot be rigorously excluded, the 
consistency in the data obtained from both the inhibitor studies and PARP-1 knockdown 
studies indicate that this is not the case. Furthermore, Cohausz and Althaus (2009) have 
shown that PARP-1 but not PARP-2 is required for expression of genes involved in 
regulation of apoptosis (Cohausz and Althaus, 2009), supporting the survival and 
apoptosis data within this investigation which has shown that AG-014699 radio-
sensitizes cells via inhibition of PARP-1, not PARP-2.  
 
There have been reports which show divergence between enzymatic inhibition and 
protein knockdown. These include studies into Aurora kinase inhibitors and siRNA 
targeting Aurora kinase B. The Aurora kinases, A, B and C, are highly conserved 
mitotic regulators. The ‘polar’ kinase, Aurora A, is required for biopolar spindle 
assembly and therefore localizes to spindle poles and the centrosome during mitosis. 
The ‘equatorial’ kinase, Aurora B, first localizes to the centromeres and the 
kinetochores during the early stages of mitosis acting as a chromosome passenger (Keen 
and Taylor, 2004).  Small molecule Aurora kinase inhibitor studies showed that Aurora 
B function was vital for checkpoint signaling following checkpoint activation. These 
showed that in inhibitor treated cells, the checkpoint response to paclitaxel was lost, 
whereas this checkpoint was activated when microtubule polymerization was prevented 
with nocodazole. Knockdown of Aurora B using siRNA also showed a compromised 
checkpoint response, however in this case this was following both paclitaxel and 
nocodezole (Biggins and Murray, 2001, Ditchfield et al., 2003, Hauf et al., 2003). The 
lack of congruence illustrated with these, and other data, highlight how loss of 
enzymatic activity can have very different effects from the loss of protein expression. 
However, the consistencies shown in the survival and apoptosis data in this chapter, 
suggest that both the physical presence of the PARP-1 protein and the catalytic activity 
are required to activate NF-κB, following ionising radiation. It is possible, that in this 
case PARP-1 may facilitate a structural role in the NF-κB transcriptional complex, as 
illustrated by Hassa et al., (2005) using TNF-α as an activator of NF-κB, and 
demonstrating that the acetylation of PARP-1 (by HDAC1 and p300) regulated NF-κB 
activity. However, this theory is less likely to be true following treatment with IR, as the 
data using the PARP inhibitor (Figures 3.8 and 3.9) has shown that enzymatic inhibition 
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generates the same reduction in cell survival as PARP-1 siRNA, and in this case PARP-
1 protein is still available to act as a scaffold for protein-protein interactions.  
 
It has been documented that non-specific/scrambled siRNA controls can have effects on 
cellular processes including cell viability, proliferation, cell cycle distribution, 
apoptosis, and migration (Jackson and Linsley, 2004, Tschaharganeh et al., 2007), when 
compared with ‘mock/transfection reagent alone’ controls. Although the Western 
analyses show that the non-specific (NS) siRNA molecules used here have no effects on 
the expression of the target proteins, p65 or PARP-1, or those downstream, there 
appears to be some effect when used in the PARP activity assay but not for the cell 
survival or apoptosis assays.  
 
The levels of SSBs in p65+/+ and p65-/- MEFs induced by IR were similar and both were 
equally proficient at their repair. AG-014699 was also able to increase the level of 
breaks to the same extent in both cell lines, consistent with the known role of PARP-1 
in BER (Durkacz et al., 1980). Thus, these novel observations have led to the 
conclusion that the potentiating effect of AG-104699 when used in conjunction with IR 
is perhaps not primarily due to the widely reported transient inhibition of SSB repair but 
a consequence of PARP-1 downstream signaling to NF-κB. This is consistent with the 
observation that cells severely compromised in DNA repair (e.g. PARP-1-/-) are able to 
divide and go on to survive despite having consistently higher levels of breaks 
compared to their wild type counterparts, even in the absence of exogenous damage 
(Trucco et al., 1998). These data are very novel and very much against the widely 
accepted dogma that the inhibition of DNA repair by PARP inhibition is the reason for 
the observed cytotoxicity. Therefore it is vital that these experiments are undertaken in 
other cell lines, perhaps using p65 siRNA to knockdown p65 expression, and with other 
DNA damaging agents, such as temozolomide, which has been shown to be sensitised 
by PARP inhibition (Calabrese et al., 2004, Chalmers, 2009, Chalmers, 2010, Daniel et 
al., 2009). 
 
There is evidence that the effects shown within this chapter, using the Comet assay are 
likely to be due to SSBs, even though the alkaline Comet assay can detect a small 
amount of DSBs as well as SSBs, as discussed in section 2.7.1.2. Firstly, Ogorek and 
Bryant (1985) showed that at the low doses of IR as used in our experiments, the ratio 
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of SSB to DSB is approximately 20:1 (Ogorek and Bryant, 1985a, Ogorek and Bryant, 
1985b). Furthermore, previous work has shown that PARP-1 has a minor role in the 
repair of DSBs by NHEJ in the absence of DNA-PK (Veuger et al., 2003). However the 
p65+/+ and p65-/- cells used here have functional DNA-PK, and thus any DSBs would be 
repaired by NHEJ, with AG-014699 being solely responsible for the inhibition of SSBs.  
 
It is however, important to note that IR does induces a combination  of SSBs and DSBs. 
The overall impact of PARP inhibition, in this case and others in the literature 
(Chalmers et al., 2004, Schlicker et al., 1999), is one of modest radio-sensitisation, and 
some studies have reported very minimal sensisation in certain cell lines (Noel et al., 
2006), therefore it is important to consider other factors and roles that PARP-1 may be 
playing in the cell, other than just SSB repair. Although the data here suggests a clear 
mechanistic link between PARP-1 and NF-κB, other factors, which have not been 
assayed for should be considered, such as the role of PARP-1 in DSB repair, discussed 
previously in section 1.3.2.2. In replicating cells the unrepaired SSBs generate collapsed 
replication forks which could give rise to potentially lethal DSBs, and recent data 
suggests that it is these DSBs that are responsible for the cytotoxicity of PARP 
inhibitors (Chalmers 2009). Hence, future work could include assays for DSB repair 
such as the γH2AX foci assay, and also some cell synchronisation assays to discover 
which phase of the cell cycle is crucial in this particular case. 
 
PARP-1 is known to regulate many transcription factors (Kraus, 2008, Kraus and Lis, 
2003, Krishnakumar and Kraus, 2010) and therefore it is important to note that this may 
then involve the cross-talk, in this case between NF-κB and other transcription factors 
activated by IR, such as p53. It has been shown previously that NF-κB and p53 share 
the transcriptional co-activators, CBP and p300 as transcriptional coactivators (Webster 
and Perkins, 1999) and furthermore that the acetylation of PARP-1 by CBP and p300 is 
associated the regulation of the NF-ĸB transcriptional response (Hassa et al., 2005). 
 
The spontaneous immortalisation of MEFs can often lead to mutations in p53, meaning 
that the p65 proficient and deficient MEFs may not be a truly isogenic pair. In order to 
address this p65-/- cells that had been genetically complemented with wild-type p65 
protein were used (Figures 3.10 and 3.14). These data support the original findings that 
the extent of the inhibition of SSB repair by AG-014699 is the same, regardless of the 
p65 status, and that inhibiting SSB repair with AG-014699 does not lead to radio-
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sensitisation in the absence of NF-κB. Hence, this now allows the conclusion that the 
radio-sensitisation observed with AG-014699 is mediated via inhibition of NF-κB 
activation, and not the widely reported transient inhibition of SSBs. 
 
Inhibition of NF-κB is clearly an attractive target for cancer therapeutics although, as 
previously mentioned, the direct inhibition of a transcription factor, is very challenging 
in terms of drug discovery. Most pharmacological approaches have concentrated on 
inhibition of proteosomal degradation, or the IKK complex (Gilmore and Herscovitch, 
2006). However, global inhibition using these types of agents may have some negative 
aspects. For example, NF-κB plays a vital role in the inflammatory response, and thus 
complete inhibition of NF-κB, for example with an IKK inhibitor, may have adverse 
effects. The IKK complex has many known functions within the cell (Chariot, 2009, 
Criollo et al., 2010), and inhibition may be cytotoxic. Long-term NF-κB inhibition may 
also increase the likelihood of immunodeficiency, since it plays a pivotal role in the 
innate and adaptive immune response, and can possibly delay bone marrow recovery 
due to some reports of chemotherapeutic induced apoptosis of hematopoietic 
progenitors (Grossmann et al., 1999, Turco et al., 2004). The data here suggest that AG-
014699 specifically inhibits IR-induced NF-κB activation and thus may overcome these 
potential toxicities. It is important to note that the effects on NF-κB when using AG-
014699, are very much a transient (i.e. during and in the short period following DNA 
damage), thus it would be fair to hypothesise that AG-014699 would not affect the NF-
κB induced by inflammatory stimuli, and hence the NF-κB mediated inflammatory 
response, which is known to be hugely important to the cell. However, this requires 
further investigation into the role of PARP-1 and other activators of NF-κB (Chapters 4 
and 5).  Importantly however, therapeutic inhibition of PARP has been shown by many 
to be relatively non-toxic to normal cells (Drew and Plummer, 2009).  
 
AG-014699 has been shown to be efficacious both in vitro and in vivo (Daniel et al., 
2010, Daniel et al., 2009, Drew et al., 2011, Plummer et al., 2008, Zaremba et al., 
2009). Moreover, AG-014699 was the first PARP inhibitor to enter clinical trials for 
cancer therapy and Phase I trials showed that profound and sustained PARP inhibition 
could be achieved after a single intravenous infusion (Plummer et al., 2005). Phase II 
trials combining AG-014699 with temozolomide in metastatic melanoma patients 
showed an improvement in the response rate in comparison with temozolomide alone 
(Plummer et al., 2008). Furthermore, AG-014699 is currently in phase II trials for 
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BRCA defective breast and ovarian cancer as a single agent (www.clinicaltrials.gov). A 
number of pharmaceutical companies are now undertaking clinical trials of PARP 
inhibitors for the treatment of cancer (Drew and Plummer, 2009); however, the data 
here represent the first investigation of the clinically relevant PARP inhibitors in the 
context of their potential utility as inhibitors of DNA-damage induced NF-κB 
activation, and these data are now published in Oncogene (Hunter et al., 2011). 
3.5 Summary and future work 
The data in this chapter, using AG-014699 and siRNA targeting NF-κB p65 and MEFs 
proficient and deficient for NF-κB p65, show that inhibition of PARP-1 modulates the 
apoptotic response to IR, and that the potentiation of IR-induced cytotoxicity by PARP-
1 inhibition is due to the loss of NF-κB activation. Strikingly, the Comet assay data are 
the first to demonstrate that radio-sensitisation by PARP inhibition is exclusively due to 
inhibition of NF-κB, and not due to the widely reported prevention of DNA repair.  
 
However, these data do highlight further questions regarding the use of PARP inhibitors 
for the inhibition of NF-κB. The work in this chapter has concentrated on the activation 
of NF-κB by the DNA damaging agent, ionising radiation, and the role PARP-1 plays in 
the context of NF-κB following this stimulus. It would therefore be interesting to 
determine whether PARP-1 is required for the activation of NF-κB following other 
known stimulators of NF-κB, such as TNF-α, and furthermore, whether any activation 
is dependent on PARP-1 enzymatic function.  The literature suggests that PARP-1 
catalytic activity may be dispensable for TNF-α induced NF-κB activation (Hassa et al., 
2001) leading to the hypothesis that AG-014699 may specifically inhibit DNA-damage 
induced NF-κB activation and therefore overcome toxicity obstacles seen with other 
NF-κB inhibitors. In order to test this, it will be important to investigate the role of 
PARP-1 in the activation of NF-κB dependent gene transcription after both 
inflammatory and DNA-damaging stimuli. These studies will be undertaken as part of 
this thesis (Chapter 4 and 5). 
 
Moreover, it is well documented that the activation of NF-κB is dependent on the cell 
type and stimulus, and therefore it would be important to investigate the role of PARP-1 
in the co-activation of NF-κB in other cell lines and contexts. The data within this 
chapter suggest that the PARP inhibitor AG-014699, may have a potential uses in 
cancers in order to overcome NF-κB mediated therapeutic resistance. To this end it is 
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vital to discover which types of cancer would benefit from this type of therapeutic 
intervention, and to investigate whether PARP inhibition can re-sensitise cancer cell 
lines to DNA-damaging agents (IR and perhaps, other chemo-therapeutic agents) via the 
inhibition of NF-κB. This study will be undertaken as part of this thesis (Chapter 6). 
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Chapter 4. PARP-1 is differentially required in the activation of NF-κB 
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4.1 Introduction 
Although there is a mounting body of evidence describing a role for PARP-1 in the co-
activation of NF-κB, the role of PARP-1 catalytic activity in NF-κB activation is 
somewhat contentious. This is discussed at length in section 1.5. Some groups have 
reported that PARP-1 enzymatic activity directly influences NF-κB dependent 
transcription after DNA damage (Chang and Alvarez-Gonzalez, 2001, Chiarugi and 
Moskowitz, 2003, Nakajima et al., 2004, Stilmann et al., 2009, Veuger et al., 2009, 
Zingarelli et al., 2003b)whilst others have described how PARP-1 protein alone is 
required for NF-κB activation following inflammatory stimuli (Hassa et al., 2001, Hassa 
and Hottiger, 1999, Martin-Oliva et al., 2004). It is highly likely that the differential 
requirements reported in the literature are both cell-type and stimulus-dependent. 
 
Le Page et al., (1998) used the classical PARP inhibitor, 3-AB in the macrophage cell 
line, 264.7 and showed that NF-κB activation by LPS was reduced in combination with 
3-AB. They also showed that transcription of the NF-κB target gene, iNOS, was reduced 
in cells treated with LPS and 3-AB compared with LPS alone (Le Page et al., 1998). 
This was the first indication that inhibition of PARP-1 could modulate NF-κB-
dependent gene expression. Chang and Alvarez-Gonzalez, 2001, demonstrated that pre-
incubation with 3-AB inhibited H202 activated NF-κB p50 DNA binding and activation.  
A report using rat glial and neuronal cultures showed that the use of PARP inhibitors 
significantly reduced activation of NF-κB target genes, including iNOS, IL-1β and TNF-
α, resulting in a reduced neuro-inflammation and the neurotoxic potential of activated 
glia (Chiarugi and Moskowitz, 2003). Zingerilli et al., (2003) used the PARP inhibitors, 
3-AB and 1,5-dihydroxyisoquinoline in combination with the inflammatory stimulant 
2,4,6-trinitrobenzene sulfonic acid (TNBS) and showed that this combination markedly 
reduced DNA binding of both NF-κB and AP-1 in a rat model of colitis (Zingarelli et 
al., 2003b). Nakajima et al., (2004) also used cultured murine glial cells to show that the 
auto-ribosylation of PARP-1 led to enhanced LPS-induced NF-κB DNA binding and in 
particular NF-κB p50-dependent gene transcription in this model (Nakajima et al., 
2004). Furthermore, PARP-1 inhibition was able to alleviate TNF-α-stimulated NF-κB-
dependent MMP-9-mediated neurotoxicity in microglia in a model of brain injury 
(Kauppinen and Swanson, 2005). 
  
169 
 
More recently, Stilmann et al (2009) showed that a PARP-1 signalling scaffold via 
direct protein-protein interactions with NEMO, PIASγ and ATM formed in response to 
DNA damage (Figure 1.13). In particular, this group detail that impaired sumoylation 
following treatment with the PARP inhibitor, 3-AB, results in reduced IKK activation 
and therefore inhibition of p65 induction. They describe the formation of a signalosome 
which relies on binding with PAR and leads to pro-survival NF-κB activation (Stilmann 
et al., 2009).  
 
A different approach was taken by, Hassa et al., (2001) which demonstrated that TNFα-
mediated PARP-1 co-activation of the NF-κB transcription factor was attenuated in 
PARP-1 null cells, but was unaffected by over-expression of a PARP-1 catalytic mutant 
(Hassa et al., 2001). A later study by Martin-Oliver et al., (2006 Cancer Res), used the 
carcinogen, TPA ((12-O-tetradecanoyl-phorbol-13-acetate) in combination with the 
PARP inhibitor, DPQ, and showed that in a model system of murine papillomas, PARP-
1 activity did not alter NF-κB activation following TPA treatment. 
 
4.2 Aims 
Studies to date have concentrated on the role of PARP-1 in the activation of NF-κB 
following either an inflammatory stimulus or a DNA-damaging agent. However, head-
to-head studies in one model system are absent. Hence, this chapter aims to directly 
compare activation by the inflammatory cytokine, TNF-α and the DNA-damaging 
agent, ionising radiation, and thus determine whether PARP-1 is differentially required 
in the activation of NF-κB and importantly whether this is stimulus-dependent. 
Furthermore, these studies will test the hypothesis that any differential observed would 
be dependent on the ability of the stimuli to activate PAR. 
 
The potent and specific PARG inhibitor, Adenosine 5'-diphosphate (hydroxymethyl) 
pyrrolidinediol, referred to hereafter as, ADP-HPD (Slama et al., 1995) will also be 
used to investigate the role of PAR r in the activation of NF-κB following DNA 
damage. PARG is the major enzyme responsible for the catabolism of PAR (Bonicalzi 
et al., 2005), and therefore PARG inhibition results in a reduction in PAR degradation. 
Hence, the ADP-HPD is a very useful tool for testing the hypothesis that DNA-damage-
activated NF-κB is mediated via PAR. 
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4.3 Results 
4.3.1 IR or TNF-α induced nuclear translocation of NF-κB is unaffected by AG-
014699 or PARP-1 knockdown 
NF-κB subunits are held inactive in the cytoplasm through their interaction with IκB 
proteins. Upon stimulus, by DNA damage or inflammatory cytokines, the canonical 
pathway of NF-κB activation is induced and signalling cascades converge at the IKK 
complex which phosphorylates IκBα, targeting this for degradation and promoting 
nuclear translocation of the p65/p50 heterodimer, activating transcription of many genes 
(Ghosh and Karin, 2002). One method of investigating whether an NF-κB subunit is 
activated by a particular stimulus, is to assess the nuclear translocation by Western 
blotting. Previous reports would suggest that both IR and TNF-α would induce the 
nuclear translocation of the p65 subunit (Beg and Baltimore, 1996, Veuger et al., 2009), 
and moreover that IR-induced p65 nuclear translocation would be unaffected by PARP 
inhibition (Veuger et al., 2009). However, it was important in this study to assess the 
activation of p65 following either stimuli in the p65+/+ MEFs. To this end it was also 
interesting to determine whether p65 siRNA, AG-014699, PARP-1 siRNA or a 
combination of p65 siRNA and AG-014699 had any effect on the nuclear translocation 
of p65 following either IR or TNF-α. 
 
Briefly, p65+/+ MEFs were transfected with 50 nM p65 siRNA, 50 nM PARP-1 siRNA , 
50 nM NS siRNA (optimised previously, Chapter 3), or vehicle alone control. Cells 
were then incubated for a further 48 h prior to treatment with either 10 Gy IR or 10 
mg/ml TNF-α (or 0.1 % BSA diluted in PBS control). Cells were harvested 1 h later and 
nuclear extracts prepared using the NE PER kit, (section 2.5.2). The levels of p65, 
Lamin or β-actin were determined by Western analyses in nuclear extracts. 
Densiometric analysis was used to assess the levels of p65 compared to the nuclear 
protein, Lamin. β-actin was used as a control in order to ensure that there was no 
cytoplasmic contamination of the nuclear extracts.  
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Figure 4.1A and 4.1B show the nuclear translocation of p65 1 hour following treatment 
with either IR or TNF-α in nuclear extracts of the p65+/+ MEFs. The effect of co-
incubation with either stimulus and p65 siRNA, AG-014699, PARP-1 siRNA or a 
combination of p65 siRNA and AG-014699 was also assessed at this timepoint. The bar 
charts representing that densiometric analysis Figures 4.1C and 4.1D show that nuclear 
translocation of p65 was induced to a similar extent by either 10 Gy IR or 10 ng/ml 
TNF-α,compared to controls, as the blots shown following TNF-α treatment were 
exposed for longer than those following treatment with IR. Importantly, this IR- or 
TNF-α-induced translocation was unaffected by AG-014699 or PARP-1 siRNA 
(p=0.854 and p=0.721, respectively IR; p=0.542 and p=0.399, respectively, TNF-α, 
Figure 4.1: p65 nuclear translocation is unaffected by AG-014699 or PARP-1 
siRNA 
Western blotting data showing nuclear translocation of p65 following (A) IR or TNF-α 
(B) ± p65 siRNA ± AG-014699 (AG) ± PARP-1 siRNA ± (p65 siRNA + AG-014699) 
± NS siRNA control, in p65+/+ MEFs. Bar charts showing densiometric analysis of 
Western blotting data (C) IR and (D) TNF-α. Cells were treated with relevant siRNA, 
or control, left for 48 h, pre-treated with AG-014699, or control 1 h prior to IR and 
harvested 1 h post-IR. Loading was normalised to lamin nuclear loading control in all 
cases. Nuclear extracts were shown to be free of any cytoplasmic contamination by 
blotting with β-Actin antibody. 
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unpaired Student’s t-tests). It should also be noted that although the PARP-1 siRNA 
does appear to have a slight effect on p65 translocation following TNF-α, this is not the 
case as the Lamin control indicates under loading of the protein extract in this case 
(Figure 4.1B). Knockdown of p65, either alone or in combination resulted in the loss of 
p65 protein, hence no nuclear translocation was observed following either stimulus. 
Loading was normalised to Lamin, and to ensure the nuclear extracts had no 
contamination of cytoplasmic proteins blots were probed for β-actin, and showed no 
presence of this protein. These data suggest that PARP-1 does not affect nuclear 
translocation, and must be acting further downstream in the activation cascade, perhaps 
at the DNA binding or transcriptional level. 
 
4.3.2 IR or TNF-α induced NF-κB DNA binding in a time dependent manner 
The data in Figure 4.1 illustrated that PARP-1 inhibition or siRNA did not affect p65 
nuclear translocation, and hence PARP-1 must be acting further downstream in the 
activation of NF-κB, perhaps at the DNA binding or transcriptional level. In order to 
determine whether this was the case, an assessment of p65 DNA binding, using an 
ELISA-based assay was undertaken. However, the timepoint at which maximal DNA 
binding occurred following either 10 Gy IR or 10 ng/ml TNF-α had to be determined 
before any further investigation could take place. 
 
The ELISA-based assay, described in detail in section 2.8.1 was utilised. Briefly, p65+/+ 
MEFs were plated and left to adhere for 24 h prior to treatment with 10 Gy IR or 10 
ng/ml TNF-α. Cells were then harvested at various timepoints (0, 1, 2, 4, 6, 8 24 h) and 
DNA binding of nuclear extracts assessed using the ELISA assay. Figures 4.2A and 
4.2B illustrate that DNA binding of p65 following either IR or TNF-α increased after 1 
h when compared with untreated controls (p=0.0091 and p=0.0007, respectively, 
unpaired Student’s t-test). Moreover, in the case of both stimuli DNA binding was 
maximal 2 h following treatment (p<0.0001 and p0.0001, compared with untreated 
controls, unpaired Student’s t-test). DNA binding of p65 was still significantly 
increased 4 h after treatment with 10 Gy IR and 10 ng/ml TNF-α, and in both cases 
DNA binding activity returned to basal levels 24 h post treatment. 
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4.3.3 NF-κB DNA binding requires PARP protein and enzymatic activity following 
IR, but PARP-1 protein alone following TNF-α 
Once it had been determined that DNA binding of p65 was maximal 2 h following 
treatment with 10 Gy IR or 10 ng/ml TNF-α, the ELISA was utilised to assess the 
effects of AG-014699, p65 or PARP-1 siRNA on IR- and TNF-α-induced NF-κB DNA 
binding. In this case, p65+/+ MEFs were transfected with 50 nM p65, PARP-1 or NS 
siRNA (or vehicle control). Cells were then left for 48 h, and pre-treated with AG-
014699, or DMSO control 1 h prior to treatment with 10 Gy IR or 10 ng/ml TNF-α. 
Cells harvested 2 h later and nuclear extracts were prepared before running on the 
ELISA as described in 4.3.2.  
 
The open bars in Figure 4.3 show that 10 Gy IR increased DNA binding activity 2-fold 
compared with Mock treated p65+/+ cells. Also, siRNA targeting p65 or a combination 
of p65 siRNA and AG-014699 reduced IR-induced DNA binding > 85% following IR 
in p65+/+ cells (p=0.006 and p=0.008, compared to IR in combination with NS siRNA, 
respectively, unpaired Student’s t-tests). PARP-1 siRNA inhibited DNA binding by 
approximately 60% (p=0.02, compared to IR in combination with NS siRNA, unpaired 
Student’s t-test). Significantly, AG-014699 also reduced IR-induced DNA binding to 
levels comparable with untreated controls (p=0.03, compared to IR in combination with 
NS siRNA, unpaired Student’s t-test). Non-specific siRNA had no effect on DNA-
binding following IR. The black bars in Figure 4.3 illustrate that 10 ng/µl TNF-α 
Figure 4.2: Maximal activation of NF-κB by either IR or TNF-α is 2 h post-
treatment Bar chartshowing the effect of IR or TNF-α over time on NF-κB DNA 
binding activity, measured using an ELISA-based assay, in p65+/+ MEFs. All results 
are the mean of three independent experiments with SEM. Significance relative to 
mock treated control using unpaired Student’s t-test *** p<0.001, ** p<0.01  
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increased p65 DNA binding activity 2.3-fold compared with Mock treated p65+/+ cells. 
p65 siRNA or a combination of p65 siRNA and AG-014699 reduced DNA binding to 
levels relative to Mock treated controls, following TNF-α (p=0.01 and p=0.008, 
compared to TNF-α in combination with NS siRNA, respectively, unpaired Student’s t-
tests). Importantly, PARP-1 siRNA also reduced DNA binding after TNF-α treatment 
(p=0.02, compared to TNF-α in combination with NS siRNA, unpaired Student’s t-test). 
In marked contrast, AG-014699 had no effect on p65 DNA binding following TNF-α.  
 
 
 
 
 
 
 
4.3.4 IR or TNF-α induced NF-κB-dependent gene transcription in a time dependent 
manner 
The data in Figure 4.3 illustrated that PARP-1 inhibition or siRNA inhibited IR-induced 
p65 DNA binding but that PARP-1 protein alone was required for p65 DNA binding 
following TNF-α treatment. Hence, it was vital to determine the role of PARP-1 in the 
activation of NF-κB-dependent gene transcription following both stimuli. For this a 
luciferase reporter assay was utilised. However, the timepoint at which luciferase 
activity was maximal following either 10 Gy IR or 10 ng/ml TNF-α had to be 
determined before any further investigation could take place. 
 
Figure 4.3: PARP activity is essential for NF-κB DNA binding following IR, 
not TNF-α Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± AG-
014699 (AG) ± PARP-1 siRNA ± (p65 siRNA + AG-014699) ±Non-specific (NS) 
siRNA control on NF-κB DNA binding activity, measured using an ELISA-based 
assay in p65+/+ MEFs. Open bars IR, black bars TNF-α. All results are the mean of 
three independent experiments with SEM. Significance relative to NS siRNA 
control using unpaired Student’s t-test *** p<0.001, ** p<0.01 
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Briefly, p65+/+ MEFs were seeded and incubated for 24 h before transient transfection 
with 200 ng of an NF-κB-luciferase construct and 200 ng of a pCMB-β-galactosidase 
plasmid (section 2.9). Following further 48 h incubation, cells were treated with either 
10 Gy IR or 10 ng/ml TNF-α. Cells were lysed after 0, 2, 4, 6, 8 or 24 h and assayed for 
luciferase activity using the Promega Luciferase assay system, according to the 
manufacturer’s instructions. Luciferase activity was corrected for β-galactosidase 
activity as described previously (Brady et al., 1999), and relative activities expressed as 
fold changes. 
 
Figures 4.4A and 4.4B illustrate that luciferase reporter activity increased steadily 
following either IR or TNF-α when compared with untreated controls. Four hours after 
either stimuli, luciferase reporter activity was significantly increased when compared 
with untreated controls (p=0.0086; IR and p=0.0071; TNF-α, respectively, unpaired 
Student’s t-test). Moreover, in the case of both stimuli NF-κB-dependent luciferase 
activity was maximal 8 h following treatment (p=0.0005; IR and p=0.0008; TNF-α, 
compared with untreated controls, unpaired Student’s t-test). Luciferase reporter activity 
returned to basal levels 24 h post treatment with either stimulus. 
 
 
 
 
 
4.3.5 NF-κB-dependent gene transcription requires PARP protein and enzymatic 
activity following IR, but PARP-1 protein alone following TNF-α 
Once it had been determined that NF-κB-dependent luciferase activiation was maximal 
8 h following treatment with 10 Gy IR or 10 ng/ml TNF-α, the luciferase reporter assay 
Figure 4.4: Maximal activation of NF-κB-dependent gene transcription by either 
IR or TNF-α is 8 h post-treatment. Bar chart showing the effect of IR or TNF-α over 
time on NF-κB-dependent gene transcription, measured using a luciferase reporter 
assay, in p65+/+ MEFs. All results are the mean of three independent experiments with 
SEM. Significance relative to mock treated control 001 using unpaired Student’s t-test 
*** p<0.001 ** p<0.01  
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was utilised to assess the effects of AG-014699, p65 or PARP-1 siRNA on IR- and 
TNF-α-induced NF-κB-dependent gene transcription. In this case, p65+/+ MEFs were 
seeded and incubated for 24 h before transient transfection 200 ng of an NF-κB-
luciferase construct and 200 ng of a pCMB-β-galactosidase plasmid (section 2.9). 
siRNA transfection was undertaken simultaneously in this case. Following a further 48 
h incubation, cells were assayed for luciferase actiavity expressed as fold changes. 
 
 
 
 
 
 
Consistent with the increased DNA binding (Figure 4.3), following either 10 Gy IR or 
10 ng/ml TNF-α, luciferase activity was increased 2- and 2.5-fold respectively, 
compared to Mock treated controls (Figure 4.5). Also, siRNA targeting p65 or a 
combination of p65 siRNA and AG-014699 reduced luciferase activity > 80% following 
IR alone or in combination with NS siRNA (p=0.01 and p=0.007, respectively, unpaired 
Student’s t-tests) or TNF-α alone or in combination with NS siRNA (p=0.009 and 
p=0.01, respectively, unpaired Student’s t-tests) in p65+/+ MEFs. PARP-1 siRNA 
inhibited luciferase activity by approximately 70%, following either stimulus (p=0.03 
compared to IR, p=0.05 compared to TNF-α, unpaired Student’s t-tests). Significantly, 
AG-014699 also reduced IR-induced luciferase reporter activity to levels comparable 
with untreated controls (p=0.04, unpaired Student’s t-test). However, AG-014699 had 
no effect on luciferase activity following TNF-α compared with TNF-α alone, consistent 
Figure 4.5: PARP activity is essential for NF-κB-dependent gene transcription 
following IR, not TNF-α Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± 
AG-014699 (AG) ± PARP-1 siRNA ± (p65 siRNA + AG-014699) ±Non-specific (NS) 
siRNA control on NF-κB-dependent transcriptional activation, measured using a luciferase 
reporter assay, in p65+/+ MEFs. Open bars IR, black bars TNF-α. All results are the mean 
of three independent experiments with SEM. Significance relative to NS siRNA control 
using unpaired Student’s t-test ** p<0.01, * p<0.05 
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with other reports which have shown that a NF-κB transcriptional activation was 
attenuated in PARP-1 null cells but unaffected by over-expression of a PARP-1 
catalytic mutant (Hassa et al., 2001). 
 
4.3.6 IR, not TNF-α stimulates PAR formation 
The p65 DNA binding and NF-κB-dependent transcriptional activation results have 
shown that PARP-1 activity and protein is required for NF-κB activation following IR, 
whereas PARP-1 protein alone is essential for NF-κB activation following treatment 
with TNF-α. It is well documented that PARP-1 is activated following DNA, resulting 
in the automodification of the protein and formation of PAR (Jagtap and Szabo, 2005). 
However, there are no reports in the literature investigating the activation of PARP-1 
following the cytokine, TNF-α. Therefore, in order to determine whether PARP-1 was 
activated by IR or TNF-α, PARP activity was assessed in the p65+/+ MEFs using a 
validated assay (Plummer et al., 2005, Zaremba et al., 2009). Briefly, p65+/+ MEFs were 
plated and allowed to adhere for 24 h before treatment with increasing doses of either 
IR (0–20 Gy) or TNF-α (0-50 ng/ml). Cells were permeabilised immediately following 
IR or TNF-α treatment and PARP activity assay undertaken (section 2.4) 
 
Figure 4.6A shows that IR-induces PAR formation in a dose-dependent manner. After 
treatment with as little as 2 Gy IR, PARP activity is significantly increased (p=0.011, 
unpaired Student’s t-test). Statistical analysis using unpaired Student’s t-tests, show that 
at all doses tested, PARP-1 activity is significantly increased (p=0.0023; 5 Gy, 
p=0.0017; 10 Gy, p=0.0002; 20 Gy, respectively). However, Figure 4.6B illustrates that 
a range of concentrations of TNF-α (5 – 50 ng/ml) fail to stimulate PARP-1 activity 
compared with untreated controls in the p65+/+ MEFs. Statistical analysis using unpaired 
Student’s t-tests, show that at all doses tested, PARP-1 activity was not significantly 
different from untreated cells (p=0.109; 5 ng/µl, p=0.112; 10 ng/µl, p=0.578; 20 ng/µl, 
p=0.765; 50 ng/µl respectively). These data suggest that PAR formation is vital in the 
IR-induced NF-κB. 
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4.3.7 The PARG inhibitor, ADP-HPD, prevents degradation of PAR  
The PARP-1 activity assay data suggested that PAR formation is important in mediating 
the IR-induced NF-κB response, this observation required further testing. PARG is the 
enzyme responsible for the catabolism of the PAR. It is ubiquitously expressed at low 
levels in all cells and tissues (Bonicalzi et al., 2005). Hence, ADP-HPD, a commercially 
available potent PARG inhibitor (Slama et al., 1995) was used in order to further 
investigate the importance of the PAR in IR-induced NF-κB activation. 
 
In this case the validated PARP activity assay (Plummer et al., 2005, Zaremba et al., 
2009) was utilised in order to determine whether specific inhibition of the PARG 
enzyme would prevent degradation of the PAR. It must noted that ADP-HPD is highly 
specific for PARG and does not inhibit PARP, even if used at millimolar concentrations 
(Slama et al., 1995). Briefly, p65+/+ MEFs were plated and allowed to adhere for 24 h 
before a 1 h pre-treatment with 1 µM ADP-HPD prior to treatment with 10 Gy IR. Cells 
were permeabilised at various timepoints following IR (0, 15, 30, 60, 120, 240 min) and 
the reaction undertaken as in section 2.4. 
 
The open bars in Figure 4.7 represent p65+/+ MEFs treated with 10 Gy IR and the black 
bars represent p65+/+ MEFs treated with 10 Gy IR and ADP-HPD. Figure 4.7 illustrates 
that co-incubation with ADP-HPD results in increased stability of the PAR in IR-treated 
cells. PAR formation is significantly increased following treatment with IR (p<0.0001, 
unpaired Student’s t-test). However, polymer is degraded rapidly and returns to basal 
Figure 4.6: PARP-1 is activated following IR, not TNF-α 
Bar chart showing PARP activity, measured using a validated immunoblot assay which 
quantifies PAR formation, in p65+/+ MEFs after increasing doses of IR (A) and TNF-α (B) 
All results are the mean of three independent experiments with SEM. All results are the 
mean of three independent experiments with SEM. Significance relative to mock treated 
control using unpaired Student’s t-test *** p<0.001, ** p<0.01,* p<0.05  
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levels 1-2 hours following IR. In cells treated with both IR and ADP-HPD treated cells 
PAR was further activated compared with IR alone treated cells, all time-points 
investigated. Significantly, in the presence of ADP-HPD, PAR formation persists for 
upto 4-hours post-IR treatment (p=0.023, compared with untreated controls, unpaired 
Student’s t-test). 
  
 
 
 
 
4.3.8 PARG inhibition results in the persistence of IR-induced NF-κB DNA binding  
Figure 4.7 showed that the PARG inhibitor, ADP-HPD resulted in the persistence of 
PAR formation following IR. Hence, it was therefore vital to assess the effects of this 
extended polymer presence on NF-κB DNA binding. The DNA binding ELISA (section 
2.8.1) was used for this. Briefly, p65+/+ MEFs were plated and left to adhere for 24 h 
before pre-treatment with ADP-HPD (or DMSO control) 1 h prior to treatment with 10 
Gy IR. Cells harvested 2 h later and nuclear extracts were before running on the ELISA 
as described in 4.3.2. The results shown are the mean of three independent experiments. 
 
Figure 4.8 illustrates that polymer stability correlates with a persistence in NF-κB DNA 
binding. The open bars represent represent p65+/+ MEFs treated with 10 Gy IR and the 
black bars represent p65+/+ MEFs treated with 10 Gy IR and ADP-HPD. IR significantly 
increased p65 DNA binding 2 h following treatment (p<0.0001, compared with 
untreated controls, unpaired Student’s t-test). After this time-point, however, p65 DNA 
rapidly decreased and returned to basal levels by 8 h. Markedly, p65+/+ MEFs treated 
Figure 4.7: PARG inhibition leads to increased PAR stability 
Bar chart showing PARP activity timecourse, measured using a validated immunoblot assay 
which quantifies PAR formation, in p65+/+ MEFs following 10 Gy IR ± ADP-HPD (open bars IR, 
black bars IR + ADP-HPD). All results are the mean of three independent experiments with 
SEM. Significance relative to mock treated control using unpaired Student’s t-test *** p<0.001, 
** p<0.01,* p<0.05 
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with a combination of IR and ADP-HPD, DNA binding was also maximal 2 h following 
treatment (p=0.0078, compared with untreated controls, unpaired Student’s t-test). 
However, DNA binding persists for upto 8 hours following IR and ADP-HPD, and 
statistical analysis using Student’s unpaired t-test confirm that this is significant 
(p=0.0019, compared with untreated controls). 
 
 
 
 
 
 
4.3.9 The effect of ADP-HPD in combination with ionising radiation on cell survival 
The DNA binding data using the PARG inhibitor, ADP-HPD confirmed that a 
persistence of the PAR resulted in prolonged p65 DNA binding, and hence it was 
therefore important to determine whether this increased NF-κB activation had any effect 
on cell survival. Thus, the effect of ADP-HPD on cell survival following IR was 
assessed in the p65+/+ and p65-/- MEFs was assessed using colony forming assays. In this 
case, p65+/+ or p65-/- cells were plated and left for 24 hours to adhere before being 
treated with ADP-HPD or a DMSO control for 1 h prior to increasing doses of IR.  
 
Figure 4.9A shows that co-incubation with IR and ADP-HPD protects against IR-
induced cell kill in the p65+/+ MEFs compared with IR alone. Furthermore, sstatistical 
analysis using an unpaired Student’s t-test confirmed that, at the LD50 values, cells 
treated with ADP-HPD exhibited a significant radio-protective effect in the p65+/+ MEFs 
compared with IR alone (p=0.024). Markedly, Figure 4.9B shows that IR in 
Figure 4.8: Persistence of NF-κB DNA binding following PARG inhibition 
Bar chart showing NF-κB DNA binding timecourse measured using an ELISA-
based method following IR ± ADP-HPD (open bars IR, black bars IR + ADP-
HPD). All results are the mean of three independent experiments with SEM. 
Significance relative to mock treated control using unpaired Student’s t-test *** 
p<0.001, ** p<0.01,  * p<0.05  
 
181 
 
combination with ADP-HPD had no effect on cell survival in the p65-/-MEFs compared 
with IR alone (p=0.914, unpaired Student’s t-test).  
 
 
 
 
 
 
 
4.3.10 The effect of ADP-HPD in combination with IR on the transcription of NF--
κB-dependent anti-apoptotic genes 
In order to demonstrate that the DNA binding (Figure 4.8) and survival data (Figure 
4.9) obtained using ADP-HPD, were physiologically relevant it was important to 
determine whether PARG inhibition by ADP-HPD, and subsequent persistence of PAR, 
leads to an increase of the expression of some known NF-κB-mediated anti-apoptotic 
genes following IR. The genes chosen to investigate were; Bcl-xL (Lee et al., 1999b), 
cFLAR (Kreuz et al., 2001) and XIAP (Turner et al., 2007) in the p65+/+ MEFs.  
 
This method is described in detail in 2.10. In this particular case, p65+/+ MEFs were 
seeded and left for 24 h to adhere before a 1 h pre-treatment with 1 µM ADP-HPD prior 
to treatment with 10 Gy IR. Cells were then harvested at various timepoints (0 – 6 h) 
and RNA extracted using the RNeasy kit, and subsequently transcribed into cDNA 
using the High Capacity cDNA reverse transcription kit. cDNA was then used in a qRT-
Figure 4.9: ADP-HPD has a radio-protective effect in the p65+/+, but not p65-/- MEFs 
The effects of increasing doses of IR on cell survival, either alone (solid line) or co-
incubated with ADP-HPD (dashed line) were assessed using the clonogenic survival in 
p65+/+ and p65-/- MEFs. Cells were pre-treated with ADP-HPD, or control 1 h prior to IR 
then re-plated after a further 24 h and allowed to form colonies for 7-21 days. All results 
are the mean of three independent experiments with SEM. 
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PCR reaction using Taqman primers to confidently quantify the mRNA levels of either 
Bcl-xL, cFLAR or XIAP in each sample. 
 
Figure 4.10A shows that treatment with IR significantly increases expression of Bcl-xL 
at 2h after treatment (p=0.041 compared with untreated controls, unpaired Student’s t-
test) and importantly, that co- incubation with ADP-HPD significantly increased IR-
induced Bcl-xL expression at this timepoint (p=0.0089 compared with ADP-HPD alone 
controls, unpaired Student’s t-test). cFLAR expression (Figure 4.10B) was also 
increased following IR although this was not statistically significant (p=0.103, 0 h, 
compared to untreated controls, unpaired Student’s t-test) and this again was increased 
further by co-incubation with ADP-HPD at the 4 h timepoint (p=0.0098, unpaired 
Student’s t-test). A similar trend was also observed with XIAP expression, however this 
was not statistically significant (Figure 4.10C). 
 
 
 
 
 
 
Figure 4.10: ADP-HPD increases the transcription of NF-κB-dependent anti-
apoptotic genes following IR Bar chart showing the effect of IR ± ADP-HPD 
(Denoted as +) over time on the expression of the anti-apoptotic genes (A) Bcl-xL, 
(B) cFLAR and (C) XIAP. All results are the mean of three independent 
experiments with SEM. Significance compared to relevant control using unpaired 
Student’s t-test was **p<0.01, * p<0.05. 
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4.4 Discussion 
In this chapter, PARP-1 knockdown and the PARP inhibitor, AG-014699 were used to 
investigate the role of PARP-1 in the activation of NF-κB, following treatment with 
either IR or TNF-α. While knockdown of the PARP-1 protein abrogated NF-κB 
activation following the inflammatory stimulus, PARP-1 enzymatic inhibition had no 
effect. In contrast, PARP-1 protein and activity were necessary to inhibit the IR-induced 
NF-κB response. Therefore, the data presented here illustrate that PARP-1 is 
differentially required in the induction of NF-κB, and this is dependent on the activation 
stimulus and the ability of such stimuli to activate PAR.  
 
It has been documented that TNF-α stimulation induces an NF-κB response 
approximately 20 minutes following treatment in some model systems. The data 
obtained within this study illustrated that NF-κB DNA binding was maximal 2 hours 
following either TNF-α or IR. However, other reports in the literature suggest that this 
phenomenon is cell type-dependent. For example, Nelson et al., (2004) showed the 
oscillatory nature of p65 in and out of the nucleus following TNF-α treatment in HeLa 
and SK-N-AS cells, and that the first oscillation is clearly seen 100 minutes following a 
TNF-α pulse of 10 ng/ml (the same concentration used within this chapter). This leads 
to an NF-κB response by up-regulating early-response genes, with subsequent 
oscillations then resulting in the activation of mid- and late-response NF-κB dependent 
genes (Nelson et al., 2004). Furthermore, Criswell et al., (2003) comprehensively 
reviewed the activation of transcription factors by IR and found that the IR-induced NF-
κB is consistently reported to peak 0.5-2 hours following damage (Criswell et al., 2003). 
Hence, the literature and these data presented within this chapter concur, suggesting that 
the time-points used here are the optimum for the chosen cell line model. 
 
The role of PARP-1 protein rather its catalytic activity as a co-activator of NF-κB is 
contentious. The data here are consistent with some studies which have shown that 
PARP-1 enzymatic activity is not required for NF-κB activation (Hassa et al., 2001, 
Hassa and Hottiger, 1999, Martin-Oliva et al., 2004), however, others, for example, 
Kauppinen and Swanson, (2005), have shown that PARP-1 inhibition was able to 
alleviate TNF-α-stimulated NF-κB-dependent MMP-9-mediated neurotoxicity in 
microglia in a model of brain injury. This differential is highly likely to be cell line or 
model system dependent and may also vary depending on the activation and the levels 
of other NF-κB subunits. For example, ongoing work in this institute, has shown that 
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subunit activation is a complex balance in CLL (Mulligan EA et al., 2010).  This work 
showed that constitutive activation of the p65 and p50 subunits in CLL correlated 
closely and predicted shorter time to first treatment (TTFT) and overall survival (OS). 
p52 and c-Rel activation correlated with p65 and p50 activation. However although high 
p65 and p50 activation predicted shorter OS and TTFT, increased p52 and c-Rel 
activation were associated with a longer TTFT. Moreover, activation of RelB was 
absent is all cases unless there was an ATM mutation, which is known to confer poor 
prognosis and resistance to treatment. Hence, demonstrating the complex crosstalk 
between the different NF-кB subunits in CLL.  
 
The data shown here suggesting that PARP-1 protein alone is required for TNF-α-
induced NF-κB activation, supports reports that PARP-1 can act as a transcriptional co-
regulator via direct interaction and protein-protein interactions. It is possible that PARP-
1 may facilitate a structural role in the NF-κB transcriptional complex, following TNF-α 
in the p65+/+ MEFs. This is consistent with the work of Hassa et al., (2003), which 
illustrated how the physical presence of the PARP-1 C-terminal catalytic domain, but 
not its enzymatic activity, was required for PARP-1 and p300 to synergistically activate 
NF-κB-dependent transcription following either TNF-α or LPS (Hassa et al., 2003). 
Further work by this group also found that the acetylation of PARP-1, by HDAC1 and 
p300 was in key in the regulation of NF-κB activity by PARP-1 (Hassa et al., 2005). 
 
Nuclear translocation of p65 was similar following both stimuli, and this was unaffected 
by either AG-014699 or PARP-1 knockdown. This therefore suggests that the 
differential requirements of PARP-1 for IR- and TNF-α-activated NF-κB must occur at 
the DNA binding and transcription stage. The requirement of PAR in DNA damage-
activated NF-κB has been demonstrated (Stilmann et al., 2009) and this is consistent 
with our data that IR, but not TNF-α stimulates polymer formation. Stilmann et al. 
(2009) clearly identified a novel mechanism of pro-survival NF-κB activation mediated 
via PAR. This group showed that a PARP-1 signalling scaffold via direct protein-
protein interactions with NEMO, PIASγ and ATM formed in response to DNA damage. 
In particular, this report details that impaired sumoylation following treatment with the 
PARP inhibitor, 3-AB, which resulted in reduced IKK activation and therefore 
inhibition of p65 induction. Furthermore, this report also describe the formation of a 
signalosome (Figure 1.13) which relies on binding with PAR and leads to pro-survival 
NF-κB activation.  
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Based on the observations within this chapter, a further mechanism detailing the role of 
PAR in DNA-damage-induced NF-κB activation can be proposed (Figure 4.11). Ghosh 
et al., (1999) reported that the DNA binding interface of p65 is buried until a 
conformational change is induced, usually when p65 is in close proximity to the 
negatively charged region of its DNA consensus sequence (Ghosh, 1999), and 
importantly PAR is known to have a large overall negative charge (Ueda and Hayaishi, 
1985). The increase in DNA binding observed following IR could be due to that either a 
persistence of p65 on the DNA, to promote transcription, or a greater concentration of 
p65 molecules. Importantly, the Western blot data showed increased nuclear p65 levels 
following DNA damage, as well as following TNF-α treatment (Figure 4.1). The DNA 
binding ELISA showed that p65 binding increased upon stimulation of polymer 
formation. Taken together, these data support the concept that DNA damage stimulates 
upstream pathways to free p65 for activation. Markedly, the amount of p65 in the 
nucleus was unaffected by AG-014699. Thus, it can be postulated that the negative 
charge on the polymer induces a conformational change in p65, similar to the one 
described by Ghosh et al., (1999), which would lead to the increased binding and 
transcriptional activation observed in Figures 4.8 and 4.10, in the presence of ADP-
HPD. 
 
Althaus et al., (1994) proposed that the large overall negative charge of PAR had the 
ability to relax the chromatin structure, which is usually extremely tightly wound, and 
displace histones from DNA. This PAR-induced relaxation would then allow large 
regions surrounding the DNA strand breaks to become accessible to other repair 
proteins; however it is very plausible that this theory can be extended to other proteins, 
such as p65 (Althaus et al., 1994). Hence, the mechanism described in Figure 4.11, 
corroborates the work of Althaus et al., (1994), by suggesting that PARP-1 regulates 
IR-induced NF-κB, in part by chromatin structure remodelling. Moreover, a recent 
study has investigated the promoter recruitment of PARP-1, using ChIP-chip 
techniques, and has shown that peaks of promoter-proximal PARP-1 binding can be 
upto 3kb shoulder-to-shoulder (Krishnakumar et al., 2008). This study further supports 
the hypothesis that PARP-1 activation (by virtue of PAR formation) has the ability to 
relax the chromatin structure, and allows transcription factors to access the DNA, as 
postulated in the model shown in Figure 4.11. 
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Stilmann et al., (2009)  reported that impaired sumoylation following treatment with the 
PARP inhibitor, 3-AB, resulted in reduced IKK activation and therefore inhibition of 
p65 induction. Stilmann et al., (2009) use the non-specific PARP inhibitor, 3-AB, which 
has been shown to have many off target effects (Moses et al., 1990), and this group 
report a reduced nuclear translocation of p65 following use of 3-AB in combination 
Figure 4.11: PAR is essential for DNA damage activated NF-κB 
(A) DNA damage, such as IR, activates PARP-1, recruiting it to the site of damaged DNA. 
This results in formation of negatively charged PAR. The NF-κB p65-p50 heterodimer is also 
translocated to the nucleus following DNA damage via activation of the canonical pathway 
of NF-κB activation. When in proximity to regions with overall negative charge, such as that 
of PAR, a conformational change in p65 can be induced, exposing the positively charged 
DNA binding interface of p65. Thus, negatively charged PAR has the ability to attract p65 to 
DNA bind, (as PARP-1 and the polymer are recruited to sites of damaged DNA), up-
regulating transcription of NF-κB-dependent genes, protecting against apoptosis and 
conferring radio-resistance.  
(B) When the PARP inhibitor, AG-014699 is present, PARP-1 is no longer active and cannot 
form the polymer. Hence in this case, there is reduced DNA binding and transcriptional 
activation following IR, with induction of apoptosis and ultimately radio-sensitisation.  
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with IR. However, Western blotting data presented here (Figure 4.1) showed that p65 
translocation was unaffected by AG-014699 in combination with IR, when compared 
with IR alone. This suggests that the phenomenon reported by Stilmann et al., (2009) 
could be due to the off target effects of 3-AB, which was used at millimolar 
concentrations. However, a further explanation for this discrepancy could be that 
Stilmann et al., (2009) used hyper-lethal doses of IR (80 Gy), whereas the doses used 
within this study are more clinically relevant. Stilmann et al., (2009) utilised a different 
cell line model, and the activation of NF-κB has shown to be very cell type and stimulus 
dependent. Importantly, however, the data presented within this chapter not only agree 
with the major findings of Stilmann et al., (2009) (i.e. that PAR formation is essential in 
the activation of NF-κB) but also extend these data by showing a further way in which 
PAR is specifically involved in NF-κB DNA binding and activation, importantly, by 
using a highly specific PARP inhibitor that is currently in clinical trials. Significantly, 
the overall consequences of both the Stilmann hypothesis and the model proposed here 
in Figure 4.11 are the same; a reduction in NF-κB-dependent gene expression. 
However, the slightly different, yet complementary mechanisms do highlight the 
importance of determining the role of PARP-1, and subsequently the formation of PAR, 
in the regulation of NF-κB, in different cell types and tissues. 
 
The data presented here using the PARG inhibitor, ADP-HPD, also further support the 
model shown in Figure 4.11. PARG is ubiquitously expressed, at low levels in all cells 
and tissues, and is responsible for the catabolism of PAR (Bonicalzi et al., 2005). 
Increased polymer stability following IR, by virtue of inhibition of polymer degradation 
by using ADP-HPD, led to a persistence of NF-κB DNA binding, increased expression 
of anti-apoptotic genes and a protection against IR-induced cell death. These data not 
only confirm a role for PAR in the activation of NF-κB following DNA damage, but 
they show that the findings here are physiologically relevant as they demonstrate a 
direct impact of poly(ADP-ribosylation) on the transcription of key genes involved in 
apoptosis. 
 
Using a similar approach, Majewski et al., (2010) used over-expression of PARG to 
support their findings that that NF-κB and PARP-1 work co-operatively in the TNF-α 
induced inhibition of PHEX, which is expressed in osteoblasts and known to contribute 
to bone mineralisation. Inhibition of PHEX has been linked with the loss of bone mass 
density in chronic inflammatory diseases, such as inflammatory bowel disease. 
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Following treatment with TNF-α, the RelA/p50 NF-κB complex interacted with two cis-
elements of the PHEX promoter and found that PARP-1 could bind immediately 
upstream of the NF-κB sites. Furthermore, TNF-α induced poly(ADP-ribosyl)ation of 
RelA when bound to the PHEX promoter, which was abrogated in vitro by 
overexpression of PARG (Majewski et al., 2010).  
 
4.5 Summary and future work 
The data shown within this chapter using AG-014699 and siRNA targeting PARP-1 
illustrate that PARP-1 is differentially required in the activation of NF-κB, and that this 
differential is stimulus dependent. While knockdown of the PARP-1 protein abrogated 
NF-κB activation following the inflammatory stimulus, TNF-α, PARP-1 enzymatic 
inhibition had no effect. Conversely, PARP-1 protein and catalytic activity were 
necessary to inhibit the IR-induced NF-κB response. Furthermore, these data have 
shown that the differential requirements of PARP-1 are also dependent on the ability of 
the activation stimuli to activate PAR.  
 
There is one major caveat associated with this study and that is the use of the DNA 
binding ELISA. Although this method has been favoured here, and in many other 
studies, in most cases because it is a high throughput method, it does not give a true 
indication of what is happening in vivo within the cell. Therefore, any future work 
should include chromatin immunoprecipitation (ChIP) assays in order to ascertain how 
NF-κB is DNA binding to the promoter region of individual genes following DNA 
damage. 
  
The data shown here using the PARG inhibitor, ADP-HPD showed that increased 
polymer stability following IR, by virtue of inhibition of polymer degradation by using 
ADP-HPD, led to a persistence of NF-κB DNA binding, increased expression of anti-
apoptotic genes and a protection against IR-induced cell death. Importantly, the qRT-
PCR data presented using the PARG inhibitor, ADP-HPD, indicate that these findings 
do have physiological relevance, although this should be further confirmed. It is well 
documented that inhibition of NF-κB is an attractive target for cancer therapeutics 
(Gilmore and Herscovitch, 2006). However, global inhibition may also have some 
negative aspects. For example, NF-κB plays a vital role in the inflammatory response, 
and thus complete inhibition of NF-κB, for example with an IKK inhibitor, may have 
189 
 
adverse effects. The IKK complex has many known functions within the cell (Carrillo et 
al., 2004, Chariot, 2009), and inhibition may be cytotoxic. Long-term NF-κB inhibition 
may also increase the likelihood of immunodeficiency, since it plays a pivotal role in 
the innate and adaptive immune response, and can possibly delay bone marrow recovery 
due to some reports of chemotherapeutic induced apoptosis of hematopoietic 
progenitors (Grossmann et al., 1999, Turco et al., 2004). The data here suggest that AG-
014699 inhibits IR-induced NF-κB activation but not an inflammatory stimulus and thus 
may overcome these potential toxicities. It is important to ascertain whether the effects 
seen within this and the previous chapter translate to the gene expression level. 
Currently these data these data suggest that blockade of DNA-damage activated NF-κB 
by AG-014699 could represent a viable therapeutic strategy, since the data has 
demonstrated that the survival function of NF-κB can be directly inhibited without 
compromising other functions, such as the immune response. A possible strategy for 
determining the effects of AG-014699 on NF-κB-dependent gene expression, following 
either IR or TNF-α, would be to undertake a microarray study, and subsequent 
confirmation by qRT-PCR, to ensure that vital inflammatory responses, known to be 
regulated by TNF-α-induced NF-κB activation, are still intact following treatment with 
AG-014699. This study will be performed as part of this thesis (Chapter 5). 
 
The model developed from this investigation present a novel mechanism for PARP-1 in 
the regulation of NF-κB and importantly these data highlight important new therapeutic 
avenues for the use of PARP inhibitors. However, determining the potential utility in 
other model systems is vital, but must also proceed with caution. Although the model 
described within this chapter and the one proposed by Stilmann et al., (2009) are very 
complementary, they do have some differences, thus highlighting the importance of 
defining a clear mechanism within a certain cell type or tissue before these data can be 
used in clinical models. Radio-therapy is the most widely used treatment for cancer, and 
is the main-stay of therapy for glioblastoma, breast and lung cancers. Importantly 
aberrantly active NF-κB, known to mediate therapeutic resistance, has been reported in 
cell line models and primary material of each of these types of cancer. Hence, when 
investigating the utility of AG-014699 in combination with IR, in order to inhibit DNA-
damage activated NF-κB activation, these model systems could well provide an 
interesting starting point and most definitely warrant further investigation. This study 
will be performed as part of this thesis (Chapter 6). 
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It would also be important to investigate the role of PARP-1 in the activation of NF-κB 
after other chemo-therapeutic agents, known to damage the DNA. For example, PARP 
inhibitors have previously been shown to potentiate the cytotoxic effects of 
temozolomide (Calabrese et al., 2004, Chalmers, 2009, Chalmers, 2010), and it would 
be interesting to determine whether these effects are mediated via the inhibition of NF-
κB. Other agents, such as the topoisomerase II poison, doxorubicin are known to 
activate NF-κB (Campbell et al., 2006a), and there is a report from Munoz-Gamez et 
al., (2005) showing that PARP inhibitors can sensitise breast cancer cells to this agent, 
although it is now known whether this phenomenon is mediated via NF-κB (Munoz-
Gamez et al., 2005). 
 
Other more classically known activators of NF-κB would also be of interest in order to 
further this study. These data presented here are a head-to-head comparison of TNF-α 
and IR, however it would provide further insight into the mechanism by which PARP-1 
is acting if other agents, such as LPS were used. Some groups have used LPS (Le Page 
et al., 1998, Nakajima et al., 2004), but not in direct comparison with a DNA damaging 
agent.  
 
Furthermore, the activation of the NF-κB in leukaemias, such as CLL, along with how 
chemotherapeutic agents are inducing an NF-κB response in patients with the disease, is 
currently being studied by this research group and others. CD40 ligand is used to induce 
proliferation of primary CLL cells in culture (Weston et al., 2010) and it is also known 
to activate NF-κB (Hayden and Ghosh, 2004). Recently, Weston et al., (2010), have 
suggested the use of PARP inhibitors as a potential novel therapeutic strategy in patients 
with ATM mutant CLL after using CD40 ligand to induce cell proliferation in culture 
(Weston et al., 2010). They suggest a possible mechanism of synthetic lethality, similar 
to that observed with PARP inhibitors in BRCA mutant backgrounds (Bryant et al., 
2005, Farmer et al., 2005). However, it would be important to elucidate whether the 
effects observed by PARP inhibitors in ATM mutant CLL were due to the effect on 
homologous recombination repair as postulated, or whether the inhibition of CD40 
ligand-induced NF-κB activation by PARP-1 is also playing a role. 
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Chapter 5. Investigation into the effects of AG-014699 on NF-κB-
dependent gene transcription following IR and TNF-α 
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5.1 Introduction 
The stress-inducible transcription factor, NF-κB has the ability to both induce and 
repress gene expression (Perkins, 2007) and plays a crucial role in many biological 
processes. There are a number of genes regulated by NF-κB, including those controlling 
apoptosis, cell adhesion, inflammation, proliferation, immune responses, cellular stress 
and tissue remodelling (Bonizzi and Karin, 2004, Hayden and Ghosh, 2004, Pahl, 
1999). NF-κB is sometimes referred to as ‘the central mediator of the immune response’ 
because it regulates the expression of inflammatory chemokines, cytokines, immune-
receptors and cell adhesion molecules (Pahl, 1999). 
 
Activated NF-κB is known to promote the expression of hundreds of target genes (Pahl, 
1999). It should be noted however, that the transcriptional response is directly 
attributable to the activation stimuli. For example, a number of bacteria, bacterial 
proteins, viruses and inflammatory cytokines are known to activate NF-κB. These 
include the bacterial product LPS (Sen and Baltimore, 1986), the Epstein Barr Virus 
(EBV) (Hammarskjold and Simurda, 1992) and the inflammatory cytokine, TNF-α 
(Israel et al., 1989a, Osborn et al., 1989). Hence, the majority of proteins encoded by 
NF-κB target genes participate in the host immune response. These include numerous 
different cytokines and chemokines, such as TNF-α (Collart et al., 1990, Shakhov et al., 
1990) and IL-6 (Libermann and Baltimore, 1990, Shimizu et al., 1990), as well as 
receptors required for immune recognition, including those which recognise major 
histocompatibility complex (MHC) proteins (Israel et al., 1989a, Israel et al., 1989b, 
Johnson and Pober, 1994). NF-κB also regulates that expression of genes which are 
associated with antigen presentation and proteins required for neutrophil adhesion and 
transmigration across blood vessel walls, for example, VCAM-1 (Iademarco et al., 
1992). Taken together, these data suggest that that NF-κB activation is vital for the 
inflammatory and immune responses. 
 
As well as being a hugely important mediator of the immune response, NF-κB is also 
known to respond to both physiological stress conditions, such as ischemia/reperfusion, 
liver regeneration and haemorrhagic shock, and also physical stresses, such as 
irradiation and oxidative stress. It is widely accepted that the genes activated following 
these stimuli differ from those activated following the inflammatory stimuli, discussed 
above. For example, it has been documented that NF-κB activation following IR 
induces the expression of the anti-apoptotic genes, Bfl1/A1 (Grumont et al., 1999, Zong 
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et al., 1999), Bcl-xL (Lee et al., 1999a) and the inhibitor of apoptosis proteins (IAPs) 
(Stehlik et al., 1998, You et al., 1999), resulting in cell survival. Jeremias et al., (1998), 
were the first to report that NF-κB inhibition could restore drug-induced apoptosis 
sensitivity to resistant leukaemic cell lines and primary samples, suggesting that the 
inhibition of NF-κB activation induced by DNA-damaging drugs could provide a 
potential therapeutic strategy in leukaemia and cancers (Jeremias et al., 1998). 
Conversely, TNF-α-induced NF-κB activation is known to up-regulate the expression of 
the Fas receptor (Chan et al., 1999) and its ligand (Matsui et al., 1998), which induce 
apoptosis. Thus it is important to establish which genes are affected by each individual 
stimulus, and most importantly their role in the cell. 
 
It is therefore also very important to assess the effect of NF-κB inhibitors on the 
transcriptional response, after different stimuli. Complete or global inhibition of NF-κB, 
for example with an IKK inhibitor, may have adverse effects, as this may result in the 
inhibition of genes known to have vital roles in the inflammatory response. There have 
been two reports suggesting that long-term NF-κB inhibition may have a negative 
impact on the haematopoietic system, in particular, due the pivotal role NF-κB plays in 
the innate and adaptive immune response, the first indicating that this increases the 
likelihood of immunodeficiency, and the second reporting that this can delay bone 
marrow recovery due to chemotherapeutic induced apoptosis of hematopoietic 
progenitors (Grossmann et al., 1999, Turco et al., 2004). However, NF-κB is an 
attractive therapeutic target, particularly in cancer as in this context, and specifically 
after activation by DNA-damaging chemo- or radio-therapy, it is known to up-regulate 
genes associated with the protection against apoptosis, cell proliferation, angiogenesis 
and metastasis (Ghosh and Karin, 2002), thus contributing to disease progression and 
severity.  
 
Hence, it is vitally important to develop inhibitors of NF-κB which target these aspects 
of NF-κB-dependent gene transcription, without compromising its essential role in the 
inflammatory response. Data from chapters 3 and 4 in this thesis suggest that AG-
014699 inhibits IR-induced NF-κB activation but not an NF-κB activation following an 
inflammatory stimulus. Therefore targeted inhibition of DNA-damage-activated NF-κB 
using a PARP inhibitor may overcome the potential toxicities observed with other NF-
κB inhibitors, however it is important to assess the effect of AG-014699 on NF-κB-
dependent gene transcription following either stimuli in order to confirm the findings. 
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5.2 Aims 
The data within chapters 3 and 4 here currently suggest that blockade of DNA-damage 
activated NF-κB by AG-014699 could represent a viable therapeutic strategy, since the 
data has demonstrated that the survival function of NF-κB can be directly inhibited 
without compromising other NF-κB activation stimulated by the inflammatory cytokine, 
TNF-α. These data require confirmation, and therefore the first aim of this chapter is to 
utilise gene expression arrays to assess to change in gene expression in cells treated 
with IR versus cells treated with TNF-α. NF-κB-dependent genes regulated by TNF-α 
are widely known and include a range of cytokines, chemokines and cell adhesion 
molecules, all known to have a vital role in the inflammatory response, whereas NF-κB-
dependent genes regulated by IR are not so well documented. Hence, this head-head-
comparison will potentially identify novel IR-induced-NF-κB-dependent genes. Any 
genes identified in the array studies will subsequently be confirmed using qRT-PCR. 
 
The second aim of this chapter is to assess the effects of the PARP inhibitor, AG-
014699 in combination with both of each of stimuli, IR or TNF-α. It would be expected 
that the genes regulated by TNF-α were associated with the inflammatory and immune 
responses, and hence hypothesised that genes would not be affected by co-incubation 
with AG-014699. Furthermore, it would be hypothesised that NF-κB-dependent genes 
activated by IR, would be inhibited by co-incubation with AG-014699 thus supporting 
the data from chapter 4 which showed that NF-κB activated following DNA damage 
required PARP-1 protein and enzymatic activity, whereas TNF-α induced NF-κB 
activation required PARP-1 protein alone. Any genes of interest identified during this 
portion of the study would also be confirmed using qRT-PCR, along with siRNA 
targeting p65 or PARP-1 and the pan-IKK inhibitor, BAY-117082 in order to confirm 
any findings.  
 
5.3 Materials and Methods 
5.3.1 Gene expression microarrays 
5.3.1.1 The general principle of gene expression microarrays 
Gene expression microarrays allow the simultaneous genome wide analysis of transcript 
expression. Sample RNA is labelled with the water-soluble B-complex vitamin, biotin 
and then this labelled copy RNA (cRNA) is allowed to hybridise to the microarray. 
cRNA hybridises to specific probes for each gene, and any excess unbound cRNA is 
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washed from the chip. The bound biotinylated cRNA is stained with fluorescent tagged 
streptavidin complexes to visualise the extent of hybridisation to individual sequence 
specific probes on the array. Photometric scanning of the arrays is then used to capture 
the relative fluorescence intensities and the relative amount of each transcript is 
estimated from the intensity values. 
 
5.3.1.2 Illumina MouseWG-6 v2.0 Expression BeadChip array 
Illumina MouseWG-6 v2.0 Expression BeadChip was used for this study. The Illumina 
MouseWG-6 is a murine genome wide array that contains probes for the analysis of  
more than 45,200 different transcripts. Illumina MouseWG-6 content is derived from 
the National Center for Biotechnology Information Reference Sequence (NCBI RefSeq) 
database, supplemented with probes derived from the Mouse Exonic Evidence Based 
Oligonucliotide set and exemplar protein-coding sequences described in the RIKEN 
FANTOM2 database. Furthermore, six samples can be analysed simultaneously on a 
single BeadChip, reducing the inter-BeadChip variation. 
5.3.1.3 Probe sets 
In standard microarrays, probes are synthesised and then attached via surface 
engineering to a solid surface by a covalent bond to a chemical matrix. The solid surface 
tends to be glass or a silicon chip, whereas, in this case, the Illumina array platform uses 
microscopic beads, instead of the large solid support. Candidate probe sequences for use 
in the Illumina MouseWG-6 undergo extensive bioinformatic screening prior to 
selection. 50-mer gene-specific probe sequences are coupled with "address" sequences 
which are immobilised on a bead along with hundreds of thousands of probes of the 
same sequence. The major advantage of having multiple probes for each transcript is 
that this therefore allows multiple independent measurements for each transcript. 
 
5.3.1.4 Advantages and disadvantages of gene expression microarrays 
There a number of techniques that can be used to examine global gene expression. 
These include spotted DNA microarrays, oligonucleotide arrays, and serial analysis of 
gene expression (SAGE). The advent of next-generation sequencing has made sequence 
based expression analysis an increasingly popular alternative to microarrays. The major 
advantage of using platforms such as Illumina or Affymetrix is that several probes are 
used for one transcript, giving more reliable data. However, the ability to analyse six 
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samples simultaneously on the Illumina MouseWG-6, eliminates the requirement for 
technical replicates with this platform, when compared with the Affymetrix platform.  
 
However, one of the disadvantages of examining global gene expression patterns, in 
general, not just with the platform described here, is the reliability of the results at the 
lower end of the confidence scale (i.e. when the probe signal is weak, or perhaps it has 
reached saturation).  There can be discrepancies between various gene lists derived from 
different studies, and this in part may be attributed to the differential sensitivities 
between the different platforms or different methods used to examine whole genome 
expression. However, the major drawback is that changes in transcript level do not 
always reflect what is occurring at the protein level: for example proteins may be 
subject to post-translational modifications, or targeted for degradation. 
 
5.3.2 Planning and designing gene expression microarray experiments 
Previous data in this thesis has shown that both PARP-1 activity and protein are 
required for the activation of NF-κB following IR, but that PARP-1 protein alone is 
required following TNF-α. Hence, it was hypothesised that PARP-1 inhibition could 
overcome the toxicities observed with more global inhibition of NF-κB, by transiently 
inhibiting DNA damage activated NF-κB,  and not affecting its vital role in the 
inflammatory response. Therefore, the major aim of this study was to determine the 
effects of the PARP inhibitor, AG-014699, on IR- or TNF-α-induced gene expression in 
the p65+/+ MEFs.  
 
It was decided to determine the changes in gene expression at two timepoints following 
treatment with either IR or TNF-α. To determine early changes in gene expression, as 
the DNA damage response in particular, is known to be fairly rapid, samples were 
harvested 2 h following treatment with either agent. A number of reports in the 
literature suggested that the TNF-α-induced expression of some NF-κB-dependent 
genes, including VCAM1 and IL-6, was also maximal 2 h following treatment (Shu et 
al., 1993, Ulich et al., 1991). Cells were also harvested 8 h following treatment as the 
luciferase assays (section 4.3.4), showed that NF-κB-dependent gene transcription was 
maximal at this time-point following either agent. The experimental plan is shown in 
Figure 5.1.  
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5.3.2.1 Replicates 
Replicates are defined as either technical or biological replicates. Technical replicates 
for gene expression microarray studies determine the variation in RNA preparation, 
handling, hybridisation and inter -assay/-chip variations. Importantly, the ability to 
analyse six samples simultaneously on the Illumina MouseWG-6, eliminates the 
requirement for technical replicates with this platform. However, an additional check of 
RNA quality was undertaken prior to amplification at the Cambridge Genomics Service 
(Section 5.3.3.2).  
 
Biological replicates include testing independent samples and repeating the treatment 
with AG-014699 (or DMSO control), IR or TNF-α. The Illumina platform was chosen, 
as it is the most well characterised platform for the study of the mouse genome, it has 
been thoroughly tested, standardised and validated and therefore, in this case biological 
variation outweighs any variation caused by technique. All IR or TNF-α (alone or in 
combination with AG-014699, see Figure 5.1) were performed in triplicate to obtain 
Figure 5.1: Microarray experimental plan The changes in gene expression in 
p65+/+ MEFs will be assessed at two timepoints (2 hours or 8 hours) after 
treatment with either IR or TNF-α, alone or in combination with AG-014699 
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biological analysis. The use of triplicates of each sample would also allow for a more 
robust statistical analysis and interpretation of data. 
 
5.3.3 Protocol for Illumina MouseWG-6 v2.0 Expression BeadChip array 
This section very briefly describes the standard protocol used at the Cambridge 
Genomics Service for Illumina MouseWG-6 v2.0 Expression BeadChip arrays and is 
based on information detailed at 
http://www.cgs.path.cam.ac.uk/services/genexpression/wg-gex.html 
 
5.3.3.1 RNA extraction from samples 
Cells were seeded and allowed to adhere for 24 h before to a 1 h pre-treatment with AG-
014699 (or DMSO control) prior to treatment with either 10 Gy IR or 10 ng/µl TNF-α. 
Cells were then harvested for RNA extraction either 2 h or 8 h following treatment. 
RNA extraction was carried out using the RNeasy midi kit (Qiagen) according to 
manufacturers’ instructions, as described in section 2.10.1.2. It is important to note here 
that the DNase step was omitted from the RNeasy procedure, as this is not 
recommended by Illumina. Before RNA samples were sent to for labelling and 
microarray experiments at the Cambridge Genomics Service 
(http://www.cgs.path.cam.ac.uk/), the RNA was quantified, and the quality checked 
using the Nanodrop spectrophotometer (using methods described previously section 
2.3.3). In total 30 samples were sent to the Cambridge Genomic Service for microarray 
analysis.  
 
5.3.3.2 RNA integrity analysis 
It is vital to assess the RNA integrity in order to obtain meaningful gene expression 
array data. Therefore the quality of the 30 RNA samples to be used for the gene 
expression arrays were examined on a 2100 Bioanalyser (Agilent) by the Cambridge 
Genomics Service. This technique uses electrophoretic separation on micro-fabricated 
chips, in which RNA samples can be separated and then detected using laser induced 
fluorescence detection. The software then generates an electropherogram which allows 
visual assessment of the RNA quality, and calculates an RNA Integrity Number (RIN) 
based on a software algorithm. An example of four electropherograms, with varying 
RIN scores, are shown in Figure 5.2. A sample with a RIN score of 10 (Figure 5.2A) is 
regarded as containing high quality intact RNA which has not undergone any 
degradation. RNA degradation is a gradual process is observed in Figure 5.2B, 5.2C and 
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5.2D. As this proceeds an increase in the base-line signal between the peaks at 18S and 
26S, and the lower marker is observed. A decrease in the ratio between the 18S and the 
26S bands is also visible. RIN scores for each of the 30 samples sent for array analysis 
were generated by the Cambridge Genomic Service and are detailed in Table 5.1. The 
RIN scores from all the samples indicated that all of the samples contained high quality 
RNA, and that could be subsequently used for array analysis. 
 
 
 
 
 
 
 
Sample ID Sample name RIN 
1 Control 2 h 1 9.90 
2 Control 2 h 2 9.70 
3 Control 2 h 3 10.00 
4 IR 2 h 1 9.90 
5 IR 2 h 2 10.00 
6 IR 2 h 3 10.00 
7 IR + AG 2 h 1 10.00 
8 IR + AG 2 h 2 10.00 
9 IR + AG 2 h 3 9.80 
10 TNF-α 2 h 1 10.00 
11 TNF-α 2 h 2 10.00 
12 TNF-α 2 h 3 10.00 
13 TNF-α + AG 2 h 1 10.00 
14 TNF-α + AG 2 h 2 10.00 
15 TNF-α + AG 2 h 3 10.00 
Figure 5.2: Example RNA Integrity electropherograms One showing a RIN 
score of 10 (A) and the others showing RNA which has degraded (B, C and D), 
and hence have lower RIN scores, depending on the extent of the degradation. 
From:http://www.agilent.com/about/newsroom/lsca/background/rna_integrity.pdf 
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16 Control 8 h 1 10.00 
17 Control 8 h 2 10.00 
18 Control 8 h 3 10.00 
19 IR 8 h 1 8.10 
20 IR 8 h 2 10.00 
21 IR 8 h 3 8.40 
22 IR + AG 8 h 1 10.00 
23 IR + AG 8 h 2 10.00 
24 IR + AG 8 h 3 8.30 
25 TNF-α 8 h 1 10.00 
26 TNF-α 8 h 2 10.00 
27 TNF-α 8 h 3 10.00 
28 TNF-α + AG 8 h 1 10.00 
29 TNF-α + AG 8 h 2 10.00 
30 TNF-α + AG 8 h 3 10.00 
 
 
 
 
 
5.3.3.3 Amplification of RNA 
Once the integrity of the RNA had been verified, the samples were amplified using the 
Illumina TotalPrep96 RNA Amplification Kit (Ambion). Described in Figure 5.3. The 
procedure begins with reverse transcription with an oligo(dT) primer bearing a T7 
promoter. The cDNA then undergoes second strand synthesis and clean up to become a 
template for in vitro transcription with T7 RNA Polymerase. Hunderds to thousands of 
biotinylated, antisense RNA copies of each mRNA are generated in each sample, and 
this is generally referred to as cRNA. The labelled cRNA produced is then used for 
hybridisation with Illumina MouseWG-6 BeadChip arrays. 
 
Table 5.1: RIN scores for each of the samples provided for microarray analysis 
30 RNA samples to be used for the gene expression arrays were examined on a 2100 
Bioanalyser (Agilent) by the Cambridge Genomics Service, and all scores >8, indicating 
RNA of high integrity 
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5.3.3.4 Hybridisation and scanning 
Biotin labelled cRNA was hybridised to the Illumina MouseWG-6 v2.0 Expression 
BeadChip arrays using the Illumina Direct Hybridization Assay (Figure 5.4). Each bead 
has a 50-base gene specific probe immobilised onto it via a short ‘address’ sequence. 
This probe is then used to directly hybridise the labelled cRNA. The arrays were then 
washed, blocked and stained with streptavidin-Cy3 and run on the iScan and Autoloader 
2 system (Illumina), which measured fluorescence emission by Cy3, which allowed 
quantitative downstream analysis.  
 
Figure 5.3: Workflow of RNA processing steps using the Illumina TotalPrep96 
RNA Amplification Kit (Ambion) 
From: http://www.ambion.com/techlib/prot/fm_4393543.pdf 
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5.3.4 Analysis of array data received from the Cambridge Genomics Service 
This section very briefly describes the bioinformatics processes used by Dr Dan Swan at 
the Newcastle University Bioinformatics Service in order to interpret and analyse the 
array data received from the Cambridge Genomics Service. Two software packages 
were utilised and these were Genespring GX 11, to generate gene lists, and Ingenuity 
Pathway Analysis, to indenify processes and pathways affected by either IR or TNF-α, 
in the presence or absence of AG-014699. 
 
5.3.4.1 Genespring GX 11 
Data exported from Illumina Bead Studio in a GeneSpring compatible format was 
loaded into GeneSpring GX 11 for analysis and analysed using the 
Illumina.SingleColor.MouseWG-6_V2_0_R2_11278593_A technology annotation 
package.  Expression values below 1 were thresholded to 1.0 on import and transformed 
to log base 2 prior to analysis.  Quantile normalisation was applied across the samples 
with a baseline transformation to the median of all samples.  To support flag based 
filtering, detection p-values <0.6 were marked as 'absent' and p-values >0.8 marked as 
'present'. Detection p-values >0.6 but <0.8 were marked as 'marginal'. 
 
Of 45281 entities, 22125 remained after filtering on flags so that 80 of the samples 
across the experiment had 'present' or 'marginal' flags associated with each probe. 
 
Figure 5.4: Direct hybridization Assay overview 
From: http://www.illumina.com/technology/direct_hybridization_assay.ilmn 
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Differential gene expression analysis was performed using ANOVA in GeneSpring 
(Benjamini-Hochberg FDR multiple testing correction applied) where probes had a 
corrected p-value of <0.05 and a fold change of >1.2 to be considered significantly 
differentially expressed. 
 
5.3.4.2 Ingenuity Pathway Analysis (IPA) 
Pathway analysis was carried out with Ingenuity Pathway Analysis 8 (Ingenuity 
Systems http://www.ingenuity.com) on probesets differentially expressed on selenium 
treatment.  Canonical pathways analysis and biological process analysis identified the 
pathways and processes from the Ingenuity library that were most significant to the data 
set.  
The significance of the association between the data set and the canonical 
pathway/process was measured in 2 ways:  
1) A ratio of the number of molecules from the data set that map to the 
pathway/process divided by the total number of molecules that map to the canonical 
pathway/process is displayed.  
2) Fisher’s exact test was used to calculate a p-value determining the probability that 
the association between the genes in the dataset and the canonical pathway/process is 
explained by chance alone. 
 
5.3.5 Microarray validation experiments using qRT-PCR 
The genes selected for validation by qRT-PCR are listed in Table 5.2, alongside the 
details of the primers and probes from Applied Biosystems. The method for qRT-PCR 
is described in detail in section 2.10. Seven genes were validated as those that were 
regulated following IR treatment; AURKA, AURKB, BIRC6, CDC20, PLK1, PLK2 and 
TOP2A. Two inflammatory response genes were validated as those regulated following 
TNF-α; CCL5 and CXCL10. Three genes were validated as those regulated following 
both IR and TNF-α; IRF1, JUNB and TNIP1. Levels of the housekeeping gene, ACTN 
were also assessed by qRT-PCR. 
 
Gene name Assay reference Probes 
AURKA Mm01248179_g1 FAM 
AURKAB Mm01718146_g1 FAM 
BIRC6 Mm00464380_m1 FAM 
CCL5 Mm01302427_m1 FAM 
CDC20 Mm00650983_g1 FAM 
CXCL10 Mm00445235_m1 FAM 
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FAS Mm00433237_m1 FAM 
IRF-1 Mm01288580_m1 FAM 
JUNB Mm01251660 _s1 FAM 
PLK1 Mm00440924_g1 FAM 
PLK2 Mm01306047_g1 FAM 
TNIP1 Mm00457957_m1 FAM 
TOP2A Mm01296339_g1 FAM 
ACTN Mm02619580_g1 FAM 
 
 
 
5.4 Results 
5.4.1 Differentially expressed genes 2 hours following treatment with IR  
One of the main aims of this chapter was to assess the different types, and functions of 
the genes up- or down-regulated following treatment with either IR or TNF-α at an early 
timepoint after either agent. It is well documented that TNF-α induces NF-κB 
activation, and in particular a transcriptional response associated with the induction of 
inflammatory- or immune-responses (Pahl, 1999). However, although there have been 
reports in the literature suggesting that DNA damage, in particular IR, up-regulates NF-
κB-dependent genes associated with the protection against apoptosis (Grossmann et al., 
1999, Lee et al., 1999a, Stehlik et al., 1998, You et al., 1999, Zong et al., 1999), 
information about other genes are less common. Hence, it was decided to undertake a 
head-to-head comparison of the genes regulated by IR or TNF-α in the p65+/+ MEFs, 
using an array based approach, within this chapter.  
 
Once the array data was received from the Cambridge Genomics Service, Genespring 
GX 11 was utilised by Dr Dan Swan in order to generate to lists of genes differentially 
expressed 2 hours after treatment with 10 Gy IR, compared with controls. Table 5.3 
details a list of genes differentially expressed following treatment with IR as well as the 
accession/identification number and the fold change.  
Gene  Symbol ID Fold change 
Aminoadipate-semiadlehyde 
dehydrogenase 
AADDH NM_173765.2 1.218 
ADP-ribosylation factor 2 Arf2 NM_007477.4 1.258 
ADP-ribosylation factor like-6 
interacting protein 
ARL6IP1 NM_019419.1 1.355 
Aurora kinase A AURKA NM_011497.3 2.283 
Baculoviral IAP repeat 
containing 6 
BIRC6 AK038699 1.285 
Table 5.2: Details of primers and probes from Applied Biosystems 
(FAM=fluorescein) 
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cDNA sequence BC003965 BRPF1 NM_030178.1 -1.203 
Chromosome 10 open reading 
frame 34 
C13orf34 NM_175265.4 1.559 
Chromosome 1 open reading 
frame 51 
C1orf51 NM_001033302.1 -1.313 
Chromosome 6 open reading 
frame 211 
C6orf211 NM_24261.2 1.214 
Chromosome 9 open reading 
frame 100 
C9orf100 NM_131404.3 1.924 
Chromosome 9 open reading 
frame 140 
C9orf140 
 
NM_130053.2 1.975 
Coiled-coil domain containing 
99 
CCDC99 NM_027411.1 1.424 
Cyclin B1 Ccnb1 NM_172301.3 1.497 
Cyclin F CCNF NM_007634.2 1.625 
Cell division cycle 20 homolog CDC20 NM_023223.1 1.468 
Cell division cycle 6 homolog CDC6 NM_011799.2 -1.692 
Cell division cycle associated 2 CDCAA2 NM_175384.2 1.702 
Cyclin-dependent kinase 
inhibitor 1A (p21) 
CDKN1A NM_007669.2 1.501 
Cyclin-dependent kinase 
inhibitor 2C (p18) 
CDKN2C AK087461 1.311 
Cyclin-dependent kinase 
inhibitor 2D (p19) 
CDKN2D NM_009878.3 1.351 
Chromatin licencing and DNA 
replication factor 
CDT1 NM_026014.3 1.454 
Centromere protein L CENPL NM_027429.2 2.179 
Cation transport regulator 
homolog 1 
CHAC1 NM_026929.3 1.374 
Cysteine rich hydrophobic 
domain 2 
CHIC2 AK015681 -1.275 
Choline kinase alpha CHKA AK014174 1.517 
CAP-GLY domain containing 
linker protein family 4 
CLIP4 NM_030179.2 1.239 
Component of oligomeric golgi 
complex 8 
COG8 NM_139229.2 1.239 
Cleavage stimulating factor CSTF1 NM_139229.2 1.237 
DBF4 homolog DBF4 NM_013726.2 1.284 
DEAD box polypeptide DDX11/DDX12 NM_128714.3 1.224 
DEP domain containing 1B DEPDC1B NM_178683.4 1.459 
Enoyl CoA hydratase short 
chain 1 
ECHS1 AK086762 1.274 
ERI1 exoribonuclease family 
member 2 
ER12 NM-027698.4 1.311 
v-ets erythroblastosis virus E26 
oncogene 
ETS1 NM_011809.2 -1.271 
Family with sequence 
similarity 110, member A 
FAM110A NM_028666.2 -1.321 
Family with sequence 
similarity 13, member C 
FAM13C NM_024244.2 -1.279 
Family with sequence 
similarity 83, member D 
FAM83D NM_027975.1 2.144 
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FERM domain containing 4A FRMD4A AK089210 1.260 
G2/M-phase specific E3 ligase G2E3 NM_00105099.1 1.466 
Growth arrest and DNA 
damage inducible beta  
GADD45B NM_008655.1 1.586 
Growth arrest specific 2 like 3 GAS2L3 NM_001079876.1 1.827 
GATS-protein like 2 GatsL2 NM_030719.3 -1.238 
Glutathione peroxidase 8 GPX8 NM_027127.1 1.208 
GTP binding protein 2 GTPBP2 NM_019581.2 1.324 
G-2 and S phase expressed 1 GTSE1 NM_013882.1 1.737 
Homo-cysteine inducible 
endoplasmic reticulum 1 
HERPUD1  NM_022331.1 -1.454 
Histone cluster 1, H2ae HIST1H2AB NM_178182.1 1.716 
Histone cluster 1, H2ac HIST1H2AC NM_175659.1 1.667 
Histone cluster 2, H2ab HIST2H2AB NM_178213.3 1.613 
Heterogeneous nuclear 
ribonuclear protein D-like 
HNRPDL NM_0166690.2 1.380 
Immediate early response 3 IER3 NM_133662.2 1.380 
Inner centromere antigens 
135/155 kDa 
INCENP NM_016692.1 1.268 
Inversin INVS AK040307 1.298 
Interferon regulatory factor 1 IRF1 NM_008390.1 -1.584 
Kinesin family member 11 KIF11 NM_001615.1 1.401 
Kinesin family member 18A KIF18A NM_139303.1 1.900 
Kinesin family member 18B KIF18B NM_197959.1 1.834 
JunB proto-oncogene JUNB NM_008416.1 1.643 
Kinesin family member 20B KIF20B NM_183046.1 1.712 
Kinesin family member 22 KIF22 NM_145588.1 1.452 
Kinesin family member 2C KIF2C NM_134471.3 1.572 
Kinesin family member C1 KIFC1 NM_001479207.1 1.796 
Kruppel like factor 16 KLF16 NM_078477.1 -1.356 
Kruppel like factor 4 KLF4 NM_001081150.1 -1.409 
LON peptidase N-terminal 
domain and ring finger 
LONRF1 NM_001081150.1 -1.207 
LIM domain contained 
preferred translocation peptide 
LPP AK051937 1.367 
Minixsome maintanience 
complex component 10 
MCM10 NM_027290.1 1.395 
Meis homobox 1 MEIS1 NM_010789.2 -1.257 
MIS18 binding protein 1 MIS18BP1 NM_172578.2 1.570 
Nuclear autoantigenic sperm 
protein 
NASP NM_016777.3 -1.363 
Nuclear factor 1/X NFIX NM_001081981.1 1.216 
OMA1 homolog OMA1 NM_025909.1 1.277 
Pre-B cell leukemia homolog 1 PBX1 AK037006 1.442 
PHD finger protein 15 PHF15 NM_199299.3 1.211 
PIF1 5’-3’DNA helicase 
homolog 
PIF1 NM_172453.1 3.122 
Polo-like kinase 1 PLK1 NM_011121.3 1.651 
Protein regulator of cytokinesis PRC1 NM_145150.1 1.345 
Proline rich 11 PRR11 NM_175563.3 1.210 
Pseudouridylate synthase 7 
homolog 
PUS7L NM_172437.2 1.210 
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Receptor accessory protein 4 REEP4 NM_180588.1 1.276 
Ribosomal protein S24 Rps24 AK052480 1.397 
Sestrin 2 SESN2 NM_144907.1 -1.347 
SH3 and PX domain 2B SH3PXD2B  AK043324 1.244 
Shugoshin like 1 SG0L1 NM_028232.1 1.433 
Shugoshin like 2 SGOL2 NM_199007.1 1.445 
Seven in absentia homolog 1 SIAH1 NM_009172.1 -1.203 
Spindle and kinetochore 
associated complex subtype 2 
SKA2 NM_0253771 1.243 
Solute carrier family 30 SLC30A1 NM_009579.3 1.390 
Slit homlog 2  SLIT2 AK053913 1.575 
Structural maintenance of 
chromosomes 4 
SMC4 AK10848 1.429 
Sperm associated antigen 5 SPAG5 NM_017407.1 1.371 
SPC25, NDC80 kinetochore 
complex component 
SPC25 NM_025565.1 1.288 
splA/ryanodine receptor 
domain and SOCs box 
SPSB1 NM_029035.2 -1.457 
Telomeric repeat binding factor 
1 
TERF1  AK036615 1.346 
Transducin-like enhancer of 
split 4 
TLE4 NM_011600.2 -1.316 
Tousled like kinase 1 TLK1 NM_172664.2 -1.205 
Topoisomerase (DNA) II alpha 
170 kDa 
TOP2A AK028218 1.659 
TNFAIP3 interacting protein 1 TNIP1 NM_021327.1 1.846 
Trafficking protein particle 
complex 2 
TRAPPC2 AK034967 1.213 
Tribbles homolog 3 TRIB3 NM_175093.2 -1.297 
Tastin TROAP XM_912265.2 1.682 
Trichorhinophalangeal 
syndrome 1 
TRPS1 AK036590 1.461 
Vascular endothelial growth 
factor 
VEGFA NM_009505 1.413 
Exportin 4 XPO4 NM_20506.1 -1.201 
Zinc finger, SWIM-type 
containing 4 
ZSWIM 4 NM_172503.3 -1.259 
 
 
 
 
This list of genes of was then entered into the pathway analysis software, IPA, in order 
to determine the key pathways and processes affected by treatment with IR in the p65+/+ 
MEFs. Interestingly, the most frequent functional annotations given by the software 
were associated with cellular assembly and organisation. A network diagram, produced 
by IPA, is shown in Figure 5.5. This shows the genes up- (in red) or down- (in green) 
regulated by IR that associated with that particular network. It also shows the known 
Table 5.3: Differentially expressed genes 2 hours following treatment with IR in p65+/+ 
MEFs, compared with untreated controls 
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interactions between any two molecules with a solid line, and any putative interactions 
with a broken line. These data are derived from literature searches and algorithms built 
into the software package. 
 
 
 
 
 
 
 
IPA assigns functional annotations to sets of molecules known to be associated within a 
certain cellular pathway or process, and lists the genes within these annotations. For 
example one of the genes up-regulated by IR, aurora kinase A (which had one of the 
greatest fold changes, increasing by 2.2-fold) was associated with the alignment of 
chromosomes, as well as being involved in the amplification of the centrosome and the 
mitotic spindle. A range of kinesin family (KIF) proteins were also up-regulated and are 
known to be associated with the alignment and congression of chromosomes, along with 
being involved in the formation of the mitotic spindle and the organisation of spindle 
fibres. Polo-like kinase 1 (PLK-1) was up-regulated 1.6-fold and is known to involved 
in the formation of the mitotic spindle as well having other roles with the centrosome. 
Both PLK1 and Aurora kinase A (AURKA) have been shown to be over-expressed in 
Figure 5.5: Genes associated with the cell cycle, cellular movement, cellular 
assembly and organisation Network generated by IPA with genes that were up-
regulated (shown here in red) or down-regulated (shown here in green) in p65+/+ MEFs 
2 hours after treatment with 10 Gy IR 
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different forms of cancer (Goepfert et al., 2002, Musacchio and Salmon, 2007, Sakakura 
et al., 2001, Tanaka et al., 1999b), and there are known targeted inhibitors for these 
proteins in development as potential cancer therapeutics (Dar et al., 2010, Degenhardt 
and Lampkin, 2010). This will be discussed in detail later in this chapter. A summary of 
the functional annotations from the IPA software, the associated molecules and p-values 
are shown in Table 5.4. The significance of the association between the molecules 
within the data set and the pathway/process was measured, by the software algorithms, 
using a Fisher’s exact test to calculate a p-value determining the probability that the 
association between the genes in the dataset and the pathway/process is not explained 
by chance alone. 
Functional annotations P value Molecules 
Alignment of chromosomes 2.43E-11 AURKA, KIF18A, KIF22, KIF2C, KIF1C, 
SMC4, PLK1 
Chromosomal congression 
of chromosomes 
8.71E-10 SGOL2, KIF18A, KIF2C, KIFC1 
 
Segregation of 
chromosomes 
1.67E-08 DDX11/DDX12, INCENP, KIF2C, SGOL1, 
SMC4, SKA2, SPC25, TOP2A 
Quantity of mitotic spindle 2.51E-07 AURKA, KIF11, PLK1, SPC25 
Organisation of spindle 
fibres 
7.47E-07 C13orf34, KIF11, KIFC1, SPC25, SIAH1(-
) 
Amplification of 
centrosome 
9.96E-06 AURKA, KIF1C, PLK1, KLF4(-) 
Organisation of mitotic 
spindle 
1.66E-05 C13orf34, KIF11, SPC25, SIAH1(-) 
Replication of DNA 6.37E-05 CDKN1A, DBF4, PUS7L, TERF1, CDC6(-
), CDT1(-), MCM10(-), NASP(-) 
Formation of mitotic 
spindle 
1.65E-04 KIF11, KIF2C, KIFC1, PLK1 
Elongation of mitotic 
spindle 
2.14E-04 PRC1, SPC25 
Quality of centrosome 3.43E-04 AURKA, CDKN1A, PLK1 
 
 
 
 
Table 5.4 indicates that a large proportion of the gene expression altered following IR 
treatment in the p65+/+ MEFs is associated with cellular organisation and assembly, and 
this is something which warrants further investigation. There is a very little literature 
detailing the regulation of gene transcription associated with cellular assembly by NF-
κB, however one group have shown the polo like kinase 3 (PLK3) is an NF-κB 
regulated gene (Li et al., 2005). The data here suggests that PLK1 could therefore 
perhaps be an NF-κB target gene. It is up-regulated 1.6-fold following IR, and other 
Table 5.4: Functional annotations associated with cellular assembly and organisation 
assigned by IPA Summary of the functional annotations from the IPA software, the 
associated molecules and p-values (-) denotes a gene which was down-regulated 2 hours 
after treatment with 10 Gy IR 
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associated proteins are also up-regulated following treatment with IR. PLK1 is involved 
in the metaphase to anaphase transition, and also mitotic exit (shown in Figure 5.6), 
along with CDC20, Cyclin B and PRC1, all of which are up-regulated after treatment 
with 10 Gy IR in the p65+/+ cells. Therefore, this warrants further investigation, by qRT-
PCR, to determine whether any of these genes are novel NF-κB regulated genes 
following DNA damage. It will also be essential to assess whether co-incubation with 
the PARP inhibitor, AG-014699, in combination with IR, had an effect on any of these, 
or other genes known to be associated with cellular assembly that were up-regulated 
with treatment with IR alone. Based on the observations from chapter 3 and 4, it would 
be reasonable to hypothesise that if a gene was regulated by NF-κB, treatment with 
PARP inhibitor prior to IR would inhibit the expression of that particular gene, 
compared with IR alone. 
 
Another group have shown that CDKN1A/p21 (a cyclin dependent kinase) is an NF-κB 
target gene (Hinata et al., 2003). CDKN1A/p21 is up-regulated 1.5-fold in the array data 
presented here, and is also known to have a role in the both the G1/S and G2/M cell 
cycle checkpoints (Niculescu et al., 1998). CDKN1A/p21 is the primary downstream 
target in p53-mediated damage response. DNA damage, such as IR is known to activate 
kinases ATM and ATR, which phosphorylate and activate the Chk effector kinases. 
These kinases go on to stabilise p53 through a series of phosphorylation events resulting 
in the increased transcription of its target p21 (Bartek and Lukas, 2001) hence it is 
perhaps not surprising that the transcription of CDKN1A/p21 is induced following 
treatment with IR, but further investigation into whether this is, mediated wholly, or in 
part by NF-κB, should be undertaken. In particular the effect of TNF-α treatment on 
CDKN1A expression should be noted, as TNF-α is not known to induce a DNA damage 
response, hence if increased expression of this gene is observed after treatment with this 
agent, it is most likely to be due to an NF-κB response in this particular cell line.  
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Similarly, the TOP2A gene, which encodes the topoisomerase II alpha protein, was up-
regulated following treatment with IR. Topoisomerase II is a nuclear enzyme which 
controls and alters the topologic states of DNA during transcription and replication. It is 
involved in processes such as chromosome condensation, chromatid separation, and the 
relief of torsional stress that occurs during DNA transcription and replication. It 
catalyses the transient breaking and rejoining of two strands of DNA thus allowing the 
strands to pass through one another, and altering the topology of DNA. There are many 
known inhibitors of the enzyme currently used in cancer therapeutics (Liu and D'Arpa, 
1992). Although the TOP2A gene has not previously been shown to be regulated by NF-
κB, it could be something to further investigate. Topoisomerase II poisons are often 
used in combination with radio-therapy for the treatment of cancers, such as breast 
(Hoogstraten et al., 1976) and are widely used for the treatment of acute myeloid 
leukaemia (AML). Reports have also shown that doxorubicin, daunorubicin and 
mitoxantrone induce NF-κB activity (Campbell et al., 2006a), hence it is possible that 
Figure 5.6: Metaphase to anaphase transition and mitotic exit 
Genes which were identified as up-regulated 2 hours after treatment with 10 Gy IR 
are in red, those unaffected are in black. Adapted from Ingenuity Pathway analysis 
(IPA) 
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there is a feedback loop occurring with NF-κB inducing the TOP2A gene, perhaps 
resulting in the acquired resistance sometimes observed with these types of treatments. 
Other genes of interest up-regulated following IR, include the proto-oncogene JunB, 
which has previously been shown to be regulated by NF-κB after induction with the 
inflammatory cytokine, IL-6 (Brown et al., 1995). However, this gene has not been 
shown to be regulated by NF-κB following treatment with a DNA damaging agent. 
Furthermore, TNFAIP3 interacting protein 1 (TNIP1) gene is also shown to be up-
regulated following treatment with IR. TNIP1 encodes the protein ABIN1 and interacts 
with the putative tumour suppressor TNFAIP3/A20 (Compagno et al., 2009, Heyninck 
et al., 1999). TNIP1 is regulated by NF-κB following treatment with TNF-α, and is 
associated with TNF-α mediated apoptosis, in concert with TNFAIP3 (Hymowitz and 
Wertz, 2010), therefore it would interesting to determine whether this gene is regulated 
by NF-κB following IR, and its function in this context.  
5.4.2 Differentially expressed genes 2 hours following treatment with IR versus IR in 
combination with AG-014699 
Following on from the section studying the genes which were differentially expressed 
following IR treatment compared with controls, it was decided to directly compare IR 
treated p65+/+ MEFs with p65+/+ MEFs treated with a combination of IR and AG-
014699. A number of genes which were up-regulated after IR treatment were associated 
with cellular assembly and organisation, which are not widely known as NF-κB-
regulated genes. Hence, it was important to assess the expression of these genes, and 
others following IR with co-incubation with the PARP inhibitor, AG-014699.  Previous 
data, presented in chapters 3 and 4 of this thesis, have shown that radio-sensitisation by 
the AG-014699 is mediated via NF-κB, and is independent of SSB repair. This leads to 
the hypothesis that genes, such as PLK1 which were up-regulated following treatment 
with IR, would be down-regulated by co-incubation with a PARP inhibitor, if they were 
regulated by NF-κB. Hence, Genespring GX 11 was utilised by Dr Dan Swan in order 
to generate to a list of genes differentially expressed following treatment with 10 Gy IR, 
compared with 10 Gy IR in combination with AG-014699. These genes are listed in 
Table 5.5 along with the accession/identification number and the fold change.  
 
Gene  Symbol ID Fold change 
Rho/Rac guanine nucleotide 
exchange factor 2 
ARHGEF2 AK035683 -1.716 
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Atonal homolog 8 ATOH8 NM_153778.3 1.247 
Aurora kinase A AURKA NM_011497.3 -1.853 
Baculoviral IAP repeat containing 6 BIRC6 AK038699 -1.200 
Cell division cycle 20 homolog CDC20 NM_023223.1 -1.288 
Cyclin-dependent kinase inhibitor 2D 
(p19) 
CDKN2D NM_009878.3 -1.221 
Cation transport regulator homolog 1 CHAC1 NM_026929.3 -1.240 
FERM domain containing 4A FRMD4A AK089210 -1.268 
Inversin INVS AK040307 -1.238 
Importin 5 IPOS AK017701 -1.165 
Interferon regulator factor 1 IRF1 NM_008390.1 1.563 
Jun proto-oncogene JUN NM_010591.1 -1.305 
Katanin p60 subunit A like 1 KATNAL1 NM_135572.7 -1.277 
Mitogen activated kinase 11 MAPK11 NM_011161.4 -1.253 
Polo like kinase 1 PLK1 NM_011121.3 -1.468 
Protease, serine 8 PRSS8 NM_13351.1 1.238 
Ribosomal protein S24 Rps24 AK052480 -1.428 
Slit homlog 2  SLIT2 AK053913 -1.328 
Stabilin 1 STAB1 AK087634 -1.414 
TNFAIP3 interacting protein 1 TNIP1 NM_021327.1 -1.273 
Topoisomerase (DNA) II alpha 170 
kDa 
TOP2A AK028218 -1.207 
 
 
Interestingly, Table 5.5 shows that a number of the genes up-regulated following IR, 
including TOP2A, PLK1, AURKA, CDC20, and others which are all known to play a 
role in cellular organisation and assembly, are down-regulated in the presence of AG-
014699. This is summarised in the subsequent Table 5.6, along with the fold change 
following IR alone, and the fold change of IR in combination with AG-014699, 
allowing a direct comparison. 
Gene Symbol Fold change 
(IR) 
Fold change 
(IR + AG-
014699) 
Aurora kinase A AURKA 2.2832 -1.853 
Baculoviral IAP repeat containing 
6 
BIRC6 1.285 -1.200 
Cell division cycle 20 homolog CDC20 1.468 -1.288 
Cyclin-dependent kinase inhibitor 
2D (p19) 
CDKN2D 1.351 -1.221 
Cation transport regulator 
homolog 1 
CHAC1 1.374 -1.240 
FERM domain containing 4A FRMD4A 1.260 -1.268 
Inversin INVS 1.298 -1.238 
Table 5.5: Differentially expressed genes 2 hours following treatment with IR + AG-
014699 in p65+/+ MEFs, compared with IR alone 
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Interferon regulator factor 1 IRF1 -1.584 1.563 
Jun proto-oncogene JUN 1.643 -1.305 
Polo like kinase 1 PLK1 1.651 -1.468 
Ribosomal protein S24 Rps24 1.397 -1.428 
Slit homlog 2  SLIT2 1.575 -1.328 
TNFAIP3 interacting protein 1 TNIP1 1.846 -1.273 
Topoisomerase (DNA) II alpha 
170 kDa 
TOP2A 1.659 -1.207 
 
 
The data here shows that the baculoviral IAP (inhibitor of apoptosis) repeat containing 6 
gene (BIRC6) is induced 1.3-fold following IR in the p65+/+ MEFs, however this 
induction is abrogated in the presence of AG-104699. This is an anti-apoptotic gene and 
therefore supports existing literature from two groups stating that NF-κB activation 
following IR induces the expression of the anti-apoptotic genes, including the IAPs 
(Stehlik et al., 1998, You et al., 1999), resulting in cell survival. These data should be 
further confirmed using qRT-PCR. 
Interestingly, the gene encoding interferon regulatory factor 1 (IRF-1) was down-
regulated 1.6-fold by IR, however this fold change was reversed by co-incubation with 
AG-014699. Previous literature has shown that this gene is regulated by NF-κB 
following the inflammatory stimuli TNF-α and interferon-γ (IFN-γ) (Harada et al., 
1994, Robinson et al., 2006). These data suggest that IRF-1 is also regulated by IR 
following DNA damage. It has been suggested that IRF-1 has a role as a tumour 
suppressor, and there has been one report showing that IRF-1 promotes apoptosis 
following DNA damage (Clarke et al., 2003), however the data presented here indicate 
that IR alone inhibits the transcription of this gene, whereas the PARP inhibitor induces 
mRNA expression of IRF-1. IRF-1 is a transcription factor itself and it has recently 
been shown that NF-κB p65 is a transcriptional target of IRF-1 (Ning et al., 2010), 
suggesting the presence of the feedback loop between the two transcription factors. 
Furthermore, there have a number of reports suggesting that over-expression, or 
induction of IRF-1 by IFNγ induces apoptosis and inhibits tumourigenesis, particularly 
in breast cancers (Bouker et al., 2005, Bowie et al., 2004, Pizzoferrato et al., 2004). 
These data therefore indicate that the inhibition of IRF-1 expression by IR and the 
subsequent induction of the gene by AG-014699, requires further investigation. It is 
well documented that NF-κB can repress gene transcription (Perkins, 2007), therefore in 
Table 5.6: Fold changes of genes which were up-regulated following IR, and 
subsequently down-regulated in the presence of IR and AG-014699 
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this case the expression of IRF-1 could be inhibited by IR-induced NF-κB activation 
and the inhibition of NF-κB by AG-014699, restores expression of IRF-1. 
Genes associated with cellular assembly and organisation, including AURKA, PLK-1, 
TOP2A and CDC20 were all up-regulated following treatment with IR (2.2-fold, 1.6-
fold, 1.7-fold and 1.5-fold, respectively). The expression of these genes was inhibited 
when p65+/+ cells were pre-treated with AG-014699 prior to IR treatment. This therefore 
suggests that these genes may be regulated by NF-κB following DNA damage, and 
indicate that these genes require further validation using qRT-PCR. As previously 
mentioned the proto-oncogene, Jun and the TNIP-1 gene (both known to be regulated 
by NF-κB, following inflammatory stimuli (Brown et al., 1995, Compagno et al., 2009, 
Heyninck et al., 1999, Tian et al., 2005)) were also found to be up-regulated following 
treatment with IR. This up-regulation was abrogated in the presence of AG-014699, and 
therefore these genes also warrant further investigation. A list of the interesting genes 
identified from the gene expression study on IR alone, and IR in combination with AG-
014699 are in Table 5.7. 
Gene Symbol Fold 
change 
(IR) 
Fold change (IR + 
AG-014699) 
Aurora kinase A AURKA 2.283 -1.853 
Baculoviral IAP repeat containing 
6 
BIRC6 1.285 -1.200 
Cell division cycle 20 homolog CDC20 1.468 -1.288 
Interferon regulator factor 1 IRF1 -1.584 1.563 
Jun proto-oncogene JUN 1.643 -1.305 
Polo like kinase 1 PLK1 1.651 -1.468 
TNFAIP3 interacting protein 1 TNIP1 1.846 -1.273 
Topoisomerase (DNA) II alpha 
170 kDa 
TOP2A 1.659 -1.207 
 
 
 
5.4.3 Differentially expressed genes 2 hours following treatment with TNF-α 
Once Genespring GX 11 and IPA had been used to assess the different types, and 
functions of the genes up- or –down-regulated following treatment with IR, these 
software packages were used again, by Dr Dan Swan, to determine the types or genes 
and canonical pathways regulated following treatment with 10 ng/ml TNF-α in the 
p65+/+ MEFs. It is well documented that TNF-α induces NF-κB activation, and in 
particular a transcriptional response associated with the induction of inflammatory- or 
Table 5.7: A list of the interesting genes identified from the data on IR alone, and IR 
in combination with AG-014699 
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immune-responses (Pahl, 1999). Hence, it is possible to hypothesise that this would be 
the transcriptional response observed with the data obtained from the arrays undertaken 
at the Cambridge Genomics Service. This would be very different from the response 
observed following IR, in the p65+/+ MEFs, which showed that the majority of genes up-
regulated after IR were associated with cellular organisation and assembly. Table 5.8 
details a list of genes differentially expressed following treatment with TNF-α as well as 
the accession/identification number and the fold change.  
Gene Symbol ID Fold 
change 
AE binding protein 2 AEBP2 AK04538 1.354 
Adhesion molecule interacts with 
CXADR antigen 1 
AMICA1 NM_001005421.3 -1.336 
BAH domain and coiled coil 
containing 1 
BAHCC1 NM_198423.3 2.010 
BCL2 binding component 3 BBC3 NM_133234.1 1.304 
B-cell CLL/lymphoma 10 BCL10 NM_009740.1 1.337 
B-cell CLL/lymphoma 3 BCL3 NM_033601.1 1.394 
BCL6 co-repressor BCOR NM_175045.2 1.334 
Basic helix-loop-helix family 
member e40 
BHLHE40 NM_011498.4 1.523 
BH3 interacting domain death 
agonist 
BID NM_007544.3 1.859 
Bone morphogenic protein 4 BMP4 NM_007554.2 -1.613 
Chromosome 5 open reading frame 
13 
C5orf13 NM_053078.3 -1.214 
Chromosome 6 open reading frame 
203 
C6orf203 NM_026411.1 -1.350 
Chemokine (C-C motif) ligand 13 CCL13 NM_011333.3 5.503 
Chemokine (C-C motif) ligand 5 CCL5 NM_013653.2 2.981 
CCR4 carbon catabolite repression-
4-like 
CCRN4L NM_009834.1 1.464 
CD47 molecule CD47 NM_175169.2 1.445 
Cyclin dependent kinase 5 
regulatory subunit associated 
protein 1 
CDK5RAP1 NM_025876.2 -1.163 
Cyclin dependent kinase inhibitor 3 CDKN3 NM_919022.2 -1.255 
Cyclin-dependent kinase inhibitor 
1A (p21) 
CDKN1A NM_007669.2 1.597 
Cation transport regulator homolog 
1 
CHAC1 NM_026929.3 1.274 
Chemokine (C-XC motif) ligand 10 CXCL10 NM_021274.1 3.771 
DAB2 interacting protein  DAB21P NM_001001602 1.241 
Deafness, autosomal dominant 5 DFNA5 NM_018769.3 -1.213 
Dolichyl pyrophosphate 
phosphatase 1 
DOLPP1 NM_020329.3 -1.229 
EH domain containing 1 END1 NM_010119.5 1.360 
Family with sequence similarity 
102 member A 
FAM102A NM_153560.4 -1.375 
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Family with sequence similarity 13 
member C 
FAM13A NM_024244.3 1.413 
F-box protein 40 FBXO40 NM_156083.3 -1.143 
Fibroblast growth factor 7 FGF7 NM_008008.3 1.313 
Four jointed box 1 FJX1 NM_010218.2 1.293 
FERM domain containing 4A FRMD4A AK089210 1.282 
Growth arrest and DNA damage 
inducible beta  
GADD45B NM_008655.1 1.759 
Glial cell derived neutotrophic 
factor 
GDNF NM_010275.3 1.399 
Histocompatibility 2, Q region 
locus 5 
H2-Q5 NM_010393.3 1.533 
Human immunodeficiency virus 
type I enhancer binding protein 3 
HIVEP3 NM_010657 1.290 
Major histocompatibility complex, 
class I, C 
HLA-C NM_010380.3 1.243 
Intercellular adhesion molecule 1 ICAM1 NM_010439.2 1.532 
Inhibitor of DNA binding 1 ID1 NM_010495.2 -1.601 
Inhibitor of DNA binding 4 ID4 NM_031166.2 -1.671 
Immediate early response 3 IER3 NM_133662.2 1.689 
Immediate early response like 5 IERL5 NM_030244.3 -1.379 
Immunoglobulin superfamily 
member 9 
IGSF9 NM_033608.2 1.572 
Interleukin 1 receptor like 1 IL1RL1 NM_010743.1 1.695 
Immunity related GTPase family Q IRGQ NM_153134.2 1.431 
Interferon regulatory factor 1 IRF1 NM_008390.1 2.845 
Interferon regulatory factor 5 IRF5 NM_012057.3 1.792 
JunB proto-oncogene JUNB NM_008416.1 1.867 
Leukemia inhibitory factor LIF NM_001039537.1 1.458 
Lysophosphatidic acid receptor 6 LPAR6 NM_175116.2 -1.474 
Mastermind-like 2 MAML2 XM_001481278.2 1.290 
Mitogen activated protein kinase 
kinase kinase 11 
MAPK311 NM_022012.3 1.312 
Mitogen activated protein kinase 
11 
MAPK11 NM_011161.4 1.215 
Mitogen activated protein kinase 6 MAPK6 NM_027418.1 1.363 
Meis homobox 1 MEIS1 NM_010789.2 -1.298 
Malignant fibrous histio-cytoma 
amplified sequence 1 
MFAHAS1 NM_001081279.1 1.738 
Myotubularin related protein 4 MTMR14 NM_026849.1 1.246 
N-myc downstream regulator 1 NDRG1 NM_008681 1.569 
Nuclear factor of activated T-cells, 
calcineurin-dependent 4 
NFATC4 NM_023699.3 -1.303 
Nuclear factor (erythroid derived 
2)-like 1 
NFE2L1 NM_008686.2 1.281 
Nuclear factor of kappa light 
polypeptide gene enhancer in B 
cells (p49/p100) 
NFKB2 NM_019408.1 1.635 
Nuclear factor of kappa light 
polypeptide gene enhancer 
inhibitor epsilon 
NFKBIE NM_008690.2 2.125 
NIPA-like domain containing 1 NIPAL1 NM_001081205.1 1.736 
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Neuregulin 1 NRG1 NM_178591.2 1.490 
OCIA domain containing 2 OCIAD2 NM_026950.3 -1.209 
Opitneurin OPTN NM_181848.3 1.346 
Photocadherin 7 PCDH7 NM_018764.1 1.419 
Platelet derived growth factor beta 
polypetptide 
PDGFB NM_011057.2 2.426 
Platelet derived growth factor 
receptor like 
PDGLRL NM_026840.2 1.218 
6-phosphofructo-2-kinase PFKFB4 NM_173019.5 -1.206 
Pleckstrin homology-like domain, 
family B, member 1 
PHLDB1 NM-153537.3 1.784 
Paroxysmal nonkinosigenc 
dyskinesia 
PNKD NM_019999.3 1.579 
Plasminogen activator, tissue PLAT NM_008872 1.219 
Peroxisome proliferator activated 
receptor gamma, coactivator-
related 1 
PPRC1 NM_001081214.1 1.165 
Proline rich 7 PPR7 NM_001030296.3 1.311 
Proteosome 26S subunit, non-
ATPase, 10 
PSMD10 NM_016883.3 1.203 
RAB32, member RAS oncogene 
family 
RAB32 NM_026405.3 1.572 
RAB3A, member RAS oncogene 
family 
RAB3A NM_009001.3 -1.255 
Ras associated domain family (N-
terminal) member 7 
RASSF7 NM_025886.3 1.244 
Receptor interacting serine-
threonine kinase 2 
RIPK2 NM_138952.3 1.515 
Ring finger protein 19B RNF19B XM_910375.2 1.770 
Shroom family member 2 SHROOM2 NM_172441.2 -1.317 
SMAD family member 3 SMAD3 NM_016769.2 1.449 
Solute carrier family 44, member 1 SLC44A1 AK008866.1 1.122 
Smg-7 homolog SMG7 NM_001005507.1 1.266 
Sorting nexin 16 SNX16 NM_029068.2 -1.206 
SplA/ryanodine receptor domain 
and SOCS box containing 1 
SPSB1 NM_029035.2 1.724 
Syntaxin 11 STX11 NM_203312.6 3.259 
TAP binding protein like TAPBPL NM_145391.1 1.424 
T-box 3 TBX3 NM_0011535.2 1.417 
T-cell immune regulator 1 TCIRG1 NM_016921.2 1.607 
Toll like receptor 4 TLR4 NM_021297.1 -1.216 
TNF-alpha-induced protein 2 TNFAIP2 NM_009396.1 2.969 
TNF-alpha-induced protein 3 TNFAIP3 NM_009397.2 3.351 
TNFAIP3 interacting protein 1 TNIP1 NM_021327.1 2.284 
TNF receptor associated factor 1 TRAF1 AK089281 -1.738 
Vascular cell adhesion molecule 1 VCAM1 AK030195 1.730 
Zinc finger protein36, C3H type 
homolog 
ZFP36 NM_011756.4 1.810 
Zinc finger protein36, C3H type-
like 1 
ZFP36L1 NM_007564.2 1.388 
Zinc finger, SWIM-type containing 
4 
ZSWIM 4 NM_172503.3 -1.624 
Table 5.8: Differentially expressed genes 2 hours following treatment with TNF-α 
in p65+/+ MEFs, compared with untreated controls 
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In order to clearly to determine whether there were differentially expressed genes 
following IR and TNF-α, a Venn diagram (Figure 5.7) was generated comparing the 
genes which were up- or down-regulated following either agent compared with controls.  
 
 
 
 
 
The Venn diagram in Figure 5.7 shows that, using the parameters set in Genespring 
GX11 (section 5.3.4.1), there were 103 genes with a fold change greater than 1.2-fold 
following TNF-α treatment, and 109 genes with a fold change greater than 1.2-fold in 
cells treated with IR. However, of these genes, only 11 common genes were found to be 
regulated by both agents. These are listed, along with their fold changes after either 
agent, in Table 5.9. The table also details whether it is known if these genes are NF-κB 
regulated. This information was obtained by cross-referencing with the website from the 
laboratory of Dr. Thomas Gilmore (Boston University) http://www.bu.edu/nf-kb/the-
gilmore-lab/home/, and where appropriate, references have been included. 
 
Gene Symbol Fold 
Change 
(IR) 
Fold 
change 
(TNF-α) 
NF-κB 
regulated? 
Reference 
Cyclin-dependent 
kinase inhibitor 1A 
(p21) 
CDKN1A 1.501 1.597 Yes (Hinata et 
al., 2003) 
Cation transport CHAC1 1.374 1.274 No  
Figure 5.7: Venn Diagram showing the number of gene differentially expressed 
following either IR or TNF-α compared with untreated controls in the p65+/+ 
MEFs, and importantly the number of common genes which were regulated 
following both stimuli. 
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regulator homolog 
1 
Growth arrest and 
DNA damage 
inducible beta  
GADD45B 1.586 1.759 Yes (De 
Smaele et 
al., 2001) 
FERM domain 
containing 4A 
FRMD4A 1.260 1.282 No  
Immediate early 
response 3 
IER3 1.380 1.689 Yes (Wu et al., 
1998) 
Interferon 
regulatory factor 1 
IRF1 -1.584 2.845 Yes (Harada et 
al., 1994) 
JunB proto-
oncogene 
JUNB 1.643 1.867 Yes (Brown et 
al., 1995) 
Meis homobox 1 MEIS1 -1.257 -1.298 No  
splA/ryanodine 
receptor domain 
and SOCs box 
SPSB1 -1.457 1.724 No  
TNFAIP3 
interacting protein 
1 
TNIP1 1.846 2.211 Yes (Tian et 
al., 2005) 
Zinc finger, SWIM-
type containing 4 
ZSWIM 4 -1.259 -1.624 No  
 
 
 
 
 
Table 5.9 shows the 11 genes up- or down- regulated by treatment with either IR or 
TNF-α, and also that 6 of these genes are known to be regulated by NF-κB. In the case 
of CDKN1A, TNIP1, JUNB, IER3 and IRF-1 these genes have been shown to regulated 
by NF-κB following inflammatory stimuli (Brown et al., 1995, Harada et al., 1994, 
Hinata et al., 2003, Tian et al., 2005, Wu et al., 1998), and not by DNA damage. Hence, 
further investigation into some of these genes in order to confirm the array findings 
would be advantageous. 
 
The Venn diagram in figure 5.7, shows that of the 103 genes with altered expression 
following TNF-α, there were 92 genes which showed altered expression, different from 
those differentially expressed following IR treatment in the same p65+/+ MEFs. IPA 
pathway analysis software showed (Figure 5.5 and Table 5.4) that the networks and 
functional annotations assigned to the differentially expressed genes following IR were 
cellular assembly and organisation, which also has cross-talk with the cell cycle and 
cellular movement. Therefore, it was important to perform the same analysis with the 
Table 5.9: Information regarding fold change on the 11 genes which were 
differentially expressed following both IR and TNF-α in the p65+/+ MEFs 
Information regarding whether any of these genes are known to be regulated by NF-κB 
regulated following either stimulus is also included 
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gene list (Table 5.8) generated for TNF-α regulated genes in IPA, in order to determine 
which pathways and cellular processes were involved with the differentially expressed 
genes following this stimulus.  
 
It is well documented that TNF-α induces NF-κB dependent transcription of genes 
associated with the inflammatory and immune responses, including numerous different 
cytokines and chemokines, such as CXCL10 (Hein et al., 1997) and IL-8 (Kunsch and 
Rosen, 1993), as well as receptors required for immune recognition, including those 
which recognise MHC proteins (Israel et al., 1989a, Israel et al., 1989b, Johnson and 
Pober, 1994). NF-κB also regulates that expression of genes which are associated with 
antigen presentation and proteins required for neutrophil adhesion and transmigration 
across blood vessel walls, for example, VCAM-1 (Iademarco et al., 1992). Hence, it was 
perhaps unsurprising that the top canonical pathways and functional annotations 
assigned to the list of genes regulated by TNF-α within this study were associated with 
the inflammatory response and the cell mediated immune response. 
 
A summary of the functional annotations, associated molecules and p-values generated 
by the IPA software from the list of genes in Table 5.9, the are shown in Table 5.10. 
Table 5.10 details the genes assigned to functional annotations associated with the 
inflammatory response and also with the cell mediated immune response by IPA. The 
significance of the association between the molecules within the data set and the 
canonical pathway/process was measured, by the software algorithms, using a Fisher’s 
exact test to calculate a p-value determining the probability that the association between 
the genes in the dataset and the canonical pathway/process is not explained by chance 
alone.  
Functional annotations P value Molecules 
Accumulation of lymphocytes 4.17E-09 BCL10, BCL3, CCL13, CCL5, CXCL10, 
ICAM1, IER3, VCAM1 
Quantity of phagocytoes 1.02E-08 BID, CCL13, CD47, CXCL10, FGF7, 
ICAM1, IRF1, MIES1(-), NFKB2, PLAT, 
SMAD3, TRL4(-) 
Immune response 3.79E-08 BCL10, BCL3, BID, CCL13, CCL5, 
CD47, CDKN1A, CXCL10, HLA-C, 
ICAM1, IER3, IL1RL1, IRF1, JUNB, 
NDRG1, NFATC4, NFE2L1, NFKB2, 
PDGFB, PNKD, RIPK2, SMAD3, 
TC1RG1, TLR4(-), TNFAIP3, VCAM1, 
ZPF36 
CD4 T-cell response 3.95E-08 BCL3, CCL13, CCL5, CXCL10, ICAM1, 
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IL1RL1, IRF1, RIPK2, TLR4(-) 
Inflammation 1.10E-07 BID, CCL13, CCL5, CD47, CXCL10, 
ICAM1, IL1RL1, JUNB, NFE2L1, PNKD, 
SMAD3, TLR4(-), TNFAIP3, VCAM1, 
ZPF36 
CD4 T-cell response of 
organism 
1.34E-07 BCL3, CCL13, CCL5, CXCL10, IL1RL1, 
IRF1, TLR4(-) 
Activation of leukocytes 5.82E-07 BCL10, BCl3, BID, CCL13, CCl5, CD47, 
CDKN1A, CXCL10, HLA-C, ICAM1, 
ILR1L1, NDRG1, NFKB2, SMAD3,  
TLR4(-), VCAM1 
T-cell development 4.10E-10 BBC3, BCL10, BID, BMP4(-), CCL13, 
CCL5, CD47, CDKN1A, HLA-C, 
ICAM1, ID1(-), IER3, ILR1L1, IRF1, 
JUNB, LIF, RIPK2, DMAD3, TLR4(-), 
TRAF1 
Apoptosis of T lymphocytes 4.26E-08 BBC3, BCL10, BCL3, BID, BMP4(-), 
CCL13, CCL5, CD47, CDKN1A, 
ICAM1, IER3, TRAF1 
Differentiation of T 
lymphocytes 
9.44E-06 BCL3, BMP4(-), HLA-C, ICAM1, ID1(-
), ILR1L1, IRF1, JUNB, LIF, RIPK2, 
SMAD3 
Chemotaxis of Th1 cells 1.09E-05 CCL13, CCL5, CXCL10 
Recruitment of T lymphocytes 1.09E-05 CCL13, CCL5, CXCL10, ICAM1, 
VCAM1 
Differentiation of helper T 
lymphocytes 
3.00E-05 BCL3, ICAM1, ILR1L1, IRF1, JUNB, 
RIPK2, SMAD3 
NK cell migration 8.41E-05 CCL13, CCL5, CXCL10, VCAM1 
 
 
 
 
 
As anticipated, the functional annotations assigned by IPA to the genes up-or down- 
regulated by TNF-α were associated with both the inflammatory and immune response, 
with many genes, such as the chemokines CCL13, CCL5 and CXCL10 associated with 
many of the different functions identified by the software. It should also be noted that 
some of the greatest fold changes were also associated with these genes. For example, 
CCL13 was up-regulated 5.5-fold, which is much higher than any of the genes activated 
by IR (see Table 5.3). Moreover, as expected, a number of these genes are also known 
to regulated by NF-κB, when cross-referenced with the website http://www.bu.edu/nf-
kb/the-gilmore-lab/. These include those previously mentioned, such as CXCL10 (Hein 
et al., 1997), IRF1 (Harada et al., 1994, Robinson et al., 2006), JUNB (Brown et al., 
1995), and VCAM1 (Iademarco et al., 1992), as well as others including CCL5 
Table 5.10: Functional annotations associated with the inflammatory and immune 
responses assigned by IPA. Summary of the functional annotations from the IPA 
software, the associated molecules and p-values (-) denotes a gene which was down-
regulated 2 hours after treatment with 10 ng/ml TNF-α 
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(Wickremasinghe et al., 2004), RIPK2 (Matsuda et al., 2003), TRAF1 (Schwenzer et al., 
1999) and BCL3 (Brocke-Heidrich et al., 2006), along with many of the other genes 
listed in Table 5.10. 
 
Both TRAF1 and BCL3 are associated with the activation of NF-κB, and the subsequent 
activation or repression of gene transcription. The former is a TNF-receptor associated 
factor known to mediate the signals from the cytokine receptor to their downstream 
effectors, whilst the latter is a known co-activator for the NF-κB subunits p50 and p52 
(Perkins, 2007). There is a large body of literature which suggests that the activation of 
NF-κB is known to up-regulate the transcription of genes which encode proteins related 
to the NF-κB activation pathway, and many of these are known to be vital for both the 
inflammatory and immune responses. For example, NFKB2 (which encodes the p100 
NF-κB subunit precursor protein) is shown to be up-regulated 1.6-fold following 
treatment with TNF-α, in these p65+/+ MEFs (Table 5.8), and the IPA software package 
assigns it to functions associated with the immune response and the activation of 
leukocytes (Table 5.10). Once again, it is a known NF-κB target gene (Lombardi et al., 
1995). Furthermore, the gene (NFKBIE) which encodes the inhibitor of kappaB (IKK) 
subunit IKKε protein is also shown be up-regulated 2.1-fold (Table 5.8), highlighting 
the complex feedback loops associated with the activation of NF-κB and associated 
pathway components. 
 
IPA software generates networks based on the transcriptional response observed, and it 
is perhaps unsurprising that the network it has produced from the gene list in Table 5.8, 
is one which highlights the complex cross-talk of both the activation of NF-κB and 
immunological signalling (Figure 5.8). This shows the genes up- (in red) or down- (in 
green) regulated by TNF-α that are associated with gene expression, antigen 
presentation and immunological cell signalling.  
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This network diagram shows that NF-κB signalling is vital for a functional 
inflammatory and immune response within a cell, and once again highlights how 
challenging drug discovery is in the context of the inhibition of NF-κB.  It shows that 
the activation of NF-κB by an inflammatory stimulus, such as TNF-α, is essential for 
the transcription of numerous pro-inflammatory cytokines, which are known to function 
primarily in the host immune response (Table 5.10). Therefore, complete or global 
inhibition of NF-κB may have a detrimental effect on the cell, as this may result in the 
inhibition of these genes known to have vital roles in the inflammatory response. Hence, 
it is vital to assess the effect of the PARP inhibitor, on the transcription of these 
inflammatory response genes following TNF-α, in order to determine whether the use of 
a PARP inhibitor is a viable therapeutic strategy when targeting NF-κB, as suggested by 
the previous data in Chapter 4. 
 
 
Figure 5.8: Genes associated with gene expression, antigen presentation and 
immunological cell signalling. Canonical network generated by IPA with genes that 
were up-regulated (shown here in red) or down-regulated (shown here in green) in p65+/+ 
MEFs 2 hours after  treatment with 10 ng/ml TNF-α 
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5.4.4 Differentially expressed genes 2 hours following treatment with TNF-α versus 
TNF-α in combination with AG-014699 
The data in Chapter 4 of this thesis has shown that the PARP inhibitor, AG-014699, had 
no effect on TNF-α-induced NF-κB DNA binding or NF-κB-dependent gene 
transcription (measured using a luciferase reporter assay in p65+/+ MEFs) whereas 
PARP-1 siRNA inhibited TNF-α-induced DNA binding and luciferase activity in the 
same cells. These data indicated that PARP-1 protein, but not its enzymatic activity was 
important in activating NF-κB following the inflammatory stimulus. However, these 
data also showed that AG-014699 attenuated the observed IR-induced NF-κB DNA 
binding and transcriptional activation in the p65+/+ MEFs, suggesting that the PARP 
inhibitor would be a viable therapeutic strategy in inhibiting DNA-damage-induced NF-
κB, which is known to drive therapeutic resistance in cancer (Prasad et al., 2010), 
without comprising the vital inflammatory functions of the transcription factor. This 
hypothesis therefore warranted much further testing, using the array based approach 
within this chapter. A small number of genes have been shown to be induced by IR, and 
this induction was abrogated in the presence of AG-014699 (Table 5.7). A number of 
the genes up-regulated by TNF-α treatment alone (Table 5.8) were associated with the 
inflammatory and immune responses, hence it was vital to determine the expression of 
these genes was altered in the presence of AG-016499. In order to do this it was decided 
to directly compare TNF-α treated p65+/+ MEFs with p65+/+ MEFs treated with a 
combination of TNF-α and AG-014699. 
 
Genespring GX 11 was utilised by Dr Dan Swan in order to generate to lists of genes 
differentially expressed following treatment with 10 ng/ml TNF-α, compared with TNF-
α in combination with AG-014699. Table 5.11 details a list of genes differentially 
expressed following treatment with TNF-α + AG-014699 as well as the 
accession/identification number and the fold change.  
Gene Symbol ID Fold change 
Family with sequence similarity 
165, member B 
FAM165B NM_138743.2 -1.205 
Nicastrin NCSTN NM_021607.2 1.226 
Transducin (beta)-like 1X linked TBL1X NM_0206301.2 -1.477 
 
 
 
Table 5.11: Differentially expressed genes 2 hours following treatment with TNF-
α + AG-014699 in p65+/+ MEFs, compared with TNF-α alone 
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Table 5.11 shows that there were only three genes differentially expressed in the 
presence of AG-014699, when compared with TNF-α alone. This therefore suggests that 
AG-014699 in combination with TNF-α has no effect on any of the inflammatory or 
immune response associated genes compared with TNF-α, thus supporting the data in 
Chapter 4, which showed that AG-014699 had no effect on TNF-α-induced NF-κB 
DNA binding or NF-κB-dependent gene transcription. This should be confirmed using 
qRT-PCR, to assess the effect of PARP-1 siRNA on known NF-κB regulated genes 
which were induced in this this array study. Therefore, a selection of NF-κB-dependent 
inflammatory and immune response genes, including CCL5 and CXCL10, which 
showed large fold changes following TNF-α treatment in the p65+/+ MEFs, were chosen 
for further investigation in this manner. These are detailed in section 5.4.9 
The three genes identified as being differentially expressed when comparing TNF-α 
treated p65+/+ MEFs and TNF-α in combination with the PARP inhibitor, AG-014699 
included the TBL1X gene, which encodes the transducin β-like 1X-linked protein. Array 
data indicated that transcription was decreased in the presence of AG-014699. A related 
protein family member, transducin β-like protein 1 (TBL1) has sequence similarity with 
F-box and WD-40-domain containing proteins (Guenther et al., 2000, Li et al., 2000), 
and is reported to play a role in the ubiquitin-conjugating/19S proteosome complex that 
mediates the exchange of co-repressors for co-activators by some nuclear receptors and 
transcription factors, including NF-κB (Perissi et al., 2004). Most recently, one group 
reported that TBL1 was required for the recruitment of NF-κB p65 to NF-κB target 
gene promoters, using TBL1 siRNA. Moreover, this group illustrated that TBL1 
knockdown in the MDA-MB-231 breast cancer cell line decreased invasion through 
inhibition of NF-κB-dependent gene transcription (Ramadoss et al., 2011). 
Another gene, NCSTN, which encodes the nicistrin protein, was up-regulated in the 
presence of AG-014699, compared with TNF-α alone. Nicastrin is part of the gamma 
secretase protein complex, along with presenilin, anterior pharynx-defective 1 (APH-1), 
and presenilin enhancer 2 (PEN-2). Together these proteins are involved in processing 
amyloid precursor protein (APP) to the short Alzheimer's disease-associated peptide 
amyloid beta (Kaether et al., 2006). Presenilin is catalytically active subunit, whereas 
nicastrin promotes the maturation and proper trafficking of the other proteins in the 
complex, all of which undergo significant post-translational modification before 
becoming active in the cell (Zhang et al., 2005b). 
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5.4.5 Differentially expressed genes 8 hours following treatment with IR  
One of the main aims of this chapter was to assess the different types, and functions of 
the genes up- or –down-regulated following treatment with either IR or TNF-α at the 8 
hour timepoint. This time-point was chosen because previous data, presented in chapter 
4, using a luciferase reporter assay, found that NF-κB-dependent gene transcription was 
maximal following either IR or TNF-α at this timepoint. Data obtained at the early (2 
hour) timepoint during this array study (section 5.4.3) has shown that, in concordance 
with the literature, TNF-α induced the transcription of many genes associated with the 
induction of inflammatory- or immune-responses (Pahl, 1999). Interestingly, the genes 
regulated following treatment with IR at the 2 hour timepoint were in the most part 
associated with cellular assembly and organisation, therefore it would be interesting to 
determine whether the expression of these genes is still up-regulated 8 hours following 
IR treatment, or whether others involved in new cellular process and pathways are 
affected.  
In order to do this, the array data received from the Cambridge Genomics Service was 
input into Genespring GX 11 by Dr Dan Swan in order to generate to lists of genes 
differentially expressed 8 hours following treatment with 10 Gy IR, compared with 
controls. Table 5.12 details a list of genes differentially expressed following treatment 
with IR as well as the accession/identification number and the fold change. 
Gene Symbol ID Fold change 
Amiloride-sensitive cation channel 2, 
neuronal 
ACCN2 NM_009597.1 -1.305 
Acyl-CoA synthetase family member 
3 
ACFS3 NM_144932.3 -1.249 
Acyl-CoA synthetase long chain 
family member 3 
ACSL3 NM_028817.2 1.260 
Acidic nuclear phosphoprotein 32 
family member A 
ANP32A NM_009672.2 1.254 
Rho GTPase activating protein 18 ARHGAP18 NM_176837.2 1.203 
Aurora kinase B AURKAB NM_011496.1 1.251 
Chromosome 20 open reading frame 
194 
C20orf194 NM_029432.1 -1.237 
Chromosome 5 open reading frame 
13 
C5orf13 NM_053078 1.320 
Cell division cycle 20 homolog CDC20 NM_023223.1 1.293 
Cyclin dependent kinase inhibitor 3 CDKN3 NM_919022.2 1.228 
Cellular retinoic acid binding protein 
2 
CRABP2 NM_007759.2 -1.239 
Cullin 7 CUL7 NM_025611.5 1.250 
Dickkopf homolog 3 DKK3 NM_015814.2 1.236 
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Ecotrophoic viral integration site 2A EVI2A NM_010161.3 -1.413 
Family with sequence similarity 104, 
member A 
FAM104A NM_138598.5 1.221 
Histone cluster 1, H1c HIST1H1C NM_015768 1.846 
Histone cluster 1, H2bk HIST1H2BK NM_023422.3 1.408 
Histone cluster 1, H2be HIST1H2BE NM_178195.1 1.202 
Major histocompatibility complex, 
class 1C 
HLA-C NM_010380.3 -1.236 
Meis homobox 2 MEIS2 NM_010825.3 1.249 
Nuclear autoantigenic sperm protein NASP NM_016777.2 1.204 
Neuroblastoma, suppression of 
tumorigenicity 1 
NBL1 NM_008675.1 -1.224 
Nestin NES NM_016701.3 -1.305 
Nuclear respiratory factor 1 NRF1 NM_010938.3 1.313 
Osteoglycin OGN NM_008760.2 1.582 
Platelet derived growth factor 
receptor alpha polypeptide 
PDGFRA NM_011058.2 1.259 
Prolactin family 2, subfamily C, 
member 2 
Prl2cl NM_011118.1 -1.295 
Ras associated domain family 
member 1 
RassF1 NM_019713.3 -1.368 
Retinoblastoma binding protein 4 RBBP4 NM_009030.3 1.227 
Structural maintenance of 
chromosomes 4 
SMC4 AK10848 1.569 
Sorting nexin 16 SNX16 NM_099068.2 1.271 
Stromal antigen 1 STAG1 NM_009282.3 1.234 
Ubiquitin-like with PHD and ring 
finger domains 1 
UHRF1 NM_010931.2 1.239 
Exportin 4 XPO4 NM_20506.1 -1.203 
Zinc finger protein36, C3H type-like 
1 
ZFP36L1 NM_007564.2 1.318 
 
 The gene list generated from the differentially expressed genes 8 hours after treatment 
with IR in Table 5.11 contains a very different list of genes compared with those 
regulated 2 hours post IR treatment (section 5.4.1). There are only four genes which are 
present in both lists; NASP, XPO4, SMC4 and CDC20. Interestingly, CDC20 was 
identified as a potential gene of interest and selected for future study previously (section 
5.4.2), due the effects observed following treatment with AG-014699. Two hours 
following treatment with IR, CDC20 expression was up-regulated 1.5-fold, and this up-
regulation was abrogated in the presence of AG-014699. It will be interesting to see 
whether this is also the case at the later, 8 hour, timepoint.  
SMC4, the gene which encodes the protein structural maintenance of chromosomes 4 
was up-regulated 1.6-fold at the late timepoint and 1.4-fold at the early timepoint. This 
Table 5.11: Differentially expressed genes 8 hours following treatment with IR in 
p65+/+ MEFs, compared with untreated controls 
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gene is known to be involved in cellular assembly and organisation and was assigned 
such functional annotations by the IPA analysis used at on the IR-early time-point gene 
lists. It does not appear that any of the other genes assigned these functions are 
differentially expressed in the list in Table 5.11. AURKA was up-regulated at the 2 hour 
timepoint and interestingly, AURKB, which encodes the aurora kinase B protein is up-
regulated, although modestly at 1.3-fold, at 8 hours after IR treatment in the p65+/+ 
MEFs. This protein is also associated with cellular organisation and assembly. 
In order to gain insight into the other canonical pathways and processes involved with 
the genes in Table 5.11, the list was uploaded into IPA software by Dr Dan Swan, as 
previously stated in section 5.3.4.2. Once again, the network associated with cellular 
assembly and organisation, DNA replication, recombination and repair, and the cell 
cycle were identified by the software. Figure 5.9 shows the network generated by IPA 
in this case.  
 
 
 
 
Interestingly, many of these genes were also associated with cellular proliferation and 
were assigned this functional annotation by the IPA software package. These are listed 
in Table 5.12. The significance of the association between the molecules within the data 
Figure 5.9: Genes associated with cellular assembly and organisation, DNA 
replication, recombination and repair, and the cell cycle. Network generated by 
IPA with genes that were up-regulated (shown here in red) or down-regulated 
(shown here in green) in p65+/+ MEFs 8 hours after treatment with 10 Gy IR 
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set and the canonical pathway/process was measured, by the software algorithms, using 
a Fisher’s exact test to calculate a p-value determining the probability that the 
association between the genes in the dataset and the canonical pathway/process is not 
explained by chance alone.  
Functional Annotation P value Molecules 
Cellular proliferation 2.91E-03 ANP32A, AURKA, C5orf13, CDC20, 
CDKN3, CUL7(-), NASP, NRF1, 
PDGFRA, Prl2c1, RBBP4, UHRF1, 
ZFP36L1 
 
 
 
NF-κB is known to regulate genes involved in a number of cellular processes, including 
apoptosis, angiogenesis, metastasis and cellular proliferation (Ghosh and Karin, 2002). 
It is also known to contribute to therapeutic resistance (Prasad et al., 2010). Hence, it is 
unsurprising that, following IR, the genes which are up-regulated are associated with 
cell proliferation. It is plausible that these cells are evading cell death by inducing the 
transcription of a number of genes with known roles in cell proliferation, in response to 
the DNA damaging agent. Two of the genes associated with cell proliferation in Table 
5.12 are known to be regulated by NF-κB; PDGFRA (Khachigian et al., 1995) and 
RBBP4 (Pacifico et al., 2007). Therefore, it is possible some of the others listed could 
perhaps be novel genes regulated by NF-κB following IR. 
 
5.4.6 Differentially expressed genes 8 hours following treatment with IR versus IR in 
combination with AG-014699 
It was decided to directly compare IR treated p65+/+ MEFs with p65+/+ MEFs treated 
with a combination of IR and AG-014699 harvested at the 8 hour timepoint. A number 
of the genes which were up-regulated 8 hours after with IR treatment were associated 
with cellular assembly and organisation, and also cell proliferation. Hence, it was 
important to assess the expression of these genes, and others following IR with co-
incubation with the PARP inhibitor, AG-014699.  Data in section 5.4.2 of this array 
study showed that there were a number of genes up-regulated 2 hours after IR, in which 
the effects seen were attenuated in the presence of AG-014699 at this timepoint. 
Therefore, it was essential to determine whether the same effects were seen with the any 
Table 5.12: Functional annotations associated with proliferation assigned by IPA 
Summary of the functional annotations from the IPA software, the associated molecules and 
p-values (-) denotes a gene which was down-regulated 8 hours after treatment with 10 Gy 
IR 
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of the genes listed in section 5.4.5, which explored genes regulated 8 hours after IR 
treatment.  Dr Dan Swan used Genespring GX 11 software in order to generate to a list 
of genes differentially expressed 8 hours following treatment with 10 Gy IR, compared 
with 10 Gy IR in combination with AG-014699. These genes are listed in Table 5.13 
along with the accession/identification number and the fold change.  
Gene Symbol ID Fold change 
Bcl-2 binding component 3 BBC3 NM_133234.1 1.305 
Cell division cycle 20 homolog CDC20 NM_023223.1 -1.296 
Prolactin family 2, subfamily C, 
member 2 
Prl2cl NM_011118.1 1.260 
 
Table 5.13 shows that there were only three genes which were identified as being 
differentially expressed when comparing cells harvested 8 hours after treatment with IR 
and those harvested 8 hours after treatment of IR in combination with AG-014699. One 
of these genes, CDC20 was up-regulated 1.3-fold 8 hours after treatment with IR, and 
then array data showed that the presence of AG-014699 resulted in the gene being 
down-regulated 1.3-fold. This gene was also identified as a potential gene of interest in 
section 5.4.2, when a similar regulation of the gene was observed 2 hours after IR 
treatment. The Prl2c1 gene which encodes the prolactin family 2, subfamily C, member 
2 protein is down-regulated 1.3-fold 8 hours after treatment with IR, and then array data 
showed that the presence of AG-014699 resulted in the gene being up-regulated 1.3-
fold, however there is little literature on this gene, however it appears to be primarily 
murine. 
The fold changes observed 8 hours after IR (Table 5.11, section 5.4.5) were very subtle. 
Genes associated with cellular assembly and organisation, including AURKB and 
CDC20 were up-regulated following treatment with IR (1.2-fold and 1.3-fold, 
respectively). The expression of CDC20 was inhibited when p65+/+ cells were pre-
treated with AG-014699 prior to IR treatment at this timepoint. This therefore suggests 
that these genes may be regulated by NF-κB following DNA damage, and indicate that 
this gene, in particular requires further validation using qRT-PCR, especially as this 
mirrors the regulation observed with CDC20 at the earlier (2 hour) timepoint.  
Interestingly, the gene that encodes aurora kinase A was up-regulated 2 hours after IR 
treatment whereas the gene which encodes the aurora kinase B protein was up-regulated 
Table 5.13: Differentially expressed genes 8 hours following treatment with IR + 
AG-014699 in p65+/+ MEFs, compared with IR alone 
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8 hours after IR treatment. The Aurora kinases, A, B and C, are highly conserved 
mitotic regulators. The ‘polar’ kinase, Aurora A, is required for biopolar spindle 
assembly and therefore localizes to spindle poles and the centrosome during mitosis. 
The ‘equatorial’ kinase, Aurora B, first localizes to the centromeres and the 
kinetochores during the early stages of mitosis acting as a chromosome passenger (Keen 
and Taylor, 2004).  Small molecule Aurora kinase inhibitor studies showed that Aurora 
B function was vital for checkpoint signaling following checkpoint activation (Biggins 
and Murray, 2001, Ditchfield et al., 2003, Hauf et al., 2003). Hence, as aurora kinase A 
was identified due to the down-regulation of the gene in presence of AG-014699 at the 
early timepoint, it was decided to also further investigate aurora kinase B by qRT-PCR. 
A full list of the gene chosen for further study is in section 5.4.9. 
5.4.7 Differentially expressed genes 8 hours following treatment with TNF-α 
Once Genespring GX 11 and IPA had been used to assess the different types, and 
functions of the genes up- or –down-regulated 8 hours after treatment with IR, these 
software packages were used again, by Dr Dan Swan, to determine the types or genes 
and networks regulated 8 hours after treatment with 10 ng/ml TNF-α in the p65+/+ 
MEFs. Data obtained at the early (2 hour) timepoint during this array study (section 
5.4.3) has shown that, in concordance with the literature, TNF-α induced the 
transcription of many genes associated with the induction of inflammatory- or immune-
responses (Pahl, 1999). Therefore it would be interesting to determine whether the 
expression of these genes is still up-regulated 8 hours following TNF-α treatment, or 
whether others involved in new cellular process and pathways are affected. Table A.1, 
which contains a list of genes of over 400 genes differentially expressed following 
treatment with TNF-α, as well as the accession/identification number and the fold 
change, is in Appendix A.  
 
IPA pathway analysis software showed (Figure 5.9 and Table 5.12) that the networks 
functions associated with the genes differentially expressed 8 hours after treatment with 
IR were cellular assembly and organisation, and also cellular proliferation. Therefore, it 
was important to perform the same analysis with the gene list (Table A.1) generated 8 
hours after treatment with TNF-α using IPA software, in order to determine which 
pathways and cellular processes were involved with the differentially expressed genes 
following this stimulus. It was perhaps unsurprising that here the top networks and 
functional annotations assigned to the list of genes regulated by TNF-α, 8 hours after 
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treatment, were also associated with the inflammatory response and the cell mediated 
immune response. A summary of the functional annotations generate by the IPA 
software from the list of genes in Table A.1, the associated molecules and p-values are 
shown in Table 5.14. Table 5.14 details the genes assigned to functional annotations 
associated with the cell mediated immune response by IPA. The significance of the 
association between the molecules within the data set and the canonical 
pathway/process was measured, by the software algorithms, using a Fisher’s exact test 
to calculate a p-value determining the probability that the association between the genes 
in the dataset and the canonical pathway/process is not explained by chance alone.  
Functional annotation P value Molecule 
Immune response 9.75E-09 Abcb1b, ASS1, BCL211, C3, CASP4, CCL13, 
CCL17, CCL5, CCL7, CD151, CD74, CDKN1A, 
CXCL10, CXCL2, DCN, EGIR3(-), F2R(-), FAS, 
FOS(-), GBP2, GRN(-), HBP1(-), HADC5(-), 
HLA-B, HLA-C, HLA-G, IER3, IFNGR2, IL1RL1, 
IRF1, ITGBS(-), MMP9, MRC1, NFATC4, 
NFKB2, NFKBIA, NUPR(-), PLSCR1, PML(-), 
PNKD, PPARD, PPBP, PSMB10, PSMBB, 
PSME1, PTPN22, RAP1GAP(-), RELA, RELB, 
SLC11A1, SOCS2, SPHK1(-), SPON2(-), SPP1, 
STAB1(-), TAPBP, TLR4(-), TNC, TNFAIP3, 
TNFRSF11B, TNFRSF9, WAS1(-) 
Activation of antigen 
presenting cells 
1.82E-05 C3, CCL5, CCL7, CD74, CXCL10, FAS, HBP1(-
),. HLA-C, IL1RL1, PSMBB, PSME1, RELB, 
SLC11A1, SPON2(-), TLR4(-) 
Infiltration of 
granulocytes 
2.61E-05 C3, CCL5, CXCL10, CXCL2, F2R(-), FAS, 
IL1RL1, NFKBIA, PPBP, RELA, SPP1(-), TLR4(-
), TNFAIP3, TNFRSF9 
Activation of 
leukocytes 
4.48E-05 C3, CCL5, CCL13, CCL17, CCL7, CD74, 
CDKN1A, CXCL10, EGR3(-), FAS, FOS, HBP1(-
), HDAC5(-), HLA-C, IL1RL1, NFKB2, PSMBB, 
PSME1, PTPN22, RELA, RELB, SLC11A1, 
SOCS2, SPON2(-), SPP1(-), TLR4(-), TNC, 
TNFRSF9 
Inflammation 8.18E-05 C3, CASP4, CAV1(-), CCL13, CCL5, CXCL10, 
CXCL2, F2R(-), FAS, GRN(-), IL1RL1, MMP9, 
NFKBIA, PNKD, PPARD, RELA, RELB, 
SLC11A1, SPHK1, SPP1(-), TLR4(-), TNFAIP3, 
TNFRSF9 
 
 
 
Table 5.14: Functional annotations associated with cell mediated immune response 
assigned by IPA. Summary of the functional annotations from the IPA software, the 
associated molecules and p-values (-) denotes a gene which was down-regulated 8 hours 
after treatment with 10 ng/ml TNF-α 
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As anticipated, the functional annotations assigned by IPA to the genes up-or down- 
regulated by TNF-α were associated with both the inflammatory and immune response, 
with many genes, such as the chemokines CCL13, CCL5, CCL7, CCL17, CXCL2 and 
CXCL10 associated with many of the different function identified by the software. It 
should also be noted the some of the greatest fold changes were also associated with 
these genes, as was the case with chemokines up-regulated 2 hours after treatment with 
TNF-α. At this later tiempoint, the chemokine CCL5 was up-regulated 6.5-fold. It is 
also noteworthy that the expression of the three chemokines which was up-regulated 2 
afters after TNF-α treatment; CCL13, CCL5 and CXCL10, remained high 8 hours after 
treatment with this stimulus. Moreover, as expected a number of these genes are also 
known to regulated by NF-κB, when cross-referenced with the website 
http://www.bu.edu/nf-kb/the-gilmore-lab/. These include those mentioned in section 
5.4.4, as well as others including, the complement pathway component, C3, which is 
known to be essential for the cellular immune response (Moon et al., 1999), and also 
FAS and CASP4, both of which are known to have pro-apoptotic roles (Chan et al., 
1999, Schauvliege et al., 2002). 
 
As previously mentioned (section 5.1), the TNF-α-induced NF-κB response is known to 
be very important in the induction of cell death through the induction of genes such as 
FAS and CASP4.  Once again, Dr Dan Swan used IPA software to generate networks 
based on the transcriptional response observed. In this particular case the network 
produced from the gene list in Table A.1, highlights the activation of cell death and 
immunological signalling (Figure 5.10). Hence it is important to follow up these results 
by assessing the effect of AG-014699 or PARP-1 siRNA on inflammatory genes such as 
FAS, following TNF-α in the qRT-PCR validation of these data. 
 
The network in Figure 5.10 and the gene list in Table A.1 support the data obtained at 
the early timepoint following TNF-α treatment, in that there appears to be an up-
regulation of the genes encoding the NF-κB subunits and pathway components 8 hours 
after TNF-α treatment. For example, at this later timepoint NFKB2 is shown to be up-
regulated 1.7-fold following treatment with TNF-α, whilst RELB is shown to up-
regulated 2-fold, once again highlighting the complex feedback loops associated with 
the activation of NF-κB and associated pathway components. 
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Interestingly, the gene PLK2, which encodes the polo-like kinase 2 protein is up-
regulated 1.5-fold 8 hours after treatment with TNF-α whereas the gene which encodes 
its family member polo-like kinase 1 was shown to be up-regulated 1.6-fold 2 hours 
after IR treatment. In the case of the latter the up-regulation observed was abrogated in 
the presence of AG-014699, suggesting that PLK1, like PLK3 (Li et al., 2005), could be 
an NF-κB target gene. Therefore, further investigation into the induction of PLK2 using 
qRT-PCR should be undertaken. 
 
5.4.8 Differentially expressed genes 8 hours following treatment with TNF-α versus 
TNF-α in combination with AG-014699 
The data in Chapter 4 of this thesis has shown that the PARP inhibitor, AG-014699, had 
no effect on TNF-α-induced NF-κB DNA binding or NF-κB-dependent gene 
transcription, measured using a luciferase reporter assay in p65+/+ MEFs, whereas 
PARP-1 siRNA inhibited TNF-α-induced DNA binding and luciferase activity in the 
same cells. Indicating that PARP-1 protein, but not its enzymatic activity was important 
Figure 5.10: Genes associated with activation of cell death and immunological 
signalling. Canonical network generated by IPA with genes that were up-regulated 
(shown here in red) or down-regulated (shown here in green) in p65+/+ MEFs 8 hours 
after treatment with 10 ng/ml TNF-α 
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in activating NF-κB following the inflammatory stimulus. However, these data also 
showed that AG-014699 attenuated the observed IR-induced NF-κB DNA binding and 
transcriptional activation in the p65+/+ MEFs, suggesting that the PARP inhibitor would 
be a viable therapeutic strategy in inhibiting DNA-damage-induced NF-κB, which is 
common in cancers, and is known to mediate therapeutic resistance (Prasad et al., 
2010), without comprising the vital inflammatory functions of the transcription factor. 
This hypothesis was therefore tested at an early timepoint (2 hours) following treatment 
with TNF-α, (section 5.4.4) and it was found that that there were only three genes 
differentially expressed in the presence of AG-014699, when compared with TNF-α 
alone. This therefore suggests that AG-014699 in combination with TNF-α had no 
effect on any of the inflammatory or immune response associated genes compared with 
TNF-α, at this early timepoint, thus supporting the data in chapter 4. However, it was 
also important to test this hypothesis once more, at a later timepoint when the 
inflammatory gene expression was still found to be high (5.4.7). 
 
Genespring GX 11 was utilised by Dr Dan Swan in order to generate to lists of genes 
differentially expressed 8 hours following treatment with 10 ng/ml TNF-α, compared 
with TNF-α in combination with AG-014699. Table 5.15 details a list of genes 
differentially expressed following treatment with TNF-α + AG-014699 as well as the 
accession/identification number and the fold change.  
 
Gene Symbol ID Fold change 
Post-GPI attachment to proteins 2 Pgap2 NM_145583.2 1.290 
Zinc finger, SWIM-type containing 3 ZSWIM3 NM_178375 -1.316 
 
 
 
Table 5.15 shows that there were only two genes differentially expressed in the presence 
of AG-014699, when compared with TNF-α, in cells harvested 8 hours after treatment 
with the cytokine. This therefore suggests that AG-014699 in combination with TNF-α 
has no effect on any of the inflammatory or immune response associated genes 
compared with TNF-α, thus supporting the data in Chapter 4, and section 5.4.4 of this 
chapter, which showed that AG-014699 had no effect on TNF-α-induced NF-κB DNA 
binding or NF-κB-dependent gene transcription. It is however to further confirm these 
data using qRT-PCR, and assess the effect of PARP-1 siRNA on known NF-κB 
Table 5.15: Differentially expressed genes 8 hours following treatment with TNF-α 
+ AG-014699 in p65+/+ MEFs, compared with TNF-α alone 
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regulated genes which were induced in this this array study. Therefore, a selection of 
NF-κB-dependent inflammatory and immune response genes, which showed large fold 
changes following TNF-α treatment in the p65+/+ MEFs, were chosen for further 
investigation in this manner. Some of these genes showed an up-regulation at both 
timepoints after TNF-α treatment, and others at either the early or late timepoint. These 
are all listed in section 5.4.9. 
5.4.9 Genes of interest identified for qRT-PCR validation 
Table 5.16 details the genes of interest identified from the microarray analysis 
performed by Dr Dan Swan using Genespring GX 11 and IPA. The reasons for 
choosing each gene is discussed in the relevant sections (5.4.1-8), but is also briefly 
explained in Table 5.16. 
Gene symbol Timepoint Reason 
AURKA 2 h  Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699 
AURKAB 8 h Up-regulated expression 8 hours after IR treatment. 
Interesting as associated family gene (AURKA) also 
up-regulated by IR 
BIRC6 2 h  Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699.  
IAP proteins are known to be NF-κB regulated 
following DNA damage (Stehlik et al., 1998, You et 
al., 1999) 
CCL5 2 h/8 h Up-regulated following TNF-α treatment, unaffected 
by AG-014699. Known NF-κB regulated gene 
(Wickremasinghe et al., 2004) Would PARP-1 siRNA 
alter TNF-α expression of this gene? 
CDC20 2 h/ 8 h Up-regulated expression 2 hours after IR treatment, 
which was abrogated is the presence of AG-014699 
CXCL10 2 h/8 h Up-regulated following TNF-α treatment, unaffected 
by AG-014699. Known NF-κB regulated gene (Hein et 
al., 1997) Would PARP-1 siRNA alter TNF-α 
expression of this gene? 
FAS 8 h Up-regulated following TNF-α treatment, unaffected 
by AG-014699. Known NF-κB regulated gene 
following TNF-α (Chan et al., 1999) Would PARP-1 
siRNA alter TNF-α expression of this gene? 
IRF-1 2 h Down-regulated expression 2 hours after IR treatment, 
which was reversed in the presence of AG-014699. Up-
regulated following TNF-α, but unaffected by AG-
014699 after this stimulus. IRF1 is known to be NF-κB 
regulated following TNF-α, not DNA damage (Harada 
et al., 1994) 
JUNB 2 h Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699.  
Also up-regulated following TNF-α, but unaffected by 
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AG-014699 after this stimulus. JUNB is known to NF-
κB regulated following inflammatory stimuli, not DNA 
damage (Brown et al., 1995) 
PLK1 2 h Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699 
PLK2 8 h Up-regulated expression 8 hours after TNF-α 
treatment. Interesting as associated family gene (PLK1) 
was up-regulated by IR 
TNIP1 2 h/ 8 h Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699 
Up-regulated by TNF-α at both timepoints but 
unaffected by AG-014699 following this stimulus. 
Known NF-κB regulated gene following TNF-α 
(Heyninck et al., 1999)  
TOP2A 2 h Up-regulated expression 2 hours after IR treatment, 
which was abrogated in the presence of AG-014699 
 
 
5.4.10 qRT-PCR validation of microarray genes of interest 
In order to validate the microarray findings, the genes of interest (shown in Table 5.16, 
section 5.4.9) were also investigated using q-RT-PCR. Specifically, the induction or 
down-regulation of the chosen genes were assessed at the timepoints shown in Table 
5.16 following either 10 Gy IR or 10 ng/ml TNF-α in the presence or absence of the 
PARP inhibitor, AG-014699 in the p65+/+ MEFs. To further confirm whether the genes 
are truly regulated by NF-κB, siRNA targeting p65 or the pan IKK inhibitor, BAY11-
7082 (Mori et al., 2002), was assessed as a direct comparison to AG-014699. Existing 
data, presented in Chapter 4 of this thesis showed that the physical presence of the 
PARP-1 protein is vital for the activation of NF-κB following TNF-α, hence PARP-1 
siRNA or a non-specific (NS) control siRNA was also used in the qRT-PCR assays 
presented here. The knockdown of either p65 or PARP-1 in the p65+/+ MEFs were 
previously optimised (Chapter 3). 
 
This method is described in detail in section 2.10. For these assays; p65+/+ MEFs were 
seeded and left for 24 h to adhere prior to transfection with 50 nM p65, PARP-1 or NS 
siRNA (or vehicle control). Cells were incubated left for 48 h, and pre-treated with 
either 0.4 µM AG-014699 or 10 µM BAY11-7082, (or DMSO control) for 1 h prior to 
treatment with 10 Gy IR or 10 ng/ml TNF-α. Cells were then harvested at the timepoints 
stated in Table 5.16 and RNA extracted using the RNeasy kit. RNA was subsequently 
transcribed into cDNA using the High Capacity cDNA reverse transcription kit, 
Table 5.16: A list of the interesting genes identified from the microarray data, with 
brief justifications 
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according to manufacturers’ instructions. cDNA was then used in a qRT-PCR reaction 
using Taqman primers to confidently quantify the mRNA levels of either AURKA, 
AURKB, BIRC6, CDC20, CCL5, CXCL10, FAS, IRF1, JUNB, PLK1, PLK2, TNIP1, 
TOP2A and the housekeeping gene ACTN, which encodes the β-actin protein, in each 
sample. All results shown are the mean of three independent experiments. 
 
Table 5.17 briefly details the results from all of the qRT-PCR validation assays, and 
includes the fold change from the gene expression microarray, and also whether each 
gene was up- or down-regulated by either IR or TNF-α using qRT-PCR. Moreover, 
Table 5.17 the significance level (p value), obtained using unpaired Student’s t-tests, for 
any up- or down-regulation is also included. The effect of p65 siRNA, AG-014699, 
BAY11-7082 or PARP-1 siRNA is also explained, where relevant. In all cases the qRT-
PCR assays for the genes of interest that were validated have been included in 
Appendix A.  
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Gene Array fold change qRT-PCR fold change 
(IR) 
qRT-PCR fold change 
(TNF-α) 
Notes 
AURKA 2.2 (IR 2 h) 2 (p=0.0006) No change IR induced expression of AURKA significantly 
inhibited in the presence of BAY11-7082 
AURKB 1.2 (IR 8 h) No change No change AURKB not regulated by NF-κB following either 
stimuli 
BIRC6 1.2 (IR 2 h) 1.2 (p=0.027) No change IR induced expression of BIRC6 inhibited by p65 
siRNA, AG-014699, BAY11-7082 or PARP-1 siRNA, 
although this was not significant 
CCL5 3 (TNF-α 2 h) 
6.5 (TNF-α 8 h) 
No change at either 
timepoint 
5 (p<0.0001) (2 h) 
5.5 (p=0.0001) (8 h) 
TNF-α induced expression of CCL5 significantly 
inhibited by p65 siRNA, BAY11-7082 or PARP-1 
siRNA, but unaffected by AG-014699 at both 
timepoints 
CXCL10 3.7 (TNF-α 2 h) 
6 (TNF-α 8 h) 
No change at either 
timepoint 
6.5 (p=0.0005) (2 h) 
5.5 (p=0.0002) (8 h) 
TNF-α induced expression of CXCL10 significantly 
inhibited by p65 siRNA, BAY11-7082 or PARP-1 
siRNA, but unaffected by AG-014699 at both 
timepoints 
CDC20 1.5 (IR 2 h) 
1.3 (IR 8 h) 
1.4 (p=0.0016) (2 h) 
1.4 (p=0.0257) (8 h) 
No change at either 
timepoint 
IR induced expression of CDC20 significantly 
inhibited by p65 siRNA, AG-014699, BAY11-7082 or 
PARP-1 siRNA, at the 2 h timepoint 
FAS  3.6 (TNF-α 8 h) No change 2.4 (p=0.027) TNF-α induced expression of FAS inhibited by p65 
siRNA, BAY11-7082 or PARP-1 siRNA (not 
significant), but unaffected by AG-014699 
IRF1 -1.5 (IR 2 h) 
2.8 (TNF-α 2 h) 
-1.4 (p=0.0004) 2 (p=0.0003) Reduction in IRF1 mRNA observed following 
treatment with IR alone or in combination with p65 
siRNA or BAY11-7082, however IR in combination 
with AG-014699 or PARP-1 siRNA increased IRF1 
expression back to levels comparable to untreated 
controls. TNF-α induced expression of IRF1 inhibited 
by p65 siRNA, BAY11-7082 or PARP-1 siRNA, but 
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unaffected by AG-014699 
JUNB 1.6 (IR 2 h) 
1.9 (TNF-α 2 h) 
No change 1.6 (p=0.041) TNF-α induced expression of JUNB inhibited by p65 
siRNAor BAY11-7082(not significant), but unaffected 
by AG-014699or PARP-1 siRNA   
PLK1 1.6 (IR 2 h) 1.5 (p=0.0001) No change IR induced expression of PLK1 significantly inhibited 
by p65 siRNA, AG-014699, BAY11-7082 or PARP-1 
siRNA 
PLK2  1.5 (TNF-α 8 h) No change No change PLK2 not regulated by NF-κB following either stimuli 
TNIP1 1.6 (IR 2 h) 
2.8 (TNF-α 2 h) 
No change 2 (p=0.0046) TNF-α induced expression of TNIP1 inhibited by p65 
siRNA, BAY11-7082 or PARP-1 siRNA (not 
significant), but unaffected by AG-014699 
TOP2A 1.6 (IR 2 h) No change No change TOP2A not regulated by NF-κB following either 
stimuli 
 
 
 
 
 
 
 
 
 
    
 
 
Table 5.17: Summary of qRT-PCR validation assays 
Genes of interest identified from the gene expression microarray study, and the associated fold change from this study. Also the effect of either 
IR or TNF-α on these genes assessed using qRT-PCR and were relevant, the significance level (p value), obtained using unpaired Student’s t-
tests, for any up- or down-regulation is also included. The effect of p65 siRNA, AG-014699, BAY11-7082 or PARP-1 siRNA is also explained 
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5.5 Discussion 
Gene expression profiling was utilised here in order to assess any changes in gene 
expression in p65+/+ cells treated with IR versus cells treated with TNF-α, and 
furthermore to investigate the effect of the PARP inhibitor, AG-014699 on the 
transcriptional response to each agent. Two software packages, Genespring GX 11 and 
IPA were used by Dr Dan Swan at the Bioinformatics Service (Newcastle University) to 
aid in the identification of genes which were differentially expressed after treatment 
with either IR or TNF-α, and also assign functional information in the form of canonical 
pathways/processes which were affected by the transcriptional outcome of either agent.  
 
It is well documented that inflammatory cytokines, such as TNF-α and IL-1β, induce an 
NF-κB-dependent transcriptional response associated with the up-regulation of many 
genes known to be essential for the immune and inflammatory responses (Pahl, 1999), 
and the array data in sections 5.3.3 and 5.3.7 support this existing literature. The 
canonical pathways and processes identified by IPA analysis included networks 
associated with immunological signalling and functional annotations, such as those 
involved in the immune response or inflammation were assigned. Importantly, further 
computational analysis indicated that these genes, including many cytokines and 
chemokines, were unaffected by co-incubation with AG-014699, suggesting that PARP 
inhibition did not affect the vital inflammatory functions of NF-κB transcriptional 
activation following TNF-α stimulation. This supported that data in chapter 4 of this 
thesis which found that PARP-1 protein was required for the activation of NF-κB p65 
DNA binding and transcriptional activation following TNF-α treatment, whereas both 
PARP-1 protein and enzymatic activity were required for NF-κB activation following 
IR.  
 
However, in order to further confirm these data, qRT-PCR analysis was performed on a 
selection of genes including the cytokines CCL5 and CXCL10. In this case siRNA 
targeting either p65 or PARP-1 and the pan-IKK inhibitor BAY11-7082 (Mori et al., 
2002) were used as a direct comparison to the PARP inhibitor, AG-014699, to assess 
the effects these other treatment would have on NF-κB-dependent gene expression. It 
must be noted that both array and qRT-PCR data show that the inflammatory response 
genes were unaffected by treatment with IR at the dose tested here. Importantly, the 
qRT-PCR data shows an induction of the known NF-κB-dependent inflammatory 
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response genes, including CCL5 and CXCL10 following treatment with TNF-α,  
supporting the both the array data and existing literature (Hein et al., 1997, 
Wickremasinghe et al., 2004). These data also show that TNF-α induced expression of 
these genes is inhibited by either p65 siRNA or the pan-IKK inhibitor, BAY11-7082, 
which has been shown to inhibit NF-κB activation via inhibition of the IKK complex 
components (Mori et al., 2002), further confirming that these genes are regulated by 
NF-κB in response to TNF-α stimulation. Markedly, PARP-1 siRNA is found to inhibit 
the TNF-α-induced expression of CCL5 and CXCL10 whereas the PARP inhibitor, AG-
014699 had no effect, thus confirming the hypothesis that PARP-1 protein alone is 
essential for TNF-α-induced NF-κB activation perhaps facilitating a structural role in 
the NF-κB transcriptional complex. This is consistent with the work of Hassa et al., 
(2001), which illustrated how the physical presence of the PARP-1 C-terminal catalytic 
domain, but not its enzymatic activity, was required for PARP-1 and p300 to 
synergistically activate NF-κB-dependent transcription following either TNF-α or LPS 
(Hassa et al., 2001). 
 
The qRT-PCR data investigating the activation of CXCL10 following TNF-α illustrated 
that PARP-1 protein knockdown could inhibit the TNF-α-induced up-regulation of this 
gene, suggesting that physical presence of PARP-1 at the CXCL10 promoter facilitates 
the transcription of this particular gene. Interestingly, another group have reported that 
PARP-1 can regulate the transcription of known cytokines through sequence-specific 
binding to DNA regulatory elements. Amiri et al., (2006) found that inactive PARP-1 
could bind to a DNA element in the CXCL1 promoter and in this case act to block NF-
κB to an adjacent element, thus repressing the transcription in this case. Furthermore, 
they showed that activation of PARP-1 (as has been shown to occur by DNA damage, 
but not by TNF-α in Chapter 4 of this thesis), leads to a loss of PARP-1 binding and 
enhanced CXCL1 expression by virtue of increased access of NF-κB to the DNA (Amiri 
et al., 2006). Inactive PARP-1 in this case in the literature is analogous to the use of 
AG-014699 within this chapter, which was found to have no effect on a related family 
gene, CXCL10. This could be explained by the fact that two genes have related, but still 
distinct functions, as well as the fact that the data generated by Amiri and collegues was 
in a different cell line background, multiple myeloma, and it is well documented that 
NF-κB activation and consequently effects on gene transcription are very dependent on 
the stimulus and model system used. 
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The finding from the array study and the qRT-PCR analysis of key inflammatory 
cytokines has important implications for the wider use of AG-014699 in the inhibition 
of NF-κB activation for the treatment of cancer. These data have shown that the genes 
associated with the inflammatory response induced by NF-κB are unaffected by AG-
014699. NF-κB inhibition is an attractive target for cancer therapeutics however, global 
inhibition for example with an IKK inhibitor, may have adverse effects. The IKK 
complex has many known functions within the cell (Carrillo et al., 2004, Chariot, 2009), 
meaning that inhibition of NF-κB in this manner might be cytotoxic. Moreover, long-
term complete NF-κB inhibition may also increase the likelihood of immunodeficiency, 
since it plays a pivotal role in the innate and adaptive immune response, and can 
possibly delay bone marrow recovery due to some reports of chemotherapeutic induced 
apoptosis of hematopoietic progenitors (Grossmann et al., 1999, Turco et al., 2004). 
This could be even more of an issue in cancer patients which may already have a 
compromised immune system due to the nature of other therapeutic agents. The data 
here corroborate the data in Chapter 3 and 4 which suggested that blockade of DNA-
damage activated NF-κB by AG-014699 could represent a viable therapeutic strategy, 
since the data has demonstrated that the survival function of NF-κB can be directly 
inhibited without compromising other functions, such as the immune response. The 
gene expression profiling and and subsequent confirmation by qRT-PCR within this 
chapter have shown that the vital inflammatory responses, known to be regulated by 
TNF-α-induced NF-κB activation, are still intact following treatment with AG-014699.  
 
Interestingly, the array data here (sections 5.3.1 and 5.3.5) has shown that genes 
associated with cellular organisation and assembly, including those encoding the mitotic 
kinases, aurora kinase A (AURKA), aurora kinase B (AURKB), polo-like kinase 1 
(PLK1) and polo-like kinase 2 (PLK2), (as well as many others) were up-regulated 
following treatment with IR. These genes have not previously been shown to be 
regulated by NF-κB, and were thus investigated further within this study. AUKRA, 
PLK1 and also cell division cycle 20 (CDC20) were also investigated as these were up-
regulated in p65+/+ MEFs harvested after treatment with 10 Gy IR, and this affect was 
abrogated in the presence of AG-014699, suggesting that these might be novel NF-κB 
regulated genes following DNA damage. The associated kinases, AURKB and PLK2 
were up-regulated by IR and TNF-α, respectively, but unaffected by co-incubation with 
AG-014699 nonetheless these genes were investigated further due to their close 
functional relationships to other genes of interest. 
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Aurora kinase A is known to regulates a number of events from late S- to M-phase of 
the cell cycle, including centrosome maturation, separation and assembly, mitotic entry 
and exit, cytokinesis and bipolar spindle assembly (Berdnik and Knoblich, 2002, Hirota 
et al., 2003, Marumoto et al., 2003). Its kinase function is tightly regulated during the 
cell cycle, however overexpression or amplification of the AURKA gene is frequent in 
many tumour types (Goepfert et al., 2002, Sakakura et al., 2001, Tanaka et al., 1999b) 
and correlates with poor prognosis (Jeng et al., 2004). The oncogenic potential of 
AURKA activation was reported by Zhou et al., (1998) who showed that the gene had 
transforming abilities both in vitro and in vivo, and also induced multipolar mitotic 
spindles resulting in genomic instability (Zhou et al., 1998).  
 
Aurora kinase B is known to regulate kinetochore-microtubule attachment and also 
ensure faithful chromosome separation (Biggins and Murray, 2001). AURKB is also 
overexpressed in cancers including prostate, breast, lung and kidney (Katayama et al., 
1999) and is known to be associated with errors in chromosomal segregation and 
cytokinesis, and chromosomes lagging in metaphase, thus contributing to 
carcinogenesis (Ota et al., 2002). Therefore aurora kinase inhibitors are generating a lot 
of interest in the field of cancer therapeutics, and the array data here indicated that 
AURKA, in particular, might be regulated via NF-κB following DNA damage, and 
consequently inhibited using AG-014699. However, although the qRT-PCR data 
showed that AURKA was up-regulated 2-fold following IR, co-incubation with AG-
014699 did not inhibit the expression of this gene. Knockdown of p65 or PARP-1 also 
had no effect on the IR-induced expression of AURKA, but interestingly the pan-IKK 
inhibitor BAY11-7082 significantly decreased AURKA expression following IR. 
BAY11-7082 has been shown to inhibit all of the NF-κB subunits to some extent (Mori 
et al., 2002), and therefore it is plausible that AURKA is not a p65 target gene, but the 
target of perhaps of one of the one of the other NF-κB subunits. For example, E2F3a is 
known to be a target of c-Rel (Cheng et al., 2003). Another explanation for this 
phenomenon is that this is the result of an off target effect of BAY11-7082, which has 
been suggested previously (Mahadevan et al., 2011). This warrants further 
investigation, as discussed in section 5.6. 
 
The polo-like- and aurora- kinases are cell cycle regulated, and in particular play vital 
roles in promotion in M-phase. It is therefore possible that in this study IR has arrested 
these p65+/+ cells at the point, in late G2- or early M-phase of the cell cycle, where both 
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PLK1 and AURKA are known to be highest, thus accounting for the increased mRNA 
levels of both of these genes. This does not however explain the effects observed by 
treatment with p65 siRNA or AG-014699 in the case of PLK1, or BAY11-7082 in the 
case of AURKA. Nevertheless, it would be interesting to determine whether in this case 
IR has arrested these the p65+/+ MEFs at the timepoints chosen for this study, perhaps 
using FACs analysis. 
 
CDC20, a homolog of Saccharomyces cerevisiae cell division cycle 20 protein, is vital 
in controlling the spindle checkpoint (Fang et al., 1998). Mammalian CDC20 interacts 
with the anaphase-promoting complex/cyclosome (APC/C), and is involved in anaphase 
onset and late mitotic events (Fung and Poon, 2005). A number of groups have shown 
that overexpression of CDC20 at the mRNA level is common in cancer (Kidokoro et al., 
2008, Kim et al., 2005, Mondal et al., 2007). Furthermore, siRNA knockdown of 
CDC20 of various cancer cell lines resulted in a G2/M arrest and consequently growth 
arrest (Kidokoro et al., 2008). The array data here indicated that CDC20, might be 
regulated via NF-κB following DNA damage, and consequently inhibited using AG-
014699. The qRT-PCR support that array data in that they show that CDC20 is up-
regulated 2 hours after treatment with IR, and this up-regulation is attenuated by co-
incubation with either p65 siRNA, BAY11-7082, AG-104699 or PARP-1 siRNA. 
Therefore, these data strongly indicate that CDC20 is a novel NF-κB regulated gene 
following DNA damage at early timepoints. It should be noted that this phenomenon 
was not observed at the later, 8 hour, timepoint, as it had been in the array data. This 
warrants further investigation, and is discussed in section 5.6.  
 
The family of polo-like kinases are also attractive targets for cancer therapeutics with a 
number of compounds in pre-clinical and clinical development (Degenhardt and 
Lampkin, 2010). They are a family of serine-threonine kinases associated with many of 
the functions associated with mitosis not only through phosphorylation activities but 
also via protein-protein interactions (Golsteyn et al., 1995). Overexpression of PLK1 is 
common in cancer (Ito et al., 2004, Takahashi et al., 2003, Yamamoto et al., 2006), 
making it the main target for drug discovery at the moment, especially given that PLK1 
is only expressed in dividing cells (Golsteyn et al., 1995). Overexpression of PLK1 is 
known to promote proliferation and has also been described as oncogenic as it has the 
ability to promote chromosome instability and aneuploidy via the regulation of cell 
cycle checkpoints (Musacchio and Salmon, 2007). Importantly, another member of 
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polo-like kinase family, PLK3, has been shown to be regulated by NF-κB (Li et al., 
2005). The array data here indicated that PLK1, in particular might be regulated via NF-
κB following DNA damage, and consequently inhibited using AG-014699. The qRT-
PCR support that array data in that they show that PLK1 is up-regulated following 
treatment with IR, and this up-regulation is attenuated by co-incubation with either p65 
siRNA, BAY11-7082, AG-104699 or PARP-1 siRNA. Therefore, these data strongly 
indicate that PLK1 is a novel NF-κB regulated gene following DNA damage, and 
perhaps that through its inhibitory effects on NF-κB, AG-014699 is also reducing the 
DNA-damage-induced expression of the putative oncogene. This warrants further 
investigation, which is discussed in section 5.6.  
Although array analyses showed that 8 hours after IR or TNF-α the expression of 
AURKB and PLK2, respectively, was induced, this was not corroborated when using 
qRT-PCR analyses. The dose of IR given to these p65+/+ MEFs is very transient and it is 
well documented that the DNA damage response (DDR) is induced very quickly after 
treatment with this agent. For example, there have been a number of reports showing 
that the DDR is activated as quickly as 15 minutes or 1 hour after treatment with IR 
(Elliott et al., 2011). Therefore, the up-regulation observed in the array may perhaps be 
explained by the point of the cell cycle these cells were in at the time, as it has been 
demonstrated that the levels of the polo-like kinases oscillate during cell cycle 
progression (Golsteyn et al., 1995). 
 
Array analysis also indicated that genes associated with the protection against apoptosis, 
such as BIRC6, encoding one of IAP family proteins, are up-regulated by IR. This was 
consistent with other reports suggesting that associated genes were regulated by NF-κB 
following IR (Stehlik et al., 1998, You et al., 1999). Furthermore, the array data showed 
that the up-regulation of BIRC6 was attenuated in the presence of the PARP inhibitor 
AG-014699. These data were confirmed by the qRT-PCR validation assays, although 
the inhibition of IR-induced BIRC6 by co-incubation with either p65 siRNA, BAY11-
7082, AG-014699 or PARP-1 siRNA, was not statistically significant.  These data 
highlight that AG-014699 inhibits DNA-damage-induced NF-κB anti-apoptotic gene 
transcription, thus supporting the survival data presented with this inhibitor in chapter 3. 
 
NF-κB is also known to regulate genes associated with the induction of apoptosis, 
particularly following stimulation by TNF-α, and therefore it was important to 
determine whether AG-014699 was having an effect on these genes following treatment 
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with the cytokine. Previous reports have shown that TNF-α-induced NF-κB activation 
up-regulated the expression of the Fas receptor (Chan et al., 1999) and its ligand 
(Matsui et al., 1998), both of which are known induce apoptosis. Data from the gene 
expression profiling showed that the FAS gene was unaffected by treatment with IR 
alone, or in combination with AG-014699 but, that as expected, TNF-α induced the 
expression of the pro-apoptotic gene. Importantly the induction of this gene was 
unaffected in the presence of AG-014699. These data were also corroborated by the 
qRT-PCR validation, with TNF-α inducing the expression of FAS, and this induction 
being inhibited by co-incubation with p65 siRNA, BAY11-7082 or PARP-1 siRNA. 
Once again, AG-014699 had no effect, supporting the previous finding that PARP 
inhibition does not affect TNF-α-induced NF-κB-dependent gene transcription, and 
most markedly in this case, AG-014699 does not inhibit the induction of vital pro-
apoptotic genes.  
 
IRF1 is a nuclear transcription factor which is known to regulate genes associated with 
the inflammatory and immune responses (Kroger et al., 2002), and also genes which 
promote apoptosis, including the caspases 3, 7 and 8 (Bouker et al., 2005, Sanceau et 
al., 2000). Microarray data showed that IRF1 gene expression was up-regulated 
following TNF-α treatment (section 5.3.4) but down-regulated following treatment with 
IR (section 5.3.1). Validation using qRT-PCR assays supported the microarray data 
following TNF-α, showing that IRF1 expression was induced following stimulation by 
the cytokine. Furthermore, co-incubation with either p65 siRNA or BAY11-7082 
attenuated the TNF-α-induced up-regulation of IRF1, thus corroborating the existing 
literature which states that IRF1 is an NF-κB-regulated gene following inflammatory 
stimuli (Harada et al., 1994, Robinson et al., 2006). 
 
Validation of the microarray data which showed that IRF1 expression was down-
regulated 2 hours after treatment with IR (section 5.4.1) but up-regulated following co-
incubation with AG-014699, supported these data to some extent. qRT-PCR assays 
illustrated that there was a small but significant decrease in IRF1 expression following 
treatment with IR. Interestingly, a report in the literature states that the IRF1 
transcription factor is activated following DNA-damage and promotes apoptosis 
through the up-regulation of caspase-1 in T lymphocytes (Tamura et al., 1995). The 
qRT-PCR data here also show that the IR-induced decrease in IRF1 expression was 
unaffected by co-incubation with p65 siRNA or BAY11-7082, suggesting that this gene 
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is not regulated by NF-κB following DNA damage. Importantly, IR in combination with 
AG-014699 or PARP-1 siRNA significantly increased the transcript levels of IRF1 
compared with IR alone, suggesting that PARP-1 protein and activity are important for 
the activation of this gene. One explanation is that IRF1 may be under the 
transcriptional control of one of the other transcription factors, for which PARP-1 is 
known to have a role as a co-activator. For example, there is one report suggesting that 
IRF1 expression may be regulated by Sp1 (Sanceau et al., 1995), and other reports have 
suggested that PARP-1 is a co-activator of the transcription factor, Sp1 (Zaniolo et al., 
2007). 
 
Microarray data showed that the JUNB gene expression was up-regulated following 
TNF-α treatment (section 5.3.4) and also following treatment with IR (section 5.3.1). 
Validation using qRT-PCR assays supported the microarray data following TNF-α, 
showing that JUNB expression was induced following stimulation by the cytokine. 
Furthermore, co-incubation with either p65 siRNA or BAY11-7082 inhibited this TNF-
α-induced up-regulation of JUNB, although this was not statistically significant. These 
data do support the existing literature which shows that JUNB is an NF-κB-regulated 
gene following inflammatory stimuli (Brown et al., 1995). However, qRT-PCR 
validation assays did not support the microarray data following IR, as they showed that 
JUNB expression was unaffected following the DNA damaging agent. 
 
Microarray data (section 5.4.1) showed that the gene TOP2A which encodes the 
topoisomerase (DNA) II alpha was up-regulated 1.6-fold 2 hours after treatment with 
IR, but appeared to be unaffected by treatment with TNF-α. However, although qRT-
PCR analysis showed that TOP2A expression was unaffected was TNF-α in the p65+/+ 
MEFs, qRT-PCR data did not corroborate the microarray data following IR, suggesting 
that the expression of TOP2A was unchanged following DNA damage. The discordance 
of these results may be explained by the decreased sensitivity of the microarray per se 
or by the relatively low expression levels of this gene in the initial array analysis. 
 
5.6 Summary and future work 
Interestingly, this study has identified genes which could potentially be novel NF-κB 
regulated genes following IR, however these data require much further confirmation. 
Intriguingly, these genes include PLK1, CDC20 and AURKA, all of which are 
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associated with the cellular assembly and organisation. The most interesting genes are 
PLK1 and CDC20, both of which have been implicated in the progression of cancer 
(Kidokoro et al., 2008, Kim et al., 2005, Mondal et al., 2007, Musacchio and Salmon, 
2007) which were both up-regulated following IR. This up-regulation was reduced in 
the presence of either p65 siRNA, BAY11-7082, AG-014699 or PARP-1 siRNA. 
However, in order to further confirm these results chromatin immune-precipitation 
(ChIP) assays should be undertaken to determine whether NF-κB can interact with the 
promoters of the PLK1 or CDC20 genes.  
 
Analysis of the protein expression of PLK1 and CDC20 following IR alone or in 
combination with p65 siRNA, BAY11-7082, AG-014699 or PARP-1 siRNA should 
also be undertaken. This is essential, because one of the major limitations of gene 
expression profiling can be that changes at the mRNA levels do not always translate to 
the protein level, as proteins may be subject to post-translational modifications, or 
targeted for degradation. To this end the fold changes observed within this study are 
relatively small (approximately 1.5-fold for these genes of interest), and thus observing 
this at the protein level might be difficult.  
 
The other gene of interest which was identified was AURKA, which encodes the aurora 
kinase B protein. In this case the qRT-PCR data illustrated that this gene was up-
regulated 2-fold following IR treatment and intriguingly that this affect abrogated in the 
presence of BAY11-7082, but not p65 siRNA, AG-014699 or PARP-1 siRNA. In order 
to determine whether this is a true NF-κB-mediated affect, and not a result of BAY11-
7082 having off target effects, knockdown of the other NF-κB subunits should be 
undertaken and the qRT-PCR assay repeated using following this. This should provide 
insight into whether AURKA is a target of one of the other NF-κB subunits, for 
example p52, rather than p65, following DNA damage.  
 
The gene expression profiling and subsequent confirmation by qRT-PCR within this 
chapter have shown that the vital inflammatory responses, known to be regulated by 
TNF-α-induced NF-κB activation, are still intact following treatment with AG-014699. 
These data have very important implications for the wider use of AG-014699 in the 
inhibition of NF-κB activation for the treatment of cancer, due to the fact that NF-κB 
inhibition is an attractive target for cancer therapeutics. Reports have suggested that 
long-term global inhibition for example with an IKK inhibitor, may have adverse 
251 
 
effects, such as increased likelihood of immunodeficiency (Grossmann et al., 1999, 
Turco et al., 2004), which could be a significant problem for cancer patients which may 
already have a compromised immune system due to the nature of other therapeutic 
agents. Importantly, the data here support that in Chapter 3 and 4 which suggest that 
blockade of DNA-damage activated NF-κB by AG-014699 could represent a viable 
therapeutic strategy, since the data have demonstrated that the survival function of NF-
κB can be directly inhibited, using AG-014699, without compromising other functions, 
such as the immune response. 
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Chapter 6: Investigation into the potential utility of AG-014699 
inhibiting DNA-damage-induced NF-κB activation in cancer cell line 
models 
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6.1 Introduction 
There have been numerous reports that have detailed the use of PARP inhibitors to 
chemo- and radio-sensitise cancer cell lines, xenograft models and primary samples 
(Drew and Plummer, 2009). It is widely accepted that these effects are due to the 
inhibition of DNA repair, specifically single strand break repair. This is very likely to 
be the case in terms of the use of PARP inhibitors as a mono-therapy for BRCA-
deficient or –mutant breast or ovarian cancers (Bryant et al., 2005, Farmer et al., 2005). 
However, data in chapter 3 of this thesis suggests that PARP inhibition by AG-014699, 
can re-sensitise cells to irradiation and that this is mediated directly via NF-κB, rather 
than the widely reported inhibition of SSB repair. These data were generated using 
p65+/+ and p65-/- MEFs and this therefore needs to be further investigated within this 
chapter using other model systems and in the context of the existing literature. 
 
Radio-therapy is widely used in many major therapeutic regimens used in the treatment 
of cancers, including glioblastoma, breast and lung cancer. IR induces both SSBs and 
double strand breaks, thus activating PARP-1, and consequently activating cellular 
DNA repair pathways. Hence, the ability of PARP inhibitors to radio-sensitise cancer 
cells has been assessed by a number of groups. Studies have shown radio-sensitisation 
in vitro in a wide range of cell types including human colorectal cancer, lung cancer and 
murine sarcoma (Albert et al., 2007, Brock et al., 2004, Calabrese et al., 2004, Donawho 
et al., 2007). In vivo radio-sensitisation has also been observed in xenograft models of 
glioblastoma, lung cancer and colon cancer (Calabrese et al., 2004, Donawho et al., 
2007). 
 
The ability of PARP inhibitors to chemo-sensitise has been assessed using a variety of 
agents. Combination studies using various PARP inhibitors with the alkylating agent 
temozolomide (TMZ) have been undertaken in a range of cellular backgrounds, 
including human lung cancer cell lines, colorectal cancer cell lines and glioblastoma and 
medulloblastoma cell lines and xenografts (Calabrese et al., 2004, Chalmers, 2009, 
Chalmers, 2010, Daniel et al., 2009). These studies have shown pronounced chemo-
sensitisation in vitro and tumour growth inhibition in vivo. PARP inhibitors have also 
been used in combination with the topoisomerase I poisons, topotecan and irinotecan, 
and similar results to those seen with TMZ have been reported, in lung, colorectal, 
breast, and ovarian cancer cell lines, as well as lung, colorectal, ovarian and prostate 
cancer xenograft models (Cheng et al., 2005, Smith et al., 2005). A synergism between 
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the Abbott laboratories PARP inhibitor, ABT-888, was observed with cisplatin, 
carboplatin and cyclophosphamide in murine melanoma, rat glioma, human B-cell 
lymphoma and breast cancer cells (Donawho et al., 2007).  
 
Many of the model systems used to investigate the role of PARP inhibitors in chemo- or 
radio-sensitisation are known to have constitutive- or inducible- NF-κB activation. For 
example, aberrant activation of NF-κB is known to play a role in the tumourigenesis of 
both diffuse and high-grade gliomas (Kanzawa et al., 2003, Wang et al., 2004). Elevated 
NF-κB DNA binding activity has been demonstrated both in breast cancer cell lines and 
primary breast cancer tissues (Biswas et al., 2004, Nakshatri et al., 1997, Sovak et al., 
1997), and shown to contribute to malignant progression through the regulation of gene 
expression. Constitutive NF-κB activation in all of these tumours types has been 
associated with chemo- and radio-resistance as well as an increased metastatic potential 
(Prasad et al., 2010). Thus, inhibition of NF-κB represents a promising therapeutic 
strategy for many different types of cancer. 
6.2 Aims 
Data presented in Chapter 3 of this thesis suggests that PARP inhibition by AG-014699 
can re-sensitise cells to irradiation and that this is mediated, in part, via NF-κB, rather 
than just by the inhibition of SSB repair, as previously thought. These data were 
generated with p65+/+ and p65-/- MEFs, and there are caveats associated with using these 
cells lines, not least that these are murine and not human cells. Therefore one aim of this 
chapter was to further investigate the hypothesis that radio-sensitisation observed with 
AG-014699 is due, in part, to the inhibition of NF-κB activation. In order to do this, 
cancer cell line models will be utilised that have previously been shown to be radio-
sensitised by PARP inhibition. This chapter will therefore also explore potential tumour 
models in which the use of PARP inhibitors may be beneficial, for example tumours in 
which radio-therapy is a major part of the therapeutic regimen. It is also important to 
investigate the role of PARP-1 in NF-κB activation following other DNA-damaging 
agents, such as TMZ. PARP inhibition has been shown to sensitise cells to this agent 
(Calabrese et al., 2004, Daniel et al., 2009). Hence, this chapter will investigate the 
potential for AG-014699 to inhibit TMZ-induced NF-κB activation in a cell line model, 
in which this chemo-therapeutic agent is widely used, both alone and in combination 
with radio-therapy.  
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6.3 Results 
6.3.1 IR-induced nuclear translocation of NF-κB p65 in glioblastoma cell lines 
Initially, it was important to choose a type of cancer in which to study the effects of 
AG-014699 on DNA-damage-induced NF-κB activation. Glioblastoma was chosen 
because there are a number of reports that detail both radio- and chemo-sensitisation by 
PARP inhibitors, in both cell line and xenograft models of the disease (Chalmers, 
2010). However, these reports showed that this was due to the inhibition of SSB repair, 
and other mechanistic investigations were not undertaken. There are also reports which 
suggested that aberrant activation of NF-κB played an important role in the 
tumourigenesis of both diffuse and high-grade gliomas (Kanzawa et al., 2003, Wang et 
al., 2004). Taken together, this made glioblastoma, in which cell line models were 
readily available, an obvious choice for further study in this chapter. 
 
Firstly, it was essential to determine whether any of the three cell lines, U251, MO59J 
or MO59J-Fus-1, had constitutive activation of NF-κB p65, and most importantly 
whether p65 was further inducible by treatment with IR. At this stage, it was decided 
that concentrating on the p65 subunit was most relevant as all of the other data 
generated the Chapter 3 and 4 of this thesis had centred on p65, by virtue of access to 
the p65+/+ and p65-/- MEFs. In order to investigate the activation of NF-κB p65 by IR, an 
assessment of p65 nuclear translocation following the DNA-damaging agent was 
undertaken. Briefly, U251, MO59J or MO59J-Fus-1 cells were seeded and allowed to 
adhere for 24 h before treatment with either 2 Gy or 10 Gy IR. Previous data (Chapter 
4) would suggest that the response to IR would be rapid, hence cells were harvested at 
early timepoints (0 and 2 h). Nuclear extracts were prepared (section 2.5.2) and the 
levels of p65, Lamin or β-actin were determined by Western analyses in nuclear extracts 
from all three cell lines. Densiometric analysis was used to assess the levels of p65 
compared to the nuclear protein, Lamin. β-actin was used as a control in order to ensure 
that there was no cytoplasmic contamination of the nuclear extracts. 
 
Figure 6.1A illustrates that p65 is translocated to the nucleus of U251 cells at early 
timepoints following IR, and that this translocation is concentration-dependent. Nuclear 
translocation of p65 in these cells is induced 1.8-fold immediately following 10 Gy IR, 
and approximately 2.2-fold 2 h following 10 Gy IR. The blots shown are representative 
of three experiments whilst the densiotometry data is the mean of three, hence allowing 
statistical analysis to be performed. Unpaired Student’s t-tests indicated that there is a 
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significant increase of p65 in the nucleus of U251 following 10 Gy IR at the 0 h and 2 h 
timepoints (p=0.0016 and p=0.024, respectively). Figure 6.1B shows that p65 nuclear 
translocation was induced by both 2 Gy and 10 Gy in the MO59J-Fus-1 cells, but that 
the greatest increase in nuclear p65 levels was observed immediately after treatment 
with IR (2.2-fold following 2 Gy IR and 2.6-fold following 10 Gy). Unfortunately, due 
to time constraints, the experiments with the MO59J and Fus-1 cells were not repeated, 
therefore statistical analyses could not be performed. Interestingly, p65 nuclear 
translocation following IR was not observed in the MO59J cells (Figure 6.1C), although 
this is not surprising. The MO59J cells lack DNA-PK (Lees-Miller et al., 1995), and 
this protein is not only vital for the DNA-damage response (Smith and Jackson, 1999) 
but has also been implicated in the activation of NF-κB (Basu et al., 1998, Ju et al., 
2010, Liu et al., 1998, Panta et al., 2004). This is will be discussed later. 
 
 
 
 
 
 
 
 
 
6.3.2 Knockdown of target proteins using siRNA technology in U251 cells 
Since p65 nuclear translocation was significantly induced by IR in U251 cells (Figure 
6.2), this cell line was used to further investigate the role of PARP-1 in the activation of 
NF-κB, for a number of reasons. The MO59J cells did not show any p65 activation 
Figure 6.1: p65 nuclear translocation by IR in gliobastoma cells 
Western blotting data and bar charts showing nuclear translocation of p65 and 
densiometric analysis, following IR in three glioblastoma cell lines (A) U251, (B) 
MO59J-Fus-1 and (C) MO59J. Cells were harvested 0 or 2 h post-IR and nuclear 
extracts prepared. Loading was normalised to lamin nuclear loading control in all cases. 
Nuclear extracts were shown to be free of any cytoplasmic contamination by blotting 
with β-Actin antibody. Densiotometry was used to assess the levels of p65 compared to 
the nuclear protein and fold change in p65 expression levels are shown in the bar charts 
below the relevant Western blot 
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following IR and are from a glioblastoma tumour lacking DNA-PK (Lees-Miller et al., 
1995). The role of DNA-PK in the DNA-damage and NF-κB-responses is also 
discussed in section 6.3.1, suggesting that this cell line model was not suitable for 
further study in this chapter. The MO59J-Fus-1 cells (Hoppe et al., 2000) are a 
derivative of the MO59J cells in which chromosome 8, (on which DNA-PK is located, 
(Sipley et al., 1995)), has been re-introduced, in its entirety. Hence, these cells are likely 
to have multiple copies of many genes found on chromosome 8, and are not be optimal 
for this study, the U251 cells were used. 
 
siRNA targeting either p65 or PARP-1 were used to silence each of the proteins in the 
U251 cells, in order to use knockdown of p65 or PARP-1 in direct comparison with 
AG-01699, as had been done previously in the p65+/+, p65-/-, PARP-1+/+ and PARP-1-/- 
MEFs. U251 cells were incubated for 24 h prior to lipid transfection with 50 nM of 
siRNA oligos targeting either p65 or PARP-1, or a non-specific (NS) control (Table 
2.2). Cells were harvested 48 h later and whole cell extracts were prepared (section 
2.5.1) It should be noted that this concentration of siRNA and timepoint were chosen as 
these conditions had been optimal in other cell lines (Chapter 3). The levels of p65 or 
PARP-1 were determined by Western analyses and densiometric analysis was used to 
assess the knockdown compared to β-actin. 
 
Figure 6.2A shows that a reproducible significant reduction in p65 protein expression (>  
95%) was observed in the U251 cells (p<0.0001, compared with untreated controls, 
unpaired Student’s t-test). Similarly, a reproducible knockdown of PARP-1, (> 97 %), 
was achieved (p<0.0001) (Figure 6.2B). Importantly, there were no significant 
differences in p65 or PARP-1 protein expression between the control NS siRNA and 
untreated control cell extracts. 
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6.3.3 Radio-sensitisation by p65 knockdown, PARP-1 knockdown or AG-014699 
It was important to determine what effects these treatments, and AG-104699 had on cell 
survival, in combination with IR. Previous data (Chapter 3) and other reports using a 
PARP inhibitor in glioblastoma cells (Chalmers et al., 2004, Cheng et al., 2005, Dungey 
et al., 2009) suggest that a radio-sensitisation would be expected. Therefore, this was 
investigated using classical colony forming assays (section 2.2.7). This assay would use 
a range of doses of IR and compare this to either to a fixed concentration of AG-
014699, or siRNA in combination with IR. 
 
U251 cells were incubated for 24 h before transfection with 50 nM p65 or 50 nM 
PARP-1 siRNA, (or vehicle control). Cells were then left for 48 h, and pre-treated with 
AG-014699, or DMSO control 1 h prior to treatment with increasing doses of IR before 
Figure 6.2: siRNA knockdown of p65 and PARP-1 in U251 cells 
(A) Western blot and quantification of densiotometry of whole cell extracts of U251 
cells at 48 h after transfection with vehicle alone (untreated), non-specific (NS) 
siRNA or p65 siRNA. p65 protein expression in U251 cells expressed as a 
percentage of Mock treated cells. (B)Western blot of whole cell extracts of U251 
cells at 48 h after transfection with vehicle alone (untreated), NS siRNA or PARP-1 
siRNA. PARP-1 protein expression in U251 cells expressed as a percentage of Mock 
treated cells.  
Results shown are the mean + SEM of 3 independent experiments. *** Significance 
relative to Mock transfected control was p<0.0001 using Student’s unpaired t-tests. 
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being re-plated after a further 24 h and allowed to form colonies for 7-21 days (Figure 
6.3). 
 
The data here show that the U251 cells are quite resistant to IR alone, consistent with 
reports that the aberrant activation of NF-κB can lead to radio-resistance (Criswell 
Oncogene 2003). Furthermore, Figure 6.3 illustrates that co-incubation with IR and 
either AG-014699, p65 siRNA or PARP-1 siRNA reduced survival of the U251 cells by 
2.5-fold compared with IR alone. The unpaired Student’s t-test confirm that, at the LD50 
values (lethal dose which reduces survival to 50 %) AG-014699, p65 or PARP-1 siRNA 
significantly radio-sensitised the U251 cells compared with IR alone (p=0.0002, 
p<0.0001 and p=0.0004, respectively). Importantly, a co-incubation with p65 and AG-
014699 in combination with IR, did not further reduce U251 cell survival compared 
with either agent alone, confirming previous data (Chapter 3), suggesting that NF-κB 
and PARP-1 are mechanistically linked in a common pathway.   
 
 
 
 
 
 
 
 
 
Figure 6.3: Radio-sensitisation of U251 cells by p65 knockdown, PARP-1 knockdown 
or AG-014699 
The effects of increasing doses of IR either alone, or co-incubated with p65 siRNA, AG-
014699, PARP-1 siRNA or a combination of p65 siRNA and AG-014699, on cell survival 
were assessed using the clonogenic survival assay. Cells were treated with relevant siRNA, 
(or vehicle control), incubated for 48 h, pre-treated with AG-014699, or DMSO control 1 h 
prior to IR then re-plated after a further 24 h and allowed to form colonies for 7-21 days. 
Results shown are the mean + SEM of three independent experiments 
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6.3.4 NF-κB activation following IR in U251 cells is time dependent 
In order to confirm that the results observed in the clonogenic assays (Figure 6.3) were 
in fact due to the effect of AG-014699 on NF-κB activation, the effects of AG-104699, 
p65 siRNA and PARP-1 siRNA on NF-κB DNA binding were assessed. Although a 
timecourse for the activation of IR-induced p65 DNA binding had been determined for 
the MEFs (Chapter 4), it was necessary to determine the peak activation of both p65 and 
p50 following 10 Gy IR (the dose shown to induce nuclear translocation of p65 at early 
timepoints, section 6.3.1). 
 
Exponentially growing U251 cells treated with 10 Gy IR. Cells were harvested at 
various timepoints (0, 2, 4, 6,8 24 h), and nuclear extracts were prepared and assessed 
on the ELISA assay (section 2.8).  
 
Figures 6.4A and 6.4B illustrate that DNA binding of both p65 and p50 increased 
immediately following IR when compared with untreated controls (p=0.044 and 
p=0.0087, respectively, unpaired Student’s t-test). Moreover, in the case of both p65 
and p50, DNA binding was maximal 2 h following treatment with IR (p=0.0006 and 
p=0.0093, compared with untreated controls, unpaired Student’s t-test). DNA binding of 
both subunits was still significantly increased 4 h after treatment with 10 Gy IR and in 
both cases DNA binding activity returns to basal levels 24 h post treatment. 
 
 
 
 
 
 
 
 
Figure 6.4: Maximal activation of NF-κB p65 or p50 by IR is 2 h post-treatment 
Bar charts showing the effects of IR over time on NF-κB p65 (A) or p50 (B) DNA 
binding activity in U251 cells. Cells were treated with 10 Gy IR and nuclear extract 
prepared at various timepoints before measurement in an ELISA-based assay. All results 
are the mean of three independent experiments with SEM. Significance relative to mock 
treated control using unpaired Student’s t-test *** p<0.001, ** p<0.01,  * p<0.05  
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6.3.5 NF-κB p65 DNA binding requires PARP protein and enzymatic activity 
following IR, whereas p50 DNA binding requires PARP-1 protein alone 
The ELISA was utilised to assess the effects of AG-014699, p65 or PARP-1 siRNA on 
IR-induced NF-κB DNA binding. U251 cells were incubated for 24 h prior to 
transfection with 50 nM p65, PARP-1 or NS siRNA (or vehicle control). Cells were 
then left for 48 h, and pre-treated with AG-014699, or DMSO control 1 h prior to 
treatment with 10 Gy IR. Cells were harvested 2 h later, nuclear extracts were prepared 
and loaded onto the ELISA-plates. 
  
Figure 6.5A shows that 10 Gy IR significantly increased p65 DNA binding compared 
with mock treated controls (p=0.0012, unpaired Student’s t-test), and that co-incubation 
with p65 siRNA, AG-014699 or PARP-1 siRNA reduced this IR-dependent increase in 
p65 DNA binding (p65 siRNA; p=0.0002, AG-014699; p=0.0043, PARP-1 siRNA; 
0.0035, compared to IR). Markedly, a combination of p65 siRNA and AG-014699 did 
not further decrease IR-induced p65 DNA binding compared to either agent alone, 
confirming the survival data which suggested that NF-κB and p65 are linked in a 
common pathway. Importantly, NS siRNA had no effect on IR-induced p65 DNA 
binding when compared with IR alone (p=0.981). 
 
Figure 6.5B shows that 10 Gy IR significantly increased p50 DNA binding compared 
with mock treated controls (p=0.016, unpaired Student’s t-test). Both p65 and PARP-1 
siRNA clearly inhibit IR-induced p50 DNA binding, but the outcome is just below the 
level of significance (p=0.078 and p=0.076, compared to IR in combination with NS 
siRNA). This observation is not due to the transfection process, since NS siRNA had no 
effect on IR-induced p50 DNA binding when compared with IR alone (p=0.641). 
Interestingly, AG-014699 alone or in combination with p65 siRNA had no effect on IR-
induced p50 DNA binding when compared with IR in combination with NS siRNA 
(p=0.653 and p=0.834, respectively). 
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6.3.6 AG-014699 inhibits Single strand break (SSB) repair to a similar extent 
regardless of cellular NF-κB status in U251 cells 
Previous data (Chapter 3), generated using the p65+/+ and p65-/- MEFs, showed that both 
of those cell lines had the same level of SSBs immediately following IR, and that the 
repair of SSBs kinetics were identical in both sets of MEFs (section 3.3.5), regardless of 
their differing p65 status. Most importantly however, AG-014699 inhibited SSB repair 
to the same extent in both of these cell lines but radio-sensitisation by the PARP 
inhibitor was only observed in the p65+/+  cells. This leads to the hypothesis that radio-
sensitisation by AG-014699 was mediated by inhibition of NF-κB activation, and 
independent of the role PARP inhibitors play in the inhibition of DNA repair. In order 
to confirm these novel data, it was decided to undertake a similar approach in the U251 
cells, utilising p65 siRNA (shown in Figure 6.7). 
 
The alkaline Comet assay was used to measure SSB as described previously (section 
2.7). U251 cells were incubated overnight before transfection with 50 nM p65 siRNA or 
vehicle control. Cells were then left for 48 h, and pre-treated with AG-014699, or 
DMSO control 1 h prior to treatment with 10 Gy IR. Cells were harvested at various 
Figure 6.5: PARP-1 protein and enzymatic activity are required for activation of p65 
DNA binding following IR whereas p65 or PARP-1 protein knockdown inhibit IR-
induced p50 
Bar chart showing the effect of IR ± p65 siRNA ± AG-014699 ± PARP-1 siRNA ± Non-
specific (NS) siRNA control on IR-induced NF-κB  (A) p65 or (B) p50 DNA binding, 
measured using an ELISA-based assay, in U251 cells. All results are the mean of three 
independent experiments with SEM. Significance relative to NS siRNA control using 
unpaired Student’s t-test *** p<0.001, ** p<0.01 
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timepoints following IR and the alkaline comet assay undertaken as described in section 
2.7. 
 
Figure 6.6A versus 6.6B shows that the number of SSBs is greatest immediately 
following IR, and importantly that the olive tail moment is very similar, regardless of 
the p65 status of the cells. These scatter plots also illustrate that all breaks are repaired 
30 minutes following irradiation. Markedly, there was no significant difference in the 
SSB levels remaining in the presence of absence of p65 siRNA 30 min post-IR, with > 
90 % of breaks repaired. AG-014699 inhibited SSB repair (as demonstrated by 
increased residual SSB levels at all time-points post-IR) to the same extent regardless of 
whether p65 was present or not. The kinetics of SSB repair clearly show that the SSBs 
generated by IR are repaired rapidly over time and that in both cell populations the 
kinetics of repair were very similar. Furthermore, regardless of p65 status, cells pre-
treated with AG-014699 prior to treatment with IR, have slower repair kinetics, thus 
supporting the earlier observations in the p65+/+ and p65-/- MEFs. 
 
 
 
 
 
 
Figure 6.6: AG-014699 inhibits SSB repair to a similar extent regardless of cellular NF-κB 
status 
(A)Scatter diagramshowing the extent of single strand breaks (SSBs) in U251cells treated 
with 10 Gy IR ± AG-014699 (AG, denoted by +) and allowed to repair (0 min, 15 min, 
30 min). 
(B) Scatter diagramshowing the extent of single strand breaks (SSBs) in U251cells treated 
with 10 Gy IR ± AG-014699 ±p65 siRNA and allowed to repair (0 min, 15 min, 30 min). 
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6.3.7 The effect of temozolomide alone, or in combination with IR on U251 cell 
viability 
The data presented thus far in this chapter, using IR to assess the role of PARP-1 in the 
activation of NF-κB following DNA, has supported the results in Chapter 3 and 4. 
However, it was important to investigate the role of PARP-1 in the activation of NF-κB 
following a different DNA-damaging agents. The alkylating agent, TMZ, was chosen 
because there have been a number of reports showing that PARP inhibitors potentiate 
TMZ-induced cytotoxicity in various tumour types (Calabrese et al., 2004, Chalmers, 
2009, Chalmers, 2010, Daniel et al., 2009) as this agent is known to induce SSBs. Also, 
TMZ is used alone and in combination with radio-therapy in the treatment of 
glioblastoma (Danson and Middleton, 2001), hence the U251 cell line is an appropriate 
model system. Moreover, a direct comparison between TMZ alone and TMZ in 
combination with IR could be undertaken, as these two agents are used in conjunction in 
the treatment of glioblastoma. This could generate therapeutically relevant data, whilst 
importantly gaining further insight into the role of PARP-1 in DNA-damage activated 
NF-κB. 
 
The effect of TMZ alone, and in combination with a low dose of IR was assessed using  
the Roche XTT Cell Proliferation assay, (section 2.2.6). This is a high throughtout 
method used to determine a GI50 values for a chemo-therapeutic agent, such as TMZ. 
The use of such assays allowing the simultaneous assessment of a large variation of 
drug concentrations, something which cell survival assay, such as the clonogenic assay 
do not allow with such ease. U251 cells were incubated overnight before a 1 h pre-
treatment with AG-014699, or DMSO control, prior to treatment with TMZ or DMSO 
control, and where relevant 2 Gy IR. This dose of IR was chosen as it the single dose 
used clinically. After treatment, the cells were incubated for a further 72 h before a 
further 4 h incubation in the presence of XTT labelling solution. Absorbance at 450 nm 
was then measured and results shown are the mean of three independent experiments. 
 
Figure 6.7A shows the growth inhibition of U251 cells following increasing doses of 
TMZ (0.5- 500 µM) in the presence or absence of AG-014699. The GI50 values indicate 
that AG-014699 sensitises U251 cells to TMZ; GI50 TMZ alone, 32.5 µM compared 
with GI50 value TMZ in combination with AG-014699, 20.5 µM, a potentiation factor 
of 1.6-fold (p=0.019, unpaired Student’s t-test). 
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The effects of a combination of IR and TMZ on U251 cell viability were assessed as a 
direct comparison to TMZ alone. Figure 6.7B shows the growth inhibitory effects of 
increasing doses of TMZ alone (0.5- 500 µM), TMZ in combination with 2 Gy IR, and 
also TMZ in combination with both 2 Gy IR and AG-014699.  The combination of 
TMZ and IR reduces cell viability compared with TMZ alone, although when 
comparing the GI50 values (22.8 µM and 32.5 µM, respectively), this was not 
statistically significantly (p=0.094, unpaired Student’s t-test). However, that the 
potentiation factor here was 1.6-fold, which is the same as what was previously 
observed with TMZ in combination with AG-014699.  Markedly, AG-04699 in 
combination with IR and TMZ significantly potentiated the effects of TMZ alone or IR 
in combination with TMZ (p=0.0061 and p=0.021, respectively). Importantly, AG-
014699 in combination with IR and TMZ potentiated the effects of TMZ alone 3.3-fold, 
and the effects of IR and TMZ 2.3-fold. These data suggest that a combination of TMZ 
and IR, which is used in the clinic for treatment of glioblastoma, is more efficacious 
than TMZ alone, and moreover that the addition of the PARP inhibitor, AG-014699 
may provide further therapeutic benefit in the disease. 
 
 
Figure 6.7: Growth inhibitory effects of temozolomide in the presence or 
absence of a fixed concentration of IR and AG-014699 
 (A) U251 cells were treated with increasing concentrations of temozolomide (0.5-
500 µM) in the absence (solid line) or presence (dotted line) of AG-014699.  
  (B) U251 cells were treated with increasing concentrations of temozolomide (0.5-
500 µM) ± 2 Gy IR ± AG-014699. After 72 h of exposure, cells were stained with 
XTT and OD450nm was quantified. Results shown are the mean of three independent 
experiments ± SEM. 
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6.3.8 The effect of temozolomide alone, or in combination with IR on U251 cell 
survival 
Once the effects of TMZ alone or in combination with IR on cell viability had been 
assessed, it was important to determine the effects on these agents on cell survival. For 
this the clonogenic survival assay (section 2.2.7). U251 cells were plated and left to 
adhere for 24 h before pre-treatment with AG-014699, or DMSO control 1 h prior to 
treatment with increasing doses of TMZ, and where appropriate 2 Gy IR. Figure 6.8A 
shows the effect of 0, 10 and 30 µM TMZ alone or in combination with 2 Gy IR. This 
survival data confirms the growth inhibition data by showing that the combination of IR 
and TMZ reduces U251 cell survival to a greater extent than TMZ alone. When 
comparing the percentage cell survival following 10 µM TMZ alone (35.5 %) versus IR 
in combination with TMZ (22.0 %) these values are significantly different (p=0.031, 
unpaired Student’s t-test). Since the curves are very steep, with very low percentage of 
surviving cells at 30 µM TMZ, these experiments could be repeated with lower 
concentrations of TMZ. Sincetime constraints meant that this was not possible for this 
thesis, the 10 µM concentration has been used for future comparisons in this Chapter. 
 
These data are also represented in the bar chart in Figure 6.8B, which directly compares 
untreated U251 cells, or those treated with either 2 Gy IR, 10 µM TMZ or a 
combination of 2 Gy IR and 10 µM TMZ. Figure 6.8B shows that 2 Gy IR significantly 
reduced U251 cell survival by 30 % compared to untreated cells (p=0.0003, unpaired 
Student’s t-test). Treatment with 10 µM TMZ significantly reduced cell survival by 
>55% compared with untreated controls (p<0.0001). Importantly, a combination of IR 
and TMZ further reduced U251 cell survival compared with either agent alone 
suggesting the two are additive (p=0.0002 IR versus IR in combination with TMZ, 
p=0.0019 TMZ versus IR in combination with TMZ, unpaired Student’s t-tests). 
Furthermore, overall cell survival was reduced by 75 % compared with untreated 
controls, with this combination therapy. Taken together these data support the growth 
inhibition data in section 6.3.7 and also support the simultaneous use of both radio-
therapy and TMZ in a clinical setting. 
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6.3.9 Potentiation of temozolomide cytotoxicity either by p65 knockdown, PARP-1 
knockdown or AG-014699 
Once the cell survival of U251 cells in response to 10 µM TMZ and 2 Gy IR had been 
determined it was important to investigate whether there were any further effects on cell 
survival using AG-014699, p65 siRNA or PARP-1 siRNA, as had been observed 
(section 6.3.3). Knockdown of p65 and PARP-1 could be reproducibly achieved, in the 
U251 cells, hence it was decided to investigate this using classical colony forming 
assays (section 2.2.7). This assay used a fixed dose of both TMZ (10 µM) and IR (2 Gy) 
and compare this to either to a fixed concentration of AG-014699, or p65 or PARP-1 
siRNA in combination with either IR or TMZ, or a combination of the two DNA-
damaging agents. 
 
Figure 6.9 shows six data sets, each containing four individual bars – one for control 
cells (open bars), one treated with IR (black bars), one treated with TMZ (hatched bars) 
and one treated with a combination with IR and TMZ (striped bars). The six sets are 
categorised by the presence or absence of siRNA or inhibitor used in combination with 
the four treatments. These six sets include p65 siRNA, AG-014699, PARP-1 siRNA, 
Figure 6.8: U251 cell survival following either IR or temozolomide or a combination 
of IR and temozolomide.  
(A) U251 cells were treated with increasing concentrations of temozolomide (0-30 µM) 
in the absence (solid line) or presence of 2 Gy IR (dotted line).  
 (B) U251 cells were treated 2 Gy IR ± 10 µM TMZ ± AG-014699. Results shown are 
the mean of three independent experiments ± SEM. 
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NS siRNA, a combination of p65 siRNA and AG-014699, or cells without any of these 
siRNAs or inhibitors. All statistical analyses were performed using Student’s unpaired 
t-tests, and are summarised in Table 6.1. 
 
 
 
 
 
 
 
 
Firstly, Figure 6.9 shows U251 cells without any siRNA or inhibitor treatment, and this 
set of bars set the bench-mark for any comparisons drawn with each of the siRNAs or 
inhibitor combinations used. In this case, 2 Gy IR reduced cell survival by 30 % 
compared to untreated cells, whereas treatment with 10 µM TMZ significantly reduced 
cell survival by 58% compared with untreated controls. Importantly, a combination of 
IR and TMZ further reduced U251 cell survival (compared with either agent alone) by 
75 % compared with untreated controls.  
 
It should be noted that all p-values (shown in Table 6.1) were generated by comparing 
each data set to the first set of bars (U251 cells without any siRNA or inhibitor), after it 
had been established that there were no significant differences between U251 cells 
transfected with NS siRNA and U251 cells without any siRNA or inhibitor. To this end, 
the final data set in Figure 6.9 shows U251 cells treated with NS siRNA 48 h prior to 
treatment with IR, TMZ or a combination of IR and TMZ. When comparing these data 
to the first set of bars (U251 cells without any siRNA or inhibitor), it is clear that NS 
Figure 6.9: Chemo- and radio-sensitisation of U251 cells by p65 knockdown, 
PARP-1 knockdown or AG-014699 
U251 cells were treated 2 Gy IR ± 10 µM TMZ ± p65 siRNA ± AG-014699 (AG) ± 
PARP-1 siRNA ± NS siRNA. Cells were treated with relevant siRNA, (or vehicle 
control), incubated for 48 h, pre-treated with AG-014699, or DMSO control 1 h prior 
to IR then re-plated after a further 24 h and allowed to form colonies for 7-21 days. 
Results shown are the mean + SEM of three independent experiments 
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siRNA has no effect on cell survival in combination with IR, TMZ or a combination of 
IR and TMZ, compared with these DNA-damaging agents alone. Similarly, U251 cell 
survival was unchanged with NS siRNA in conjunction with TMZ, compared with TMZ 
alone. NS siRNA in combination with IR and TMZ, was not significantly different from 
cells treated with IR and TMZ alone. 
 
The second data set in Figure 6.9 shows U251 cells treated with p65 siRNA 48 h prior 
to treatment with IR, TMZ or a combination of IR and TMZ. p65 siRNA significantly 
reduced cell survival further in combination with IR, TMZ or a combination of IR and 
TMZ, compared with these DNA-damaging agents alone. U251 cell survival was 
significantly decreased with p65 siRNA in conjunction with TMZ, compared with TMZ 
alone, or in combination with IR and TMZ, compared with IR and TMZ alone. 
 
The third data set in Figure 6.9 show U251 cells treated with AG-014699 1 h prior to 
treatment with IR, TMZ or a combination of IR and TMZ. In this case, treatment with 
the PARP inhibitor significantly reduced cell survival further in combination with IR, 
TMZ or a combination of IR and TMZ, compared with these DNA-damaging agents 
alone. AG-014699 in combination with IR significantly decreased U251 colony forming 
ability compared with U251 cells treated with IR alone. U251 cell survival was 
significantly decreased with AG-014699 in conjunction with TMZ, compared with 
TMZ alone or in combination with IR and TMZ, compared with IR and TMZ alone.  
 
The fourth set of bars on Figure 6.9 show U251 cells treated with PARP-1 siRNA 48 h 
prior to treatment with IR, TMZ or a combination of IR and TMZ.  It is clear that 
treatment with the PARP-1 siRNA reduced cell survival further in combination with IR, 
TMZ or a combination of IR and TMZ, compared with these DNA-damaging agents 
alone. PARP-1 siRNA in combination with IR significantly decreased U251 colony 
forming ability compared with U251 cells treated with IR alone (p=0.0022). Similarly, 
U251 cell survival was significantly decreased with PARP-1 siRNA in conjunction with 
TMZ, compared with TMZ alone or in combination with IR and TMZ, compared with 
IR and TMZ alone.  
 
The fifth data set in Figure 6.9 show U251 cells treated with a combination of p65 
siRNA and AG-014699 prior to treatment with IR, TMZ or a combination of IR and 
TMZ. When comparing these to the controls, it is clear that treatment with this 
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combination of p65 siRNA and the PARP inhibitor reduced cell survival further in 
combination with IR, TMZ or a combination of IR and TMZ, compared with these 
DNA-damaging agents alone. The combination of p65 siRNA and AG-014699 in 
conjunction with IR significantly decreased U251 colony forming ability compared with 
U251 cells treated with IR alone. Similarly, U251 cell survival was significantly 
decreased with p65 siRNA and AG-014699 in conjunction with TMZ, compared with 
TMZ alone, or in combination with IR and TMZ, compared with IR and TMZ alone 
(p=0.001, unpaired Student’s t-test). Most importantly however, there is no difference 
between U251 cells treated with the combination of p65 siRNA and AG-014699, 
compared with either of these agents alone, in combination any of the DNA-damaging 
agents, supporting the existing data, that PARP-1 and NF-κB are mechanistically linked 
in a common pathway, and that that radio- or chemo-sensitisation by the PARP 
inhibitor, AG-014699 is mediated via NF-κB. 
 
 
 
IR alone TMZ IR + TMZ 
p65 siRNA +IR 0.0010 **   
p65 siRNA + T  0.0001 ***  
p65 siRNA + (IR +T)   0.0005 *** 
AG + IR 0.0018 **   
AG + T  0.0001 ***  
AG + IR + T (IR +T)   0.0007 *** 
PARP-1 siRNA + IR 0.0022 **   
PARP-1 siRNA + T  0.0003 ***  
PARP-1 siRNA + (IR + 
T) 
  0.0008 *** 
(p65 siRNA + AG) + IR 0.0014 **   
(p65 siRNA + AG) + T  <0.0001 ***  
(p65 siRNA + AG) +  
(IR + T) 
  0.001 ** 
NS siRNA + IR 0.6096 ns   
NS siRNA + T  0.1151 ns  
NS siRNA + (IR + T)   0.9484 ns 
 
 
 
 
 
6.3.10 TMZ induced-NF-κB DNA binding is time-dependent 
In order to confirm that the results observed in the clonogenic assays (Figure 6.9) were 
in fact due to the effect of AG-014699 on NF-κB activation, the effects of AG-104699, 
Table 6.1: Statistical analysis of data sets represented in Figure 6.9 
Statistical analysis perfomed using Student’s unpaired t-tests generated by comparing 
each data set to the first set of bars (U251 cells without any siRNA or inhibitor), shown 
in Figure 6.12. ***Significance relative to suitable control p<0.001 **Significance 
relative to suitable control was p<0.01 using unpaired Student’s t-test. Ns Not-
significant 
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p65 siRNA and PARP-1 siRNA on NF-κB DNA binding were assessed. Firstly, a 
timecourse for the activation of TMZ-induced, or TMZ + IR-induced p65 DNA binding 
was determined following 10 µM TMZ (the concentration used in the clonogenic assays 
in section 6.3.9) using the DNA binding ELISA. Figures 6.10A and 6.10B illustrate that 
DNA binding of both p65 and p50 increased immediately following TMZ when 
compared with untreated controls, although this was only statistically significant for p65 
DNA binding (p=0.017, unpaired Student’s t-tests). Moreover, in the case of both p65 
and p50, DNA binding was maximal 2 h following treatment with TMZ (p<0.0001 and 
p=0.0037). DNA binding of the p65 subunit was still significantly increased 4 h after 
treatment with 10 µM TMZ and in both cases DNA binding activity returned to basal 
levels 24 h post treatment. 
 
 
 
 
 
 
 
 
 
Figure 6.10: Maximal activation of NF-κB p65 or p50 by TMZ, or TMZ+IR is 2 
h post-treatment 
Bar charts showing the effects of TMZ over time on NF-κB p65 (A) or p50 (B) DNA 
binding activity, or TMZ + IR over time on p65 (C) or p50 (D) DNA binding activity  
in U251 cells. Cells were treated with 10 µM TMZ ± IR and nuclear extract prepared 
at various timepoints before measurement in an ELISA-based assay. All results are 
the mean of three independent experiments with SEM. Significance relative to mock 
treated control using unpaired Student’s t-test *** p<0.001, ** p<0.01 
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Figures 6.10C and 6.10D illustrate that DNA binding of both p65 and p50 increased 
immediately following TMZ in combination with IR when compared with untreated 
controls, (significant for p65 DNA binding (p=0.0033, unpaired Student’s t-tests)). In 
the case of both p65 and p50 DNA binding was maximal 2 h following treatment with a 
combination of TMZ and IR (p<0.0001 and p<0.0001). DNA binding of the p65 subunit 
was still significantly increased 4 h after treatment with 10 µM TMZ and 2 Gy IR and in 
both cases DNA binding activity returns to basal levels 24 h post treatment. These 
assays were undertaken simultaneously with TMZ-induced DNA binding timecourse 
ELISA assays (Figures 6.10A and B), and are therefore directly comparable. Thus, all 
timepoints tested a combination of 10 µM TMZ and 2 Gy IR induced a greater level of 
both p65 and p50 DNA binding compared to 10 µM TMZ alone. 
 
 
6.3.11 NF-κB p65 DNA binding requires PARP protein and enzymatic activity 
following TMZ alone or in combination with IR 
The ELISA was utilised to assess the effects of AG-014699, p65 or PARP-1 siRNA on 
IR-induced NF-κB DNA binding, as previously described in section 6.3.5. Figure 6.11A 
shows that 10 µM TMZ significantly increased p65 DNA binding compared with mock 
treated controls (p=0.012, unpaired Student’s t-test). Co-incubation with p65 siRNA, 
AG-014699 or PARP-1 siRNA reduced this TMZ-dependent increase in p65 DNA 
binding (p=0.0042, p=0.027, p=0.041, respectively,compared to TMZ in combination 
with NS siRNA). Markedly, a combination of p65 siRNA and AG-014699 did not 
further decrease TMZ-induced p65 DNA binding compared to either agent alone, 
confirming the survival data which suggested that NF-κB and p65 are linked in a 
common pathway. Importantly, NS siRNA had no effect on TMZ-induced p65 DNA 
binding when compared with TMZ alone (p=0.788, unpaired Student’s t-test). 
 
Figure 6.11B shows that a combination of 10 µM TMZ and 2 Gy IR significantly 
increased p65 DNA binding compared with mock treated controls (p=0.0047, unpaired 
Student’s t-test). Furthermore, Figure 6.15B illustrates that co-incubation with p65 
siRNA reduced this TMZ and IR-increase in p65 DNA binding (p=0.0027). Treatment 
with AG-014699 or PARP-1 siRNA decreased DNA-damage-induced p65 activation, 
although this was not statistically significant (AG-014699; p=0.182, PARP-1 siRNA; 
0.084, compared to TMZ + IR in combination with NS siRNA).  Markedly, a 
combination of p65 siRNA and AG-014699 did not further decrease TMZ and IR-
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induced p65 DNA binding compared to p65 siRNA alone, confirming the survival data 
which suggested that NF-κB and p65 are linked in a common pathway. Importantly, NS 
siRNA had no effect on TMZ and IR-induced p65 DNA binding when compared with 
TMZ and IR-alone (p=0.950, unpaired Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11: PARP-1 protein and enzymatic activity are required for activation of 
p65 DNA binding following TMZ alone, or in combination with IR 
Bar charts showing the effect of TMZ ± IR ± p65 siRNA ± AG-014699 ± PARP-1 siRNA 
± Non-specific (NS) siRNA control on IR-induced NF-κB p65 DNA binding, measured 
using an ELISA-based assay, in U251 cells. (A) TMZ alone, (B) TMZ in combination 
with IR.  
 
Bar charts showing the effect of TMZ ± IR ± p65 siRNA ± AG-014699 ± PARP-1 siRNA 
± Non-specific (NS) siRNA control on IR-induced NF-κB p50 DNA binding, measured 
using an ELISA-based assay, in U251 cells. (C) TMZ alone, (D) TMZ in combination 
with IR.  
All results are the mean of three independent experiments with SEM. Significance relative 
to NS siRNA control using unpaired Student’s t-test ** p<0.01, * p<0.05 
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Figure 6.11C shows that 10 µM TMZ significantly increased p50 DNA binding 
compared with mock treated controls (p=0.0004, unpaired Student’s t-test). In this case, 
both p65 and PARP-1 siRNA significantly inhibited TMZ-induced p50 DNA binding 
(p=0.0057 and p=0.0099, compared to TMZ in combination with NS siRNA). It is 
unlikely that this observation is due to the transfection process since NS siRNA had no 
effect on TMZ-induced p50 DNA binding when compared with IR alone (p=0.520). 
Interestingly, AG-014699 alone or in combination with p65 siRNA had no effect on 
TMZ-induced p50 DNA binding when compared with TMZ in combination with NS 
siRNA (p=0.696 and p=0.887, respectively). 
 
Figure 6.11D shows that a combination of 10 µM TMZ and 2 Gy IR significantly 
increased p50 DNA binding compared with mock treated controls (p=0.020). Both p65 
and PARP-1 siRNA significantly inhibited TMZ-induced p50 DNA binding (p=0.033 
and p=0.05, compared to TMZ + IR in combination with NS siRNA). Again, it is 
unlikely that this observation is due to the transfection process as NS siRNA had no 
effect on TMZ-induced p50 DNA binding when compared with IR alone (p=0.641). 
Interestingly, AG-014699 alone or in combination with p65 siRNA had no effect on 
TMZ-induced p50 DNA binding when compared with TMZ alone (p=0.389 and 
p=0.257, respectively). 
 
6.3.12 Investigation into the induction of single strand breaks following temozolomide 
Previous data showed that regardless of the p65 status of U251 cells, the numbers of 
SSBs were very similar following IR, and that in cells pre-treated with AG-014699 
prior to treatment with IR, the repair kinetics were similar. This data supports the 
conclusion drawn in Chapter 3 that radio-sensitisation by AG-014699 was mediated 
solely by inhibition of NF-κB activation, and independent of the role AG-014699 is 
known to play in the inhibition of SSB repair. This very novel observation therefore 
requires further testing with another DNA damaging agent. Therefore, it was decided to 
undertake a similar set of experiments in the U251 cells, utilising p65 siRNA in 
combination with TMZ.  
 
The induction of SSBs following treatment with TMZ was determined using the 
alkaline Comet assay (section 2.7). U251 cells were incubated overnight prior to 
treatment with 10 µM TMZ, the dose used for all other assays within this study. Cells 
were incubated with TMZ and harvested at various timepoints (0, 2, 4, 6 h) and 
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resuspended in ice-cold PBS before performing the Comet assay (section 7.3.6). 
Analysis was performed as described in section 2.7. The scatter plot in Figure 6.12 
shows that the induction of SSBs following TMZ is time dependent. The maximal 
number of SBBs was observed 2 h following treatment with TMZ, and this persisted 4 h 
after treatment, but then decreased 6 h following TMZ treatment. The 2 h timepoint was 
selected to use for future Comet assay using TMZ, i.e., cells would be exposed to TMZ 
for 2 h, then the media on cells changed and the repair of SSBs assessed over a short 
time-course (0-30 mins), as previously used for IR (Section 6.3.6). 
 
 
 
 
 
 
 
6.3.13 AG-014699 inhibits temozolomide induced-single strand breaks to a similar 
extent in U251 cells regardless of cellular NF-κB status  
The alkaline Comet assay was utilised to assess the effects of p65 siRNA, AG-014699 
or a combination of the two agents on TMZ-induced SSB repair kinetics. U251 cells 
were plated and allowed to adhere overnight before transfection with 50 nM p65 siRNA 
or vehicle control. Cells were then left for 48 h, and pre-treated with AG-014699, or 
DMSO control 1 h prior to treatment with 10 µM TMZ alone or in combination with IR. 
Cells harvested at various timepoints following IR (0, 15, 30 min) and resuspended in 
ice-cold PBS before performing the Comet assay (section 7.3.6). Analysis was 
performed as described in section 2.7. 
Figure 6.12: Single strand DNA breaks are maximal 2 h following TMZ 
treatment 
Scatter diagram showing the extent of single strand breaks (SSBs) in U251cells 
treated with 10 µM TMZ at for various exposure times (0, 2, 4, 6 h). 
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Figure 6.13A versus 6.13B shows that immediately following treatment with 10 µM 
TMZ the number of SSBs is greatest, and importantly that the olive tail moments are 
very similar, regardless of the p65 status of the cells. These scatter plots also illustrate 
that all breaks are repaired 30 minutes following TMZ treatment. Markedly, there was 
no significant difference in the SSB levels remaining in the presence of absence of p65 
siRNA 30 min post-treatment with TMZ, with > 85 % of breaks remaining (shown in 
Figures 6.13A and 6.13B). Most importantly however, AG-014699 inhibited SSB repair 
(as demonstrated by increased residual SSB levels at all time-points post-TMZ) to the 
same extent regardless of whether p65 was present or not. The kinetics of SSB repair in 
cells with or without p65 clearly show that the SSBs generated by TMZ are repaired 
rapidly over time and that in both cell populations the kinetics of repair were very 
similar. Furthermore, regardless of p65 status, cells pre-treated with AG-014699 prior to 
treatment with TMZ, have slower repair kinetics, thus supporting the observations in 
Chapter 3. 
 
Furthermore, figures 6.13C versus 6.13D also illustrate that immediately following 
treatment with a combination of 10 µM TMZ and 2 Gy IR, the number of SSBs is once 
again greatest. Importantly, the numbers of breaks are also very similar, regardless of 
the p65 status of the cells. These scatter plots illustrate that all breaks are repaired 30 
minutes following TMZ treatment. Markedly, there was no significant difference in the 
SSB levels remaining in the presence of absence of p65 siRNA 30 min post-TMZ 
treatment, with 80% of breaks still remaining (shown in Figures 6.13C and 6.13D). 
 
Most importantly however, AG-014699 inhibited SSB repair to the same extent 
regardless of the p65 status. The kinetics of SSB repair in cells with or without p65 
clearly show that the SSBs generated by TMZ are repaired rapidly over time and that in 
both cell populations the kinetics of repair were very similar. Importantly, the assays 
investigating TMZ alone and in combination with IR were carried out simultaneously, 
making them directly comparable. Hence, it should also be noted here that there was an 
increase in the OTM observed in cells treated with TMZ and IR compared with TMZ 
alone. For example, the mean OTM at 0 h in the case of TMZ alone was 18.6 compared 
with a mean OTM of 27.3 for TMZ + IR, suggesting that the two DNA damaging 
agents used in combination induce more SSBs than either agent alone.  
277 
 
 
 
 
 
 
 
Figure 6.13: AG-014699 inhibits SSB repair to a similar extent regardless of cellular NF-
κB status 
Scatter diagramshowing the extent of SSBs in U251cells treated with 10 µM TMZ ± IR ± AG-
014699 (AG, denoted by +) and allowed to repair (0 min, 15 min, 30 min). (A) TMZ ± AG, (B) 
TMZ + p65 siRNA ± AG, (C) TMZ + IR ± AG, (B) TMZ + IR + p65 siRNA ± AG 
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6.3.14 Investigation into IR-induced nuclear translocation of NF-κB p65 in cancer 
cell line models 
Once the effects of IR or TMZ (alone or in combination) on NF-κB activity in the 
glioblastoma U251 cells had been determined, it was decided that a screen a series of 
other cell lines, in a similar manner to that described in section 6.3.1, to find any other 
model systems that may warrant further study. Six cell lines were chosen – two lung 
cancer, one sarcoma and three breast cancer. The rationale behind choosing the lung 
cancer cell lines, H522 and A549 was three fold; firstly radio-therapy is a main-stay of 
lung cancer treatment (Bleehen and Cox, 1985), secondly, there have reports which 
have shown that a PARP inhibitor may have a therapeutic benefit in combination with 
either radio- or chemo-therapy in the disease (Calabrese et al., 2004) and finally the 
literature suggests that both lung cancer cell line models and primary tissues have 
aberrantly active NF-κB (Tang et al., 2006). The sarcoma cell line, U2OS, was chosen 
because a number of groups use this as a model system for studying NF-κB and have 
reported that activation of the subunits after DNA-damaging agents (Campbell et al., 
2006a). 
 
The three breast cancer cell lines, MDA-MB-231, MCF7 and T47D were chosen 
because there is a large body of evidence which details the potential utility of PARP 
inhibitors in breast cancers, and clinical trials with AG-014699 and other compounds 
have been initiated based on these data (Bryant et al., 2005, Drew et al., 2011, Farmer et 
al., 2005, Veuger et al., 2009). Moreover, elevated NF-κB DNA binding activity has 
been demonstrated both in breast cancer cell lines and primary breast cancer tissues 
(Biswas et al., 2001, Nakshatri et al., 1997, Sovak et al., 1997) where it is known to 
contribute to malignant progression through the regulation of gene expression. 
Furthermore, constitutive NF-κB activation is also associated with chemo- and radio-
resistance and also increased metastasis of breast tumours (Biswas et al., 2001, Wu and 
Kral, 2005). Most recently, however, a study was published which showed that PARP-1 
activity was vital for NF-κB activation following IR using the MDA-MB-231 and T47D 
cell lines, and the small molecule inhibitor of PARP-1, AG-14361 (Veuger et al., 2009). 
 
Firstly, constitutive activation of NF-κB p65 and inducible activation by treatment with 
IR was assessed by measuring p65 nuclear translocation following the DNA-damaging 
agent. Briefly, H522, A549, U2OS, MDA-MB-231, MCF7 or T47D cells were seeded 
and allowed to adhere for 24 h before treatment with either 2 Gy or 10 Gy IR. Previous 
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data (Chapter 4) suggested that the response would be rapid, hence cells were harvested 
at early timepoints (0 and 2 h). The levels of p65, Lamin or β-actin were determined by 
Western analyses in nuclear extracts from all three cell lines. Densiometric analysis was 
used to assess the levels of p65 compared to the nuclear protein, Lamin. β-actin was 
used as a control in order to ensure that there was no cytoplasmic contamination of the 
nuclear extracts. 
 
Figure 6.14A illustrates that p65 is translocated to the nucleus of A549 cells at 
immediately following IR, and that this translocation is concentration-dependent. 
Nuclear translocation is induced 3.2-fold immediately following 10 Gy IR but these 
levels return to basal 2 h after treatment with IR. Figure 6.14B shows that p65 nuclear 
translocation was immediately induced by both 2 Gy (1.4-fold) and 10 Gy in the H522 
cells (2.2-fold), but that once again p65 levels return to basal 2 h following IR 
treatment. Figure 6.14C illustrates that p65 is translocated to the nucleus of U2OS cells 
at early timepoints following IR, and that this translocation is concentration-dependent  
(1.6-fold immediately following 10 Gy IR, and approximately 1.7-fold 2 h following 10 
Gy IR). Interestingly, maximal translocation was observed 2 h after treatment with 2 Gy 
IR in the U2OS cells, in which a 2.1-fold increase was observed. Taken together these 
data suggest that further investigation into the use of AG-014699 as a combination 
therapeutic agent with radio-therapy in order to overcome NF-κB-mediated therapeutic 
in lung cancers and sarcomas, are warranted.  
 
Figures 6.14D, 6.14E and 6.14F show that there was no induction of p65 translocation 
at any of the IR doses tested in the MDA-MB-231, MCF7 and T47D cells, respectively. 
In all cases the nuclear extracts were not contaminated with any cytoplasmic proteins, as 
shown by the negative β-actin western blots. These results are somewhat unexpected as 
data generated by Veuger et al., (2009) showed nuclear translocation and activation of 
NF-κB p65 and p50 DNA-binding in both the MDA-MB-231 and T47D cell lines 
following IR. This therefore warrants further investigation.  
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Figure 6.14: p65 nuclear translocation by IR in cancer cell line models 
Western blotting data and bar charts showing nuclear translocation of p65 and 
densiometric analysis, following  IR in cancer cell lines (A) A549, (B) H522 (C) 
U2OS, (D) MDA-MB-231, (E) MCF7 and (F) T47D. Cells were harvested 0 or 2 h 
post-IR and nuclear extracts prepared. Loading was normalised to lamin nuclear 
loading control in all cases. Nuclear extracts were shown to be free of any cytoplasmic 
contamination by blotting with β-Actin antibody. Densiotometry was used to assess 
the levels of p65 compared to the nuclear protein and fold change in p65 expression 
levels are shown in the bar charts below the relevant blotting data. 
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6.3.15 Investigation into the role of PARP-1 in the activation of NF-κB following IR 
using the MDA-MB-231 and T47D cell lines, and the small molecule inhibitor of 
PARP-1, AG-14361  
A previous study performed in the most part by Dr Stephany Veuger using the analogue 
and predecessor to AG-014699 (AG-14361) and the breast cancer cell lines, MDA-MB-
231 and T47D, showed that PARP-1 activity was vital for NF-κB activation following 
IR in these cell lines (Veuger et al., 2009). Hence, these cell lines were chosen for 
further study with the clinically used inhibitor, AG-014699. A summary of the data 
generated by Dr Veuger and to a lesser extent as part of this thesis, using the MDA-MB-
231 and T47D will now be presented here.  
 
Firstly, Veuger et al., (2009) found that the MDA-MB-231 cells had higher nuclear 
expression of both the p65 and p50 subunits compared with the T47D cell line. This is 
consistent with the data presented here (Chapter 7) and reports in the literature 
(Nakshatri et al., 1997). Figure 6.15A and 6.15B shows the induction of p50 and p65 
nuclear translocation, respectively, following 20 Gy IR in the T47D cells, suggesting 
perhaps that the dose of IR used previously in section 6.3.14 of this chapter was too 
low. However, this figure does indicate that this translocation was unaffected by pre-
treatment with the PARP inhibitor, AG-14361, supporting the data shown in Chapter 4 
of this thesis. 
 
 
 
 
 
 
Figure 6.15: Kinetics of p50 and p65 nuclear translocation following IR in T47D cells 
Western blots of nuclear extracts prepared from T47D cells treated with 20 Gy IR ± AG-
14361. Blots were probed for (A) p50 and (B) p65. Bar charts show densitometry 
normalised to Lamin loading controls 
Taken from: (Veuger et al., 2009) 
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Dr Veuger also observed that treatment with IR induced DNA binding of both p65 and 
p50 in the MDA-MB-231 and T47D cells and that the PARP inhibitor, AG-14361 
abrogated induction of DNA binding. The ELISA-based assay (described in section 
2.8.1) revealed that high doses of IR were required to induce an NF-κB response in 
these cell lines, for example, 20 Gy IR was sufficient to activate p65 or p50 in the 
MDA-MB-231 cells whereas a dose of 50 Gy was required to activate DNA binding in 
the T47D cells (Figures 6.16A versus 6.16B. Consistent with these data, Dr Veuger also 
reported that maximal luciferase activity in the MDA-MB-231 cells occurred at a lower 
dose compared with the T47D cell line (10 versus 50 Gy, respectively) using a 
luciferase reporter assay (described in section 2.9). Moreover, AG-14361 inhibited this 
IR-induced transcriptional activation by at least 80% at all IR doses tested (Figure 
6.16C versus 6.16D).  
 
 
 
 
 
 
 
Similar to the work presented in this thesis using the clinical PARP inhibitor (AG-
014699, used in the p65+/+ and p65-/- MEFs, PARP-1+/+ and PARP-1-/- MEFs and the 
U251 cells), Dr Veuger showed that AG-14361 radio-sensitised both the MDA-MB-231 
Figure 6.16: AG-14361 inhibits IR-induced NF-κB DNA binding and 
transcriptional activation 
Bar chart showing the effect of IR ± AG-14361 NF-κB p65 and p50 DNA binding, 
measured using an ELISA-based assay, in MDA-MB-231 (20 Gy) (A) and T47D (50 
Gy) (B) cells. Bar chart showing the effect of IR ± AG-14361 NF-κB transcriptional 
activation, measured using a luciferase reporter assay, in MDA-MB-231 (C) and T47D 
(D) cells.  
Taken from: (Veuger et al., 2009) 
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and T47D cells. In order to confirm these data for the subsequent publication of our 
joint data in Oncogene (Veuger et al., 2009), studies were also undertaken as a 
contribution to this thesis. To this end, it was essential to confirm the results of the 
survival data generated by Dr Veuger, to demonstrate an induction of apoptosis in the 
breast cancer cell lines. Caspase-3 activity is up-regulated in cells with reduced NF-κB 
activity (Cardoso and Oliveira, 2003), hence caspase-3 activity assays were to 
undertaken following IR alone, and in combination with AG-14361. However, to 
further confirm these data, it was decided to directly compare AG-14361 with p65 
siRNA in this case in order to strengthen the existing body of data by Dr Veuger. 
 
It was important to ascertain whether knockdown of p65 was achievable in the MDA-
MB-231 and T47D cells. Thus, siRNA targeting p65 were used to silence this protein in 
these cells, in order to use knockdown of p65 in direct comparison with AG-14361, as 
had been done previously in the p65+/+, p65-/-, PARP-1+/+ and PARP-1-/- MEFs. Briefly, 
MDA-MB-231 or T47D cell were seeded and left for 24 h to adhere before lipid 
transfection with 50 nM of siRNA oligos targeting p65, or a non-specific (NS) control 
(Table 2.2). Cells were harvested 48 h later, whole cell extracts were prepared (as 
described in section 2.5.2). The levels of p65 were determined by Western analyses and 
densiometric analysis was used to assess the levels of protein knockdown compared to 
the house-keeping protein, β-actin. 
 
Figure 6.17 shows that there is a reproducible reduction in p65 protein expression, 
(>95%) in both the MDA-MB-231 and T47D cells, and when compared with untreated 
control cells, using an Unpaired Student’s t-test, there was a significant knockdown in 
both cell lines (p<0.0001, MDA-MB-231 and p<0.0001, T47D). (Figures 6.17A and 
6.17B). Importantly, there were no significant differences in p65 or PARP-1 protein 
expression between the control NS siRNA and untreated control cell extracts. Blots 
shown are representative of three independent experiments. 
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Once p65 knockdown was reproducibly achieved in both cell lines, caspase-3 assays 
were undertaken, as described in section 2.6.2. Briefly, MDA-MB-231 or T47D cells 
were incubated for 24 h. Cells were then transfected with 50 nM p65 siRNA, 50 nM NS 
siRNA or vehicle alone control (mock-treated cells) and incubated for 48 h. Cells were 
pre- treated with AG14361 for 1 h prior to treatment with 20 Gy IR and allowed to 
recover at 37 5 % CO2 for 24 h before the Caspase-Glo 3/7 assay was performed. Data 
were normalised to mock treated controls. 
 
Figure 6.18A shows that when compared with IR alone (mock), both p65 knockdown 
and AG-14361 significantly increased caspase 3/7 activation following 20 Gy IR in the 
MDA-MB-231 cell line (p=0.007 and p=0.008, respectively, unpaired Student’s t-test). 
Importantly, when AG-14361 was used in conjunction with p65 knockdown, there was 
no further increase in caspase 3/7 activity in the MDA-MB-231 cells, compared to 
either agent alone. These results were echoed in the T47D cells (Figure 6.18B); when 
compared with IR alone (mock), both p65 knockdown and AG-14361 significantly 
increased caspase 3/7 activation following 20 Gy IR in the T47D cell line (p<0.0001 
and p=0.0008, respectively). When AG-14361 was used in conjunction with p65 
Figure 6.17: siRNA knockdown of p65 and PARP-1 in breast cancer cells 
(A) Western blots (left panel) of whole cell extracts of MDA-MB-231 cells at 48 h after 
transfection with vehicle alone (Mock), non-specific (NS) siRNA or p65 siRNA. p65 
protein expression in MDA-MB-231 cells expressed as a percentage of NS siRNA cells 
(right panel). (B)Western blots of whole cell extracts of T47D cells at 48 h after 
transfection with vehicle alone (Mock), NS siRNA or p65 siRNA. P65 protein 
expression in T47Dcells expressed as a percentage of NS siRNA cells. Results shown 
are the mean + SEM of 3 independent experiments. *** Significance relative to NS 
siRNA control was p<0.0001 using Student’s unpaired t-tests. 
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knockdown, there was no further increase in caspase 3/7 activity in the T47D cells, 
compared to either agent alone. Furthermore, no increase in apoptosis was observed 
when NS siRNA was used in combination with IR, compared with IR alone, in either 
cell line (p=0.879, MDA-MB-231 and p=0.115, T47D). Taken together, the data 
generated by Dr Veuger here, and as part of this thesis, demonstrate that PARP-1 
activity was vital for NF-κB activation following IR using the MDA-MB-231 and T47D 
cell lines, when using the PARP inhibitor, AG-14361. 
 
 
 
 
6.3.16 Investigation into the nuclear translocation of p65 in breast cancer cell lines 
following TNF-α 
The data presented in section 6.3.18 (Veuger et al., 2009), provided a clear rationale for 
further investigation into the use of AG-014699 in breast cancer cell lines. However, the 
Western blotting data in section 6.3.17, using MDA-MB-231, MCF7 and T47D cells 
showed that induction of p65 nuclear translocation was not achievable at relatively low 
doses of IR (Figures 6.14D, 6.14E and 6.14F). In the other studies within this thesis, the 
dose of IR has been low, with the maximum dose used being 10 Gy, however, data from 
the study by Dr Veuger suggests that higher doses of IR may be required. This is not 
considered to be clinically relevant, since 2 Gy is the used as a single dose in the clinic 
and sequential dosing results in an increased cumulative dose. Therefore, before testing 
p65 translocation following high doses of IR, it was decided to determine whether p65 
nuclear translocation was achievable at low concentrations of TNF-α, such as the 10 
ng/ml used previously in Chapter 4. The cytokine, TNF-α, is widely considered to be 
the most classical activator of NF-κB (Perkins, 2007), and is therefore used as a 
reference point for many studies measuring activity the transcription factor. 
Figure 6.18: Induction of caspase-3 activity following IR in breast cancer cell lines 
The effect of IR ± AG14361 ± p65 siRNA on the induction of caspase-3 activity at 24 h 
A B
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Western blotting was used in order to determine whether TNF-α could induce p65 
nuclear translocation in the breast cancer cell lines. MDA-MB-231, MCF7 or T47D 
cells were incubated for 24 h before treatment with10 ng/ml TNF-α. Previous data 
(Chapter 4) suggested that the response to TNF-α would be rapid, hence cells were 
harvested at early timepoints (0 and 2 h) and nuclear extracts were prepared from all 
three cell lines before the levels of p65, Lamin or β-actin were determined by Western. 
Figure 6.19 shows that p65 is translocted to the nucleus of MDA-MB-231, MCF7 and 
T47D cells with a fold increase of 3.1-, 2.5- or 2.1-fold, respectively, 2 hours after 
treatment with TNF-α. These data clearly show that translocation of p65 to the nucleus 
of all of the breast cancer cell lines was achievable at low concentrations of TNF-α, 
warranting further investigations with higher concentrations of IR and perhaps other 
DNA damaging agents. 
 
 
 
 
 
 
 
 
 
 
6.3.17 Investigation into the activation of NF-κB following DNA damaging agents in 
breast cancer cell lines 
Figure 6.19: p65 nuclear translocation by TNF-α in breast cancer cell line models 
Western blotting data and bar charts showing nuclear translocation of p65 and 
densiometric analysis, following  TNF-α in three breast cancer cell lines (A) MDA-MB-
231, (B) MCF7 and (C) T47D. Cells were harvested 0 or 2 h post-TNF-α and nuclear 
extracts prepared. Loading was normalised to lamin nuclear loading control in all cases. 
Nuclear extracts were shown to be free of any cytoplasmic contamination by blotting with 
β-Actin antibody. Densiotometry was used to assess the levels of p65 compared to the 
nuclear protein and fold change in p65 expression levels are shown in the bar charts below 
the relevant blotting data. 
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Once it had been shown that low concentrations of TNF-α could induce nuclear 
translocation of p65, it was decide to investigate further using a higher dose of IR (20 
Gy), as this dose had been utilised in the study by Dr Veuger (2009). Another DNA 
damaging agent, the topoisomerase II poision, doxorubicin (DOX) was also studied 
because it is one of the most widely used treatments for breast cancer (Hoogstraten et 
al., 1976), and it has also been shown to induce an NF-κB response (Campbell et al., 
2006a). Both IR and DOX are known to induce a DNA damage response (DDR) in 
cells, and therefore these agents were used to confirm that the breast cancer cells had an 
intact DDR, in parallel with Western blotting to measure p65 translocation. It has been 
well documented that the DNA-PK undergoes automodification following DNA 
damage and a marker of this is phosphorylation of the serine residue at 2056 (S2056) 
(Chen et al., 2005a). Therefore, Western blots would be probed with antibodies against 
phosphorylated-DNA-PK (S2056) and full length protein (DNA-PK). 
 
MDA-MB-231, or T47D cells were incubated 24 h before treatment with either 20 Gy 
or 1 µM DOX. Previous data (Chapter 4) suggested that the response to IR would be 
rapid (Chapter 4), however, in this case a range of time-points were investigated (0, 2, 6 
and 24 h) to ensure no activation was missed. The levels of p65, DNA-PK (S2056), 
DNA-PK, Lamin or β-actin were determined by Western analyses in nuclear extracts 
from all three cell lines. β-actin was used as a control in order to ensure that there was 
no cytoplasmic contamination of the nuclear extracts. 
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Figures 6.20A and 6.20B show the results from MDA-MB-231 and T47D cells, 
respectively. The nuclear levels of p65 appear to be constant in both of these cell lines 
regardless of the treatment they had received or the time-point at which they were 
harvested. This indicates that p65 is not translocated to the nucleus of these cells 
following DNA damage. These blots have cytoplasmic extracts alongside the nuclear 
extracts of interest and it is clearly visible that there is no contamination of the nuclear 
fraction with cytoplasmic proteins, by virtue of the absence of β-actin in the nuclear 
extracts. Similarly, there were no nuclear proteins leftover during the cytoplasmic 
fractionation, as indicted by the fact that no Lamin or DNA-PK, was present in these 
lanes. Moreover, treatment with either 20 Gy IR or 1 µM DOX induced a DDR at all 
time-points tested, as indicated by an increase in the phosphorylation of DNA-PK at 
serine 2056, compared with untreated controls. This shows that these cells have an 
intact DDR, and the lack of NF-κB activation by DNA damaging agent cannot be 
attributed to a non-functional DDR. 
 
It was thought that any change in the expression of p65 following DNA may be too 
subtle to view by Western blotting, hence it was decided to run the extracts that had also 
been used in Western blotting, and others prepared independently, on the DNA binding 
Figure 6.20: Investigation into the activation of NF-κB following DNA damaging 
agents in MDA-MB-231 and T47D cells. Western blotting data showing nuclear 
translocation of p65 and phosphorylation of DNA-PK, following  IR or DOX in  MDA-MB-
231 (A) and T47D (B)  cells. Cells were harvested 0, 2, 6 or 24 h post-IR or DOX and 
nuclear extracts prepared. Loading was normalised to lamin nuclear loading control in all 
cases. Nuclear extracts were shown to be free of any cytoplasmic contamination by blotting 
with β-Actin antibody. 
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ELISA. Using this method any effect on the other subunits, p52, RelB or c-Rel could be 
assessed simultaneously. In this case, MDA-MB-231 or T47D cells incubated for 24 h 
prior to treatment with 1 µM DOX or 20 Gy IR. Cells were harvested at various 
timepoints (0, 2, 6, and 24 h), the nuclear extracts were prepared and DNA binding 
binding was assessed using the TransAM NF-κB family ELISA kits (section 2.8.2).  
 
Each one of the five bar charts in Figure 6.21 represent the DNA binding activity of the 
MDA-MB-231 cells over time of each individual subunit, p65, p50, p52, RelB and c-
Rel. In all cases, the open bars represent untreated cells, the black bars represent cells 
treated with 20 Gy IR, and the hatched bars represent cells treated with 1 µM DOX. The 
data presented indicates that there is no induction of DNA binding, in any of the five 
subunits, at any of the time-points tested, by either of the DNA damaging agents tested. 
These data support the Western blotting data shown in Figures 6.20B. Similar data was 
obtained using the T47D cell line (Figure 6.22). 
 
 
 
Figure 6.21: Investigation into the activation of NF-κB DNA binding following DNA 
damaging agents in MDA-MB-231 cells. Bar charts showing DNA binding of p65 (A), p50 
(B), p52 (C), RelB (D) and c-Rel (E), following  IR or DOX in  MDA-MB-231 cells.  
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6.4 Discussion 
Previous work within this thesis has demonstrated that PARP-1 knockdown and the 
PARP inhibitor, AG-014699 significantly decreased survival and induced apoptosis 
following IR in p65+/+ MEFs whilst having no effect in p65-/- MEFs. A combination of 
AG-014699 and p65 knockdown did not further enhance this response, which is 
consistent with reports that PARP-1 and NF-κB are mechanistically linked in a common 
pathway (Chang and Alvarez-Gonzalez, 2001, Hassa et al., 2001, Hassa and Hottiger, 
1999, Martin-Oliva et al., 2004, Stilmann et al., 2009, Veuger et al., 2009). Moreover, 
the very novel observations in Chapter 3, detail how the levels of IR-induced SSBs in 
p65+/+ and p65-/- MEFs were similar and that both cell lines were equally proficient at 
their repair. AG-014699 was also able to increase the level of breaks to the same extent 
in both cell lines, consistent with the known role of PARP-1 in base excision repair 
(Durkacz et al., 1980). Thus, these data lead to the conclusion that the potentiating 
effect of AG-104699 when used in conjunction with IR is, in part, a consequence of 
PARP-1 downstream signaling to NF-κB. However, all of these data were generated 
Figure 6.22: Investigation into the activation of NF-κB DNA binding following DNA 
damaging agents in T47D cells. Bar charts showing DNA binding of p65 (A), p50 (B), 
p52 (C), RelB (D) and c-Rel (E), following  IR or DOX in  T47D cells.  
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using MEFs, and it was vital to determine the potential utility in cancer model systems, 
and also test the hypothesis that PARP inhibitors would not only inhibit IR-induced NF-
κB activation, but also NF-κB activation by other clinically-used DNA damaging 
agents. 
 
The choice of model in which to study the effects of AG-014699 on DNA-damage-
induced NF-κB activation was important. Glioblastoma was selected. Firstly, because 
there had been a number of reports that had detailed both radio- and chemo-sensitisation 
by PARP inhibitors, in both cell line and xenograft models of the disease (Chalmers, 
2010). However, these reports showed that this sensitisation was due to the inhibition of 
SSB repair, and other mechanistic investigations were not undertaken. Secondly, there 
were also reports in the literature which suggested that aberrant activation of NF-κB 
played an important role in the tumourigenesis of both diffuse and high-grade gliomas 
(Kanzawa et al., 2003, Wang et al., 2004). Taken, together this made glioblastoma, in 
which cell line models were readily available, an obvious choice for further study. 
 
The initial screen of three glioblastoma cell lines, showed that all three had 
constitutively nuclear p65, consistent with reports that NF-κB is aberrantly active in this 
tumour type (Kanzawa et al., 2003, Wang et al., 2004). Importantly, in two of the three 
cell lines, p65 activation, by virtue of its nuclear translocation, was further induced by 
relatively low doses of IR. However, only the U251 cell line was chosen for further 
investigation. The MO59J line was derived from a glioma tumour lacking DNA-PK 
(Lees-Miller et al., 1995), and in this case p65 nuclear translocation was not inducible 
following IR in this cell line. DNA-PK is vital for the DNA damage response (Zhou and 
Elledge, 2000), in particular mediating the repair of double stranded DNA breaks via 
the non-homologous end joining pathway (Sancar et al., 2004). Moreover, DNA-PK has 
been implicated in the activation of NF-κB following DNA damage (Basu et al., 1998, 
Ju et al., 2010, Liu et al., 1998, Panta et al., 2004), as discussed in section 1.4.2.  
 
There is an increasing body of evidence in the literature which details how PARP 
inhibitors may be of therapeutic value in glioblastoma (Chalmers et al., 2004, Cheng et 
al., 2005, Dungey et al., 2009). However, in general, studies lack a clear mechanistic 
aspect, something which has been addressed in this chapter by investigating the use of a 
PARP inhibitor in glioblastoma in the context of the inhibition of NF-κB. Glioblastoma 
multiforme (GBM) tumours are the most common and most aggressive primary brain 
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tumours. Current treatment comprises surgical resection followed by radio-therapy with 
concomitant and subsequent adjuvant TMZ, and despite such an aggressive treatment 
regimen, median survival in the UK is only 1 year (Chalmers, 2009). Hence, the 
decision to investigate the role of the PARP inhibitor, AG-014699 following IR or 
TMZ, or the combination of both DNA damaging agents, as novel treatment strategies 
was justified.  
 
The data presented here are in concordance with existing data that the addition of a 
PARP inhibitor can sensitise glioblastoma cells to either radio- or chemo-therapy. It is 
however, the first study in GBM to investigate the combination of IR, TMZ and a PARP 
inhibitor and show that the addition of this type of agent, in this case AG-014699, 
clearly sensitises U251 cells to this treatment regimen. Although the side effects of 
radio-therapy and TMZ, currently given concomitantly for GBM, can be severe, current 
reports from clinical trials using AG-014699 show it has a very low toxicity profile 
(Plummer et al., 2005, Plummer et al., 2008). Taken together these data strongly suggest 
that the use of AG-014699 in GBM would represent a potential therapeutic avenue. 
Furthermore, aberrant activation of NF-κB is known to play a role in the tumourigenesis 
of both diffuse and high-grade gliomas (Kanzawa et al., 2003, Wang et al., 2004). 
 
GBM is unique in that tumours exhibit high proliferation rates while the surrounding 
normal tissue dividing at an altogether much lower rate (Chalmers, 2009). Radio-
therapy is the main-stay of GBM treatment, and therefore it is necessary to treat large 
volumes of normal brain tissue which can result in irreversible neurotoxicity (Griebel et 
al., 1991), thus any agent used in combination with radio-therapy must by highly 
tumour specific, which is the case for AG-014699 has been proven against PARP 
(Plummer et al., 2008). Moreover, AG-014699 has been shown to have the ability to 
cross the blood-brain-barrier (Daniel et al., 2009), something which is essential in the 
treatment of GBM.  Interestingly, a study performed by Dungey et al., (2008) showed 
that the radio-sensitising effects of the KuDOS/AstraZeneca PARP inhibitor, KU-
0059436, were specific to cells undergoing DNA replication (Dungey et al., 2008), 
hence providing further rationale for the use of PARP inhibitors as radio-sensitising 
agents in GBM. 
 
The data presented here illustrating that AG-014699 sensitises cells to TMZ treatment 
are important. At least half of all GBM tumours are refractory to TMZ treatment 
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because they express the repair protein methyl guanine methyl transferase (MGMT) 
(Chalmers, 2009). One report showed that PARP inhibition increased TMZ sensitivity 
in cells expressing MGMT (Plummer et al., 2005), therefore the addition of AG-014699 
may open up a new therapeutic avenue, for the treatment of poor prognosis patients, in 
which current treatments remain ineffective. 
 
Importantly, this study is also the first to investigate the role of PARP in DNA-damage-
activated NF-κB in GBM. Reports in the literature suggested that aberrant activation of 
NF-κB played an important role in the tumourigenesis of both diffuse and high-grade 
gliomas (Kanzawa et al., 2003, Wang et al., 2004). Therefore, it was important to 
determine whether the observations in Chapter 3 and 4 of the thesis, showing that radio-
sensitisation by AG-014699 was mediated via NF-κB, was also the case in the U251 
glioblastoma cell line. The use of p65 siRNA, AG-014699, PARP siRNA or a 
combination of p65 siRNA and AG-014699 in the clonogenic survival assays following 
IR alone, TMZ alone or a combination of IR and TMZ clearly indicate that radio- or 
chemo-sensitisation observed with the PARP inhibitor was mediated via the inhibition 
of DNA-damaged activated NF-κB p65, supporting the existing data in this thesis.  
 
The Comet assay data generated within this chapter supported the novel findings in 
Chapter 3 that the potentiating effects of AG-104699 when used in conjunction with 
DNA damaging agents are, in part, a consequence of PARP-1 downstream signaling to 
NF-κB. These observations have greatly strengthened the data generated using the p65 
paired MEFs, and add to weight to the conclusion that chemo- or radio-sensitisation by 
AG-014699 is mediated, in part, by inhibition of NF-κB activation. The p65 DNA 
binding in the U251 cells also supports the finding described in Chapter 4, showing that 
both PARP-1 protein and enzymatic activity were required for DNA-damage induced 
p65 DNA binding. IR alone, TMZ alone or a combination of both of these agents 
induced p65 DNA binding and this was abrogated by co-incubation with either p65 
siRNA, PARP-1 siRNA or AG-014699. Importantly, the combination of p65 siRNA 
and AG-014699 had no further effect on p65 DNA binding compared with either agent 
alone, thus supporting the proposed mechanism in Chapter 4. These data suggesting that 
p65 DNA binding requires the catalytic function of PARP-1 are consistent with other 
reports in the literature (Chang and Alvarez-Gonzalez, 2001, Chiarugi and Moskowitz, 
2003, Nakajima et al., 2004, Stilmann et al., 2009, Veuger et al., 2009, Zingarelli et al., 
2003b). Importantly, the inhibitor used here is highly potent and specific for PARP, 
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compared with the use of classical compounds, such as 3-AB, which are known to have 
off target effects (Moses et al., 1990). Also the direct comparison with PARP-1 siRNA 
showed that the effects observed are mediated solely by PARP-1. 
 
However, p50 DNA binding following IR, TMZ or a combination of IR and TMZ, has 
provided some interesting observations. All of these damaging agents induced p50 
DNA binding, however this effect was mitigated by the addition of p65 siRNA or 
PARP-1 siRNA. AG-014699 alone or in combination with p65 siRNA had no effect on 
DNA-damage induced p50 DNA binding. It is perhaps not surprising that loss of p65 
protein results in an inhibition of DNA-damage induced p50 DNA binding, and in this 
case p50 has lost its most common hetero-dimeric partner (Chen et al., 1998). 
Interesting, the inhibition of DNA-damage induced p50 DNA binding by co-incubation 
with PARP-1 siRNA suggests that p50 DNA binding requires PARP-1 protein but not 
enzymatic activity, in line with reports from other research groups (Hassa et al., 2001, 
Martin-Oliva et al., 2006).  These data suggest that that PARP-1 may facilitate a 
structural role in the p50 transcriptional complex, following IR, TMZ or a combination 
of both agents in the U251 cells. This is consistent with the work of Hassa et al., (2003 
JBC), which illustrated how the physical presence of the PARP-1 C-terminal catalytic 
domain, but not its enzymatic activity, was required for PARP-1 and p300 to 
synergistically activate NF-κB-dependent transcription following either TNF-α or LPS, 
although this report did not investigate NF-κB activation following DNA damage, as 
has been undertaken here. 
 
The absence of any p65 nuclear translocation or NF-κB subunit DNA binding in 
response to DNA damaging agents in the breast cancer cells lines is somewhat puzzling. 
It is well documented that elevated NF-κB DNA binding activity in both breast cancer 
cell lines and primary breast cancer tissues contributes to malignant progression and 
resistance to treatment (Biswas et al., 2004, Nakshatri et al., 1997, Sovak et al., 1997). 
There have also been a number of reports in the literature which have shown that DNA 
damaging agents can induce an NF-κB response in various breast cancer cell lines, and 
consequently that therapeutic intervention with an NF-κB inhibitor can inhibit such an 
NF-κB response. For example, Wang et al., (2005) demonstrated that as little as 5 Gy 
IR was necessary to induce NF-κB DNA binding, measured using an electrophoretic 
mobility shift assay (EMSA), and also NF-κB-dependent gene transcription, measured 
using a luciferase reporter assay (Wang et al., 2005), similar to the one used in this 
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thesis. This data is supported by that of Guo et al., (2003), which showed that a there 
was a 2-fold induction of NF-κB-dependent gene transcription following 5 Gy IR, 
which was abrogated in the presence of the IκB super repressor (Guo et al., 2003). 
Furthermore, Madhusoodhanan et al., (2010) illustrated induction of an NF-κB response 
in MCF7 cells using an EMSA by as little as 2 Gy IR (Madhusoodhanan et al., 2010). 
These data suggest that NF-κB activation should have been observed in the MCF7 cells 
especially as in this case the doses of IR tested included were higher than that described 
in the literature. Many different batches of these cells were use for the assays 
undertaken here and in order to rule out the possibility that the cell line may have 
‘drifted’ during continuous culture. 
 
An investigation using either DOX or TNF-α to activate NF-κB in the MDA-MB-231 
cells was undertaken by Ho et al., (2005) who showed that low doses of TNF-α induced 
NF-κB DNA binding at early time-points. The data shown within this chapter illustrated 
that p65 was translocated to the nucleus 1 h following treatment with the cytokine. Chi 
Ho et al., observed that 5 µmol/L DOX also induced NF-κB DNA binding in MDA-
MB-231 cells, however the kinetics of this were slightly slower, with maximal 
activation noted 3 h following treatment (Ho et al., 2005). Moreover, Munoz-Gamez et 
al., (2005) showed that PARP inhibition using the PARP inhibitor, ANI (4-amino-1,8-
naphthalimide) sensitised MDA-MB-231 cells to 1 µM DOX, the same concentration 
tested in this chapter. This group found that NF-κB activation by DOX was maximal 24 
h after treatment, but interestingly that co-incubation with ANI had no effect on DOX-
induced NF-κB DNA binding (Munoz-Gamez et al., 2005). These data suggest that 
activation of NF-κB following DOX should have been achievable in the MDA-MB-231 
cells, at the concentrations and time-points tested, especially taken with the data 
presented here which illustrates that these cells have a functional DDR. However, the 
report from Munoz-Gamez et al., (2005) which showed that PARP inhibition had no 
effect on DOX-induced NF-κB activation, is perhaps expected. DOX is primarily an 
agent which induces double stranded DNA breaks (Lyu et al., 2007) and PARP-1 is 
known to be activated, in the main, by SSBs, hence activation of PARP-1 and 
subsequent single strand repair pathways is unlikely with DOX. However, it is 
noteworthy that DSBs are actually the most potent activator of PARP-1 activity. 
 
The published work by Dr Veuger (Veuger et al., 2009) and as part of this chapter 
showed that PARP-1 activity was vital for NF-κB activation following IR using the 
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MDA-MB-231 and T47D cell lines, and the small molecule inhibitor of PARP-1, AG-
14361. Dr Veuger showed that nuclear translocation of both p65 and p50 occurred 
following 20 Gy IR in the T47D cells, something which could not be repeated in the 
studies for this thesis. Moreover, the data from Dr Veuger’s publication also detailed 
how 20 Gy IR was required to activate p65 or p50 DNA binding in the MDA-MB-231 
cells whereas a dose of 50 Gy was required to activate DNA binding in the T47D cells. 
However, DNA binding of all subunits, which was assessed as part of this chapter 
(following 20 Gy IR) was not inducible. It was decided not to use the dose of 50 Gy, as 
this is 25 times the single clinically relevant dose. In all of the initial assays the batches 
of the MDA-MB-231 and T47D cells were from stocks frozen down by Dr Veuger, and 
subsequent assays utilised other stocks from the Northern Institute for Cancer 
Research’s cell line bank, suggesting that the cell line is not an issue and has not 
‘drifted’ in continuous culture. One explanation for the discrepancy between the data 
from Dr Veuger’s study and that obtained within this thesis could be the irradiator used. 
Although the same equipment was used for both studies, there were some technical 
issues with calibration of the instrument during the course of study. Therefore some 
variation in dose given is possible.  
 
6.5 Summary and future work 
The data shown within this chapter using AG-014699 and siRNA targeting NF-κB p65 
in the U251 glioblastoma cell line, supports the data generated from chapters 3 and 4 
using the p65 proficient and deficient MEFs. The studies in this chapter have shown that 
inhibition of PARP-1 modulates the apoptotic response not just to IR but also to the 
mono-functional alkylating agent, TMZ, and most importantly that the potentiation of 
cytotoxicity by PARP-1 inhibition is due to the loss of NF-κB activation. Strikingly, the 
Comet assay data demonstrates that both chemo- and radio-sensitisation by PARP 
inhibition is due to inhibition of NF-κB, and not the prevention of DNA repair. These 
data not only support the existing literature which suggests that the addition of a PARP 
inhibitor to current therapeutic regimen would be an advantageous (Chalmers et al., 
2004, Cheng et al., 2003, Dungey et al., 2009), but also they show the mechanism by 
which PARP inhibition functions, namely via the inhibition of DNA-damage-induced 
NF-κB activation. Since this study was undertaken in the most part in just one 
glioblastoma cell line, it would be advantageous to repeat such experiments in further 
cell line models of the disease and also importantly, in xenograft models. 
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The data within this thesis suggested that other cancers may warrant further 
investigation, but unfortunately in the time-scale this was not possible in this thesis. 
There is clear rationale for future studies in lung cancer in particular. Studies have 
shown radio-sensitisation in vitro models of the disease and in vivo radio-sensitisation 
has also been observed in xenograft models (Albert et al., 2007, Brock et al., 2004, 
Calabrese et al., 2004, Donawho et al., 2007). Combination studies using various PARP 
inhibitors with TMZ have been undertaken in human lung cancer cell lines and 
xenografts (Calabrese et al., 2004), and these studies have shown pronounced chemo-
sensitisation in vitro and tumour growth inhibition in vivo. Moreover, groups have also 
described the aberrant activation of NF-κB in lung cancer cell line models and primary 
samples, and shown that this contributes to poor prognosis and disease progression 
(Basseres et al., 2010, Tang et al., 2006). 
 
Interestingly, it appears in figures 6.5A, 6.5B, 6.11A, 6.11B, 6.11C, 6.11D and 6.18A 
that AG-014699 antagonises the effects of p65 siRNA following DNA damage. This is 
something which warrants further investigation. It is plausible that in this case one or 
more of the other NF-κB subunits is compensating for the loss of p65 and inhibition via 
AG-014699. Therefore it would be interesting to assay which dimers were present, and 
active, in these cells following p65 siRNA or the combination of p65 siRNA and AG-
014699. 
 
The interesting observations showing that p65 nuclear translocation was not inducible 
following DNA damage in the DNA-PK deficient MO59J cells but inducible in the 
DNA-PK proficient MO59J-Fus-1 cells, warrants further study. DNA-PK has been 
implicated in the activation of NF-κB following DNA damage by a number of groups 
(Basu et al., 1998, Ju et al., 2010, Liu et al., 1998, Panta et al., 2004). Interestingly, 
Panta et al., (2004) reported that DNA-PKcs activates NF-κB induction in the MEK/ 
ERK/p90rsk  to IKK signalling pathway in response to treatment with 5µM AD288, a 
catalytic inhibitor of topoisomerase II N-benzyladriamycin but not in response to DOX. 
Catalytic inhibitors of topoisomerase II do not cause DNA damage, unlike 
topoisomerase II poisons, such as DOX, suggesting that DNA-PK can activate NF-κB 
in the absence of DNA damage, something which would be interesting to study further. 
 
The inability to activate NF-κB in the three breast cancer cell lines was somewhat 
surprising, and as a consequence it meant that further study into the effects of AG-
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014699 on NF-κB activation were not applicable. However, these data require further 
investigation, and the Northern Institute for Cancer Research has recently acquired a 
piece of imaging equipment which allows the visualisation and quantification of protein 
translocation at the single cell level. This would allow observation of the shuttling of 
p65, for example, from cytoplasm to nucleus, in real-time following DNA damage. It 
could be the case that nuclear translocation is occurring in only a small percentage of 
the breast cancer cells treated following DNA damage, and this method would gain 
insight into such phenomenon. 
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Chapter 7: Preclinical testing of a series of NF-κB subunit DNA 
binding inhibitors, both in combination with radio-therapy and as 
stand-alone agents 
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7.1 Introduction 
NF-κB has been implicated in both inflammatory disease and cancer, therefore making 
inhibition of the transcription factor an attractive target for therapy. To date, there are 
over 750 known inhibitors of the NF-κB pathway and these can be divided into broad 
categories depending on which points of the NF-κB activation pathway they target. For 
example, there are naturally occurring substances or chemical inhibitors that act at the 
receptor or adaptor level or those which directly target the IKK complex, such as 
parthenolide. Proteosomal inhibitors, for example bortezomib, which is licensed for use 
in multiple myeloma, inhibit the degradation of IκB, whilst other compounds prevent 
the nuclear translocation or DNA binding of NF-κB (Gilmore and Herscovitch, 2006). 
 
Many chemical NF-κB inhibitors, such as those which target proteosmal degradation, 
do not specifically target the NF-κB pathway alone. Although bortezomib has 
demonstrated considerable efficacy against multiple myeloma both in vitro and in vivo 
(Adams, 2004), it is not clear whether these anti-tumour effects are mediated entirely by 
the inhibition of NF-κB (Hideshima et al., 2009). Many other proteins are targeted for 
proteosomal degradation, including the tumour suppressor p53 (Asher and Shaul, 2005), 
so it is possible that the efficacy of bortezomib and other proteasome inhibitors is due to 
the stabilisation of other key proteins with known roles in cancer, other than NF-κB. 
 
Moreover, NF-κB plays a vital role in the inflammatory response and it is well 
documented that the IKK subunit, IKKβ is the primary participant in the production of 
pro-inflammatory stimuli associated with NF-κB activation (Aupperle et al., 1999, Tak 
and Firestein, 2001). For example, Aupperle et al., (1999) showed that IKKβ is 
expressed in fibroblast-like synoviocytes and has a crucial role in NF-κB activation 
following either TNF-α or IL-1. Thus, complete inhibition of the IKK complex, with 
derivatives of the naturally occurring compounds like parthenolide (Yip et al., 2004), or 
even specific IKKβ inhibitors, may have adverse effects by compromising the vital 
immune functions mediated by NF-κB. Furthermore, the IKK complex has many other 
functions within the cell, including the regulation of autophagy (Carrillo et al., 2004, 
Chariot, 2009). Therefore, IKK inhibitors may not be specifically targeting the NF-κB 
pathway and may have undesirable side effects. 
 
Profectus Biosciences Inc., (Baltimore, MD) have recently developed several families 
of NF-κB inhibitors. One of these compounds, PBS-1086 was found to be a Rel 
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inhibitor of NF-κB DNA binding, specifically meaning that this compound targets the 
Rel domain of the NF-κB subunits, therefore inhibiting the DNA binding of all of the 
subunits, resulting in the inhibition of NF-κB. PBS-1086 has been reported as a more 
potent inhibitor of both RelA and RelB DNA binding than the widely known NF-κB 
inhibitors, parthenolide and DHMEQ (Oh et al., 2011).  Oh et al., (2010), reported that 
PBS-1086 suppressed spontaneous lympho-proliferation and inhibited the production of 
pro-inflammatory cytokines in PBMCs from HTLV-I–associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) patients via the inhibition of NF-κB DNA binding. To 
this end, PBS-1086 was shown to be a Rel inhibitor and therefore inhibit the DNA 
binding of p65, p50 and RelB as well as luciferase expression in a 293/NF-κB-
luciferase reporter cell line (Oh et al., 2011). 
 
7.2 Aims and hypothesis 
The aims of this chapter were to screen a panel of NF-κB inhibitors (provided by 
Profectus Biosciences Inc) in p65 proficient MEFs in order to determine which were the 
most potent and specific, and, efficacious in vitro, and to investigate the utility of such 
compounds as radio-sensitising agents. The hypothesis that any radio-sensitisation 
would be mediated via the canonical pathway would also be tested by using siRNA 
targeting the p65 subunit of NF-κB as a direct comparison with the most promising 
compounds.   
 
Furthermore, the potential utility for use of these compounds as mono-therapies would 
also be investigated using a panel of breast cancer cell lines. Elevated NF-κB DNA 
binding activity has been demonstrated both in breast cancer cell lines and primary 
breast cancer tissues (Biswas et al., 2004, Nakshatri et al., 1997, Sovak et al., 1997). 
Constitutive NF-κB activation has been shown to contribute to malignant progression 
through the regulation of gene expression. Therefore the hypothesis that inhibition of 
NF-κB DNA binding would induce cell death in breast cancer cells expressing 
aberrantly active NF-κB would be tested. 
 
Furthermore, constitutive NF-κB has been associated with chemo- and radio-resistance 
and also increased metastasis of breast tumours (Biswas et al., 2001, Wu and Kral, 
2005). Radio-therapy is one of the main-stays of breast cancer treatment, and there have 
also been a number of reports detailing the activation of NF-κB by IR breast cancer cell 
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lines (Guo et al., 2003, Veuger et al., 2009, Wang et al., 2005) Thus, the addition of an 
NF-κB inhibitor to the current therapeutic regimen represents a promising therapeutic 
strategy for breast cancers. Hence, the hypothesis that inhibitors of NF-κB DNA 
binding would radio-sensitise breast cancer cells, would also be rigorously tested within 
this chapter. 
 
7.3 Results 
7.3.1 Assay development 
The clonogenic assay (section 2.2.7) was used to assess which of the seven compounds 
from Profectus Biosciences Inc was the most potent radio-sensitising agent in MEFs 
proficient for NF-κB p65, in the first instance, with a view to determining subunit 
specificity using p65-/- MEFs. Previous work (Chapter 3) using the PARP inhibitor, AG-
014699 and siRNA targeting p65 or PARP-1 demonstrated that either AG-014699, p65 
siRNA or PARP-1 siRNA radio-sensitised p65+/+ but not p65-/- MEFs (Hunter et al., 
2011). Using the data from the survival curves of p65+/+ MEFs treated with IR alone, a 
fixed dose of IR which kills approximately 50% of p65+/+cells is 2.5 Gy. A standard 
clonogenic assay uses a range of doses of a DNA damaging agent (e.g. IR) and 
compares this to a fixed dose of an inhibitor in combination with the DNA damaging 
agent (section 2.2.7). However, a concentration range for these inhibitors was provided 
by Profectus Biosciences (0.1, 0.3, 1, 3, 10, 30 µM) and since the toxicity of these 
compounds was unknown in this system, it was decided to use a ‘window of 
potentiation’ method. Essentially, the concentration range provided for the inhibitor was 
used in combination with a fixed dose of IR (known to kill 50% of the p65+/+ MEFs). 
Briefly, cells were incubated for 24 hours before being treated with the inhibitors (or 
DMSO control) for 15 min prior to treatment with IR then re-plated after a further 24 h 
and allowed to form colonies for 7-21 days. All treatments or doses used were 
normalised to the relevant controls – for example, the inhibitor alone treated cells were 
normalised to a DMSO control of p65+/+ MEFs, whereas for the inhibitor in 
combination with IR, these were normalised to cells treated with both IR and the DMSO 
control. 
 
Prior to commencing work with the Profectus Biosciences compounds, the ‘window of 
potentiation’ clonogenic assay was tested in the p65+/+ MEFs using a dose range of the 
PARP inhibitor, AG-014699 alone or in combination with one fixed dose of IR. Cells 
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were incubated for 24 h before treatment with AG-014699 (or DMSO control) 1 hour 
treatment prior to treatment with IR then re-plated after a further 24 h and allowed to 
form colonies for 7-21 days. Figure 7.1 shows that there is a significant difference 
(p<0.0001, unpaired Student’s t-test) between the LD50 values (lethal dose producing 
50% cell kill) of AG-014699 alone (LD50 of 0.82 µM) and AG-014699 in combination 
with 2.5 Gy IR (LD50 of 0.05 µM). The visible large difference (‘window of 
potentiation’) between the solid line of AG-014699 alone, and the dotted line of AG-
014699 in combination with IR, makes it very clear that this method of the clonogenic 
assay is robust and reproducible in the p65+/+ MEFs. Moreover, this method illustrates 
that at low concentrations of AG-014699, the compound is relatively non-toxic, as has 
been shown in other studies (Calabrese et al., 2004, Daniel et al., 2010, Daniel et al., 
2009, Zaremba et al., 2009). If a compound is very toxic at low concentrations, the 
slope of the survival curve would be much steeper at the top which would also indicate 
whether the Profectus Biosciences compounds may have any stand-alone toxicity at 
lower concentrations, or the concentration used in the combination experiments.  
 
 
 
 
 
 
Figure 7.1: Survival of p65+/+ cells following treatment with increasing doses of AG-
014699 and 2.5 Gy IR. The effects of increasing doses of AG-014699 (0 – 3 µM) AG-
014699, alone (solid line) or in combination with one fixed dose of IR (2.5 Gy) (dotted line), 
on cell survival was assessed in p65+/+ MEFs. Cells were treated with AG-014699 or DMSO 
control for 1 h prior to IR (if relevant) then re-plated after a further 24 h and allowed to form 
colonies for 7-21 days. 
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7.3.2 Window of potentiation studies with five Profectus Biosciences NF-κB 
inhibitors 
Once confident with the experimental design, five inhibitors from Profectus Biosciences 
were screened:- PBS-1079, PBS-1086, PBS-1088, PBS-1110 and PBS-1135. The dose 
range used for each compound was 0-30 µM (0, 0.1, 0.3, 1, 3, 10, 30 µM), in 
combination with a fixed dose of IR (2.5 Gy) to give an indication of which of these 
NF-κB inhibitors might radio-sensitise the p65+/+ MEFs. p65+/+ cells were incubated for 
24 hours before being treated with either inhibitors (or DMSO control) for 15 min prior 
to IR then re-plated after a further 24 h and allowed to form colonies for 7-21 days. All 
survival curves shown are the mean of three independent experiments. 
 
Figure 7.2A shows the survival curve of the p65+/+ MEFs following increasing doses of 
PBS-1079 alone or in combination with 2.5 Gy IR. The ‘window of potentiation’ 
observed in Figure 7.1, using AG-014699 is not as large with PBS-1079. In this case, 
the inhibitor alone has a greater effect on cell survival at low concentration when 
compared with PBS-1079 in combination with IR. The LD50 value for PBS-1079 alone 
is 0.57 µM whereas the LD50 value for PBS-1079 in combination with IR is 1.04 µM, 
although the difference between these two values is not statistically significant (p=0.11, 
unpaired Student’s t-test).  
 
The survival curve of p65+/+ MEFs treated with increasing doses of PBS-1086 alone or 
in combination with 2.5 Gy IR (Figure 7.2B) showed that there is a significant 
difference (p=0.0016, unpaired Student’s t-test) between the LD50 values of PBS-1086 
alone (LD50 of 3.58 µM) and PBS-1086 in combination with 2.5 Gy IR (LD50 of 1.4 
µM). Furthermore, at low concentrations, PBS-1086 was relatively non-toxic alone, as 
seen previously with AG-014699 (Figure 7.1), yet there was a pronounced radio-
sensitisation with 2.5 Gy IR at these doses. These data suggest that this compound 
warrants further investigation as a radio-sensitising agent. 
 
 
305 
 
 
 
 
 
 
 
Figure 7.2: Survival of p65+/+ following treatment with increasing doses of 
Profectus Biosciences inhibitors and 2.5 Gy IR 
The effects of increasing doses of (A) PBS-1079, (B) PBS-1086, (C) PBS-1088, 
(D) PBS-1110 or (E) PBS-1135 (0 – 30 µM) PBS-1086, alone (solid line) or in 
combination with one fixed dose of IR (2.5 Gy) (dotted line), on cell survival 
was assessed in p65+/+ MEFs. Cells were treated with PBS inhibitor or DMSO 
control for 15 min prior to IR (if relevant) then re-plated after a further 24 h and 
allowed to form colonies for 7-21 days. 
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Figure 7.2C shows PBS-1088 alone or in combination with 2.5 Gy IR. At the low 
concentrations tested the inhibitor is clearly radio-sensitised in the presence of the fixed 
dose of IR used and there is a visible window of potentiation. This echoed in the doses 
which reduce survival by 25 % (LD25) with this compound alone (LD25 value of 3.39 
µM) compared with PBS-1088 in combination with IR (LD25 value of 0.48 µM, 
p=0.031). However at higher concentrations, for example LD50 values observed with 
PBS-1088, there was no significant differences observed (p=0.39), and the survival 
curves of PBS-1088 alone or in combination with 2.5 Gy IR overlap. 
 
The survival curve of p65+/+ MEFs treated with PBS-1110 alone or in combination with 
2.5 Gy IR (Figure 7.2D) showed that there is a significant difference (p=0.038, unpaired 
Student’s t-test) between the LD50 values of PBS-1110 alone (LD50 of 5.05 µM) and 
PBS-1110 in combination with 2.5 Gy IR (LD50 of 0.99 µM). These data would suggest 
that this compound should be further investigated as a potential radio-sensitising agent. 
Figure 7.2E shows that there is little difference between PBS-1135 alone or the 
combination of PBS-1135 and IR, however a small window of potentiation is seen at the 
LD50 values. Although there is approximately 3-fold difference between the LD50 of 
PBS-1135 alone (7.01 µM) and that of PBS-1135 in combination with IR (1.26 µM), 
this difference is not significant when tested using an unpaired Student’s t-test 
(p=0.169). 
 
It is very important to note that when used at higher concentrations (10 and 30 µM), two 
of the inhibitors, PBS-1079 and PBS-1088 appeared to have had a profound effect on 
the growth of these cells. The colonies formed by the p65+/+ cells are usually discrete 
and uniform in shape (Figure 7.3A). However, high concentrations of PBS-1079 or 
PBS-1088, alone or in combination with IR, have forced the colonies to be become 
elongated and appear fibroblastic, suggesting that this compound is having an effect on 
the cells morphology and growth (Figure 7.3A versus 7.3B). This therefore suggests 
that these inhibitors are quite toxic to these particular cells and taken together these data 
suggest that PBS-1079 and PBS-1086 may not be good candidates for use as radio-
sensitising agents. 
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Table 7.3 summarises the LD50 values of each of the Profectus Biosciences inhibitors, 
alone or in combination with 2.5 Gy IR. This table also includes the PF50 values for each 
of these agents, where appropriate. The PF50 value is the (potentiation factor at 50% cell 
kill) and was calculated from the ratio of the individual LD50 values:- for example, LD50 
of PBS-1086 alone divided by LD50 of PBS-1086 in the presence of IR. These data 
indicate that the most promising compounds in terms of their ability to radio-sensitise 
the p65+/+ MEFs are PBS-1086 (2.5-fold PF50 value), PBS-1110 (5-fold PF50 value) and 
PBS-1135 (5.5-fold PF50 value). However, PBS-1110 was found to have a profound 
effect on cellular growth, morphology and colony formation, and although there was a 
small window of potentiation at the LD50 values of the PBS-1135 survival curve, this 
was not seen at the other concentrations tested. It was therefore decided that any further 
studies should be undertaken with PBS-1086. 
 
 
 
 
 
Figure 7.3: Cellular growth and morphology of p65+/+ MEFs treated with either 0.3 
or 10 µM PBS-1079. The colonies formed by the p65+/+ cells are usually discrete and 
uniform in shape and this continued at low concentrations of PBS-1079 (A). However, 
high concentrations of PBS-1079, alone or in combination with IR, have forced the 
colonies to be become elongated and appear fibroblastic (B). 
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Compound LD50 (µM) LD50 +IR (µM) PF50 
PBS-1079 0.57 1.04 0.5-fold 
PBS-1086 3.58 1.40 2.5-fold 
PBS-1088 13.49 8.76 1.5-fold 
PBS-1110 5.05 0.99 5-fold 
PBS-1135 7.01 1.26 5.5-fold 
 
 
 
 
 
PBS-1086, a compound which has been rigorously tested by Profectus Biosciences is an 
inhibitor of Rel DNA binding. The compound is known to covalently modify the 
cysteine-38 residue in the Rel domain of the NF-κB subunits (Jie Zhang personal 
communication). Moreover, Oh et al., (2010) have shown that PBS-1086 inhibits DNA 
binding of p65, p50 and RelB as well as luciferase expression in a 293/NF-κB-
luciferase reporter cell line. Furthermore, PBS-1086 was also found to inhibit TNF-
alpha induced Il-6 and Il-8 release in MDA-MB-231 cells (Jie Zhang, personal 
communication). Therefore, this compound was chosen for further investigation within 
this chapter. 
 
7.3.3 Investigation into the effects of PBS-1086 as a radio-sensitising agent in NF-κB 
proficient and deficient MEFs 
The initial screen of the seven compounds identified PBS-1086 as a potential radio-
sensitising agent. Table 7.1 and Figure 7.2 illustrate that a combination of PBS-1086 
and IR reduced cell survival in the p65+/+ MEFs to a greater extent when compared with 
PBS-1086 alone. Moreover, PBS-1086 appeared to be relatively non-toxic as a mono-
therapy at low doses in the p65+/+ MEFs. Therefore, it was decided to investigate the 
ability of PBS-1086 to sensitise p65+/+ and p65-/- MEFs to IR using classical colony 
forming assays (section 2.2.7). To determine whether any potential radio-sensitisation 
observed was mediated via the p65 subunit of NF-κB, p65 siRNA was used. PBS-1086 
is known to be a Rel inhibitor and therefore inhibit DNA binding of all five NF-κB 
subunits (Oh et al., 2011). Thus, p65+/+ or p65-/- MEFs were plated and left to adhere for 
24 h before transfection with 50 nM p65 or NS siRNA, (or vehicle control). It should be 
noted that this concentration of siRNA had been optimised previously in these cells 
(Chapter 3), and known to reduce p65 expression by > 95 %. Cells were then left for 48 
h, and pre-treated with PBS-1086, (or DMSO control) 15 min prior to treatment with 
Table 7.1: LD50 values calculated from survival curves of p65+/+ cells treated with 
various Profectus Biosciences inhibitors Table 7.1 summarises the LD50 values of 
each of the Profectus Biosciences inhibitors, PBS-1079, PBS-1086, PBS-1088, PBS-
1110 or PBS-1135 alone or in combination with 2.5 Gy IR. PF50 values (potentiation 
factor at 50% cell kill) are expressed as fold changes. 
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increasing doses of IR before being re-plated after a further 24 h and allowed to form 
colonies for 7-21 days. All survival curves shown are the mean of three independent 
experiments. 
 
It should be noted that a fixed dose of 1 µM PBS-1086 was used in these experiments, 
as this dose was shown to reduce cell survival in combination with IR but to be 
relatively non-toxic alone (Figure 7.2B). This concentration reduced cell survival by 
approximately 80 % (Figure 7.2B). The data presented here (Figure 7.4) illustrate, that 
co-incubation with IR and either PBS-1086 or p65 siRNA reduced survival of the p65+/+ 
MEFs compared with IR alone. At the LD75 values (lethal dose which reduces survival 
be 75 %) PBS-1086 or p65 siRNA significantly radio-sensitised the p65+/+ MEFs 
compared with IR alone (p=0.026 and p=0.034, respectively). It is also clear from 
Figure 7.4 that NS siRNA in combination IR had no effect cell survival compared with 
IR alone in the p65+/+ MEFs (p=0.876). Markedly, Figure 7.4 shows that IR in 
combination with PBS-1086, p65 siRNA or NS siRNA had no effect on cell survival in 
the p65-/-MEFs compared with IR alone (p=0.542, p=0.489 and p=0.613 respectively). 
Taken together these data suggest that radio-sensitisation by PBS-1086 is mediated via 
NF-κB p65.  
 
 
 
 
 
 
Figure 7.4: Radio-sensitisation by PBS-1086 is mediated via p65 
The effects of increasing doses of IR either alone, or co-incubated with PBS-1086 or 
p65 siRNA on cell survival were assessed using the clonogenic survival assay. Cells 
were treated with relevant siRNA, (or vehicle control), left for 48 h, pre-treated with 
PBS-1086, or DMSO control for 15 min prior to IR then re-plated after a further 24 h 
and allowed to form colonies for 7-21 days. (Survival curve (A) shows p65+/+ MEFs 
and (B) p65-/- MEFs). All results are the mean of three independent experiments with 
SEM.  
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7.3.4 Investigation into the effects of PBS-1086 as a radio-sensitising agent in PARP-
1 proficient and deficient MEFs 
It appeared, from the clonogenic assays detailed in section 7.3.3, that PBS-1086 radio-
sensitisation was mediated via the p65 NF-κB subunit. Previous work in this thesis has 
shown that radio-sensitisation by the PARP inhibitor, AG-014699 is mediated via NF-
κB p65 (Hunter et al., 2011). Thus, from the previous work (Chapters 3 and 4) 
demonstrating the role of PARP-1 in the activation of NF-κB p65, and results using 
PBS-1086 in the p65+/+ and p65-/- MEFs, it would be expected that radio-sensitisation 
would only be achieved using an NF-κB inhibitor, such as PBS-1086, in the PARP-1+/+ 
cells.In order to test this hypothesis and confirm both the work with AG-014699 and 
that presented here with PBS-1086, the classical clonogenic assays were performed 
using increasing doses of IR in combination with one fixed dose of PBS-1086 (1 µM) in 
the PARP-1+/+ and PARP-1-/- MEFs.  
 
Figure 7.5 shows that co-incubation with IR and PBS-1086 reduced survival of the 
PARP-1+/+ MEFs compared with IR alone. It should be noted that the PARP-1-/- MEFs 
were 2.7-fold more sensitive to IR compared with PARP-1+/+ MEFs. This is consistent 
with reports that PARP-1 knockout animals are hyper-sensitive to irradiation due to 
their compromised DNA repair response (Masutani et al., 2005). Furthermore, statistical 
analysis using an unpaired Student’s t-test confirm that, at the LD50 values PBS-1086 
significantly radio-sensitised the PARP-1+/+ MEFs compared with IR alone (p=0.015). 
Markedly, Figure 7.5 shows that IR in combination with PBS-1086 had no effect on cell 
survival in the PARP-1-/-MEFs compared with IR alone (p=0.924). Taken together these 
data support the finding in section 6.3.3, and those in Chapters 3 and 4, and confirm that 
radio-sensitisation by PBS-1086 is mediated via NF-κB p65, and that only PARP-1 
proficient cells would be sensitised to IR by an NF-κB inhibitor, such as PBS-1086. 
Moreover, these data show that PARP-1 is required for radio-sensitistation. 
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7.3.5 Assessment of the effects of PBS-1086 as a novel inhibitor of IR-induced- NF-
κB DNA binding 
In order to be confident that the effects observed on cell survival in the both the p65+/+ 
(Figure 7.4) and PARP-1+/+ cells (Figure 7.5) were mediated by the inhibition of Rel 
DNA binding, ELISA-based assays were undertaken in the p65+/+ MEFs. Specifically, 
the inhibition of p65 and p50 DNA binding was investigated. siRNA targeting p65 or a 
non-specific control (section 3.3.1) was assessed as a direct comparison to PBS-1086. In 
this case, the p65 siRNA would not only allow insight into the mechanism of action, 
and specificity of the compound, but also serve as a control for the p65-specific DNA 
binding ELISA. For these experiments, p65+/+ cells were plated and left to adhere for 24 
h prior to transfection with 50 nM p65 or NS siRNA (or vehicle control). Cells were 
incubated left for 48 h, and pre-treated with PBS-1086, (or DMSO control) 15 min prior 
to treatment with 10 Gy IR. Cells were harvested 2 h later, nuclear extracts prepared and 
DNA binding assessed using the ELISA.  
 
Firstly, Figures 7.6A and 7.6B show that 1 µM PBS-1086 alone inhibited both p65 and 
p50 DNA binding compared with basal levels (p=0.052 and p=0.098, respectively), 
Figure 7.5: Investigation into the effects of PBS-1086 as a radio-sensitising agent in 
PARP-1 proficient and deficient MEFs. The effects of increasing doses of IR either 
alone, or co-incubated with PBS-1086 or p65 siRNA on cell survival were assessed 
using the clonogenic survival assay. Cells were treated with relevant siRNA, (or vehicle 
control), left for 48 h, pre-treated with PBS-1086, or DMSO control for 15 min prior to 
IR then re-plated after a further 24 h and allowed to form colonies for 7-21 days. 
(Survival curve (A) shows PARP-1+/+ MEFs and (B) PARP-1-/- MEFs). All results are 
the mean of three independent experiments with SEM.  
 
312 
 
supporting the data of Oh et al., (2010) which shows that PBS-1086 is a potent and 
specific inhibitor of NF-κB DNA binding. Moreover, Figures 7.6A and 7.6B illustrate 
that 10 Gy IR increased DNA binding of either p65 or p50, 2-fold compared with basal 
levels (p<0.0001 and p=0.002, respectively). Importantly, co-incubation with PBS-0186 
significantly reduced IR-induced p65 and p50 DNA binding, compared with IR in 
combination with NS siRNA (p=0.0011 and p=0.043, respectively). The effect of p65 
siRNA was assessed following IR in p65+/+ MEFs, and it was found that knockdown of 
the p65 subunit significantly inhibited IR-induced p65, but not p50 DNA binding 
(p<0.0001 compared to IR in combination with NS siRNA). Importantly, Non-specific 
(NS) siRNA had no effect on DNA-binding of either subunit following IR.  
 
 
 
 
 
 
 
 
7.3.6 Investigation into the effects of PBS-1086 as a novel inhibitor of IR-induced- 
NF-κB transcriptional activation 
Once the inhibition of p65 and p50 DNA binding by PBS-1086 was confirmed and it 
could be concluded that PBS-1086 mediated radio-sensitisation via the p65 subunit, it 
was important to determine any effects the compound was having on NF-κB-dependent 
gene transcription. Furthermore, Oh et al., (2010) reported that that PBS-1086 inhibited 
TNF-α-induced luciferase expression in a 293/NF-κB-luciferase reporter cell line. 
Figure 7.6: PBS-1086 is a novel inhibitor of IR-induced-NF-κB DNA binding 
Bar chart showing the effect of IR ± PBS-1086  ± p65 siRNA ±Non-specific (NS) siRNA 
control on NF-κB p65 and p50 DNA binding activity, measured using an ELISA-based 
assay (A) and (B) in p65+/+ MEFs. All results are the mean of three independent 
experiments with SEM. Significance relative to NS siRNA control using unpaired 
Student’s t-test *** p<0.0001 ** p<0.001, * p<0.05 
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Hence, the inhibitory effects of PBS-1086 on NF-κB activation were further assessed 
using a luciferase reporter assay in the p65+/+ MEFs. siRNA targeting p65 or a non-
specific control (section 3.3.1) was assessed as a direct comparison to PBS-1086. Cells 
were incubated for 24 h before transient transcfection with 200 ng of an NF-κB-
luciferase construct and 200 ng of a pCMB-β-galactosidase plasmid (section 2.9). 
Following further 48 h incubation, cells were treated with either 10 Gy IR or 10 ng/ml 
TNF-α. Cells were lysed after 0, 2, 4, 6, 8 or 24 h and assayed for luciferase activity 
using the Promega Luciferase assay system, according to the manufacturer’s 
instructions. Luciferase activity was corrected for β-galactosidase activity as described 
previously (Brady et al., 1999), and relative activities expressed as fold changes. 
 
Figures 7.7 illustrates that 1 µM PBS-1086 alone inhibited NF-κB-dependent gene 
transcription compared with basal levels, however this trend was not significant 
(p=0.117, unpaired Student’s t-test). Consistent with the increased DNA binding (Figure 
7.6), following 10 Gy IR, luciferase activity was increased 2.3-fold, compared to basal 
levels (p<0.0001). PBS-1086 reduced IR-induced luciferase reporter activity to levels 
comparable with untreated controls although this was not statistically significant when 
compared to IR in combination with NS siRNA (p=0.066). Also, siRNA targeting p65 
reduced luciferase activity > 80% following IR (p=0.03, compared to IR in combination 
with NS siRNA), whereas as NS siRNA had no effect on IR-induced luciferase reporter 
activity compared with IR alone (p=0.356).  
 
 
 
 
Figure 7.7: PBS-1086 is a novel inhibitor of IR-induced-NF-κB-dependent gene 
transcription. Bar chart showing the effect of IR ± PBS-1086  ± p65 siRNA ±Non-specific (NS) 
siRNA control on NF-κB-dependent transcriptional activation, measured using a luciferase 
reporter assay, in p65+/+ MEFs. All results are the mean of three independent experiments with 
SEM. Significance relative to NS siRNA control using unpaired Student’s t-test *** p<0.001, * 
p<0.05 
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7.3.7 PBS-1086 inhibits the transcription of NF-κB-dependent anti-apoptotic genes 
In order to demonstrate that the DNA binding (Figure 7.6), luciferase activity (Figure 
7.7) and survival data (Figure 7.4) were physiologically relevant it was important to 
determine whether NF-κB inhibition by PBS-1086 leads to an inhibition of the 
expression of some known NF-κB-mediated anti-apoptotic genes. The genes chosen to 
investigate were; Bcl-xL (Lee et al., 1999b), cFLAR (Kreuz et al., 2001) and XIAP 
(Turner et al., 2007) in the p65+/+ MEFs. This method is described in detail in section 
2.10. p65+/+ MEFs were incubated for 24 h before a 15 min pre-treatment with 1 µM 
PBS-1086 prior to treatment with 10 Gy IR. Cells were then harvested at various 
timepoints (0 – 6 h) and RNA extracted using the RNeasy kit and subsequently 
transcribed into cDNA using the High Capacity cDNA reverse transcription kit. cDNA 
was then used in a qRT-PCR reaction using Taqman primers to confidently quantify the 
mRNA levels of either Bcl-xL, cFLAR or XIAP in each sample. 
 
 
 
 
 
 
 
 
Figure 7.8: PBS-1086 inhibits the transcription of NF-κB-dependent anti-apoptotic 
genes. Histogram showing the effect of IR ± PBS-1086 (Denoted as +) over time on the 
expression of the anti-apoptotic genes (A) Bcl-xL, (B) cFLAR and (C) XIAP. All results 
are the mean of three independent experiments with SEM. Significance relative to mock 
treated control using unpaired Student’s t-test *** p<0.001 ** p<0.01, * p<0.05 
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Figure 7.8A shows that treatment with IR significantly increases expression of Bcl-xL 
at early timepoints (p<0.0001 (0 h post IR), p=0.0004 (2 h post IR), compared with 
untreated controls) and importantly, that co- incubation with PBS-1086 inhibited IR-
induced Bcl-xL expression at these timepoints (p=0.002 (0 h post IR) and p= 0.019 (2 h 
post IR)) (Figure 7.8A). cFLAR expression (Figure 7.8B) was also increased following 
IR (p=0.0047, 0 h, p=0.0007 2 h, p=0.016 4 h, compared to untreated controls) and this 
again was inhibited by co-incubation with PBS-1086 at the 2 h timepoint (p=0.034). A 
similar trend was aslo observed with XIAP expression, which was increased by IR 
(p=0.003 0 h, p=0.014 2 h) and inhibited by PBS-1086 (p=0.007) (Figure 7.8C).  
 
7.3.8 PBS-1086 radio-sensitises breast cancer cells 
The data presented in this chapter demonstrate that PBS-1086 is a potent and specific 
inhibitor of NF-κB DNA binding, and consequently transcriptional activation. As a 
result of NF-κB inhibition, data presented here also illustrate that PBS-1086 can radio-
sensitise cells, via the inhibition of p65 DNA binding, and that this radio-sensitisation is 
likely to be due to the inhibition of IR-induced transcription of anti-apoptotic genes 
known to be specifically regulated by NF-κB. However, thus far the main body of these 
data have been in one model system; the p65 proficient and deficient MEFs. Therefore, 
it was important to determine whether PBS-1086 would have the same effects in 
another model system.  
 
A panel of breast cancer cell lines was chosen to further investigate the potential utility 
of PBS-1086 as a radio-sensitising agent. Radio-therapy is one of the main-stays of 
breast cancer therapy and elevated NF-κB DNA binding activity has been demonstrated 
both in breast cancer cell lines and primary tissues (Biswas et al., 2004, Nakshatri et al., 
1997, Sovak et al., 1997). Constitutive NF-κB activation has been associated with 
chemo- and radio-resistance and also increased metastasis of breast tumours (Biswas et 
al., 2001, Wu and Kral, 2005). Inhibition of NF-κB activation via inhibition of PARP-1 
has also been shown to radio-sensitise two breast cancer cells, MDA-MB-231 and T47D 
(Veuger et al., 2009). Therefore, the ability of PBS-1086 to sensitise the breast cancer 
cells to IR using colony forming assays was assessed. Three breast cancer cells lines 
were chosen for this part of the study; MDA-MB-231, T47D and MCF7, and these are 
described in detail in section 2.2.7. 
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Figure 7.9 shows that co-incubation with 1 µM PBS-1086 radio-sensitised all three cell 
lines compared to cells treated with IR alone (Figures 7.9A-C). Figure 7.9A shows that 
co-incubation with IR and PBS-1086 reduced survival of the MDA-MB-231 compared 
with IR alone (LD50 value of 2.85 Gy IR alone, compared with an LD50 value of 1.70 
Gy, IR in combination with PBS-1086 (p=0.031). Markedly, Figure 7.9B and 7.9C also 
shows that IR in combination with PBS-1086 radio-sensitised both the MCF7 cells 
(p=0.022) and T47D cells (p=0.041), at the LD50 values. Taken together these data 
Figure 7.9: PBS-1086 radio-sensitises breast cancer cells. The effects of 
increasing doses of IR either alone, or co-incubated with PBS-1086, on cell survival 
were assessed using the clonogenic survival assay. Cells were treated with PBS-
1086 or DMSO control then re-plated after a further 24 h and allowed to form 
colonies for 7-21 days. (Survival curve (A) shows MDA-MB-231 cells, (B) shows 
MCF7 cells and (C) T47D cells). All results are the mean of three independent 
experiments with SEM.  
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expand the findings in section 6.3.3 and suggest that PBS-1086 has therapeutic potential 
as radio-sensitising agent for the treatment of breast cancer cells.  
 
7.3.9 Characterisation of the NF-κB status of breast cancer cell lines 
Section 7.3.8 showed that the three breast cancer cell lines tested, MDA-MB-231, 
MCF7 and T47D, were differentially sensitised to IR by PBS-1086. Hence, it was 
important to assess the NF-κB status of these cell lines, both at the protein and DNA 
binding levels. This would determine whether any of these cell lines had any 
constitutive activation of any of the NF-κB subunits. Therefore nuclear extracts were 
prepared for each of the three cell lines using the NE-PER kit (section 2.5.2). After 
protein quantification using the Pierce BSA protein assay (section 2.5.3), nuclear 
extracts were loaded onto the NF-κB DNA binding TransAM Family ELISA (as 
described in detail, Chapter 2.8.2) and binding of all five subunits was assessed. 
Expression of the NF-κB subunits p65, p50, p52. RelB and c-Rel proteins was also 
assessed by Western blotting (section 2.5), and normalised to the nuclear loading 
control Lamin. Western blots were also probed for β-actin, a protein only found in the 
cytoplasm, to ensure the nuclear extracts were free from any contamination.  
 
Both the Western analysis (Figure 7.10) and the DNA-binding data (Figure 7.11) 
illustrate that the MDA-MB-231 cells have the highest protein expression and DNA 
binding activity of the p65, p50 and RelB subunits. The MCF7 cells have intermediate 
protein expression and DNA binding activity of these subunits and the T47D cells have 
the lowest protein expression and DNA binding activity. Statistical analysis using an 
unpaired Student’s t-test shows that MDA-MB-231 cells have significantly higher p65 
DNA binding compared with both the MCF7 and T47D cells (p=0.0006 and p=0.046, 
respectively). This is also the case for the p50 subunit (p=0.003 MDA-MB-231 
compared with MCF7, and p<0.0001, MDA-MB-231 compared with T47D), and in the 
case of p50, MCF7 cells show significantly higher DNA binding activity compared with 
the T47D cells (p=0.0007). Furthermore, MDA-MB-231 cells have significantly higher 
RelB DNA binding activity compared with the MCF7 and T47D cells (p=0.014 and 
p<0.0001, respectively), and MCF7 cells have higher RelB binding activity compared 
with T47D cells (p=0.013). DNA binding activity of p52 (Figure 7.11) was highest in 
the MDA-MB-231 cells, and lowest in the MCF7 cells (p=0.013, MDA-MB-231 
compared with MCF7). Both the ELISA and Western blotting data shows that the 
protein levels of p52 are very similar in both the T47D and MCF7 cells. Western 
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analyses and DNA binding data (Figures 7.10 and 7.11) indicate that c-Rel expression 
and DNA binding are very similar across all three breast cancer cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10: NF-κB subunit protein expression in nuclear extracts from 
untreated breast cancer cell lines. Western blots of nuclear extracts of MDA-MB-
231, MCF7 and T47D showing protein expression of p65, p50, p52, RelB and c-Rel. 
Loading was normalised to lamin nuclear loading control and blots were probed for 
the β-actin to ensure no cytoplasmic contamination of nuclear extracts. 
 
Figure 7.11: NF-κB DNA binding in untreated breast cancer cell lines. Bar chart 
showing DNA binding of p65, p50, p52, RelB and c-Rel in untreated MDA-MB-231, 
MCF7 and T47D cells, measured using an ELISA-based assay. All results are the mean 
of three independent experiments with SEM. Significance relative to mock treated 
control using unpaired Student’s t-test *** p<0.001 ** p<0.01, * p<0.05 
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7.3.10 PBS-1086 as a mono-therapy in breast cancer expressing aberrantly active 
NF-κB 
The DNA binding and Western blotting data from untreated breast cancer cell lines 
illustrated that all of these cells had some constitutive NF-κB activity, and previous data 
(section 6.3.2), suggested that PBS-1086 may have some potential activity against NF-
κB as a mono-therapy in MEFs expressing p65. Therefore, it was important to 
determine whether PBS-1086 alone had any effect on survival in the MDA-MB-231, 
MCF7 and T47D cells. Clonogenic assays were used in which cells were plated and 
incubated for 24 h. Following this cells were treated with increasing doses of PBS-1086 
(0 – 10 µM) and left for a further 24 h. Cells were re-plated and allowed for form 
colonies for 7-21 days.  
 
Figure 7.12 shows that PBS-1086 is cytotoxic as a mono-therapy at all doses tested (0.1 
– 10 µM) in all three cells lines, however the cell lines did show differential sensitivity. 
LD50 values detailed in Table 7.2 show that the MDA-MB-231 cells (which have been 
found to have the highest NF-κB expression and DNA binding activity of the cell lines 
tested), were the most sensitive to PBS-1086 (LD50  value of 0.39 µM). MDA-MB-231 
were almost 10-fold more sensitive than the T47D cells (LD50 value of 3.13 µM), and 
17-fold more sensitive than the MCF7 cells (LD50 value of 6.68 µM). The table also 
includes the NF-κB status, as summarised from the data in section 6.3.9. Statistical 
analyses on LD50 values confirmed that MDA-MB-231 cells were significantly more 
sensitive to PBS-1086 compared with T47D and MCF7 cells (p<0.0001 and p<0.0001, 
respectively). The T47D cells were also more sensitive to PBS-1086 compared with the 
MCF7 cell, although this was not statistically significant (p=0.082). 
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Cell line LD50 (µM) NF-κB status 
MDA-MB-231 0.39 +++ 
T47D 3.10 + 
MCF7 6.68 ++ 
 
 
 
 
 
7.3.11 PBS-1086 inhibits NF-κB DNA binding in breast cancer cell lines 
In order to confirm that the results obtained in the clonogenic assays (section 7.3.10) 
were due to the inhibition of NF-κB DNA binding by PBS-1086, a series of NF-κB 
DNA binding ELISA assays in the presence or absence of PBS-1086 were undertaken 
in the breast cancer cell lines. This would also confirm the potential utility of the 
compound as a single agent therapy in breast cancer. Oh et al., (2010) reported that 10 
Figure 7.12: Clonogenic survival of three breast cancer cell lines following treatment 
with PBS-1086. The effects of increasing doses of PBS-1086 (0 – 10 µM) PBS-1086 on 
cell survival was assessed in MDA-MB-231, T47D and MCF7 cells (C). Cells were treated 
with PBS-1086 or DMSO control then re-plated after a further 24 h and allowed to form 
colonies for 7-21 days. All results are the mean of three independent experiments with 
SEM.  
 
Table 7.2: LD50 values calculated from survival curves of breast cancer cell lines 
treated with PBS-1086 Table 7.2 summarises the LD50 values of each of the breast cancer 
cell lines, MDA-MB-231, T47D and MCF7 treated with increasing doses of PBS-1086. NF-
κB status is summarised; +++ denotes high constitutive activation, ++ denoted intermediate 
constitutive activation and + denotes low constitutive activation (as determined in Figure 
7.11). 
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µM PBS-1086 suppressed spontaneous lympho-proliferation and inhibited the 
production of pro-inflammatory cytokines in PBMCs from HTLV-I–associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) patients via the inhibition of NF-
κB DNA binding. Hence, it was decided to use this concentration (10 µM), and the 1 
µM PBS-1086 concentration that had been used previously in this study (as a 
combination therapy), and assess the effects of these concentrations on NF-κB subunit 
DNA binding in the three breast cancer cell lines. MDA-MB-231, MCF7 or T47D cells 
were incubated for 24 h prior to treatment with 1 µM or 10 µM PBS-1086 or a DMSO 
control. Cells were harvested 24 h later, to duplicate the timecourse of the clonogenic 
assays (section 6.3.10) and nuclear extracts were prepared and DNA binding assessed 
using the ELISA assay. 
 
Figure 7.13A shows that 1 µM PBS-1086 significantly inhibited p65 DNA binding in 
the MDA-MB-231 cells (p=0.028, compared with untreated controls), and this trend 
was echoed in both the MCF7 and T47D cells, although this was not statistically 
significant. Moreover, 10 µM PBS-1086 further inhibited p65 DNA binding in the 
MDA-MB-231 and T47D cells (p=0.001 and p=0.014, respectively, compared to 
untreated controls). 10 µM PBS-1086 also further inhibited p65 DNA binding in the 
MCF7 cells (p=0.062). PBS-1086 also inhibited DNA binding of the other canonical 
subunit p50 (Figure 7.13B). 1 µM PBS-1086 significantly inhibited p50 DNA binding 
in the MDA-MB-231 cells (p=0.032), and this trend was echoed in both the MCF7 and 
T47D cells, although this was not statistically significantly. Moreover, 10 µM PBS-
1086 further inhibited p50 DNA binding in all of the cell lines tested (p=0.0001 (MDA-
MB-231), p=0.0004 (T47D) and p=0.0076 (MCF7)). Figure 7.13C shows that PBS-
1086 inhibited binding of the non-canonical subunit, RelB when used at the 10 µM 
concentration, consistent with the report of Oh et al. (2010). RelB DNA binding was 
significantly inhibited in both the MDA-MB-231 and T47D cells (p=0.0034, and 
p=0.029, respectively). PBS-1086 had no effect on RelB DNA binding in the MCF7 
cells at any of the concentrations tested. PBS-1086 also inhibited p52 DNA binding in 
both the MDA-MB-231 and T47D cells, compared to untreated controls (Figure 7.13D), 
although this was not statistically significant. However, both concentrations of PBS-
1086 tested increased p52 DNA binding in the MCF7 cells (p=0.013). Figure 7.13E 
shows that PBS-1086 had no effect on c-Rel DNA binding in the breast cancer cells, at 
any of the doses tested. 
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7.3.12 Window of potentiation studies with two further Profectus Biosciences NF-κB 
inhibitors 
For the duration of this study, PBS-1086 was the lead compound in the NF-κB inhibitor 
programme at Profectus Biosciences Inc, however further families of compounds were 
synthesised by the company during this time and two further compounds of interest 
were identified. These inhibitors were PBS-1169 and PBS-1170, and they underwent 
the ‘window of potentiation’ study, described in section 7.3.2 of this chapter. The 
survival curve of p65+/+ MEFs treated with increasing doses of PBS-1169 alone or in 
combination with 2.5 Gy IR (Figure 7.14A) shows that there is very little difference 
when comparing the inhibitor alone or in combination with IR. The LD50 value for PBS-
1169 alone is 1.33 µM whereas the LD50 values for PBS-1169 in combination with IR is 
Figure 7.13: The effect of PBS-1086 on NF-κB DNA binding in breast cancer cells. The 
effect of a 24 h exposure of PBS-1086 on (A) p65, (B) p50, (C) RelB, (D) p52 and (E) c-Rel 
DNA binding in MDA-MB-231, MCF7 and T47D cells, measured using an ELISA-based 
assay. Open bars denote untreated controls (UT), black bars denote cells treated with 1 µM 
PBS-1086 and hatched bars denote cells treated with 10 µM PBS-1086. All results are the 
mean of three independent experiments with SEM. Significance relative to mock treated 
control using unpaired Student’s t-test *** p<0.001 ** p<0.01, * p<0.05 
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1.72 µM, although the difference between these two values is not statistically significant 
(p=0.413). 
 
The survival curve of p65+/+ MEFs treated with increasing doses of PBS-1170 alone or 
in combination with 2.5 Gy IR (Figure 7.14B) shows that there is a clear window of 
potentiation observed between treatment with the inhibitor alone and the inhibitor in 
combination with IR, at all doses tested. A significant difference (p=0.023) was 
observed between the LD50 values of PBS-1170 alone (LD50 of 9.55 µM) and PBS-1086 
in combination with 2.5 Gy IR (LD50 of 0.75 µM). Furthermore, at low concentrations, 
PBS-1170 was relatively non-toxic alone, something had been seen previously with 
AG-014699 (Figure 7.1), yet there was a pronounced radio-sensitisation with 2.5 Gy IR 
at these doses. These data suggest that this compound warrants further investigation as a 
radio-sensitising agent. 
 
Table 7.3 summarises the LD50 values of each of the Profectus Biosciences inhibitors, 
PBS-1169 or PBS-1170 alone or in combination with 2.5 Gy IR. This table also 
includes the PF50 values for each of these agents, where appropriate. These data indicate 
that the most promising compound in terms of its ability to radio-sensitise the p65+/+ 
MEFs was PBS-1170 (12-fold PF50 value). These data suggest that PBS-1170 warrants 
much further investigation as an NF-κB inhibitor. 
 
 
 
Figure 7.14: Survival of p65+/+ following treatment with increasing doses of 
Profectus Biosciences inhibitors and 2.5 Gy IR. The effects of increasing doses of (A) 
PBS-1169 or (B) PBS-1170 (0 – 30 µM) PBS-1086, alone (solid line) or in combination 
with one fixed dose of IR (2.5 Gy) (dotted line), on cell survival was assessed in p65+/+ 
MEFs (A). Cells were treated with PBS inhibitor or DMSO control for 15 min prior to IR 
(if relevant) then re-plated after a further 24 h and allowed to form colonies for 7-21 
days. 
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Compound LD50 (µM) LD50 +IR (µM) PF50 
PBS-1169 1.33 1.72 0.75-fold 
PBS-1170 9.55 0.75 12-fold 
 
 
 
 
 
7.4 Discussion 
The initial screen of a panel of NF-κB inhibitors used p65 proficient MEFs in order to 
determine which were the most potent and specific identified four of the seven 
compounds as potential radio-sensitising agents when using LD50 values as a 
determinant (Tables 7.1 and 7.3). However, PBS-1110 was found to have a profound 
effect on cellular growth, morphology and colony formation, and although there was a 
small window of potentiation at the LD50 values of the PBS-1135 survival curve, this 
was not seen at the other concentrations tested. The largest fold potentiation (12-fold) 
was observed with PBS-1170, whilst a 2.5-fold potentiation was seen with PBS-1086. 
 
PBS-1086, a compound which has been rigorously tested by Profectus Biosciences is an 
inhibitor of Rel DNA binding. The compound is known to covalently modify the 
cysteine-38 residue in the Rel domain of the NF-κB subunits (Jie Zhang personal 
communication). Moreover, Oh et al., (2010) have shown that PBS-1086 inhibits DNA 
binding of p65, p50 and RelB as well as luciferase expression in a 293/NF-κB-
luciferase reporter cell line. Furthermore, PBS-1086 was also found to inhibit TNF-
alpha induced Il-6 and Il-8 release in MDA-MB-231 cells (Jie Zhang, personal 
communication). Therefore, this compound was chosen for further investigation within 
this chapter. 
 
The data presented here demonstrates that the Rel inhibitor, PBS-1086 and siRNA 
targeting p65 both significantly decreased survival following IR in p65+/+ MEFs whilst 
having no effect in p65-/- MEFs. This sensitisation was 1.4-fold and importantly 
occurred at clinically relevant doses of IR. Furthermore, PBS-1086 inhibited IR-induced 
DNA binding of both the p65 and p50 subunits of NF-κB, and that PBS-1086 inhibited 
IR-induced NF-κB luciferase reporter activity. Importantly, results illustrate that these 
Table 7.3: LD50 values calculated from survival curves of p65+/+ cells treated with 
two Profectus Biosciences inhibitors. Table 7.3 summarises the LD50 values of each of 
the Profectus Biosciences inhibitors, PBS-1169 or PBS-1170 alone or in combination 
with 2.5 Gy IR. PF50 values (potentiation factor at 50% cell kill) are expressed as fold 
changes. 
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findings are physiologically relevant by demonstrating that co-incubation with PBS-
1086 decreased the DNA-damage induced transcription of key anti-apoptotic genes, 
known to be regulated by NF-κB. Moreover, the data also go on to highlight new 
therapeutic avenues for the development of specific NF-κB subunit inhibitors in breast 
cancers expressing constitutively active NF-κB. Therefore, this work illustrates that 
PBS-1086 could be used either as a stand-alone agent or as in combination with radio-
therapy in a panel of breast cancer cell lines. 
 
To investigate the mechanism by which PBS-1086 radio-sensitised cells, p65 
knockdown and p65-/- MEFs were used as direct comparison for PBS-1086. Results 
show that radio-sensitisation by PBS-1086 is mediated via the p65 subunit of NF-κB, 
consistent with reports that DNA damaging agents activate the canonical pathway 
(Hunter et al., 2011).  The clonogenic survival data assessing the effect of PBS-1086 in 
PARP-1 proficient and deficient MEFs, supports the work in chapters 3 and 4, and gives 
an insight into the types of tumours and inflammatory diseases in which this inhibitor 
may be active. PBS-1086 radio-sensitises the PARP-1+/+ but not PARP-1-/- MEFs, 
supporting the previous work in this thesis, by illustrating that the presence of PARP-1 
in essential for any radio-sensitisation mediated via  NF-κB.  Furthermore, these data 
suggest that PBS-1086 may useful agents in cancers which over express PARP-1. For 
example, there are some reports which suggest that gain of chromosome 1q, on which 
PARP-1 is located, is a frequent event in aggressive breast cancers (Farabegoli et al., 
2004) Hence, inhibition of NF-κB activation (shown here to be driven by PARP-1 
activation, (Hunter et al., 2011)) may be of therapeutic benefit in such breast tumours, 
and therefore agents such as PBS-1086 the ideal candidate for such treatment benefit. 
Conversely, the survival data in PARP-1 -proficient and -deficient MEFs suggests that 
PBS-1086 may not be an ideal radio- or chemo-sensitising agent in cells or tissues 
lacking PARP-1. It has been reported that PARP-1 null mice develop low-frequency 
spontaneous tumours in multiple organs, including the mammary glands (Tong et al., 
2002, Tong et al., 2001), however it has also been shown that PARP-1 null cells display 
reduced NF-κB-dependent transcriptional activation (Oliver et al., 1999b). 
 
At low concentrations, PBS-1086 inhibited both p65 and p50 DNA binding in the p65+/+ 
MEFs compared with basal levels, although this was not statistically significant. 
Importantly, PBS-1086 inhibited IR-induced-DNA binding of both subunits. 
Unfortunately, the binding of the other subunits could not assessed in the MEFs as the 
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antibodies provided with the ELISA assay are not compatible with murine p52, RelB or 
c-Rel, because they are raised against the human forms of these proteins only. It should 
be noted that although p65 siRNA inhibited IR-induced p65 DNA binding, as would be 
expected, there was a small, but not significant decrease in IR-induced p50 DNA 
binding also. It is possible that this is due to the loss of the p65-p50 heterodimer. The 
p65 subunit is the most common heterodimeric partner of p50 (Chen et al., 1998), and 
together these subunits make up the most common NF-κB dimer. Moreover, this 
heterodimer has previously been shown to be frequently activated following DNA 
damage (Perkins, 2007). 
 
The work in this chapter illustrates that the MDA-MB-231 cells are highly sensitive to 
PBS-1086 compared with other breast cancer cell lines. Moreover, the data suggest that 
this correlates with MDA-MB-231 cells having the highest DNA binding activity and 
protein expression of all of the subunits, except c-Rel, which was found to be constant 
across all three cell lines. This is consistent with other reports that high NF-κB DNA 
binding activity correlates with sensitivity to NF-κB inhibition (Hewamana et al., 
2008a, Lopez-Guerra et al., 2009). However, clonogenic survival data showed that the 
cell line that had the lowest DNA binding and NF-κB expression, T47D, was not the 
least sensitive to PBS-1086. The cell line that was the least sensitive was in fact the cell 
line with intermediate binding and expression, MCF7. One explanation for this is that 
10 µM PBS-1086 markedly inhibited DNA binding of all subunits (except c-Rel) in the 
T47D cells, whereas in MCF7 significant inhibition of DNA binding was only observed 
in the canonical subunits, p65 and p50.  
 
Previous work has shown that there is a delicate balance and complex interplay between 
the NF-κB subunits in CLL (Mulligan EA et al., 2010), and this is undoubtedly the case 
in breast cancer. The basal levels of NF-κB subunit DNA binding varies from cell line 
to cell line, and inhibition of individual subunit by PBS-1086 also varies. For example, 
PBS-1086 shows modest inhibition of p52 DNA binding in both the MDA-MB-231 and 
T47D cells, however 10 µM PBS-1086 significantly increased p52 DNA binding in the 
MCF7 cells. It is therefore possible that these cells are addicted to non-canonical 
pathway activation, mediated in part by p52 and its subsequent downstream signalling. 
Hence, it is possible that MCF7 cells could be evading cell death by PBS-1086 through 
increased p52 activation. Further evidence for this is provided in results for RelB, 
another non-canonical subunit. PBS-1086 significantly inhibited RelB DNA binding in 
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the MDA-MB-231 and the T47D cells but it had no effect DNA binding in the MCF7 
cells, again suggesting that MCF7 are reliant to some extent on non-canonical pathway 
signalling. Moreover, clonogenic survival data (Figure 7.12) shows a greater fold radio-
potentiation by PBS-1086 in both the MDA-MB-231 and T47D cells compared with the 
MCF7 cells. These data are consistent with the report from Mineva et al., (2009), 
detailing that the inhibition of RelB is important in sensitising cells to IR. This group 
reported that RelB promoted the survival of breast cancer cells following both IR and 
doxorubicin, and moreover than specific targeting of RelB either by siRNA or 1,25-
Dihydroxyvitamin D3 radio-sensitised these cells (Mineva et al., 2009).  
 
The MDA-MB-231 cells have the highest NF-κB subunit DNA binding activity and 
protein expression and are radio-sensitised to the greatest extent by PBS-1086. 
However, the MCF7 cells exhibited intermediate DNA binding and protein expression 
but the radio-sensitisation by PBS-1086 was lower in these cells than it was in the T47D 
cells, which had the lowest NF-κB subunit DNA binding and protein expression. One 
explanation for this is that in the MCF7 cells it appears that NF-κB activation is not 
directly correlated with the cellualar response to IR, and that in this case other factors 
may contribute to the cytotoxicity observed in this cell line. Furthermore, the single 
agent concentration of PBS-1086 at which these radio-sensitisation clonogenic assays 
were performed should also be discussed. A concentration of 1 µM was used as this 
concentration had been shown previously, in the p65+/+ MEFs, to be relatively non-toxic 
alone. However, when a dose range of PBS-1086 was undertaken in the breast cancer 
cells, it appeared that this concentration had a profound effect on cell survival alone in 
all three cell lines. Therefore, it would be advantageous to repeat the radio-sensitisation 
assays in combination with lower concentrations of PBS-1086. To this end, however, it 
must also be noted that when the effects of subunit DNA binding following a prolonged 
exposure to either 1 µM or 10 µM PBS-1086 were assessed in the breast cancer cell 
lines, the lower concentration only significantly inhibited DNA binding of p65 or p50, 
whereas the 10 µM DNA binding of all subunits of c-Rel, to some extent. Hence, it 
would be important to assess any effects on subunit DNA binding with the 
concentration used in combination with IR in the clonogenic assays. 
 
The data presented here shows that the MDA-MB-231 breast cancer cells have the 
highest protein expression and DNA binding activity of both of the canonical subunits, 
p65 and p50, and that these cells are most sensitive to PBS-1086 mono-therapy. This 
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supports the recent data of Lui et al., (2010) which illustrated, by using the IκBα super 
repressor (IκBαSR), that the canonical pathway was responsible for the development of 
murine mammary tumourigenesis. This work also went on to show that NF-κB activity 
in such tumours maintained the expansion of progenitor cells (measured by CD44 
positivity), and that IκBαSR expression reduced the proportion of CD44 positive cells 
by approximately 50 % (Liu et al., 2010). Furthermore, another group have shown that 
compounds known to inhibit NF-κB activation, preferentially target breast cancer stem 
cells (Zhou et al., 2008). Taken together these data suggest that be using a potent and 
specific inhibitor, such as PBS-1086, may in fact target this stem cell niche. 
 
Mutations in Ras are common in many cancers, including lung and breast, and are 
associated with poor prognosis and therapeutic resistance (Bos, 1989); hence targeting 
Ras has become an attractive approach in cancer. It has been reported that 20 % of non-
small cell lung cancers have Ras mutations (Mascaux et al., 2005). Two recent reports 
have suggested that the NF-κB and Ras activation pathways are intimately linked 
(Barbie et al., 2009, Basseres et al., 2010). Both studies, in lung cancer cell lines and 
xenograft models, found that NF-κB inhibition is hyper-lethal to cells with mutant K-
Ras and may provide an alternative method for the pharmacological targeting of 
oncogenic K-Ras. Basseres et al., (2010) use a specific inhibitor of IKKβ and conclude 
that is it the p65 subunit that is vital for K-Ras induced tumorigenesis. The survival data 
using PBS-1086 as a mono-therapy in the breast cancer cell lines furthers these existing 
data, by showing that the MDA-MB-231 breast cancer cell line with a G13D K-Ras 
mutation (Barbie et al., 2009), Sanger cell line Cosmic database), not only has the 
highest activity and expression of p65 but also is most sensitive to PBS-1086 (almost 
10-fold more sensitive compared with the K-Ras wild-type breast cancer cell lines 
tested). Therefore, this may suggest that there is a co-dependency between the Ras and 
NF-κB pathways in cancer, which could be potentially be exploited as a mechanism of 
synthetic lethality. 
 
7.5 Summary and future work 
In summary, this chapter demonstrates that a very potent and specific Rel inhibitor, 
PBS-1086, can sensitise cells to irradiation and that this is mediated directly via the 
inhibition of NF-κB. To this end, PBS-1086 may prove useful in overcoming NF-κB-
mediated therapeutic resistance in breast, and other cancers.  The use of PBS-1086, 
329 
 
which directly targets the Rel DNA binding functions of the NF-κB subunits (Jie Zhang, 
personal communication) may overcome toxicities observed with other inhibitors of the 
NF-κB pathway. For example, the IKK complex is known to have many functions 
within the cell (Carrillo et al., 2004, Chariot, 2009), and thus global inhibition using 
IKK inhibitors, may be cytotoxic, due effects on pathways other than just that of NF-
κB. Moreover, the data presented within this chapter highlight the potential use for 
PBS-1086 as a stand-alone agent in breast cancers which express aberrantly NF-κB, 
something which warrants much further investigation. 
 
The work here has concentrated on the inhibition of NF-κB activation by PBS-1086 in 
breast cancer cell lines, therefore the further pre-clinical studies should be undertaken in 
xenograft models and primary tissues of this disease. The role of PBS-1086 as a radio-
sensitising agent has been assessed here, however many other DNA damaging agents 
are used in the treatment of breast cancer. For example, the topoisomerase II poison, 
doxorubicin, is widely used and also known to activate NF-κB (Campbell et al., 2006a). 
Hence, it would be predicted that PBS-1086 would chemo-sensitise cells to this agent, 
and others that act via NF-κB activation. Moreover, aberrantly active NF-κB has been 
reported in many different types of cancers and leukaemia (Basseres and Baldwin, 
2006). Therefore, this agent has wide ranging potential in the treatment of many 
cancers, although this must be rigorously tested in the different types of the disease both 
in vitro and in vivo. 
 
Importantly, it was not only PBS-1086 that exhibited potential as a radio-sensitiser in 
the initial screen undertaken; PBS-1170 showed a 12-fold potentiation (Table 7.3). Due 
to time constraints, it was not possible to pursue this compound further. It is therefore 
important to undertake future work with PBS-1170. This compound is known to inhibit 
p65, without effecting RelB or c-Rel (Jie Zhang, personal communication), and 
therefore it would be predicted that this compound would be a potent radio-sensitiser, as 
indicated in the data from the second compound screen (Figure 7.14B). 
 
The potential to exploit a putative mechanism for synthetic lethality in terms of the co-
dependency between the Ras and NF-κB pathways in cancer (as described by Barbie et 
al., (2009) and Basseres et al., (2010) is also something which requires much further 
investigation. The data presented here supports the existing reports demonstrating that 
the K-Ras mutation cell line, MDA-MB-231 were the most sensitive to PBS-1086 as a 
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single agent, however more work is required. A wide range of cell lines containing Ras 
mutations should be tested to screen for sensitivity to NF-κB inhibition. This approach 
was used by Bryant et al., (2005) and Farmer et al., (2005) to confirm synthetic lethality 
of PARP-1 inhibition in BRCA-defective cells. However, to further confirm the 
hypothesis that NF-κB inhibitors will be particularly effective in a Ras mutated 
background, and isogenic paired cell line containing cells that are either WT or Ras 
mutated should be used and would provide a huge amount of insight into the cross-talk 
between the NF-κB and Ras pathways. Moreover, for true synthetic lethality, the NF-κB 
inhibitor would have no effect in normal cells, and only those which contain a Ras 
mutation. It would therefore be essential to develop a very potent and specific NF-κB 
inhibitor, which could be used at low, non-toxic concentrations. 
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Chapter 8. Conclusions and future study 
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The aims of this thesis were to test the hypothesis that PARP-1 mediates cell survival 
following DNA damage primarily through activation of NF-κB. The potent and specific 
PARP inhibitor, AG-014699 and siRNA knockdown of either p65 or PARP-1, as well 
as MEFs proficient or deficient for either NF-κB p65 or PARP-1 were  used to elucidate 
the underlying molecular mechanisms that transduce signals from DNA damage-
activated PARP-1 to the activation of NF-κB. Furthermore, it was also hoped that these 
data could aid in the determination of new therapeutic avenues for use of AG-014699 in 
cancers in which aberrantly active NF-κB mediates therapeutic resistance. 
 
8.1 The role of PARP and NF-κB in radiosensitivity 
Briefly, clonogenic survival and apoptosis assays showed that p65-/- MEFs were more 
sensitive to IR than p65+/+ MEFs, consistent with reports that NF-κB confers radio-
resistance (Biswas et al., 2001, Wu and Kral, 2005). Co-incubation with p65 siRNA, 
PARP siRNA or AG-014699 radio-sensitised p65+/+, but not p65-/- MEFs, 
demonstrating that PARP-1 mediates its effects on survival via NF-κB.  Furthermore, a 
combination of p65 siRNA and AG-014699 radio-sensitised p65+/+ MEFs to the same 
extent as either agent alone, strongly indicating that PARP-1 and NF-κB are 
mechanistically linked, supporting existing data in the literature (Chang and Alvarez-
Gonzalez, 2001, Hassa et al., 2001, Hassa and Hottiger, 1999, Kauppinen and Swanson, 
2005, Martin-Oliva et al., 2004, Stilmann et al., 2009, Veuger et al., 2009). 
 
PARP-1 is known to be vital for the repair of SSBs. SSB repair kinetics, and the effect 
SSB repair inhibition by AG-014699 were similar in p65+/+ and p65-/- cells. Since 
inhibition of SSB repair did not radio-sensitise p65-/- cells, these data show that radio-
sensitisation by AG-014699 is due, in part, to downstream inhibition of NF-κB 
activation. However, further work should be undertaken to thoroughly test this 
hypothesis, and other functional roles of PARP-1 within the cell, such as it’s role in 
DSB repair, should be considered.  
 
8.2 The role of PAR in the activation of NF-κB 
PARP-1 catalytic activity was essential for IR-induced p65 DNA binding and NF-κB-
dependent gene transcription, whereas for TNF-α treated cells, PARP-1 protein alone 
was sufficient, in line with the report from Hassa et al., (2001). It can therefore be 
333 
 
hypothesised that this stimulus-dependent differential is mediated via stimulation of 
PAR, which was induced following IR, not TNF-α. PARG is the major enzyme 
responsible for the catabolism of PAR (Bonicalzi et al., 2005). In order to inhibit 
degradation of PAR a potent and specific PARG inhibitor, ADP-HPD, was used (Slama 
et al., 1995).  In this case, increased polymer stability following IR, by virtue of 
inhibition of polymer degradation, led to the persistence of NF-κB DNA binding, an 
increase in anti-apoptotic gene expression and protection against IR-induced cell death. 
These data confirm a role for PAR in the activation of NF-κB following DNA damage, 
thus supporting the work of Stilmann et al., (2009).  
 
As previously discussed, Stilmann et al., (2009), proposed an elegant model which 
detailed how DNA-damage induced NF-κB activation was mediated by PAR (Figure 
1.13). The caveats associated with this study have also been discussed at length as part 
of this thesis. An extended, complementary model for the activation of NF-κB, which is 
mediated by PAR following DNA damage, has been proposed in section 4.4. Briefly, 
DNA damage, such as IR, activates PARP-1, recruiting it to the site of damaged DNA. 
This results in formation of negatively charged PAR (Ueda and Hayaishi, 1985). The 
NF-κB p65-p50 heterodimer is also translocated to the nucleus following DNA damage 
via activation of the canonical pathway of NF-κB activation. When in proximity to 
regions with overall negative charge, such as that of PAR, a conformational change in 
p65 can be induced, exposing the positively charged DNA binding interface of p65 
(Ghosh, 1999). Thus, negatively charged PAR has the ability to attract p65 to bind DNA 
(as PARP-1 and the polymer are recruited to sites of damaged DNA) up-regulating 
transcription of NF-κB-dependent genes, protecting against apoptosis and conferring 
radio-resistance. However, in the presence of the PARP inhibitor, AG-014699, PARP-1 
is no longer active and cannot form the polymer. Hence in this case, there is reduced 
DNA binding and transcriptional activation following IR, with induction of apoptosis 
and ultimately radio-sensitisation.  
 
However, more experiments, which were beyond the scope of this thesis should be 
undertaken to further confirm this proposed mechanism. To this end, it would be 
important to perform some key immunofluorescence assays, similar to those described 
by (El-Khamisy et al., 2003) which were used to show that PAR recruits the BER 
protein XRCC1 to micro-sites of DNA damage. The aim of these experiments would be 
to determine whether p65 is recruited to the DNA through the electrostatic attraction 
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generated in the presence of PAR. In order to do this, a fluorescent-tagged p65 could be 
introduced into cells, and then these cells damaged using a laser, so that only a 
microscopic area had damaged DNA, and therefore PAR formation. Cells could then be 
stained with a PAR antibody and co-localisation studies could be undertaken, in this 
case to determine whether p65 is attracted to the negative charge of PAR. It would be 
important to use micro-sites of damage in this case as large areas of damage will result 
in a large amount of PAR formation and may mask any signal with p65. Another 
method of investigating the interaction between PAR and p65 following DNA damage 
would be to use fluorescence resonance energy transfer (FRET) (Zhang and Rudkevich, 
2007). This principle is used to describe the energy transfer between two chromophores, 
and is centered around the fact that a fluorophore labelled-donor chromophore, initially 
in its electronic excited state, may transfer energy to an fluorophore labelled-acceptor 
chromophore in close proximity (typically less than 10 nm). This technique can not only 
be used to assess protein-protein interactions, but also for monitoring protein 
conformational changes, and could therefore be utilised to analyse the proposed 
conformational change in p65 in the presence of PAR.  
 
It is important to take into account the Histone shuttling model, which states that the 
large overall negative charge of PAR has the ability to relax the chromatin structure, 
which is usually extremely tightly wound, and displaces histones from DNA. This PAR-
induced relaxation would then allow large regions surrounding the DNA strand breaks 
to become accessible to other repair proteins (Althaus et al., 1993, Althaus et al., 1994); 
however it is very plausible that this theory can be extended to other proteins, such as 
p65. The mechanism proposed in Chapter 4, corroborates the histone shuttling model, 
by suggesting that PARP-1 regulates IR-induced NF-κB, in part by chromatin structure 
remodelling. Moreover, histone associated proteins have been shown to interact with 
p65 and alter the transcriptional response. In particular, phosphorylation of p65 at 
threonine 505 (Thr-505) in response to the DNA crosslinking agent, cisplatin, has been 
shown to inhibit p65 transactivation, in turn increasing the association between p65 and 
HDAC1. This can then result in the repression of NF-κB target genes, such as the anti-
apoptotic factor, Bcl-xL. The phosphorylation of p65 at Thr-505 was shown to require 
the checkpoint kinase, Chk1 and was induced by the p14/ARF tumour suppressor 
protein. Interestingly, this phosphorylation was observed in the U2OS cancer cell line 
model, following treatment with cisplatin, but not by other agents known to activate 
Chk1 (Campbell et al., 2006b, Rocha et al., 2005). These data, once again, highlight the 
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complex crosstalk between the DNA damage and NF-κB pathways, and suggest that the 
observed response is highly likely to be both cell type- and stimulus- dependent. 
 
8.3 PARP inhibition as a method of inhibiting transcriptional activation 
Microarray analysis showed that the TNF-α driven transcription of NF-κB-dependent 
inflammatory and immune response genes was unaffected by AG-014699, suggesting 
that targeting DNA-damage activated NF-κB using AG-014699 may overcome toxicity 
observed with classical NF-κB inhibitors without compromising other vital 
inflammatory functions. These data are very encouraging in the context of the potential 
use of AG-014699 in inhibiting DNA-damage activated NF-κB in cancer, as previously 
discussed. However, there have been a number of reports which have implicated PARP-
1 in the development of both acute and chronic inflammatory diseases. For example, 
PARP-1 null mice or mice treated with PARP inhibitors have exhibited resistance to 
numerous different types of inflammation, including LPS-induced septic shock and 
streptozotocin-induced diabetes (Burkart et al., 1999, Mabley et al., 2001, Oliver et al., 
1999a). It is therefore very important to assess the effect on AG-014699 on 
inflammatory response genes after stimuli other than TNF-α, as other inflammatory 
mediators, such as LPS are known to initiate NF-κB signalling cascades. However, 
these studies should proceed with caution as LPS has been shown to induce oxidative 
stress, which is also known to induce SSBs and therefore activate PARP-1. Hence, it 
may be difficult to tease apart any effects PARP inhibitors were having on 
transcriptional activation from there role in the inhibition of SSB repair in this case. 
 
Reports have shown that PARP inhibitors may be advantageous for the treatment of 
neurological and inflammatory disorders. It is important to note that studies using PARP 
inhibitors in neurological disorders, have not just assessed the effect on these inhibitors 
on NF-κB activation, but also that of other transcription factors known to be regulated 
by PARP-1, such as AP-1. Reports have shown that PARP-1 deficient glia exhibited 
reduced binding and associated gene expression of NF-κB, AP-1, Sp1 and Oct-1 (Ha et 
al 2002 PNAS). Another report using PARP inhibitors in rat glial and neuronal cultures 
found that the expression of genes including iNOS, IL-1β and TNF-α was reduced, 
resulting in a reduced neuro-inflammation and the neurotoxic potential of activated glia 
(Chiarugi and Moskowitz, 2003). It is important to recognise that these genes are not 
solely regulated by NF-κB. Zingerilli et al., (2003) found that PARP inhibition in 
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concert with the inflammatory stimulant 2,4,6-trinitrobenzene sulfonic acid markedly 
reduced DNA binding of both NF-κB and AP-1 in a rat model of colitis. This resulted in 
a reduction in neutrophil infiltration, reduced colonic damage and induced apoptosis 
(Zingarelli et al., 2003b). These studies highlight the importance of investigating the 
effects on PARP inhibition, not just on one transcription factor, but on others too, as 
PARP-1 is a known co-regulator of at least nine transcription factors. However, the 
studies undertaken as part of this thesis not only used the potent and specific PARP 
inhibitor, AG-014699 and PARP-1 siRNA, they also used siRNA targeting p65, and 
p65 proficient and deficient MEFs, and therefore the conclusions drawn can be 
confidently attributed to the effects of PARP-1 on DNA-damage-induced NF-κB 
activation, it would be prudent, and also very interestingly to assess the effects on AG-
014699 on other transcription factors. In particular, those which are closely related to 
NF-κB, such as AP-1, which is also activated by TNF-α and IL-1β (Dutta et al., 2006) 
and NFAT (Jain et al., 1992). 
 
An investigation into the role of PARP-1 in DNA damage activated NF-κB activation in 
glioblastoma cells was also undertaken as part of this thesis in order to assess the 
potential utility of AG-014699 in tumour types known to express constitutively active 
NF-κB. PARP-1 activity was vital for both radio- and chemo-sensitisation of U251 
glioblastoma cells, and mediated its effects on survival following either IR or 
temozolomide via NF-κB in these cells. Importantly, these data confirmed the earlier 
findings in the MEFs by demonstrating that radio- or chemo-sensitisation by AG-
014699 is due to downstream inhibition of NF-κB activation, and independent of SSB 
repair inhibition. Moreover, these data highlight the potential of PARP-1 inhibitors to 
overcome NF-κB-mediated therapeutic resistance and widens the spectrum of cancers in 
which these agents may be utilised. These findings are very encouraging, and together 
with data which showed that NF-κB p65 translocation was induced following DNA 
damage in cell lines derived from other tumours types, such as lung adenocarcinoma 
(Chapter 6), they do suggest that the targeting of DNA-damage induced-NF-κB 
activation with a PARP inhibitor is a viable therapeutic strategy. However, further work 
and validation using a range of model systems is required. Most important is the use of 
preclinical modelling to assess the effects of AG-016499 on DNA-damage activated 
NF-κB in vivo.  
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8.4 Crosstalk between the mitotic spindle, DNA damage and NF-κB 
An interesting observation from the microarray study was that the genes up-regulated 
following treatment with IR were those associated with the mitotic spindle and cellular 
organisation and assembly. Furthermore, it also appeared, after qRT-PCR validation 
assays, that a subset of these genes, including PLK-1, AUKRA and CDC20 could 
potentially be regulated by NF-κB following DNA damage. Although some associated 
genes, such as PLK-3 are known to be NF-κB regulated (Li et al., 2005), the three genes 
identified as part of the gene expression profiling within this thesis could be novel 
targets, and as discussed in Chapter 5, require further investigation. However, there 
have been other reports in the literature which have postulated a link between either NF-
κB or members of the PARP superfamily and the mitotic spindle. (Briassouli et al., 
2007) demonstrated that aurora kinase A could regulate NF-κB activation through 
phosphorylation of IκBα at ser32 or ser36, however it is unclear whether this is a direct 
phosphorylation event or a result of downstream signalling. Aurora kinase inhibition 
has also been shown to sensitise a range of human tumour cell line to commonly used 
chemo-therapeutic agents via the down-regulation of NF-κB activation (Briassouli et 
al., 2007, Sun et al., 2007). These data, taken with the observations within this thesis, 
mean that a feedback loop between aurora kinase A and NF-κB could exist. It could be 
postulated that the over-expression of aurora kinase A, which is common in cancer and 
known to contribute to poor prognosis (Goepfert et al., 2002, Jeng et al., 2004, Sakakura 
et al., 2001, Tanaka et al., 1999b), in turn drives NF-κB activation, known to correlate 
with increased metastatic potential and therapeutic resistance, through the regulation of 
target genes (Prasad et al., 2010), one of which is the AURKA gene, which encodes the 
aurora kinase A protein. 
 
Members of the PARP superfamily have also been implicated in regulation of cellular 
division and assembly. Both PARP-1 and PARP-2 localise to the centromeres where 
they interact with key kinetochore associated proteins (Saxena et al., 2002a, Saxena et 
al., 2002b)). Most recently, PARP-3 has been implicated in the stabilisation of the 
mitotic spindle and in the regulation of telomeric integrity (Boehler et al., 2011) and the 
phosphorylation of the PARP superfamily member Tankyrase 1 (TNKS1) by PLK-1, 
has been shown to regulate TNKS1 function at telomeres and during mitosis (Ha et al., 
2011) The significance of this association is still somewhat unclear, however, like the 
array study here, it links the DNA damage signalling network with that of the mitotic 
fidelity checkpoint. Moreover, other reports show that aurora kinase B is a target for 
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poly(ADP-ribosyl)ation in response to DNA damage via the interaction between PARP-
1 and spindle checkpoint component, BUBR1 (Monaco et al., 2005). A further interplay 
between the spindle checkpoint and DNA damage and repair, was reported by 
Sourisseau T et al., (2010) when they showed that the expression of aurora kinase A 
inhibited the recruitment of the HRR protein, RAD51 to DSBs. This impairment of 
RAD51 function was shown to be dependent on the inhibition of Chk1 by PLK-1. This 
ultimately resulted in the cells with high expression of aurora kinase A having a 
compromised DSB repair response, and being sensitive to PARP inhibition (Sourisseau 
et al., 2010), in a similar manner to the synthetic lethality described with the use of 
PARP inhibitors in BRCA-defective breast and ovarian tumours (Bryant et al., 2005, 
Farmer et al., 2005). Together with data presented in Chapter 5 of this thesis, it follows 
that PARP inhibition may be a novel therapeutic approach to cancers with de-regulated 
mitotic spindle checkpoint signalling, and importantly, NF-κB-regulated gene 
expression could be a key link between DNA damage and mitotic spindle networks. 
 
 
The DNA repair kinase, DNA-PK, has also been implicated in the regulation of NF-κB 
(Basu et al., 1998, Ju et al., 2010, Liu et al., 1998, Panta et al., 2004). Interestingly, the 
activation of NF-κB by DNA-PK does not appear to be dependent on DNA damage. For 
example, it has been reported that the phosphorylation of the p50 NF-κB subunit by 
DNA-PKcs, in response to TNF-α was required for the expression of the NF-κB-
dependent gene, VCAM-1 (Ju et al., 2010), and most interestingly that DNA-PK 
activates NF-κB in a MEK-to-IKK signalling pathway in response to treatment with 
AD288 (N-benzyladriamycin), a catalytic inhibitor of topoisomerase II  but not in 
response to the topoisomerase II poison, DOX (Panta et al., 2004). Catalytic inhibitors 
of topoisomerase II do not cause DNA DSBs, unlike classical topoisomerase poisons, 
such as DOX, but in contrast the mechanism of action and result on the cell, is similar to 
the effects of the microtubule poisons, another group of chemotherapeutic agents.  
Intriguingly, there have been two recent reports that have suggested a role for DNA-PK 
outside its usual remit of DNA repair. These have shown that DNA-PK is required for 
cell cycle progression through mitosis, and that inhibition of DNA-PK can result in 
spindle disruption and mitotic catastrophe (Lee et al., 2011, Shang et al., 2010). These 
data, once again provide an intriguing link between the DNA-damage signalling 
networks and those associated with cellular organisation and assembly, in line with gene 
expression profiling study in Chapter 5. These data suggest that NF-κB is involved in 
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this signalling, and therefore an investigation in to the role of DNA-PK in the activation 
of NF-κB, and in the context of the spindle checkpoint, is merited.  
 
8.5 The use of DNA repair inhibitors to target NF-κB activation 
The use of DNA-damage repair inhibitors as a means of targeting NF-κB is becoming 
increasingly more interesting following the emergence of studies which have elucidated 
the mechanism by which proteins such as ATM (Hinz et al., 2010, Wu et al., 2006) and 
PARP-1 (Hunter et al., 2011, Stilmann et al., 2009, Veuger et al., 2009) activate the 
transcription factor following DNA damage. However, there are caveats associated with 
using inhibitors of such enzymes. There have been a number of studies which have 
shown that targeting DNA repair proteins in cancer cell lines and xenograft models can 
sensitise cells to DNA damaging chemo-therapeutic agents (Plummer, 2010), but 
whether this sensitisation is solely due the inhibition of NF-κB remains to be seen. 
Proteins such as ATM are involved in a huge range of cellular processes, such as gene 
regulation, apoptosis, DNA repair, and cell cycle checkpoint activation (Kurz and Lees-
Miller, 2004). It is therefore essential to determine the precise role of ATM in the cell 
before the addition of an ATM kinase inhibitor. ATM is known to phosphorylate and 
activate the p53 tumour suppressor protein in response to DNA damage, resulting in the 
initiation of the apoptotic response (Ashcroft et al., 1999). Hence, it is likely that there 
is a delicate balance between the pro-apoptotic gene expression in cancer cells with 
functional p53 and the anti-apoptotic genes induced by NF-κB-dependent gene 
transcription in response to DNA damage. 
 
Recently, Veuger and Durkacz (2011) showed that the small molecule inhibitor of ATM 
kinase activity, KU55933 (Hickson et al., 2004) sensitised breast cancer cells to IR via 
the inhibition of NF-κB activation, and as part of this work they also postulated that 
ATM inhibition could be used as a stand-alone therapy in cancers which expressed NF-
κB p65 that was constitutively nuclear. To this end, it was reported that a prolonged 
exposure to KU55933 in the MDA-MB-231 cells resulted in an inhibition of NF-κB 
DNA binding, in the absence of DNA-damage (Veuger and Durkacz, 2011). It is highly 
likely that this is an off target effect of the ATM inhibitor, as it would be thought that 
the kinase activity of ATM would have to be induced for KU55933 to have any effect. 
However another group have suggested that ATM-dependent NF-κB activation can 
occur in the absence of DNA damage as the SUMOylation of NEMO can occur without 
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DSB-inducing conditions. Importantly, in this case, electroporation stress was found to 
induce the post-translational SUMOylation of NEMO, and hypotonic shock, which 
weakly activates ATM induced NF-κB activation (Wuerzberger-Davis et al., 2007). In 
this case however, ATM was active, though not through the classical means of DNA-
damage. Other mechanisms known to induce ATM activity include oxidative stress 
(Guo et al., 2010). 
 
The work in this thesis suggests that the activation of PARP-1 is essential for the 
activation of NF-κB following DNA, hence AG-014699 is only effective in inhibiting 
NF-κB which has been induced by DNA damage, and not by TNF-α. However, cells do 
undergo oxidative damage and produce reactive oxygen species in some disease states 
(Schreiber et al., 2006b), which can result in the activation of PARP-1 in the absence of 
DNA damage. If, in such cells, NF-κB dimers were constitutively nuclear in location 
(which they often are in tumour cells), it is plausible to suggest that poly(ADP-
ribosyl)ated PARP-1 in this case could facilitate NF-κB DNA binding, as suggested in 
the model in Chapter 4. In this case, AG-014699 could perhaps be utilised as a mono-
therapy in order to inhibit NF-κB activation, however this hypothesis is very 
speculative, and requires much more investigation before any conclusions could be 
drawn. 
 
The potential use of PARP inhibitors as single agents for the treatment of BRCA-
mutated or defective breast and ovarian cancers has been well documented (Bryant et 
al., 2005, Drew et al., 2011, Farmer et al., 2005, Fong et al., 2009, Fong et al., 2010). 
Recently, Gottipati et al., (2010) demonstrated that cells which were defective in, or 
lacking, any proteins associated with HRR, such as BRCA2, WRN or RAD52, had 
hyper-activated PARP-1, as illustrated by an increased PAR formation. They also 
showed that these cells were sensitive to PARP inhibition, suggesting a synthetic 
lethality mechanism between PARP-1 and other defective HRR proteins, not just 
BRCA1 or BRCA2 (Gottipati et al., 2010). Data presented in this thesis has shown that 
PAR is key in mediating NF-κB following DNA damage, which corroborates the work 
of others (Stilmann et al., 2009). Therefore, it would be interesting to determine whether 
HRR-defective cells, which are reported as having high levels of PAR in the absence of 
DNA damage, also have an increased NF-κB DNA binding compared with cells which 
are known to have a fully functional HRR pathway. In this was in fact the case, it 
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further adds weight to therapeutic potential of PARP inhibitors as mono-therapeutic 
agents for the treatment of HRR-defective tumours.  
 
8.6 The use of targeted NF-κB inhibitors versus the use of DNA repair inhibitors to 
inhibit NF-κB activation  
The targeting of NF-κB in a more direct fashion was also assessed as part of this thesis 
in order to determine the therapeutic potential of a potent inhibitor of NF-κB subunit 
DNA binding, PBS-1086, in the NF-κB p65+/+ and p65-/- MEFs and the MDA-MB-231, 
T47D and MCF7 breast cancer cell lines. Briefly, DNA binding and luciferase reporter 
assays showed that PBS-1086 inhibited IR-induced p65 and p50 DNA binding and NF-
κB-dependent gene transcription in p65+/+ cells. Co-incubation with PBS-1086 or p65 
siRNA radio-sensitised p65+/+, but not p65-/- cells, demonstrating that PBS-1086 
mediates radio-sensitisation via the p65 NF-κB subunit. Gene expression analysis 
showed that PBS-1086 inhibited IR-induced transcription of known NF-κB-regulated 
anti-apoptotic genes. MDA-MB-231 cells were found to have the highest constitutive 
levels of DNA binding of all NF-κB subunits. PBS-1086 radio-sensitised all three breast 
cancer cell lines. In survival assays, all of the breast cancer cell lines tested were also 
sensitive to PBS-1086, however, the MDA-MB-231 cells were the most sensitive to 
PBS-1086 alone. These data therefore suggest that high NF-κB DNA binding activity 
appears to correlate with sensitivity to PBS-1086.  
 
 
The compound used here, PBS-1086 is an early lead compound in the drug discovery 
pipeline from Profectus BioSciences Inc, and is now undergoing SAR (structural 
activity relationship) chemistry to optimise properties of this molecule. PBS-1086 is is 
known to covalently modify the cysteine-38 residue in the Rel domain of the NF-κB 
subunits (Jie Zhang personal communication) and has been shown to inhibit p65, p50 
and RelB DNA binding as well as luciferase expression in a 293/NF-κB-luciferase 
reporter cell line (Oh et al., 2011). Other compounds which target this cysteine residue, 
such as epoxyquinone A monomer, a synthetic derivative of the natural product 
epoxyquinol A, have also been shown to inhibit IKKβ through modification of the 
cysteine-179 residue (Liang et al., 2006). Moreover, both IKKα and IKKβ have this 
conserved cysteine residue in the activation loop of their catalytic domain (Kapahi et al., 
2000), and this should be taken into account when interpreting results. For example, 
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PBS-0186 achieved cell kill as a stand-alone therapy in each of the three breast cancer 
cell lines tested, and although this appears to correlate with the inhibition of constitutive 
NF-κB activation, the possibility that this compound may have some activity against the 
IKK complex as well as direct subunit DNA binding should be considered. This is 
especially the case in the clonogenic assays in which PBS-1086 was used in 
combination with IR, as the IKK would have been activated by the DNA damaging 
agent and hence some of the cell kill observed may be attributable to IKK inhibition. A 
subunit specific inhibitor, such as PBS-1170, which targets p65 alone, and used in later 
experiments in Chapter 7, may be a more suitable approach for targeting NF-κB, as this 
should only target canonical pathway signalling. 
 
 
Targeting NF-κB is an attractive therapeutic avenue, not just in cancer but also in 
inflammatory diseases, such as rheumatoid arthritis. However, there is one underlying 
caveat associated with globally inhibiting the NF-κB pathway, that being that this 
transcription factor is essential for the immune and inflammatory response of the cell, as 
previously discussed. Personally speaking, targeting one type of NF-κB activation, for 
example DNA-damage activated NF-κB would be a favoured option. Although the use 
of DNA repair inhibitors may be a much less direct way of target the transcription 
factor, they do appear to have numerous benefits over traditional NF-κB pathway 
inhibitors. The main advantage would be avoiding potential toxicity associated with any 
effects on the essential immune functions of NF-κB, which has been associated with an 
increase likelihood of immunodeficiency and the delayed bone marrow recovery due to 
some reports of chemotherapeutic induced apoptosis of hematopoietic progenitors 
(Grossmann et al., 1999, Turco et al., 2004). Furthermore, IKK inhibition has been 
associated with defects in lymphopoiesis, hepatotoxicity and an increased risk of 
infection, this is exemplified by the use of anti-TNF-α biologics which have been 
associated with increased reactivation of latent tuberculosis infection (Strnad and Burke, 
2007). The data presented here, involving the inhibition of DNA-damage activated NF-
κB using a PARP inhibitor, has shown that the vital inflammatory functions of NF-κB 
are unaffected, thus helping to overcome the toxicities associated with specific NF-κB 
inhibitors. To this end, it should also be noted that during clinical trials, PARP 
inhibitors have been found to have low toxicity profiles (Drew and Plummer, 2009). 
Furthermore, a DNA repair inhibitor, such as AG-014699 affords a ‘double-hit’ to a 
cancer cell as it not only inhibits key DNA repair pathways (which tumour cells use as a 
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method of evading cell death) but also inhibits the NF-κB transcriptional response, 
which is known to contribute to malignant progression. 
 
8.7 Statistical analysis 
Throughout this thesis statistical analyses have been performed, and the most part these 
have been unpaired Student’s t-tests that have demonstrated statistical differences in the 
data. It is therefore necessary to consider the possibility that some of these tests were 
false positives, and this can be done using the Bonferroni correction. Of the 147 t-tests 
that have been performed, and assuming a 95 % confidence rate, this correction would 
assume that 7 of these outcomes would be false positives. However, the consistent 
trends seen within the data from the different assays used, for example the statististical 
differences observed in both the DNA binding and luciferase assays, suggest that the 
outcomes observed are bone fide, and are therefore unlikely to be false positives. 
 
8.8 Summary 
Collectively the data in this thesis highlight the potential of modulating NF-κB activity, 
either by PARP-1, or directly via inhibition of subunit DNA binding, to restore radio- 
and chemo-sensitivity in cancers with aberrantly active NF-κB and to overcome NF-κB-
mediated therapeutic resistance. These data also further the existing knowledge and 
understanding of how signals from DNA-damage activated PARP-1 mediate the 
activation of NF-κB and importantly suggest that the potent and specific PARP 
inhibitor, AG-014699 mediates cell survival following DNA damage primarily through 
activation of NF-κB, and independent of the role PARP inhibitors play in the inhibition 
of DNA repair. Furthermore, this thesis shows that PARP and NF-κB inhibitors may 
prove useful in overcoming NF-κB-mediated therapeutic resistance, an important goal 
in cancer therapy. 
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I.I Differentially expressed genes 8 hours following treatment with TNF-α 
 
Table A.I, below contains list of genes of over 400 genes differentially expressed following 8 hours after 
treatment with TNF-α, compared with untreated controls, as well as the accession/identification number 
and the fold change. 
 
Gene Symbol ID Fold change 
ATP-binding cassette, sub family A (ABC1), member 
3 
ABCA3 NM_013855.2 -1.320 
ATP-binding cassette, sub family A (ABC1), member 
7 
ABCA7 NM_013850.1 -1.290 
ATP-binding cassette, family B (MDR/TAP) member 
1B 
Abcb1b NM_011075.1 1.501 
Acyl-coA dehydrogenase, C-4 to C-12 straight chain ACADM NM_007382.1 -1.415 
Acyl-coA binding domain containing 4 ACBD4 NM_025988.2 -1.230 
Amiloride-sensitive cation channel 2, neuronal ACCN2 NM_009597.1 -1.567 
Acyl-coA synthetase thioesterase 7 ACOT7 NM_133348.1 1.211 
Acid phosphatase-like 2 ACPL2 NM_153420.2 1.301 
Acyl-coA synthetase long-chain family member 3 ACSL3 NM_028817.2 -1.285 
Actinin, alpha 4 ACTN4 NM_021895.2 -1.285 
ADAMTS-like 4 ADAMTSL4 NM_144899.2 -1.385 
Adenylate kinase 2 AK2 NM_016895.3 1.331 
Aldehyde dehydrogenase 3 family, member A1 ALDH3A1 NM_007436.1 -1.594 
Aldehyde dehydrogenase 6 family, member A1 ALDH6A1 NM_134042.2 -1.345 
Angiopoietin-like 2 ANGPTL2 NM_0119234 -1.310 
Annexin A8 ANXA8 NM_013473.3. -1.288 
Amyloid beta (A4) precursor protein-binding, family B 
member 1 (Fe65) 
APBB1 NM_009685.2 -1.349 
Aquaporin 1 AQP1 NM_007472.2 -1.412 
Aquaporin 5 AQP5 NM_009701.4 -2.065 
Rho GTPase activating protein 18 ARGGAP18 NM_176837.2 -1.399 
Rho GTPase activating protein 22 ARGGAP22 NM_153800.3 -1.909 
Rho GTPase activating protein 24 ARGGAP24 NM_29270.1 -1.305 
Rho guanine nucleotide exchange factor 15 ARGGEF15 AK052570 -1.219 
Rho guanine nucleotide exchange factor 18 ARGGEF18 NM_133962.3 -1.218 
Armadillo repeat containing, X-linked 2 ARMCX2 NM_026139.3 -1.264 
ARV1 homolog ARV1 NM_026855.1 1.205 
Argininosuccinate sythetase 1 ASS1 NM_007494.3 1.509 
ATPase, H+ transporting, lysosomal VO subunit a1 ATP6VOA1 NM_016920.1 -1.439 
Arginine vasopressin-induced 1 AVPI1 NM_027106.3 -1.328 
UDP-GlcNac: betaGal beta-1,3-N-acetyl 
glucosaminyltransferase-like 1 
B3GTNL1 NM_178664.3 -1.274 
Bcl-2 binding component 3 BBC3 NM_133234.1 1.358 
BCL-2 associated athanogene 6 BAG6 NM_057171.1 -1.266 
BCL-2-like 11 (apoptosis facilitator) BCL2L11 NM_009754.2 1.374 
BMP binding endothetial regulator BMPER NM_028472.1 -1.356 
BCL2/adenovirus E1B 19kDa interacting protein-3-
like 
BNIP3L NM_009761.2 -1.213 
C1q and TNF related protein 1 C1QTNF1 NM_019959.2 -1.222 
Chromosome 21 open reading frame 63 C21orf63 NM_027627.1 -1.282 
Chromosome 3 open reading frame 17 C3orf17 NM_145972.1 1.229 
Chromosome 5 open reading frame 13 C5orf13 NM_053078.3 -1.688 
Chromosome 7 open reading frame 43 C7orf43 NM_153161.1 1.211 
Complement component 3 C3 NM_009778.1 1.332 
Caspase recruitment domain family member 10 CARD10 NM_130859.2 1.750 
Caspase 4 CASP4 NM_007609.1 1.386 
Caveolin 1 CAV1 NM_007616.3 -1.399 
Coiled coil domain containing 137 CCDC137 NM_152807.3 1.306 
Coiled coil domain containing 85B CCDC85B NM_198616.2 1.576 
Chemokine (C-C motif) ligand 13 CCL13  NM_011333.3 3.293 
Chemokine (C-C motif) ligand 17 CCL17 NM_011332.2 1.606 
Chemokine (C-C motif) ligand 5 CCL5 NM_013653.2 6.558 
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Chemokine (C-C motif) ligand 7 CCL7 NM_013654 3.427 
Chemokine (C-C motif) ligand 9 CCL9 NM_011338 6.106 
CD109 molecule CD109 NM_153098.2 -1.298 
CD151 molecule CD151 NM_00942.1 1.281 
CD75 molecule CD75 NM_010545.3 1.229 
CD82 molecule CD82 NM_007656.4 1.783 
CDC42 effector protein 2 CDC42EP2 NM_026772.1 1.246 
CDC42 effector protein 5 CDC42EP5 NM_021454.3 1.343 
Cyclin-dependent kinase 19 CDK19 NM-198164.2 -1.319 
Cyclin-dependent kinase inhibitor 1A (p21) CDKN1A NM_007669.2 1.937 
Cdon homolog CDON AK040711 -1.293 
C-type lectin domain family 2, member d Cled2 NM_053109.2 1.806 
Collagen, type IV, alpha 5 COL4A5 NM_007736.2 -1.480 
Collagen, type V, alpha 1 COL5A1 NM_0157734.1 -1.394 
Collagen, type VII, alpha 1 COL7A1 NM_007738.8 -1.277 
Cellular retinoic acid binding protein 2 CRABP2 NM_007759.2 -1.674 
Cysteine and glycine ricj protein 2 CSRP2 NM_007792.3 1.409 
CTD small phosphatase like cyastathionase CTH NM_145953.3 1.329 
Catenin, alpha-like 1 CTNNAL1 NM_018761.2 1.609 
Catenin, beta interacting protein 1 CTNNBIP1 NM_023465.3 1.532 
Cystinosis, nephropathic CTNS NM_031251.4 -1.271 
Coxscakie virus and adenovirus receptor CXADR NM_001025192.2 -1.338 
Chemokine (C-XC motif) ligand 10 CXCL10 NM_021274.1 5.986 
Diasabled homolog 2, mitogen response protein DAB2 NM_23118.1 1.557 
D site of albumin promoter binding protein DBP NM_016974.1 -1.680 
Decorin DCN NM_007833.4 1.818 
Density-regulated protein DENR NM_026603.1 1.759 
Deafness-autosomal dominant 5 DFNA5 NM_08769.3 -1.280 
Dickkoff homolog 3 DKK3 NM_015814.2 -1.796 
Discs, large homolog 5 DLG5 XM_981375.2 -1.309 
DPH1 homolog DPH1 NM_144491 1.229 
DTW domain containing 1 DTWD1 NM_026981.1 1.243 
Dual specificity phosphatase 4 DUSP4 NM_176933 -1.493 
Dual specificity phosphatase 6 DUSP6 NM_026268.1 -1.315 
Dual specificity tyrosine phosphorylation regulating 
kinase 1B 
DYRK1B NM_001037957.1 -1.249 
Enoyl coA hydratase, short chain 1 ECHS1 NM_050119.1 -1.246 
Eukaryotic translation initiation factor 6 EIF6 NM_010579.2 1.389 
Ectonucleotide pyrophosphatase/phosphodiesterase 2 ENPP2 NM_015744.1 1.499 
Epoxide hydrolase 1 EPHX1 NM_010145.2 1.320 
Epidermal growth factor receptor pathway substrate 8 EPS8 NM_007945.2 1.628 
Ecotrophic viral integration site 2A EVI2A NM_010161.1 1.813 
Ecotrophic viral integration site 5 like EVI5L NM_001039578.2 -1.221 
Coagulation factor II receptor F2R NM_010169.3 -1.540 
Family with sequence similarity 114 member A1 FAM114A1 NM_026667.2 -1.362 
Family with sequence similarity 195 member A FAM195A NM_26633.3 1.350 
Family with sequence similarity 20 member A FAM20A NM_153782.1 -1.313 
Fas FAS NM_007987.1 3.635 
Fibroblast growth factor 7 FGF7 NM_008008.3 1.343 
Four jointed box 1 FJX1 NM_010218.2 1.244 
Flotillin 2 FLOT2 NM_001040403.1 -1.202 
Formin-like 3 FMNL3 NM_011711.1 -1.254 
FBI murine osteosarcoma viral oncogene homolog FOS NM_010234.2 -1.375 
Forkhead box Q1 FOXQ1 NM_008239.3 -1.839 
Growth arrest and DNA damage inducible beta  GADD45B NM_008655.1 1.322 
UDP-N-acetyl-alpha-galactosamine:polypeptide N-
acetylgalactosaminyltranferase 10 
GALNT10 NM_134189.2 -1.219 
UDP-N-acetyl-alpha-galactosamine:polypeptide N-
acetylgalactosaminyltranferase 2 
GALNT2 NM_139272.2 -1.314 
UDP-N-acetyl-alpha-galactosamine:polypeptide N-
acetylgalactosaminyltranferase like 2 
GALNTL2 NM_030166.1 -1.377 
Guanylate binding protein 2 GBP2 NM_010260.1 1.424 
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Guanylate binding protein 4 GBP4 NM_018734.4 1.266 
Glucosaminyl (N-acetyl) transferase 2 GCNT2 NM_133219.1 -1.398 
Glucosaminyl (N-acetyl) transferase 3 GCNT3 NM_028087.2 -1.242 
Gamma-glutamyl cyclotransferase  GGCT NM_026637.3 1.373 
Golgi glycoprotein 1 CLC1 NM_009149 -1.300 
GLI pathogenesis related 2 GLIPR2 NM_027450 1.551 
Glutaredoxin GLRX NM_053108.2 -1.268 
G-protein coupled estrogen receptor 1 GPER NM_029771.2 -1.266 
G-protein coupled receptor 176 GPR176 NM_201367.2 1.691 
Growth factor receptor protein 10 GRB10 NM_010345 -1.263 
Glutamate receptor, ionotrophic AMDA10 GRIA1 NM_008165.2 -1.287 
Granulin GRN NM_008175.3 -1.242 
Gasdermin D GSDMD NM_026960.1 1.572 
Glutathione S-transferase, alpha 4 Gsta4 NM+0103571.1 -1.465 
Histocompatibility 2, Q region locus 5 H2-Q5 NM_010393.1 1.767 
HECT domain and ankyrin repeat containing E3 
ubiquitin protein ligase 1 
HACE1 NM_172432.2 1.224 
HMG box transcription factor 1 HBP1 NM_135198.1 -1.488 
Histone deaccetylase 5 HDAC5 NM_001077696.1 -1.455 
High density lipoprotein binding protein HDLBP NM_133808.2 -1.238 
Major histocompatibility complex, class 1B HLA-B NM_001081032.1 1.941 
Major histocompatibility complex, class C HLA-C NM_019909.1 1.26 
Major histocompatibility complex, class E HLA-E NM_010398.1 1.976 
Major histocompatibility complex, class G HLA-G NM_013819.2 1.461 
Homeobox A2 HOXA2 NM_010451.1 -1.770 
Homeobox A5 HOXA5 NM_010453.2 -2.574 
Homeobox C6 HOXC^ NM_010465.2 1.245 
HtrA serine peptidase 2 HTRA2 NM_019752.2 1.270 
Inhibitor of DNA binding 1 ID1 NM_010495.2 -1.553 
Inhibitor of DNA binding 3 ID3 NM_008321.1 -1.531 
Interferon activated gene 20B Ifi202b NM_008327.1 -1.446 
Immediate early response 3 IER3 NM_133662.2 1.683 
Interferon induced protein 35 IFI35 NM_027320.4 1.359 
Interferon gamma receptor 2 IFNGR2 NM_008338.3 1.579 
Insulin-like growth factor binding protein 6 IGFBP6 NM_008344.2 -1.349 
Interleukin 1 receptor like 1 IL1RL1 NM_010743.1 3.318 
Interleukin 1 receptor associated kinase 1 binding 
protein  
ILAK1BP1 AK014712 1.228 
Interferon regulatory factor 1 IRF1 NM_008390.1 1.628 
Interferon regulatory factor 2 binding protein 2 IRF2BP2 NM_001002523.2 -1.346 
Insulin receptor substrate 2 TRS2 NNM_001081212.1 -1.502 
Integrin beta 5 ITGB2 NM_010580.1 -1.339 
Integrin beta-like 1 ITGBL1 NM_145467.1 -1.484 
Inositol-1,4,5-triphophate receptor interacting protein 
like 2 
ITPRIPL2 NM_001033380.3 1.700 
Isovaleryl-coA-dehydrogenase IVD NM_019826.3 -1.367 
Potassium gated channel shaker related subfamily beta 
member1 
KCNAB1 NM_010597.2 -1.455 
Potassium gated channel subfamily F, member 1 KCNF1 NM_0201531.2 -1.258 
Kin of IRRE like 3 KIRREL3 NM_026324.2 -1.730 
Keratin 13 KRT13 NM_010662.1 -1.388 
Kinesin light chain 4 KLC4 NM_029091.2 -1.341 
LIM and SH3 protein 1 LASP1 NM_010688.2 -1.320 
Limb bud and heart development homolog LBH NM_029999.3 -1.609 
Leprecan-like 4 LEPREL4 NM_176830.2 -1.279 
Neuralized homolog 3 LINCR NM_153408.2 1.312 
Lysophosphatidic acid receptor 6 LPAR6 NM_175116.2 -1.277 
Leucine rich repeats and immune globulin domains 1 LRIG1 NM_008377.2 1.251 
Leucine rich repeats and immune globulin domains 3 LRIG3 NM_172152.4 -1.329 
Leucine rich repeats kinase 1 LRRK1 NM_146191.3 -1.344 
Latent transforming growth factor beta binding protein 
3 
LTBP3 NM_008520.2 -1.552 
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Leucine zipper protein 1 LUZP1 NM_024452.2 1.370 
Melanoma antigen family D1 MAGED1 NM_019791.2 -1.276 
Melanoma antigen family E1 MAGEE1 NM_053201.2 -1.400 
MAK16 homolog MAK16 NM_026453.1 1.245 
Mitogen activated kinase 11 MAPK11 NM_011161.4 1.343 
Myristoylated alanine rich protein kinase C substrate MARCKS NM_008538.2 1.406 
Muscleblind like 2 MBNL2 NM_175341.3 -1.277 
Membrane bound O-acyltransferase domain containing 
1 
MBOAT1 NM_153546.3 -1.201 
Mediator complex substrate 11 MED11 NM_025397.2 1.301 
Mediator complex substrate 24 MED24 NM_011869.2 1.331 
Meis homobox 1 MEIS1 NM_010789.2 -1.773 
Meis homobox 2 MEIS2 NM_010825.3 -2.124 
Major facilitator superfamily domain containing 2A MFSD2A NM_029662.1 -1.362 
Matrix Gla protein MGP NM_008597.3 -2.698 
Makoglinin, ring finger 1 MRGN1 NM_029657.2 -1.223 
Microsomal glutathione S-transferase 2 MGST2 NM_174995.2 -1.419 
Mindbomb homolog 2 MIB2 NM_145124.2 -1.390 
MK167 interacting nucleolar phosphoprotein MK167IP NM_026178.3 1.315 
Monocyte to macrophage differentiation associated MMD NM_026178.2 1.419 
Matrix metallopeptidase 9  MMP9 NM_013599.2 2.013 
Myosin phosphatase Rho interacting protein MPRIP NM-201245.2 -1.248 
Mannose receptor C, type I MRC1 NM_008625.1 1.538 
Mitochondrial ribsosomal protein S18B MRPS18B NM_025878.1 1.226 
Mitochondrial ribsosomal protein S2 MRPS2 NM_080452.2 1.208 
mRNA turnover 4 homolog MRTO4 NM_023536.2 1.236 
Myotubularin related protein 11 MTMR11 NM_181409.2 -1.546 
Muscle related coiled-col protein MURC NM_026509.1 -1.386 
Major vault protein MVP NM_080638.1 1.549 
Matrix remodelling associated 8 MXRA8 NM_024263.3 -1.434 
v-myc myelocytomatosis viral oncogene homolog 1 MYCL1 NM_008506.2 1.736 
NACC2 family member 2 NACC2 NM_001037098.1 -1.44 
Neuronal calcium sensor 1 NCS1 NM_019681.3 1.218 
Nuclear factor of activated T-cells, calcineurin-
dependent 4 
NFATC4 NM_023699.3 -1.418 
Nuclear factor I/x NFIX NM_010906.2 -1.302 
Nuclear factor of kappa light polypeptide gene 
enhancer in B cells (p49/p100) 
NFKB2 NM_019408.1 1.669 
Nuclear factor of kappa light polypeptide gene 
enhancer inhibitor epsilon 
NFKBIE NM_008690.2 2.484 
Nuclear factor of kappa light polypeptide gene 
enhancer inhibitor alpha 
NFKBIA NM_010907.1 3.562 
NIPA-like domain containing 1 NIPAL1 NM_001081205.1 1.605 
Nucleolar protein 10 NOL10 NM_001008421.1 1.257 
Nucleolar protein 3 NOL3 NM_030152.4 1.255 
Notchless homolog 1 NLE1 NM_145431.1 1.310 
Natriuretic peptide receptor B NRP2 NM_173788.3 -1.204 
Neuritin 1 NRN1 NM_153529.1 -1.882 
Neuropilin 1 NRP1 NM_008737.1 -1.522 
Nuclear protein transcriptional regulator 1 NUPR1 NM_019738.1 -1.448 
Oligosaccharide-binding fold containing 2A OBFC2A NM_028696.2 1.423 
Oculocerebrorenal syndrome of lowe OCRL NM_177215.2 -1.204 
Oestogylcin OGN NM_008760.4 -1.941 
Olfactomedin-like 2B OLFML2B NM_177068.3 -1.381 
Phosphofurin acid cluster sorting protein 2 PACS2 NM_001081170.1 -1.283 
Polyamine oxidase PAOX NM_153783.2 -1.441 
PreB-cell leukemia homeobox 1 PBX1 NM_008783.1 -1.357 
PreB-cell leukemia homeobox 4 PBX4 NM_001024954.1 1.315 
Photocadherin 7 PCDH7 NM_018764.1 1.305 
Phosphate cytidylyltranscferase 1, choline beta PCYTIB NM_177546.2 -1.447 
Programmed cell death 4 PDCD4 NM_011050.3 -1.422 
Platelet derived growth factor receptor alpha PDGFRA NM-011058.2 -1.617 
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polypeptide 
Podoplanin PDPN NM_010329.1 1.259 
PDZ domain containing ring finger 3 PDZRN3 NM_018884.1 -1.235 
Pelota homolog PELO NM_134058.1 1.233 
Period homolog 2 PER2 NM_011066.1 -1.499 
6-Phosphofructo-2-kinase  PFKFB4 NM_173019.5 -1.213 
Phospofructokinase, muscle PFKM NM_021514.3 -1.277 
Pyroglutyml 1-peptidase 1 PGPEP1 NM_023217.2 -1.283 
Paired like homodomain 2 PITX2 NM_011098.3 -1.738 
Praja ring finger 2 PJA2 NM_144859.2 -1.404 
Pleckstrin homology domain containing family G, 
member 2 
PLEKHG2 NM_138752.1 -1.214 
Polo-like kinase 2 PLK2 NM_152804.1 1.527 
Phospholipid scramblase 1 PLSCR1 NM_011636.1 1.737 
Phospholipid scramblase 2 PLSCR2 NM_008880.2 1.488 
Promyelocytic leukemia `PML NM_008884.4 -1.237 
Peripheral myelin protein22 PMP22 NM_008885.2 -1.301 
Paroxysmal nonkinesigenic dyskinesia PNKD NM_019999.1 1.670 
P450 oxidoreductase POR NM_008898.1 -1.243 
Phosphatidic acid phosphate type 2A PPAP2A NM_008247.2 -1.261 
Peroxisome proliferator-activated receptor delta PPARD NM_011145.3 1.265 
Pro-platelet basic protein PPBP NM-023785.2 1.827 
PQ loop repeat containing 3 PQLC3 NM_172574.1 -1.273 
Protein kinase C, delta binding protein PRKCDBP NM_028444.1 -1.512 
PRKR interacting protein 1 PRKRIP1 NM_025774.1 1.212 
Prolactin family 2, subfamily c, member 2 Prl2c1 NM_011118.1 1.878 
Prolactin family 2, subfamily c, member 4 Prl2c4 NM_011954.2 1.746 
Proline dehydrogenase (oxidase) 1 PSMDH NM_011172.1 1.256 
Proteasome subunit, beta type 10 PSMB10 NM_013640.1 1.624 
Proteasome subunit, beta type 8 PSMB8 NM_010724 1.386 
Proteasome 26S subunit, non ATPase 10 PSMD10 NM_016883.3 1.427 
Proteasome activator subunit 1 PSME1 NM_011189.1 1.286 
Parathymosin PTMS NM_026988.1 -1.234 
Protein tyrosine phosphatase, non-receptor type 22 PTPN22 NM_008979.1 1.661 
RAB11 family interacting protein 5 RAB11FIP5 NM_001003955.2 -1.241 
RAB31, member RAS oncogene family RAB31 NM_133685.1 -1.243 
RAB1B, member RAS oncogene family RAB1B NM_024457.2 1.317 
RAP1 GTPase activating protein RAP1GAP NM_001081155.1 -1.335 
Retinoic acid receptor gamma RARG NM_011244.3 -1.542 
Regulator of calcineurin 2 RCAN2 NM_207649.1 -1.294 
RNA terminal phosphate cyclase-like 1 RCL-1 NM_021525.2 1.206 
v-rel reticuloendotheliosis viral oncogene homolog A RELA NM_009045.4 -1.264 
v-rel reticuloendotheliosis viral oncogene homolog B RELB NM_009046.2 2.074 
Raftlin family member 2 RFTN2 NM_028713.1 -1.388 
Regulatory factor X, 2 FRX2 NM_009056.1 -1.375 
Ral guanine nucleotide dissociation stimulation like 1 RGL1 NM_016846.3 -1.379 
Ribosome production factor 1 homolog REF1 NM_027371.2 1.202 
Ras-related associated with diabetes RRAD NM_019662.1 1.374 
Ribosomal processing 15 homolog RRP15 NM_026041.2 1.225 
Ribosomal processing 9 homolog RRP9 NM_145620.4 1.296 
Ribosomal L1 domain containing 1 RSL1D1 NM)025546.1 1.226 
Sphingosine-1-phosphate receptor 2 S1PR2 NM_010333 1.27 
Scavenger receptor class A, member 3 SCARA3 NM_172604.3 -1.526 
Scleraxis homolog A SCXA NM_198885.2 -1.423 
Syndecan 2 SDC2 NM_008304.2 -1.213 
Syndecan binding protein 2 SDCBP2 NM_145535.1 1.338 
Sema domain 3A SEMA3A NM_009152.2 -1.439 
Serpin peptidase inhibitor, clade B, member2 SERPINB2 NM_011111.3 1.396 
Sestrin 1 SENS1 NM_001013370.1 -1.202 
SH3 and PX domains 2B SH£PXD2B NM+177364.3 -1.418 
Shroom family member 2 SHROOM2 NM_172441.2 -1.772 
Single minded homolog 2 SIM2 NM_011377.2 -1.567 
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SIX homolog 1 SIX1 NM_009189.1 -1.753 
Solute carrier family 11, member 1 SLC11A1 NM_013612.1 1.578 
Solute carrier family 11, member 2 SLC11A2 AK083478. 1.316 
Solute carrier family 16, member 13 SLC16A13 NM_172371.3 -1.408 
Solute carrier family 19, member 1 SLC19A1 NM_031196.2 1.293 
Solute carrier family 1, member 3 SLC1A3 NM_148938.2 -1.965 
Solute carrier family 1, member 4 SLC1A4 NM_018861.2 -1.362 
Solute carrier family 25, member 33 SLC23A33 NM_027460.2 1.284 
Solute carrier family 2, member 6 SLC2A6 NM_172659.2 2.584 
Solute carrier family 44, member 2 SLC44A2 NM_152808.2 -1.268 
Solute carrier family 6, member 6 SLC6A6 NM_009320.3 -1.423 
SWI/SNF related matrix assocated, actin dependent 
regulator of chromatin, subfamily a, member 2 
SMARCA NM_011416.2 -1.233 
Snail homolog 2 SNAI3 NM_013914.2 -1.285 
Sorting nexin 16 SNX16 NM_029068.2 -1.292 
Suppressor of cytokine signalling 2 SOCS2 NM_007706.3 -1.377 
Sphingosine kinase 1 SPHK1 NM_011451.2 -1.662 
Spondin 2 SPON2 NM_133903.2 -1.736 
Secreted phosphoprotein 1 SPP1 NM_009263.1 -1.401 
Single stranded DNA binding protein 2 SSBP2 NM_024186.1 -1.334 
Single stranded DNA binding protein 3 SSBP3 NM_023672.2 -1.339 
Sacrospan SSPN NM_010656.2 -1.367 
Stabilin 1 STAB1 AK087634 -1.437 
Serine/threonine kinase 36 STK36 AK047284 -1.210 
Suppressor of ty3 homolog SUPT3H NM_178652.2 -1.230 
Surfiet 2 SURF2 NM_013678.2 1.216 
Synaptic vesicle glycoprotein 2A SV2A NM_022030.3 -1.248 
Synapsin 1 SYN1 NM_013680.3 -1.260 
TRAF family member-associated NFKB activator TANK NM_011529.1 1.370 
TAP binding protein TAPBP NM_009318.1 -1.811 
TBC1 domain containing family member 5 TBCIC5 NM_028162.2 -1.241 
Transcription factor 4 TCF4 NM_013685.2 1.531 
Transcription factor like 7 TCF7L2 NM_009333.2 -1.485 
TGF beta-induced 68 kDA TGFB1 NM_009369.1 1.543 
Translocase of inner mitochondrial membrane 44 
homolog 
TIMM44 NM_011592.1 1.237 
TIMP metalloprotease inhibitor 3 TIMP3 NM_015595.2 -1.356 
Transducin-like enhance of split 1 TLE1 NM_011599.3 -1.376 
Toll like receptor 4 TLR4 NM_021297.1 -1.272 
Transmembrane protein 130 TMEM130 NM_177735.4 1.305 
Transmembrane protein 176B TMEM176B NM_023056.3 1.732 
Transmembrane protein 199 TMEM199 NM_199199.2 1.211 
Transmembrane protein 200B TMEM200B NM_887671.3 -1.279 
Transmembrane protein 53 TMEM53 NM_026837.1 -1.96 
Transmembrane protein 86A TMEM86A NM_026436.3 -1.322 
Tenasin C TNC NM_011607.2 1.609 
TNFAIP3 interacting protein 1 TNIP1 NM_021327.1 2.211 
TNF-alpha-induced protein 3 TNFAIP3 NM_009397.2 1.931 
TNR receptor superfamily member 11B TNFRSF11B NM_008764.3 -1.603 
TNR receptor superfamily member 9 TNFRSF9 NM_011612.2 1.546 
TNF receptor associated factor 1 TRAF1 AK089281 3.162 
Tribbles homolog 3 TRIB3 NM_175093.2 -1.708 
tRNA methyltransferase 6 homolog A TRMT61A NM_177374.2 1.277 
Trichorhinophalangeal syndrome 1 TRPS1 NM_032000.1 -1.376 
Tetraspanin 17 TSPAN17 NM-028841.1 -1.212 
Tetratrocopeptide repeat domain 28 TTC28 XM_001476544.1 -1.644 
Tetratrocopeptide repeat domain 3 TTC3 NM_009441.2 -1.266 
Tetratrocopeptide repeat domain 39C TTC39C NM_028341.2 1.500 
Tubulin tyrosine ligase-like family member 5 TTLL5 NM_001081423.1 -1.389 
U2 small nuclear RNA auxiliary factor 1 U2AF1 NM_024187 1.246 
Unc-5 homolog C UNC5C NM_009472.2 -1.309 
Uridine phophorylase 1 UPP1 NM_009477.1 2.466 
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UV radiation resistance associated gene UVRAG NM_178635.2 -1.222 
Vasorin VASN NM_139307.2 -1.352 
WAS protein family member 1 WASF1 NM_031877.2 -1.278 
WD repeat domain 43 WDR43 XM_917905.3 1.223 
WD repeat domain 55 WDR55 NM_026464.2 1.281 
WD repeat domain 77 WDR77 NM_027432.3 1.221 
WAS/WASL interacting protein family member 1 WIPF1 NM_153138.3 -1.290 
Wntless homolog WLS NM_026582- -1.396 
Wingless type MMTV integration site family member 
10B 
WNT10B NM_011718.1 -1.464 
Werner syndrome, RecQ helicase like WRN NM-011721.3 -1.237 
WW domain containing E3 ubiquitin protein ligase 2 WWP2 NM_025830.1 -1.291 
Exportin 4 XPO4 NM_20506.1 1.206 
Zinc finger, CCHC domain containing 24 ZCCHCZ4 XM_908180.3 -1.275 
Zinc finger DHHC (8) ZDNNC8 NM_172151.3 -1.268 
Zer-1 homolog ZER1 NM_178694.3 -1.362 
Zinc finger homeobox 3 ZFHX3 NM_007496.2 -1.341 
Zinc finger protein 365 ZNF365 XM_980150.1 -1.309 
 
 
 
 
 
I.II qRT-PCR validation 
 
Aurora kinase A 
Microarray data (section 5.4.1) showed that the gene, AURKA, encoding aurora kinase A was up-
regulated 2.2-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR, and interestingly that 
this effect was abrogated in the presence of AG-014699 at this timepoint. This gene did not appeared to 
be differentially expressed following TNF-α at either of the timepoints assessed, suggesting that AURKA 
may be a novel NF-κB regulated gene following DNA-damage, and thus requiring further investigation 
using qRT-PCR, as described in section 5.4.10. 
 
Figure A.1A shows that the mRNA expression of AURKA is increased approximately 2-fold 2 hours 
after treatment with 10 Gy IR. This was shown to be statistically significant using an unpaired Student’s 
t-test (p=0.0006). Although knockdown of NF-κB p65 did not decrease IR-induced AURKA expression 
(p=0.8075, unpaired Student’s test), co-incubation with the pan-IKK inhibitor, BAY11-7082 significantly 
decrease this IR-induced AURKA expression (p=0.030, unpaired Student’s t-test). IR in combination 
with either AG-014699, PARP-1 siRNA or NS siRNA had no effect on the IR-induced AURKA 
expression, compared with IR alone (p=0.8047, p=0.4873 and p=9425, respectively, unpaired Student’s t-
test).  Figure A.1B shows that AURKA is not induced by TNF-α alone, and that is also unaffected by 
TNF-α in combination with p65 siRNA, BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA. These 
data suggest that AURKA expression is induced following IR and that this may be regulated by NF-κB, 
since the lack of the p65 subunit, had no effect, it is possible that one of the other subunits, was inhibited 
by BAY11-7082. 
 
 
 
Table A.1: Differentially expressed genes 8 hours following treatment with TNF-α in p65+/+ MEFs, 
compared with untreated controls 
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Baculoviral IAP repeat containing 6 
Microarray data (section 5.4.1) showed that the gene, BIRC6, encoding Baculoviral IAP repeat containing 
6 was up-regulated 1.2-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR, and 
interestingly that this affect was attenuated in the presence of AG-014699 at this timepoint. Other groups 
have showed that the inhibitor of apoptosis proteins (IAPs), of which BIRC6 is an associated gene, are 
regulated by NF-κB following DNA damage (Stehlik et al., 1998, You et al., 1999). Therefore the 
microarray data and existing literature suggested that BIRC6 required further investigation using qRT-
PCR described in section 5.4.10. 
 
Figure A.2A shows that there is a small, 1.2-fold, increase in the expression of BIRC6 2 hours after 
treatment with IR, and that using an unpaired Student’s t-test, this is statistically significant (p=0.027). It 
also illustrates that either p65 siRNA, BAY11-7082, AG-014699 or PARP-1 siRNA all inhibit this IR-
induced BIRC6 expression. However, although the results shown are the mean of three independent 
experiments, the trend observed with these treatments are not statistically significant when compared with 
IR alone (p65 siRNA: p=0.134; BAY11-7082: p=0.110; AG-014699: p=0.062; PARP-1 siRNA: p=0.091, 
unpaired Student’s t-test). Importantly, however NS siRNA has no effect on IR-induced BIRC6 
expression, compared with IR alone (p=0.8330, unpaired Student’s t-test). Figure A.2B shows that BIRC6 
is not induced by TNF-α alone, and that is also unaffected by TNF-α in combination with p65 siRNA, 
BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA. Taken together these data suggest that 
expression of BIRC6 is likely to be regulated by NF-κB following DNA damage, not TNF-α. 
Figure A.1: Expression of AURKA following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of AURKA 2 h  following treatment 
with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM. *** 
Significance relative to mock treated control p<0.001 **Significance relative to mock treated control was 
p<0.01 using unpaired Student’s t-test. *Significance relative to mock treated control was p<0.05 using 
unpaired Student’s t-test. 
380 
 
 
 
 
 
 
 
 
 
Chemokines; CCL5 and CXCL10 
Microarray data (sections 5.4.3 and 5.4.7) showed that, CCL5, encoding the chemokine ligand 5 was up-
regulated 3-fold and 6.5-fold in p65+/+ MEFs harvested 2 and 8 hours after treatment with 10 ng/ml TNF-
α, respectively. The expression of CCL5 appeared to remain unaffected by treatment with AG-014699 in 
combination with TNF-α. Furthermore, this gene did not appear to be differentially expressed following 
IR at either of the timepoints assessed. Interestingly this gene is known to be regulated by NF-κB 
following inflammatory stimuli (Wickremasinghe et al., 2004), therefore these studies allowed further 
testing of the hypothesis that NF-κB-dependent gene transcription following TNF-α requires PARP-1 
protein alone, and is unaffected by PARP-1 enzymatic inhibition by directly comparing the PARP 
inhibitor, AG-014699 and PARP-1 siRNA in qRT-PCR analyses, described in section 5.4.10. 
 
Figures A.3A and A.3B show the regulation of CCL5 gene expression in p65+/+ MEFs harvested 2 hours 
(Figure 5.13A) and 8 hours (Figure 5.13B) after IR treatment. In both cases there was no significant 
change in CCL5 expression following treatment with IR alone or in combination with p65 siRNA, 
BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA, consistent with the microarray findings. Figure 
5.13C illustrates that the mRNA expression of CCL5 was increased approximately 5-fold 2 hours after 
treatment with 10 ng/ml TNF-α. This was shown to be statistically significant using an unpaired Student’s 
t-test (p<0.0001). Furthermore, knockdown of NF-κB p65 significantly decreased this TNF-α-induced 
CCL5 expression (p=0.0013, unpaired Student’s test), as did co-incubation with BAY11-7082 (p=0.0032, 
unpaired Student’s t-test). Importantly, TNF-α in combination with knockdown of PARP-1 protein 
significantly decreased TNF-α-induced CCL5 expression (p=0.0161, unpaired Student’s t-test), whereas 
this was unaffected by co-incubation with AG-014699 (p=0.8118), thus supporting the data in Chapter 4 
which suggests that PARP-1 protein alone is essential for NF-κB-dependent gene transcription following 
TNF-α. NS siRNA had no effect on TNF-α-induced CCL5 expression, compared with TNF-α alone 
(p=0.3129, unpaired Student’s t-test). Similar results were also observed in the p65+/+ MEFs harvested 8 
hours after treatment with TNF-α (Figure 5.13D). In this case the mRNA expression of CCL5 was 
increased approximately 5.5-fold (p=0.0001, unpaired Student’s t-test). Furthermore, knockdown of NF-
κB p65 significantly decreased this TNF-α-induced CCL5 expression (p=0.0014, unpaired Student’s test), 
as did co-incubation with BAY11-7082 (p=0.0141, unpaired Student’s t-test). Importantly, TNF-α in 
combination with knockdown of PARP-1 protein significantly decreased TNF-α-induced CCL5 
expression (p=0.0066, unpaired Student’s t-test), whereas this was unaffected by co-incubation with AG-
014699 (p=0.6959). NS siRNA had no effect on TNF-α-induced CCL5 expression, compared with TNF-α 
alone (p=0.8197, unpaired Student’s t-test). These data also support the hypothesis which stated that AG-
014699 would not affect the expression of key inflammatory response genes regulated by NF-κB 
following inflammatory stimuli. 
 
Figure A.2B: Expression of BIRC6 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of BIRC6 2 h following treatment 
with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM 
*Significance relative to mock treated control was p<0.05 using unpaired Student’s t-test. 
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Microarray data (sections 5.4.3 and 5.4.7) showed that the gene, CXCL10, encoding the chemokine (C-
XC motif) ligand 10, was up-regulated 3.7-fold and 6-fold in p65+/+ MEFs harvested 2 and 8 hours after 
treatment with 10 ng/ml TNF-α, respectively. The expression of CXCL10 appeared to remain unaffected 
by treatment with AG-014699 in combination with TNF-α. Furthermore, this gene did not appear to be 
differentially expressed following IR at either of the timepoints assessed. Interestingly this gene is known 
to be regulated by NF-κB following inflammatory stimuli (Hein et al., 1997), therefore allowing further 
testing of the hypothesis that NF-κB-dependent gene transcription following TNF-α requires PARP-1 
protein alone, and is unaffected by PARP-1 enzymatic inhibition by directly comparing the PARP 
inhibitor, AG-014699 and PARP-1 siRNA in qRT-PCR analyses, described in section 5.4.10. 
 
Figures A.4A and A.4B show the regulation of CXCL10 gene expression in p65+/+ MEFs harvested 2 
hours (Figure 5.14A) and 8 hours (Figure 5.14B) after IR treatment. In both cases there was no significant 
change in CXCL10 expression following treatment with IR alone or in combination with p65 siRNA, 
BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA, consistent with the microarray away findings. 
Figure A.4C illustrates that the mRNA expression of CXCL10 was increased approximately 6.5-fold 2 
hours after treatment with 10 ng/ml TNF-α (p=0.0005, unpaired Student’s t-test). Markedly, knockdown 
of NF-κB p65 significantly decreased this TNF-α-induced CXCL10 expression (p=0.0250, unpaired 
Student’s test), as did co-incubation with BAY11-7082 (p=0.0118, unpaired Student’s t-test). 
Importantly, TNF-α in combination with knockdown of PARP-1 protein significantly decreased TNF-α-
Figure A.3: Expression of CCL5 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of CCL5 following IR at 2 h (A) 
or 8 h (B) or following TNF-α at 2 h (C) or 8 h (D) All results are the mean of three independent 
experiments with SEM. *** Significance relative to mock treated control p<0.001 **Significance relative 
to mock treated control was p<0.01 using unpaired Student’s t-test. *Significance relative to mock treated 
control was p<0.05 using unpaired Student’s t-test. 
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induced CXCL10 expression (p=0.0288, unpaired Student’s t-test), whereas this was unaffected by co-
incubation with AG-014699 (p=0.9702), thus supporting the data in Chapter 4 which suggests that PARP-
1 protein alone is essential for NF-κB-dependent gene transcription following TNF-α. NS siRNA had no 
effect on TNF-α-induced CXCL10 expression, compared with TNF-α alone (p=0.7830, unpaired 
Student’s t-test). 
 
Similar results were also observed in the p65+/+ MEFs harvested 8 hours after treatment with TNF-α 
(Figure A.4D). In this case the mRNA expression of CXCL10 was increased approximately 5.5-fold 
(p=0.0002, unpaired Student’s t-test). Moreover, knockdown of NF-κB p65 significantly decreased this 
TNF-α-induced CXCL10 expression (p=0.0022, unpaired Student’s test), as did co-incubation with 
BAY11-7082 (p=0.0046, unpaired Student’s t-test). Importantly, TNF-α in combination with knockdown 
of PARP-1 protein significantly decreased TNF-α-induced CXCL10 expression (p=0.0136, unpaired 
Student’s t-test), whereas this was unaffected by co-incubation with AG-014699 (p=0.6135). NS siRNA 
had no effect on TNF-α-induced CXCL10 expression, compared with TNF-α alone (p=0.7886, unpaired 
Student’s t-test). These data also support the results observed when investigating the regulation of CCL5 
(Figure A.4) and also the hypothesis which stated that AG-014699 would affect the expression of key 
inflammatory response genes regulated by NF-κB following inflammatory stimuli. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4: Expression of CXCL10 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) 
± PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of CXCL10 following IR at 
2 h (A) or 8 h (B) or following TNF-α at 2 h (C) or 8 h (D) All results are the mean of three independent 
experiments with SEM. *** Significance relative to mock treated control p<0.001 **Significance 
relative to mock treated control was p<0.01 using unpaired Student’s t-test. *Significance relative to 
mock treated control was p<0.05 using unpaired Student’s t-test. 
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Cell division cycle 20 
Microarray data (sections 5.4.1 and 5.4.5) showed that the gene, CDC20, encoding the cell division cycle 
20 protein was up-regulated 1.5-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR, and 
1.3-fold in p65+/+ MEFs harvested 8 hours after treatment with 10 Gy IR. Interestingly, this affect was 
abrogated in the presence of AG-014699 at both timepoints. This gene did not appear to be differentially 
expressed following TNF-α at either of the timepoints assessed, suggesting that CDC20 may be a novel 
NF-κB regulated gene following DNA-damage, and thus requiring further investigation using qRT-PCR, 
as described in section 5.4.10. 
 
Figure A.5A shows that the mRNA expression of CDC20 is increased approximately 1.4-fold 2 hours 
after treatment with 10 Gy IR (p=0.0016, unpaired Student’s t-test). Knockdown of NF-κB p65 
significantly decreased this IR-induced CDC20 expression (p=0.0237, unpaired Student’s test), as did co-
incubation with BAY11-7082 (p=0.0472, unpaired Student’s t-test). Importantly, IR in combination with 
either AG-014699 or PARP-1 siRNA also decreased IR-induced CDC20 expression (AG-014699: 
p=0.0128; PARP-1 siRNA: p=0.0486, respectively, unpaired Student’s t-test). NS siRNA had no effect on 
IR-induced CDC20 expression, compared with IR alone (p=0.8354, unpaired Student’s t-test). These data 
suggest that CDC20 maybe a novel NF-κB regulated gene following DNA damage at this timepoint. 
 
Although Figure A.5B shows that the mRNA expression of CDC20 is significantly increased 8 hours 
following treatment with 10 Gy IR (p=0.0257, unpaired Student’s t-test), it also shows that IR-induced 
CDC20 expression is unaffected by co-incubation with p65 siRNA, BAY11-7082, AG-014699, PARP-1 
siRNA or NS siRNA, at this timepoint (p65 siRNA: p=0.8157; BAY11-7082: p=0.9743, AG-014699: 
p=0.9021; PARP-1 siRNA; 0.8805; NS siRNA p=0.5883, unpaired Student’s t-test).  Figures A.5C and 
A.5D show the regulation of CDC20 gene expression in p65+/+ MEFs harvested 2 hours (Figure A.5C) 
and 8 hours (Figure A.5D) after TNF-α treatment. In both cases there was no significant change in 
CDC20 expression following treatment with TNF-α alone or in combination with p65 siRNA, BAY11-
7082, AG-014699, PARP-1 siRNA or NS siRNA, consistent with the microarray away findings. 
 
 
 
 
Figure A.5: Expression of CDC20 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) 
± PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of CDC20 following IR at 2 
h (A) or 8 h (B) or following TNF-α at 2 h (C) or 8 h (D) All results are the mean of three independent 
experiments with SEM. *** Significance relative to mock treated control p<0.001 **Significance 
relative to mock treated control was p<0.01 using unpaired Student’s t-test. *Significance relative to 
mock treated control was p<0.05 using unpaired Student’s t-test. 
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FAS 
Microarray data (section 5.4.7) showed that the gene, FAS, was up-regulated 3.6-fold in p65+/+ MEFs 
harvested 8 hours after treatment with 10 ng/ml TNF-α. The expression of FAS appeared to remain 
unaffected by treatment with AG-014699 in combination with TNF-α. Furthermore, this gene did not 
appear to be differentially expressed following IR at either of the timepoints assessed. Interestingly this 
gene is known to be regulated by NF-κB following inflammatory stimuli (Chan et al., 1999), therefore it 
was of interest to further test the hypothesis that NF-κB-dependent gene transcription following TNF-α 
requires PARP-1 protein alone, and is unaffected by PARP-1 enzymatic inhibition by directly comparing 
the PARP inhibitor, AG-014699 and PARP-1 siRNA in qRT-PCR analyses, described in section 5.4.10. 
 
Figures A.6A shows the regulation of the FAS gene expression in p65+/+ MEFs harvested 8 hours after IR 
treatment. There was no significant change in FAS expression following treatment with IR alone or in 
combination with p65 siRNA, BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA, consistent with 
the microarray away findings. Figure A.6B shows that there is a 2.4-fold increase in the expression of 
FAS 8 hours after treatment with TNF-α, and that this was statistically significant (p=0.027, unpaired 
Student’s t-test). It also illustrates that either p65 siRNA, BAY11-7082 or PARP-1 siRNA all inhibit this 
IR-induced FAS expression. However, although the results shown are the mean of three independent 
experiments, the trend observed with these treatments are not statistically significant when compared with 
TNF-α alone (p65 siRNA: p=0.066; BAY11-7082: p=0.070; PARP-1 siRNA: p=0.064, unpaired 
Student’s t-test). Importantly, however co-incubation with AG-014699 had no effect on TNF-α induced 
FAS expression (p=0.8339, unpaired Student’s t-test), once again suggesting that PARP inhibition does 
not affect TNF-α-induced NF-κB dependent gene transcription. NS siRNA also had no effect on TNF-α-
induced FAS expression, compared with TNF-α alone (p=0.8368, unpaired Student’s t-test). 
 
 
 
 
 
 
  
 
 
Interferon regulatory factor-1 
Microarray data (section 5.4.1) showed that the gene, IRF1, encoding the interferon regulatory factor-1 
protein was down-regulated 1.5-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR and 
interestingly that this gene was up-regulated in the presence of AG-014699 at this timepoint. Microarray 
data (sections 5.4.3) also showed that IRF1 was up-regulated 2.8-fold in these cells 2 hours after 
treatment with 10 ng/ml TNF-α. The expression of IRF1 appeared to remain unaffected by treatment with 
AG-014699 in combination with TNF-α. IRF1 is known to be regulated by NF-κB following 
inflammatory stimuli (Harada et al., 1994), but not following DNA damage, hence the requirement for 
further investigation here using qRT-PCR analyses, as described in section 5.4.10. 
 
Figure A.7A shows that the mRNA expression of IRF1 is significantly decreased approximately 2 hours 
after treatment with 10 Gy IR compared with mock treated controls, (p=0.0004, unpaired Student’s t-test). 
Figure A.6: Expression of FAS following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of FAS 8 h  following treatment 
with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM. *** 
Significance relative to mock treated control p<0.001 **Significance relative to mock treated control was 
p<0.01 using unpaired Student’s t-test. *Significance relative to mock treated control was p<0.05 using 
unpaired Student’s t-test. 
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This reduction in mRNA was also seen after co-incubation with either p65 siRNA or BAY11-7082. 
Interestingly, IR in combination with either AG-014699 or PARP-1 siRNA increased IR-induced IRF1 
expression back to levels comparable with mock treated controls (AG-014699: p=0.0032; PARP-1 
siRNA: p=0.0064, respectively, compared with IR alone, unpaired Student’s t-test). NS siRNA in 
combination with IR was not significantly different from either IR alone (p=0.1840, unpaired Student’s t-
test) or mock treated controls (p=0.2371, unpaired Student’s t-test).   
 
Figure A.7B illustrates that the mRNA expression of IRF1 was increased approximately 2-fold 2 hours 
after treatment with 10 ng/ml TNF-α(p=0.0003, unpaired Student’s t-test). Furthermore, knockdown of 
NF-κB p65 significantly decreased this TNF-α-induced IRF1 expression (p=0.0317, unpaired Student’s 
test). Although the trend was very similar with TNF-α in conjunction with either BAY11-7082 or PARP-
1 siRNA, this was not statistically significant compared with TNF-α alone (BAY11-7082: p=0.0625; 
PARP-1 siRNA: p=0.1756, unpaired Student’s t-test). The expression of IRF1 was not affected by co-
incubation with AG-014699 (p=0.5591, compared with TNF-α alone, unpaired Student’s t-test). NS 
siRNA had no effect on TNF-α-induced IRF1 expression, compared with TNF-α alone (p=0.3700, 
unpaired Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
JUNB proto-oncogene 
Microarray data (section 5.4.1) showed that the gene, JUNB, encoding the Jun proto-oncogene was up-
regulated 1.6-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR and interestingly this 
affect was attenuated in the presence of AG-014699 at this timepoint. Microarray data (sections 5.4.3) 
also showed that JUNB was up-regulated 1.9-fold in these cells 2 hours after treatment with 10 ng/ml 
TNF-α. The expression of JUNB appeared to remain unaffected by treatment with AG-014699 in 
combination with TNF-α. Interestingly this gene is known to be regulated by NF-κB following 
inflammatory stimuli (Brown et al., 1995), but not following DNA damage, therefore the microarray data 
warrant validation by qRT-PCR as described in section 5.4.10. 
 
Figure A.8A shows that there are is a very small increase in the expression of JUNB 2 hours after 
treatment with 10 Gy IR in the p65+/+ MEFs, however this was not significant when compared with mock 
treated controls (p=0.7249). Furthermore, IR in combination with either p65 siRNA, BAY11-7082, AG-
014699, PARP-1 siRNA or NS siRNA had no effect on JUNB expression when compared with IR alone 
(p65 siRNA: p=0.5899; BAY11-7082: p=0.7442; AG-014699: p=0.5395; PARP-1 siRNA: p=0.8402; NS 
siRNA: p=0.6641). These data suggest that JUNB is not regulated by NF-κB following DNA damage. 
Figure A.7: Expression of IRF1 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of IRF1 2 h following treatment 
with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM. *** 
Significance relative to mock treated control p<0.001 **Significance relative to mock treated control was 
p<0.01 using unpaired Student’s t-test. *Significance relative to mock treated control was p<0.05 using 
unpaired Student’s t-test. 
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Figure A.8B illustrates that JUNB mRNA expression is increased 1.6-fold 2 hours after treatment with 
10ng/ml TNF-α (p=0.041, unpaired Student’s t-test), consistent with other reports (Brown et al., 1995). 
However, although TNF-α in combination with either p65 siRNA or BAY11-7082  appeared to decrease 
this TNF-α induced JUNB expression, this was not found to be statistically significant when compared 
with TNF-α alone (p=0.4540 and p=0.3685, respectively, unpaired Student’s t-test). The expression of 
JUNB was not affected by co-incubation with either PARP-1 siRNA, AG-014699 or NS siRNA 
(p=0.8990, p=0.9140 and p=0.9743 compared with TNF-α alone, unpaired Student’s t-test).  
 
 
 
 
 
 
 
 
 
 
Polo-like kinases 1 
Microarray data (section 5.4.1) showed that the gene, PLK1, encoding polo-like kinase 1 was up-
regulated 1.6-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR, and interestingly that 
this affect was abrogated in the presence of AG-014699 at this timepoint. This gene did not appeared to 
be differentially expressed following TNF-α at either of the timepoints assessed, suggesting that PLK1 
may be a novel NF-κB regulated gene following DNA-damage, and thus requiring further investigation 
using qRT-PCR, as described in section 5.4.10. 
 
Figure A.9A show that the mRNA expression of PLK1 is significantly increased approximately 1.5-fold 2 
hours after treatment with 10 Gy IR in the p65+/+ MEFs (p=0.0001, unpaired Student’s t-test). 
Furthermore, knockdown of NF-κB p65 was shown to significantly decrease IR-induced expression, 
when compared with IR alone (p=0.0011, unpaired Student’s test). A similar decrease in PLK1 
expression was also observed following co-incubation with BAY11-7082, AG-014699 or PARP-1 siRNA 
(p=0.0134, p=0.0259 and p=0.0108, respectively, compared with IR alone, unpaired Student’s t-test). 
Importantly, NS siRNA had no effect on the IR-induced PLK1 expression, compared with IR alone 
(p=0.7916, unpaired Student’s t-test).  Figure A.9B shows that PLK1 is not induced by TNF-α alone, and 
that the expression is also unaffected by TNF-α in combination with p65 siRNA, BAY11-7082, AG-
014699, PARP-1 siRNA or NS siRNA. These data suggest that PLK1 expression is induced following IR 
and that this may be regulated by NF-κB, therefore warranting further investigation (discussed section 
5.6). 
 
Figure A.8: Expression of JUNB following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± PARP-1 
siRNA  ± Non-specific (NS) siRNA control on the transcription of JUNB 2 h  following treatment with IR (A) or 
TNF-α (B) All results are the mean of three independent experiments with SEM. *** Significance relative to mock 
treated control p<0.001 **Significance relative to mock treated control was p<0.01 using unpaired Student’s t-test. 
*Significance relative to mock treated control was p<0.05 using unpaired Student’s t-test. 
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TNFAIP3 interacting protein 1 (TNIP1) 
Microarray data (section 5.4.1) showed that the gene, TNIP1 was up-regulated 1.6-fold in p65+/+ MEFs 
harvested 2 hours after treatment with 10 Gy IR and interestingly that this gene was up-regulated in the 
presence of AG-014699 at this timepoint. Microarray data (sections 5.4.3) also showed that TNIP1 was 
up-regulated 2.8-fold in these cells 2 hours after treatment with 10 ng/ml TNF-α. The expression of 
TNIP1 appeared to remain unaffected by treatment with AG-014699 in combination with TNF-α. 
Interestingly this gene is known to be regulated by NF-κB following inflammatory stimuli (Heyninck et 
al., 1999, Tian et al., 2005), therefore allowing further testing of the hypothesis that NF-κB-dependent 
gene transcription following TNF-α requires PARP-1 protein alone, and is unaffected by PARP-1 
enzymatic inhibition by directly comparing the PARP inhibitor, AG-014699 and PARP-1 siRNA in qRT-
PCR analyses, described in section 5.4.10. 
 
Figure A.10A shows that there is no significant change in the expression of TNIP1 2 hours after treatment 
with 10 Gy IR in the p65+/+ MEFs, compared with mock treated controls (p=0.6142, unpaired Student’s 
unpaired t-test) Furthermore, IR in combination with either p65 siRNA, BAY11-7082, AG-014699, 
PARP-1 siRNA or NS siRNA had no effect on TNIP1 expression when compared with IR alone (p65 
siRNA: p0.6547; BAY11-7082: p=0.9882; AG-014699: p=0.8427; PARP-1 siRNA: p=0.6817; NS 
siRNA: p=0.6450). These data suggest that TNIP1 is not regulated by NF-κB following DNA damage. 
 
Figure A.10B illustrates that TNIP1 mRNA expression is increased 2-fold 2 hours after treatment with 
10ng/ml TNF-α (p=0.0046, unpaired Student’s t-test). PARP-1 siRNA in combination with TNF-α 
appeared to also decrease TNF-α-induced TNIP1 expression slightly, compared with TNF-α alone 
although this was not statistically significant (p=0.3286, unpaired Student’s t-test). However, although 
TNF-α in combination with either p65 siRNA or BAY11-7082 appeared to decrease this TNF-α induced 
TNIP1 expression, this trend was not found to be statistically significant when compared with TNF-α 
alone (p=0.0860 and p=0.0601, respectively, unpaired Student’s t-test), consistent with reports that TNIP1 
is regulated by NF-κB following TNF-α stimulation (Heyninck et al., 1999, Tian et al., 2005). The 
expression of TNIP1 was not affected by co-incubation with either AG-014699 or NS siRNA (p=0.6171 
and p=0.8548 compared with TNF-α alone, unpaired Student’s t-test).  
Figure A.9: Expression of PLK1 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) 
± PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of PLK1 2 h following 
treatment with  IR (A) or TNF-α (B) All results are the mean of three independent experiments with 
SEM. *** Significance relative to mock treated control p<0.001 **Significance relative to mock 
treated control was p<0.01 using unpaired Student’s t-test. *Significance relative to mock treated 
control was p<0.05 using unpaired Student’s t-test. 
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Aurora kinase B 
Microarray data showed that AURKB, which encodes the related family protein kinase, aurora kinase B, 
was up-regulated 1.2-fold in p65+/+ MEFs harvested 8 hours after treatment with 10 Gy IR (section 5.4.5) 
but that the expression of this gene was unaffected following treatment with TNF-α, suggesting that 
AURKB may be novel NF-κB regulated genes following DNA-damage, and thus requiring further 
investigation using qRT-PCR, as described in section 5.4.10. 
 
Figure A.11A illustrates that, using qRT-PCR analysis, AURKB is not induced by 10 Gy IR, 8 hours 
following treatment, as had been observed in the microarray analysis (5.4.5). It also shows that the 
expression of AURKB is unaffected by IR in combination with p65 siRNA, BAY11-7082, AG-014699, 
PARP-1 siRNA or NS siRNA. Furthermore, Figure xB  indicates that shows that AURKB is not induced 
by TNF-α alone, and that is also unaffected by TNF-α in combination with p65 siRNA, BAY11-7082, 
AG-014699, PARP-1 siRNA or NS siRNA. These data suggest that AURKB is not regulated by NF-κB 
in response to either stimuli. 
 
 
 
 
 
 
 
Figure A11: Expression of AURKB following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of AURKB 8 h  following 
treatment with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM.  
 
Figure A.10: Expression of TNIP1 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± PARP-1 
siRNA  ± Non-specific (NS) siRNA control on the transcription of TNIP1 2 h following treatment with IR (A) or 
TNF-α (B) All results are the mean of three independent experiments with SEM. *** Significance relative to mock 
treated control p<0.001 **Significance relative to mock treated control was p<0.01 using unpaired Student’s t-test. 
*Significance relative to mock treated control was p<0.05 using unpaired Student’s t-test. 
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Polo-like kinase 2 
Microarray data showed that PLK2, which encodes the protein kinase, polo-like kinase 2, was up-
regulated 1.5-fold in p65+/+ MEFs harvested 8 hours after treatment with 10 Gy IR (section 5.4.5). This 
gene did not appeared to be differentially expressed following TNF-α at either of the timepoints assessed, 
suggesting that PLK2 may be a novel NF-κB regulated gene following DNA-damage, and thus requiring 
further investigation using qRT-PCR, as described in section 5.4.10. 
 
 
Figure A.12A illustrates that, using qRT-PCR analysis, PLK2 is not induced by 10 Gy IR, 8 hours 
following treatment, in contrast to the results from the microarray analysis (5.4.5). It also shows that the 
expression of PLK2 is unaffected by IR in combination with p65 siRNA, BAY11-7082, AG-014699, 
PARP-1 siRNA or NS siRNA. Furthermore, Figure A.11B indicates that shows that PLK2 is not induced 
by TNF-α alone, and that is also unaffected by TNF-α in combination with p65 siRNA, BAY11-7082, 
AG-014699, PARP-1 siRNA or NS siRNA. These data suggest that PLK2 is not regulated by NF-κB in 
response to either stimuli. 
 
 
 
 
 
 
 
 
 
Topoisomerase (DNA) II alpha 
Microarray data (section 5.4.1) showed that the gene, TOP2A, encoding DNA topoisomerase II alpha was 
up-regulated 1.6-fold in p65+/+ MEFs harvested 2 hours after treatment with 10 Gy IR, and interestingly 
that this affect was abrogated in the presence of AG-014699 at this timepoint. This gene did not appeared 
to be differentially expressed following TNF-α at either of the timepoints assessed, suggesting that 
TOP2A may be a novel NF-κB regulated genes following DNA-damage, and thus requiring further 
investigation using qRT-PCR, as described in section 5.4.10. 
 
Figure A.13A shows that there is no significant change in the expression of TOP2A 2 hours after 
treatment with 10 Gy IR in the p65+/+ MEFs, compared with mock treated controls (p=0.1209, unpaired 
Student’s unpaired t-test) Furthermore, IR in combination with either p65 siRNA, BAY11-7082, AG-
014699, PARP-1 siRNA or NS siRNA had no effect on TOP2A expression when compared with IR alone 
(p65 siRNA: p0.9611; BAY11-7082: p=0.4093; AG-014699: p=0.7587; PARP-1 siRNA: p=0.8732; NS 
siRNA: p=0.9218). These data suggest that TOP2A is not regulated by NF-κB following DNA damage. 
Figure xB shows that TOP2A is not induced by TNF-α alone, and that is also unaffected by TNF-α in 
combination with p65 siRNA, BAY11-7082, AG-014699, PARP-1 siRNA or NS siRNA. Taken together 
these data suggest that expression of TOP2A is not likely to be regulated by NF-κB following TNF-α. 
 
Figure A.11B: Expression of PLK2 following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of PLK2 8 h following treatment with  
IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM.  
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Figure A.13: Expression of TOP2A following either IR or TNF-α 
Bar chart showing  the effect of IR or TNF-α ± p65 siRNA ± BAY11-7082 (BAY) ± AG-014699 (AG) ± 
PARP-1 siRNA  ± Non-specific (NS) siRNA control on the transcription of TOP2A 2 h following 
treatment with IR (A) or TNF-α (B) All results are the mean of three independent experiments with SEM.  
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Appendix II 
